Molecule ChEMBL ID;Molecule Name;Molecule Max Phase;Molecular Weight;#RO5 Violations;AlogP;Compound Key;Smiles;Standard Type;Standard Relation;Standard Value;Standard Units;pChEMBL Value;Data Validity Comment;Comment;Uo Units;Ligand Efficiency BEI;Ligand Efficiency LE;Ligand Efficiency LLE;Ligand Efficiency SEI;Potential Duplicate;Assay ChEMBL ID;Assay Description;Assay Type;BAO Format ID;BAO Label;Assay Organism;Assay Tissue ChEMBL ID;Assay Tissue Name;Assay Cell Type;Assay Subcellular Fraction;Target ChEMBL ID;Target Name;Target Organism;Target Type;Document ChEMBL ID;Source ID;Source Description;Document Journal;Document Year;Cell ChEMBL ID
CHEMBL304010;;0;704.91;2;2.27;5;CC(C)C[C@H](NC(=O)C(CC(N)=O)NC(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)C(O)CC(C)C(=O)NC(C(=O)NCc1ccccc1)C(C)C;Ki;'=';5.9;nM;8.23;;;UO_0000065;11.67;0.22;5.96;3.77;False;CHEMBL827180;Binding affinity against Beta-secretase;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1137865;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2004;None
CHEMBL2372119;;0;935.04;3;-0.99;13;CC(C)C[C@H](NC(=O)[C@@H](N)CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C;Ki;'=';0.3;nM;9.52;;;UO_0000065;10.18;0.20;10.51;2.51;False;CHEMBL942114;Inhibition of BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1140597;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2007;None
CHEMBL95430;;0;739.98;2;2.44;7;CC(C)C[C@H](NC(=O)[C@H](CS(C)(=O)=O)NC(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C;Ki;'=';9.4;nM;8.03;;;UO_0000065;10.85;0.21;5.59;3.84;False;CHEMBL942114;Inhibition of BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1140597;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2007;None
CHEMBL78946;;0;893.01;3;-1.74;OM99-2;CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(=O)O)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O;Ki;'=';1.6;nM;8.8;;;UO_0000065;9.85;0.19;10.54;2.34;True;CHEMBL655069;Binding affinity for human brain memapsin 2 beta-Secretase (BACE);B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1144924;1;Scientific Literature;J. Med. Chem.;2003;None
CHEMBL496451;;0;452.55;1;5.91;8;C=C(C)[C@H](CC=C(C)C)Cc1c(O)cc(OC)c2c1O[C@H](c1ccc(O)cc1OC)CC2=O;Ki;'=';10600.0;nM;4.97;;;UO_0000065;10.99;0.21;-0.94;5.84;False;CHEMBL946249;Inhibition of human BACE1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1155037;1;Scientific Literature;Bioorg. Med. Chem.;2008;None
CHEMBL362592;;0;730.95;2;2.68;3;CC(C)C[C@H](NC(=O)[C@@H]1CC(=O)NCCCCCCOC(=O)N[C@@H](C(C)C)C(=O)N1)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C;Ki;'=';25.0;nM;7.6;;;UO_0000065;10.4;0.20;4.92;3.73;True;CHEMBL2399170;Inhibition of human brain BACE1;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2396519;1;Scientific Literature;J. Med. Chem.;2013;None
CHEMBL508648;BYAKANGELICIN;0;334.32;0;2.06;34;COc1c2ccoc2c(OC[C@@H](O)C(C)(C)O)c2oc(=O)ccc12;Ki;'=';6200.0;nM;5.21;;;UO_0000065;15.58;0.30;3.15;5.09;False;CHEMBL1937035;Inhibition of recombinant human BACE1 assessed as dissociation constant of enzyme-substrate-inhibitor complex using Rh-EVNLDAEFK as substrate by Dixon and Cornish-Bowden plots analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1932923;1;Scientific Literature;Bioorg. Med. Chem.;2012;None
CHEMBL1097319;;0;656.8;1;3.90;3a;CCCN(CCC)C(=O)c1cc(C)cc(C(=O)N[C@@H](Cc2cc(F)cc(F)c2)[C@H](O)[C@H]2CN(S(=O)(=O)c3ccccc3)CCN2)c1;Ki;'=';3.0;nM;8.52;;;UO_0000065;12.98;0.25;4.62;7.16;False;CHEMBL1109071;Inhibition oh BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157894;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL443493;;0;742.96;2;2.87;12b;C=CCCOC(=O)N[C@H](C(=O)N[C@@H](CC(=O)NCC=C)C(=O)N[C@@H](CC(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C)C(C)C;Ki;'=';61.4;nM;7.21;;;UO_0000065;9.71;0.19;4.34;3.53;False;CHEMBL828805;Binding affinity for human brain memapsin 2;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1145144;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2005;None
CHEMBL363539;;0;506.45;2;5.20;4;COCCCNC(=O)c1cc(NC(=O)Nc2cc(C(F)(F)F)cc(C(F)(F)F)c2)ccc1N(C)C;Ki;'=';9400.0;nM;5.03;;;UO_0000065;9.93;0.20;-0.17;6.08;False;CHEMBL838759;Predicted binding affinity for beta secretase by linear interaction energy continuum electrostatics;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1144345;1;Scientific Literature;J. Med. Chem.;2005;None
CHEMBL3956543;;0;476.56;0;2.71;BDBM190715;C[C@@]1(c2cc(NC(=O)c3cn4ncsc4n3)ccc2F)CS(=O)(=O)C2(CCCC2)C(=N)N1;Ki;'=';18.4;nM;7.74;;341210;UO_0000065;16.23;0.33;5.03;5.98;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL1923752;;0;328.35;0;4.68;32;Fc1ccc2nc(-c3cccc(-c4cn5ccccc5n4)c3)[nH]c2c1;Ki;'=';34.0;nM;7.47;;;UO_0000065;22.75;0.41;2.79;16.24;False;CHEMBL1926456;Inhibition of BACE1 expressing APP Swedish mutant using rhodamine-labeled EVNLDAEFK-quencher as substrate after 60 mins by Michaelis-Menten equation;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1921672;1;Scientific Literature;J. Med. Chem.;2011;None
CHEMBL4085364;;0;394.52;0;3.31;25-rac;[2H]C1([2H])OC(N)=N[C@]12c1cc(-c3cncnc3)ccc1C[C@]21C[C@H](C)[C@@H](OC)[C@H](C)C1;Ki;'=';45.0;nM;7.35;;;UO_0000065;18.72;0.35;4.04;8.89;False;CHEMBL4049274;Inhibition of human BACE1 (1 to 460 residues) fused with Fc domain of IgG1 expressed in HEK293 cells preincubated for 10 mins followed by substrate addition measured after 17 mins by TR-FRET assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4043307;1;Scientific Literature;J Med Chem;2018;CHEMBL3307715
CHEMBL3640279;;0;418.86;0;1.70;BDBM102962;COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3cccc(Cl)c3)C2)nc(C)c1F;Ki;'=';39.0;nM;7.41;;220597;UO_0000065;17.69;0.35;5.71;7.64;False;CHEMBL3705045;Time-Resolved FRET Assay: A homogeneous time-resolved FRET assay was used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. The assay monitored the increase of 620nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide).;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638861;37;BindingDB Database;;2013;None
CHEMBL2178179;;0;490.35;0;4.17;17e;COc1ccc(-c2noc(C)c2C(=O)/N=C(\N)NCc2cc(Cl)c(NC(C)=O)c(Cl)c2)cc1;Ki;'=';10.0;nM;8.0;;;UO_0000065;16.31;0.33;3.83;6.07;False;CHEMBL2187886;Displacement of [3H]BMS-599240 from BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177026;1;Scientific Literature;J. Med. Chem.;2012;CHEMBL3307715
CHEMBL2178178;;0;464.38;0;4.26;17d;COc1ccc(-c2nsc(C)c2C(=O)/N=C(\N)NCc2cc(Cl)c(N)c(Cl)c2)cc1;Ki;'=';40.0;nM;7.4;;;UO_0000065;15.93;0.34;3.14;6.40;False;CHEMBL2187886;Displacement of [3H]BMS-599240 from BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177026;1;Scientific Literature;J. Med. Chem.;2012;CHEMBL3307715
CHEMBL1412710;;0;338.4;1;5.61;24;CC(C)=CCC/C(C)=C/COc1c2occc2cc2ccc(=O)oc12;Ki;'=';61900.0;nM;4.21;;;UO_0000065;12.44;0.23;-1.40;8.00;False;CHEMBL1937035;Inhibition of recombinant human BACE1 assessed as dissociation constant of enzyme-substrate-inhibitor complex using Rh-EVNLDAEFK as substrate by Dixon and Cornish-Bowden plots analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1932923;1;Scientific Literature;Bioorg. Med. Chem.;2012;None
CHEMBL1923751;;0;310.36;0;4.54;31;c1cc(-c2cn3ccccc3n2)cc(-c2nc3ccccc3[nH]2)c1;Ki;'=';926.0;nM;6.03;;;UO_0000065;19.44;0.34;1.49;13.12;False;CHEMBL1926456;Inhibition of BACE1 expressing APP Swedish mutant using rhodamine-labeled EVNLDAEFK-quencher as substrate after 60 mins by Michaelis-Menten equation;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1921672;1;Scientific Literature;J. Med. Chem.;2011;None
CHEMBL1078442;BERGAMOTTIN;0;338.4;1;5.61;SID530919;CC(C)=CCC/C(C)=C/COc1c2ccoc2cc2oc(=O)ccc12;Ki;'=';34800.0;nM;4.46;;;UO_0000065;13.18;0.24;-1.15;8.48;False;CHEMBL1936883;Inhibition of recombinant human BACE1 assessed as dissociation constant of enzyme-inhibitor complex using Rh-EVNLDAEFK as substrate by Dixon and Cornish-Bowden plots analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1932923;1;Scientific Literature;Bioorg. Med. Chem.;2012;None
CHEMBL450745;EUGENIIN;0;938.67;3;1.67;Tellimagrandin-II;O=C(O[C@@H]1O[C@@H]2COC(=O)c3cc(O)c(O)c(O)c3-c3c(cc(O)c(O)c3O)C(=O)O[C@H]2[C@H](OC(=O)c2cc(O)c(O)c(O)c2)[C@H]1OC(=O)c1cc(O)c(O)c(O)c1)c1cc(O)c(O)c(O)c1;Ki;'=';6840.0;nM;5.17;;;UO_0000065;5.5;0.11;3.49;1.16;False;CHEMBL3293240;Inhibition of BACE1 (unknown origin);B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3286369;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2014;None
CHEMBL1923750;;0;411.51;1;5.76;26;COc1ccc2nc(-c3cccc(-c4nc5ccccn5c4NC(C)(C)C)c3)[nH]c2c1;Ki;'=';253.0;nM;6.6;;;UO_0000065;16.03;0.29;0.84;9.81;False;CHEMBL1926456;Inhibition of BACE1 expressing APP Swedish mutant using rhodamine-labeled EVNLDAEFK-quencher as substrate after 60 mins by Michaelis-Menten equation;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1921672;1;Scientific Literature;J. Med. Chem.;2011;None
CHEMBL1923754;;0;346.34;0;4.82;34;Fc1ccc2nc(-c3cccc(-c4cn5ccc(F)cc5n4)c3)[nH]c2c1;Ki;'=';17.0;nM;7.77;;;UO_0000065;22.43;0.41;2.95;16.90;False;CHEMBL1926456;Inhibition of BACE1 expressing APP Swedish mutant using rhodamine-labeled EVNLDAEFK-quencher as substrate after 60 mins by Michaelis-Menten equation;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1921672;1;Scientific Literature;J. Med. Chem.;2011;None
CHEMBL3640270;;0;414.44;0;1.14;BDBM102953;CCOc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3ccccc3)C2)nc(OC)c1F;Ki;'=';137.0;nM;6.86;;220581;UO_0000065;16.56;0.31;5.72;6.46;False;CHEMBL3705045;Time-Resolved FRET Assay: A homogeneous time-resolved FRET assay was used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. The assay monitored the increase of 620nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide).;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638861;37;BindingDB Database;;2013;None
CHEMBL3627969;;0;478.38;0;3.56;12e;COc1ccc(N2CCC[C@H]2C(=O)/N=C(\N)NCc2cc(Cl)c(NC(C)=O)c(Cl)c2)cc1;Ki;'=';110.0;nM;6.96;;;UO_0000065;14.55;0.30;3.40;6.38;False;CHEMBL3630425;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 5 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL3911141;;0;449.33;0;4.05;BDBM230870;NC1=N[C@@](c2cc(NC(=O)c3cnc(C(F)F)cn3)ccc2F)(C(F)F)C(F)(F)CC1;Ki;'=';20.0;nM;7.7;;402953;UO_0000065;17.13;0.34;3.65;8.26;False;CHEMBL3888456;BACE1 Binding Assay: The binding assay was performed as SPA-based assay using a biotinylated form of human BACE1 recombinantly expressed and subsequently purified from Freestyle HEK293 cells. The binding assay was run in a 50 mM sodium acetate buffer, pH 4.5 containing 50 mM NaCl and 0.03% Tween-20 in white clear bottom 384 plates (Corning #3653). 10 nM (final concentration) radioligand ([3H]−N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N−((R)-1-phenyl-ethyl)-isophthalamide) (TRQ11569 purchased from GE Healthcare) was mixed with test compound at a given concentration, 6 nM (final concentration) human BACE1 and 25 μg Streptavidin coated PVT core SPA beads (RPNQ0007, GE Healthcare Life Sciences) in a total volume of 40 μl. Several concentrations of each test compound were tested in the assay for IC50 determination. The plates were incubated for one hour at room temperature and counted in a Wallac Trilux counter. Total and non-specific binding were determined using buffer and 1 μM (final concentration) of the high affinity BACE1 reference inhibitor (S)-6-[3-chloro-5-(5-prop-1-ynyl-pyridin-3-yl)-thiophen-2-yl]-2-imino-3,6-dimethyl-tetrahydro-pyrimidin-4-one, respectively.;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886720;37;BindingDB Database;;2016;CHEMBL3307715
CHEMBL448008;;0;658.86;1;1.43;2;Cc1cc(C)n(COC(=O)N[C@@H](CS(C)(=O)=O)C(=O)N[C@@H](CC(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NCC(C)C)C(C)C)n1;Ki;'=';0.3;nM;9.52;;;UO_0000065;14.45;0.29;8.09;4.81;False;CHEMBL3380862;Inhibition of recombinant BACE1 (unknown origin);B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3351680;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;None
CHEMBL3361311;;0;710.98;2;3.47;4a;Cc1nc(C[C@H](C)C(=O)N[C@@H](CNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NCC(C)C)C(C)C)cs1;Ki;'=';31.9;nM;7.5;;;UO_0000065;10.54;0.21;4.03;3.99;False;CHEMBL3380862;Inhibition of recombinant BACE1 (unknown origin);B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3351680;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;None
CHEMBL3361312;;0;725.01;2;3.86;4b;CC[C@@H](Cc1csc(C)n1)C(=O)N[C@@H](CNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NCC(C)C)C(C)C;Ki;'=';16.8;nM;7.78;;;UO_0000065;10.72;0.21;3.91;4.14;False;CHEMBL3380862;Inhibition of recombinant BACE1 (unknown origin);B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3351680;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;None
CHEMBL3354263;;0;505.67;1;4.80;54;CN1C(=N)N[C@](CCC2CCCCC2)(C[C@H]2CCC[C@@H](NC(=O)Nc3cnc4ccccc4n3)C2)C1=O;Ki;'=';14.0;nM;7.85;;;UO_0000065;15.53;0.29;3.05;6.38;False;CHEMBL3386389;Inhibition of purified human BACE1 by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3352601;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2014;None
CHEMBL1923706;;0;381.48;1;5.76;19;CC(C)(C)Nc1c(-c2ccc(-c3nc4ccccc4[nH]3)cc2)nc2ccccn12;Ki;'=';5312.0;nM;5.28;;;UO_0000065;13.83;0.25;-0.49;9.09;False;CHEMBL1926456;Inhibition of BACE1 expressing APP Swedish mutant using rhodamine-labeled EVNLDAEFK-quencher as substrate after 60 mins by Michaelis-Menten equation;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1921672;1;Scientific Literature;J. Med. Chem.;2011;None
CHEMBL2178193;;0;549.48;1;4.18;22a;COc1ccc(-c2nsc(C)c2C(=O)/N=C(\N)NCc2cc(Cl)c(NC(=O)CN(C)C)c(Cl)c2)cc1;Ki;'=';20.0;nM;7.7;;;UO_0000065;14.01;0.29;3.52;6.31;False;CHEMBL2187886;Displacement of [3H]BMS-599240 from BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177026;1;Scientific Literature;J. Med. Chem.;2012;CHEMBL3307715
CHEMBL2178186;;0;530.05;1;4.56;17l;COc1ccc(-c2noc(C)c2C(=O)/N=C(\N)NCc2cc(C)c(NC(=O)CCSC)c(Cl)c2)cc1;Ki;'=';30.0;nM;7.52;;;UO_0000065;14.19;0.29;2.96;5.71;False;CHEMBL2187886;Displacement of [3H]BMS-599240 from BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177026;1;Scientific Literature;J. Med. Chem.;2012;CHEMBL3307715
CHEMBL2178751;;0;364.41;0;2.90;8e;COc1ccc(-c2noc(C)c2C(=O)/N=C(\N)NCc2ccccc2)cc1;Ki;'=';4000.0;nM;5.4;;;UO_0000065;14.81;0.27;2.50;5.25;False;CHEMBL2187886;Displacement of [3H]BMS-599240 from BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177026;1;Scientific Literature;J. Med. Chem.;2012;CHEMBL3307715
CHEMBL2178163;;0;529.07;1;3.88;22f;CCNCC(=O)Nc1c(C)cc(CN/C(N)=N/C(=O)c2c(-c3ccc(OC)cc3)nsc2C)cc1Cl;Ki;'=';20.0;nM;7.7;;;UO_0000065;14.55;0.29;3.82;5.89;False;CHEMBL2187886;Displacement of [3H]BMS-599240 from BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177026;1;Scientific Literature;J. Med. Chem.;2012;CHEMBL3307715
CHEMBL2178194;;0;529.07;1;3.83;22b;COc1ccc(-c2nsc(C)c2C(=O)/N=C(\N)NCc2cc(C)c(NC(=O)CN(C)C)c(Cl)c2)cc1;Ki;'=';20.0;nM;7.7;;;UO_0000065;14.55;0.29;3.87;6.31;False;CHEMBL2187886;Displacement of [3H]BMS-599240 from BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177026;1;Scientific Literature;J. Med. Chem.;2012;CHEMBL3307715
CHEMBL2178183;;0;483.96;0;4.21;17i;CCC(=O)Nc1c(C)cc(CN/C(N)=N/C(=O)c2c(-c3ccc(OC)cc3)noc2C)cc1Cl;Ki;'=';40.0;nM;7.4;;;UO_0000065;15.29;0.30;3.19;5.61;False;CHEMBL2187886;Displacement of [3H]BMS-599240 from BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177026;1;Scientific Literature;J. Med. Chem.;2012;CHEMBL3307715
CHEMBL2179132;;0;665.86;1;3.03;6;CC(C)CNC(=O)[C@@H](NC[C@H](Cc1ccccc1)NC(=O)c1cc(C(=O)N[C@H](C)c2ccccc2)cc(N(C)S(C)(=O)=O)c1)[C@@H](C)O;Ki;'=';98.8;nM;7.0;;;UO_0000065;10.52;0.20;3.98;4.46;False;CHEMBL2185581;Inhibition of recombinant BACE1 expressed in Escherichia coli using Arg- Glu(EDANS)-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys(Dabcyl)-Arg as substrate by fluorimetric analysis;B;BAO_0000019;assay format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177024;1;Scientific Literature;J. Med. Chem.;2012;None
CHEMBL317001;;0;763.89;2;-1.09;1;CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)C(N)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(=O)O)C(=O)NC(Cc1ccccc1)C(=O)O;Ki;'=';36.0;nM;7.44;;;UO_0000065;9.74;0.19;8.53;2.41;False;CHEMBL711471;Binding affinity for human brain memapsin 2;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1134775;1;Scientific Literature;J. Med. Chem.;2001;None
CHEMBL1233206;;0;323.4;0;2.75;4;COc1cccc(-c2cccc([C@]3(C)CC(=O)N(C)C(N)=N3)c2)c1;Ki;'=';270.0;nM;6.57;;;UO_0000065;20.31;0.37;3.82;9.67;False;CHEMBL2155063;Inhibition of human recombinant BACE1 by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2150878;1;Scientific Literature;ACS Med. Chem. Lett.;2012;None
CHEMBL2019055;;0;864.95;3;-2.52;OM99-2;CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(=O)O)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O;Ki;'=';1.6;nM;8.8;;;UO_0000065;10.17;0.20;11.32;2.34;False;CHEMBL3062634;Inhibition of BACE1 (unknown origin);B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3044565;1;Scientific Literature;Med Chem Res;2012;None
CHEMBL3640254;;0;410.91;0;2.43;BDBM102936;Cc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3ccccc3)C2)nc(C2CC2)c1Cl;Ki;'=';94.0;nM;7.03;;220586;UO_0000065;17.1;0.33;4.60;8.01;False;CHEMBL3705045;Time-Resolved FRET Assay: A homogeneous time-resolved FRET assay was used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. The assay monitored the increase of 620nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide).;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638861;37;BindingDB Database;;2013;None
CHEMBL3628123;;0;521.45;1;3.10;12g;COc1ccc(N2CCC[C@H]2C(=O)/N=C(\N)NCc2cc(Cl)c(NC(=O)CN(C)C)c(Cl)c2)cc1;Ki;'=';140.0;nM;6.85;;;UO_0000065;13.14;0.27;3.75;6.10;False;CHEMBL3630425;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 5 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL3664021;;0;610.8;1;2.80;BDBM172752;CCCC(O)C(NCC(O)C(Cc1ccccc1)NC(=O)c1cc(C)cc(C(=O)N2CCCC2OC)c1)C(=O)NCC(C)C;Ki;'=';6.56;nM;8.18;;317741;UO_0000065;13.4;0.25;5.38;5.84;False;CHEMBL3707552;Inhibition Assay: Previously, one of the following compounds discussed below have been studied in memapsin 2 inhibition (Ghosh et al., 2008), which the others are previously unpublished. Given the closely related substrate specificity for memapsin 1 and memapsin 2, the inventors chose to screen these previously identified memapsin 2 inhibitors for lead compounds as memapsin 1 inhibitors. Recombinant memapsin 1 ectodomain was prepared as described by Turner et al. (2002) and assayed using a commercially purchased fluorescent substrate.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638586;37;BindingDB Database;;2015;None
CHEMBL362324;;0;640.84;1;2.30;BACE Inhibitor 3;CC(C)C[C@H](NC(=O)[C@H](CS(C)(=O)=O)NC(=O)OC(C)(C)C)C(O)CC(C)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C;Ki;'=';1129.0;nM;5.95;;;UO_0000065;9.28;0.18;3.65;3.30;False;CHEMBL828263;Binding affinity towards Beta-secretase determined using continuum electrostatics solvation;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1137231;1;Scientific Literature;J. Med. Chem.;2004;None
CHEMBL3627963;;0;434.33;0;3.75;11d;CC(=O)Nc1c(Cl)cc(CN/C(N)=N/C(=O)N[C@H]2CCc3ccccc32)cc1Cl;Ki;'=';14000.0;nM;4.85;;;UO_0000065;11.18;0.23;1.10;4.47;False;CHEMBL3630426;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 6.4 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL3628127;;0;559.5;1;3.85;20c;N/C1=N\C(=O)[C@@H]2CCCN2c2ccc(cc2)OC/C=C/CCCNCC(=O)Nc2c(Cl)cc(cc2Cl)CN1;Ki;'=';25.0;nM;7.6;;;UO_0000065;13.59;0.27;3.75;6.28;False;CHEMBL3630425;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 5 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL259083;;0;556.59;1;3.36;22;O=C(N[C@@H](Cc1ccccc1)[C@H](O)CNCc1cccc(OC(F)(F)F)c1)[C@@H]1CN(Cc2ccccc2)C(=O)N1;Ki;'=';1881.0;nM;5.73;;;UO_0000065;10.29;0.20;2.37;5.56;False;CHEMBL929344;Inhibition of human BACE1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1145643;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2008;None
CHEMBL471187;ECKOL;0;372.29;1;3.61;3;Oc1cc(O)cc(Oc2c(O)cc(O)c3c2Oc2c(O)cc(O)cc2O3)c1;Ki;'=';13900.0;nM;4.86;;;UO_0000065;13.05;0.25;1.25;3.26;False;CHEMBL1117924;Noncompetitive inhibition of human recombinant BACE1 after 60 mins by Dixon plot analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1155522;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL1098082;;0;474.65;1;5.76;14;CC(C)[C@@H]1CCC(=O)N(C2CCCCC2)CCc2cccc(c2)Oc2ccc3c(c2)CN1C(N)=N3;Ki;'=';8.0;nM;8.1;;;UO_0000065;17.06;0.32;2.34;11.38;False;CHEMBL1103872;Inhibition of BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157115;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL1098735;;0;528.74;2;7.08;13;NC1=Nc2ccc3cc2CN1[C@@H](C1CCCCC1)CCC(=O)N(C1CCCCC1)CCCc1cccc(c1)O3;Ki;'=';186.0;nM;6.73;;;UO_0000065;12.73;0.24;-0.35;9.46;False;CHEMBL1103872;Inhibition of BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157115;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL3640280;;0;446.43;0;1.90;BDBM102963;COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3cc(F)ccc3F)C2)nc(C2CC2)c1F;Ki;'=';5.6;nM;8.25;;220598;UO_0000065;18.48;0.35;6.35;8.51;False;CHEMBL3705045;Time-Resolved FRET Assay: A homogeneous time-resolved FRET assay was used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. The assay monitored the increase of 620nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide).;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638861;37;BindingDB Database;;2013;None
CHEMBL464006;MORUSIN;0;420.46;1;5.27;3;CC(C)=CCc1c(-c2ccc(O)cc2O)oc2c3c(cc(O)c2c1=O)OC(C)(C)C=C3;Ki;'=';64100.0;nM;4.19;;;UO_0000065;9.97;0.18;-1.08;4.19;False;CHEMBL1771832;Noncompetitive inhibition of human recombinant BACE-1 by Dixon plot analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1770081;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2011;None
CHEMBL3627956;;0;445.31;0;3.38;7a;CC(=O)Nc1c(Cl)cc(CN/C(N)=N/C(=O)c2ccnn2-c2ccccc2)cc1Cl;Ki;'=';490.0;nM;6.31;;;UO_0000065;14.17;0.29;2.93;5.52;False;CHEMBL3630425;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 5 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL3627969;;0;478.38;0;3.56;12e;COc1ccc(N2CCC[C@H]2C(=O)/N=C(\N)NCc2cc(Cl)c(NC(C)=O)c(Cl)c2)cc1;Ki;'=';300.0;nM;6.52;;;UO_0000065;13.64;0.28;2.96;5.98;False;CHEMBL3630426;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 6.4 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL3628124;;0;531.44;1;3.07;20a;N/C1=N\C(=O)[C@@H]2CCCN2c2ccc(cc2)OC/C=C/CNCC(=O)Nc2c(Cl)cc(cc2Cl)CN1;Ki;'=';1500.0;nM;5.82;;;UO_0000065;10.96;0.22;2.75;4.81;False;CHEMBL3630426;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 6.4 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL3353636;;0;440.65;0;3.31;31;CCCCS(=O)(=O)N1CCC[C@H](C[C@@]2(CCC3CCCCC3)NC(=N)N(C)C2=O)C1;Ki;'=';6300.0;nM;5.2;;;UO_0000065;11.8;0.24;1.89;5.56;False;CHEMBL3386389;Inhibition of purified human BACE1 by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3352601;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2014;None
CHEMBL3353635;;0;405.59;0;3.30;30;CCCNC(=O)N1CCC[C@H](C[C@@]2(CCC3CCCCC3)NC(=N)N(C)C2=O)C1;Ki;'=';8500.0;nM;5.07;;;UO_0000065;12.5;0.24;1.77;5.73;False;CHEMBL3386389;Inhibition of purified human BACE1 by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3352601;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2014;None
CHEMBL244347;;0;502.7;2;6.76;3a;CN(C(=O)CC[C@@H](C1CCCCC1)N1Cc2cc(Oc3ccccc3)ccc2N=C1N)C1CCCCC1;Ki;'=';25.0;nM;7.6;;;UO_0000065;15.12;0.28;0.84;10.68;False;CHEMBL2067011;Inhibition of recombinant beta-secretase 1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2062429;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2012;None
CHEMBL3951563;;0;370.48;0;1.88;BDBM182841;Cc1cccc(N2CC3C(c4ccccc4)(C2)NC(=N)N(C)S3(=O)=O)c1;Ki;'=';1563.0;nM;5.81;;330389;UO_0000065;15.67;0.30;3.93;7.59;False;CHEMBL3887312;BACE1 HTRF FRET Assay: A homogeneous time-resolved FRET assay was used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitored the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contained an N-terminal QSY7 moiety that served as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence was low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors was manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul were preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886269;37;BindingDB Database;;2015;None
CHEMBL3354258;;0;483.66;0;4.86;49;COc1ccccc1NC(=O)N[C@@H]1CCC[C@H](C[C@@]2(CCC3CCCCC3)NC(=N)N(C)C2=O)C1;Ki;'=';276.0;nM;6.56;;;UO_0000065;13.56;0.26;1.70;6.16;False;CHEMBL3386389;Inhibition of purified human BACE1 by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3352601;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2014;None
CHEMBL2011978;;0;367.41;0;2.86;4n;CN1C(=N)NC(c2ccccc2)(c2cccc(-c3cncc(C#N)c3)c2)C1=O;Ki;'=';470.0;nM;6.33;;;UO_0000065;17.22;0.31;3.47;6.81;False;CHEMBL2015090;Inhibition of human BACE1 using QSY7EISEVNLDAEFC-Eu-amide as substrate incubated for 30 mins prior to substrate addition measured after 90 mins by FRET analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2010674;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2012;None
CHEMBL510829;;0;621.83;1;4.30;6f;Nc1ccc(S(=O)(=O)N(CCCNCCCN(Cc2ccccc2)S(=O)(=O)c2ccc(N)cc2)Cc2ccccc2)cc1;Ki;'=';64000.0;nM;4.19;;;UO_0000065;6.74;0.13;-0.11;3.02;False;CHEMBL984419;Inhibition of recombinant beta secretase 1 by fluorescence technique;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1144181;1;Scientific Literature;Bioorg. Med. Chem.;2008;None
CHEMBL1097349;;0;705.22;1;3.54;3ff;COC[C@H]1CCCN1C(=O)c1cc(C)cc(C(=O)N[C@@H](Cc2cc(F)cc(F)c2)[C@H](O)[C@H]2CN(S(=O)(=O)c3cccc(Cl)c3)CCN2)c1;Ki;'=';1.0;nM;9.0;;;UO_0000065;12.76;0.26;5.46;7.02;False;CHEMBL1109071;Inhibition oh BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157894;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL1087742;;0;467.54;0;1.34;3dd;CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)[C@H]1CN(S(=O)(=O)c2cccc(C)c2)CCN1;Ki;'=';365.0;nM;6.44;;;UO_0000065;13.77;0.27;5.10;6.52;False;CHEMBL1109071;Inhibition oh BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157894;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL261655;;0;545.68;1;2.53;12;COc1cccc(CN2C[C@@H](C(=O)N[C@@H](Cc3ccccc3)[C@H](O)CNCc3cccc(N(C)C)c3)NC2=O)c1;Ki;'=';449.0;nM;6.35;;;UO_0000065;11.63;0.22;3.82;5.98;False;CHEMBL929344;Inhibition of human BACE1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1145643;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2008;None
CHEMBL410666;;0;501.63;1;2.53;11;CN(C)c1cccc(CNC[C@@H](O)[C@H](Cc2ccccc2)NC(=O)[C@@H]2CN(c3ccccc3)C(=O)N2)c1;Ki;'=';8177.0;nM;5.09;;;UO_0000065;10.14;0.19;2.56;5.25;False;CHEMBL929344;Inhibition of human BACE1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1145643;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2008;None
CHEMBL2063207;;0;582.79;2;7.06;4g;Cn1cc(CN(C(=O)CC[C@@H](C2CCCCC2)N2Cc3cc(Oc4ccccc4)ccc3N=C2N)C2CCCCC2)cn1;Ki;'=';11.0;nM;7.96;;;UO_0000065;13.66;0.25;0.90;8.94;False;CHEMBL2067011;Inhibition of recombinant beta-secretase 1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2062429;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2012;None
CHEMBL603120;;0;716.8;1;3.12;1f;CO[C@H](C[C@H](O)[C@H](COc1cc(F)cc(F)c1)NC(=O)c1cc(C(=O)N[C@H](C)c2ccccc2)cc(N(C)CS(C)(=O)=O)c1)C(=O)NC1CC1;Ki;'=';1800.0;nM;5.75;;;UO_0000065;8.01;0.16;2.62;3.52;False;CHEMBL1072341;Inhibition of human BACE1 expressed in Escherichia coli cells (BL21(DE3) by TRF assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157542;1;Scientific Literature;J. Med. Chem.;2010;None
CHEMBL1097348;;0;670.78;1;2.89;3ee;COC[C@H]1CCCN1C(=O)c1cc(C)cc(C(=O)N[C@@H](Cc2cc(F)cc(F)c2)[C@H](O)[C@H]2CN(S(=O)(=O)c3ccccc3)CCN2)c1;Ki;'=';1.0;nM;9.0;;;UO_0000065;13.42;0.26;6.11;7.02;False;CHEMBL1109071;Inhibition oh BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157894;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL448008;;0;658.86;1;1.43;49;Cc1cc(C)n(COC(=O)N[C@@H](CS(C)(=O)=O)C(=O)N[C@@H](CC(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NCC(C)C)C(C)C)n1;Ki;'=';0.3;nM;9.52;;;UO_0000065;14.45;0.29;8.09;4.81;True;CHEMBL981021;Inhibition of recombinant memapsin 2;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1153435;1;Scientific Literature;J. Med. Chem.;2009;None
CHEMBL510508;PHLOROFUCOFUROECKOL A;0;602.46;4;6.42;4;Oc1cc(O)cc(Oc2c(O)cc(O)c3c2Oc2c(O)cc4oc5c(Oc6cc(O)cc(O)c6)c(O)cc(O)c5c4c2O3)c1;Ki;'=';1300.0;nM;5.89;;;UO_0000065;9.77;0.18;-0.53;2.54;False;CHEMBL1117924;Noncompetitive inhibition of human recombinant BACE1 after 60 mins by Dixon plot analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1155522;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL578410;;0;299.76;0;2.37;4f;CN1C(=O)C(c2ccccc2)(c2cccc(Cl)c2)N=C1N;Ki;'=';300.0;nM;6.52;;;UO_0000065;21.76;0.42;4.15;11.11;False;CHEMBL2015090;Inhibition of human BACE1 using QSY7EISEVNLDAEFC-Eu-amide as substrate incubated for 30 mins prior to substrate addition measured after 90 mins by FRET analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2010674;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2012;None
CHEMBL2011974;;0;342.4;0;2.99;4j;CN1C(=N)NC(c2ccccc2)(c2cccc(-c3cccnc3)c2)C1=O;Ki;'=';530.0;nM;6.28;;;UO_0000065;18.33;0.33;3.29;9.08;False;CHEMBL2015090;Inhibition of human BACE1 using QSY7EISEVNLDAEFC-Eu-amide as substrate incubated for 30 mins prior to substrate addition measured after 90 mins by FRET analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2010674;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2012;None
CHEMBL2011992;;0;353.85;0;4.00;13h;CN1C(=N)NC(c2cccc(-c3cccc(Cl)c3)c2)(C2(C)CC2)C1=O;Ki;'=';190.0;nM;6.72;;;UO_0000065;18.99;0.37;2.72;11.96;False;CHEMBL2015090;Inhibition of human BACE1 using QSY7EISEVNLDAEFC-Eu-amide as substrate incubated for 30 mins prior to substrate addition measured after 90 mins by FRET analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2010674;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2012;None
CHEMBL2012069;;0;340.81;0;3.00;17h;CN1C(=N)NC(c2cccc(-c3cncc(Cl)c3)c2)(C2CC2)C1=O;Ki;'=';59.0;nM;7.23;;;UO_0000065;21.21;0.41;4.23;10.46;False;CHEMBL2015090;Inhibition of human BACE1 using QSY7EISEVNLDAEFC-Eu-amide as substrate incubated for 30 mins prior to substrate addition measured after 90 mins by FRET analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2010674;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2012;None
CHEMBL591700;;0;892.03;2;5.03;2f;CC(C)[C@H](NC(=O)[C@@H](C[C@H](O)[C@H](COc1cc(F)cc(F)c1)NC(=O)c1cc(C(=O)N[C@H](C)c2ccccc2)cc(N(C)S(C)(=O)=O)c1)OCC1CC1)C(=O)NCc1ccccc1;Ki;'=';1.3;nM;8.89;;;UO_0000065;9.96;0.19;3.86;4.62;False;CHEMBL1069651;Inhibition of human BACE1 expressed in Escherichia coli BL21(DE3) by resolved fluorescence assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1156935;1;Scientific Literature;Bioorg. Med. Chem.;2010;None
CHEMBL1097321;;0;670.82;1;4.21;3c;CCCN(CCC)C(=O)c1cc(C)cc(C(=O)N[C@@H](Cc2cc(F)cc(F)c2)[C@H](O)[C@H]2CN(S(=O)(=O)c3cccc(C)c3)CCN2)c1;Ki;'=';1.0;nM;9.0;;;UO_0000065;13.42;0.26;4.79;7.56;False;CHEMBL1109071;Inhibition oh BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157894;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL1097345;;0;705.85;1;3.00;3aa;CCNc1cc(C(=O)N[C@@H](Cc2cc(F)cc(F)c2)[C@H](O)[C@H]2CN(S(=O)(=O)c3cccc(C)c3)CCN2)cc(N2CCCCS2(=O)=O)c1;Ki;'=';1.0;nM;9.0;;;UO_0000065;12.75;0.26;6.00;6.07;False;CHEMBL1109071;Inhibition oh BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157894;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL1097351;;0;711.25;1;3.60;3hh;COC[C@H]1CCCN1C(=O)c1cc(C)cc(C(=O)N[C@@H](Cc2cc(F)cc(F)c2)[C@H](O)[C@H]2CN(S(=O)(=O)c3ccc(Cl)s3)CCN2)c1;Ki;'=';1.0;nM;9.0;;;UO_0000065;12.65;0.26;5.40;7.02;False;CHEMBL1109071;Inhibition oh BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157894;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL1097337;;0;688.84;1;3.25;3s;CCCN(CCC)C(=O)c1cc(C)cc(C(=O)N[C@@H](Cc2cc(F)cc(F)c2)[C@H](O)[C@H]2CN(S(=O)(=O)c3c(C)nn(C)c3C)CCN2)c1;Ki;'=';970.0;nM;6.01;;;UO_0000065;8.73;0.17;2.76;4.39;False;CHEMBL1109071;Inhibition oh BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157894;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL575326;;0;370.37;0;3.52;13;O=C(Nc1nc2ccncc2[nH]1)c1ccc2c(c1)Nc1ccccc1NC2=O;Ki;'=';309.0;nM;6.51;;;UO_0000065;17.58;0.32;2.99;5.82;False;CHEMBL1045676;Inhibition of human recombinant BACE1 by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1154184;1;Scientific Literature;J. Med. Chem.;2009;None
CHEMBL190346;;0;322.42;0;3.50;2;CCSc1nsc(NC(=O)Nc2cccc(C(C)=O)c2)n1;Ki;'=';28800.0;nM;4.54;;;UO_0000065;14.08;0.30;1.04;5.41;False;CHEMBL838759;Predicted binding affinity for beta secretase by linear interaction energy continuum electrostatics;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1144345;1;Scientific Literature;J. Med. Chem.;2005;None
CHEMBL2372118;;0;891.98;3;-2.62;12;CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(=O)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O;Ki;'=';1.6;nM;8.8;;;UO_0000065;9.86;0.19;11.42;2.29;False;CHEMBL942114;Inhibition of BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1140597;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2007;None
CHEMBL98238;;0;704.91;2;2.27;5;CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C;Ki;'=';5.9;nM;8.23;;;UO_0000065;11.67;0.22;5.96;3.77;False;CHEMBL942114;Inhibition of BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1140597;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2007;None
CHEMBL1097323;;0;691.24;1;4.55;3e;CCCN(CCC)C(=O)c1cc(C)cc(C(=O)N[C@@H](Cc2cc(F)cc(F)c2)[C@H](O)[C@H]2CN(S(=O)(=O)c3ccccc3Cl)CCN2)c1;Ki;'=';400.0;nM;6.4;;;UO_0000065;9.26;0.19;1.85;5.37;False;CHEMBL1109071;Inhibition oh BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157894;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL387984;;0;717.93;2;2.74;5f;CC(C)C[C@H](NC(=O)c1cc(C(=O)N[C@H](CO)c2ccccc2)cc(N(C)S(C)(=O)=O)c1)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NC(C)C)C(C)C;Ki;'=';438.0;nM;6.36;;;UO_0000065;8.86;0.17;3.62;3.27;False;CHEMBL915132;Inhibition of recombinant memapsin 2;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1139858;1;Scientific Literature;J. Med. Chem.;2007;None
CHEMBL1097333;;0;662.83;1;3.96;3o;CCCN(CCC)C(=O)c1cc(C)cc(C(=O)N[C@@H](Cc2cc(F)cc(F)c2)[C@H](O)[C@H]2CN(S(=O)(=O)c3cccs3)CCN2)c1;Ki;'=';8.0;nM;8.1;;;UO_0000065;12.22;0.25;4.14;6.80;False;CHEMBL1109071;Inhibition oh BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157894;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL591491;;0;880.02;2;5.03;2e;CCCO[C@H](C[C@H](O)[C@H](COc1cc(F)cc(F)c1)NC(=O)c1cc(C(=O)N[C@H](C)c2ccccc2)cc(N(C)S(C)(=O)=O)c1)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C;Ki;'=';3.0;nM;8.52;;;UO_0000065;9.68;0.19;3.49;4.43;False;CHEMBL1069651;Inhibition of human BACE1 expressed in Escherichia coli BL21(DE3) by resolved fluorescence assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1156935;1;Scientific Literature;Bioorg. Med. Chem.;2010;None
CHEMBL589487;;0;770.83;1;4.62;1j;CO[C@H](C[C@H](O)[C@H](COc1cc(F)cc(F)c1)NC(=O)c1cc(C(=O)N[C@H](C)c2ccccc2)cc(N(C)CS(C)(=O)=O)c1)C(=O)Nc1ccc(F)cc1;Ki;'=';100.0;nM;7.0;;;UO_0000065;9.08;0.18;2.38;4.28;False;CHEMBL1072341;Inhibition of human BACE1 expressed in Escherichia coli cells (BL21(DE3) by TRF assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157542;1;Scientific Literature;J. Med. Chem.;2010;None
CHEMBL95430;;0;739.98;2;2.44;10;CC(C)C[C@H](NC(=O)[C@H](CS(C)(=O)=O)NC(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C;Ki;'=';8.0;nM;8.1;;;UO_0000065;10.94;0.22;5.66;3.87;False;CHEMBL942114;Inhibition of BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1140597;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2007;None
CHEMBL263405;;0;514.67;1;2.98;1;CN(C)c1cccc(CNC[C@@H](O)[C@H](Cc2ccccc2)NC(=O)[C@H]2CC(=O)N(Cc3ccccc3)C2)c1;Ki;'=';2194.0;nM;5.66;;;UO_0000065;10.99;0.20;2.68;6.66;False;CHEMBL929344;Inhibition of human BACE1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1145643;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2008;None
CHEMBL411124;;0;515.66;1;2.52;3;CN(C)c1cccc(CNC[C@@H](O)[C@H](Cc2ccccc2)NC(=O)[C@@H]2CN(Cc3ccccc3)C(=O)N2)c1;Ki;'=';284.0;nM;6.55;;;UO_0000065;12.7;0.24;4.03;6.75;False;CHEMBL929344;Inhibition of human BACE1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1145643;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2008;None
CHEMBL431917;;0;577.72;2;1.49;1;CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)OC(C)(C)C)C(O)CC(C)C(=O)NC(C)C(=O)NCc1ccccc1;Ki;'=';22423.0;nM;4.65;;;UO_0000065;8.05;0.15;3.16;2.46;False;CHEMBL655069;Binding affinity for human brain memapsin 2 beta-Secretase (BACE);B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1144924;1;Scientific Literature;J. Med. Chem.;2003;None
CHEMBL305381;;0;605.78;2;2.13;2;CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)OC(C)(C)C)C(O)CC(C)C(=O)NC(C(=O)NCc1ccccc1)C(C)C;Ki;'=';3134.0;nM;5.5;;;UO_0000065;9.09;0.17;3.37;2.91;False;CHEMBL655069;Binding affinity for human brain memapsin 2 beta-Secretase (BACE);B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1144924;1;Scientific Literature;J. Med. Chem.;2003;None
CHEMBL1097334;;0;657.78;1;3.30;3p;CCCN(CCC)C(=O)c1cc(C)cc(C(=O)N[C@@H](Cc2cc(F)cc(F)c2)[C@H](O)[C@H]2CN(S(=O)(=O)c3ccncc3)CCN2)c1;Ki;'=';10.0;nM;8.0;;;UO_0000065;12.16;0.24;4.70;6.06;False;CHEMBL1109071;Inhibition oh BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157894;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL1097335;;0;661.77;1;3.20;3q;CCCN(CCC)C(=O)c1cc(C)cc(C(=O)N[C@@H](Cc2cc(F)cc(F)c2)[C@H](O)[C@H]2CN(S(=O)(=O)c3cnoc3C)CCN2)c1;Ki;'=';53.0;nM;7.28;;;UO_0000065;10.99;0.22;4.08;5.01;False;CHEMBL1109071;Inhibition oh BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157894;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL126079;;0;458.38;2;2.23;1;O=C(O[C@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1cc(O)c(O)c(O)c1)c1cc(O)c(O)c(O)c1;Ki;'=';170.0;nM;6.77;;;UO_0000065;14.77;0.28;4.54;3.43;False;CHEMBL653508;Inhibitory activity against recombinant human Beta-secretase 1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1136344;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2003;None
CHEMBL65981;;0;676.86;2;1.64;4;CC(C)C[C@H](NC(=O)C(CC(N)=O)NC(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)C(O)CC(C)C(=O)NC(C)C(=O)NCc1ccccc1;Ki;'=';61.4;nM;7.21;;;UO_0000065;10.65;0.21;5.57;3.31;True;CHEMBL655069;Binding affinity for human brain memapsin 2 beta-Secretase (BACE);B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1144924;1;Scientific Literature;J. Med. Chem.;2003;None
CHEMBL264379;;0;936.07;3;-0.11;OM00-3;CC(C)C[C@H](NC(=O)[C@@H](N)CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)NC(Cc1ccccc1)C(=O)O)C(C)C;Ki;'=';0.32;nM;9.49;;;UO_0000065;10.14;0.20;9.60;2.57;False;CHEMBL655069;Binding affinity for human brain memapsin 2 beta-Secretase (BACE);B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1144924;1;Scientific Literature;J. Med. Chem.;2003;None
CHEMBL258462;;0;583.66;1;3.54;20;CN(C)c1cccc(CNC[C@@H](O)[C@H](Cc2ccccc2)NC(=O)[C@@H]2CN(Cc3ccc(C(F)(F)F)cc3)C(=O)N2)c1;Ki;'=';4957.0;nM;5.3;;;UO_0000065;9.09;0.17;1.76;5.47;False;CHEMBL929344;Inhibition of human BACE1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1145643;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2008;None
CHEMBL260635;;0;533.65;1;2.66;14;CN(C)c1cccc(CNC[C@@H](O)[C@H](Cc2ccccc2)NC(=O)[C@@H]2CN(Cc3ccc(F)cc3)C(=O)N2)c1;Ki;'=';818.0;nM;6.09;;;UO_0000065;11.41;0.21;3.43;6.28;False;CHEMBL929344;Inhibition of human BACE1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1145643;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2008;None
CHEMBL411237;;0;529.69;1;2.57;6;CN(C)c1cccc(CNC[C@@H](O)[C@H](Cc2ccccc2)NC(=O)[C@@H]2CN(CCc3ccccc3)C(=O)N2)c1;Ki;'=';6800.0;nM;5.17;;;UO_0000065;9.76;0.18;2.60;5.33;False;CHEMBL929344;Inhibition of human BACE1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1145643;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2008;None
CHEMBL409665;;0;425.53;0;0.61;4;CN(C)c1cccc(CNC[C@@H](O)[C@H](Cc2ccccc2)NC(=O)[C@@H]2CNC(=O)N2)c1;Ki;'=';19004.0;nM;4.72;;;UO_0000065;11.09;0.21;4.11;4.47;False;CHEMBL929344;Inhibition of human BACE1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1145643;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2008;None
CHEMBL219601;;0;551.64;1;4.18;1;C[C@@H](NC(=O)c1cc(-c2nnc([C@](C)(N)Cc3ccccc3)o2)cc(N(C)S(C)(=O)=O)c1)c1ccc(F)cc1;Ki;'=';39.81;nM;7.4;;;UO_0000065;13.41;0.26;3.22;5.63;False;CHEMBL902621;Inhibition of BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1138425;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2007;None
CHEMBL1162067;;0;456.57;0;3.39;2;CC(C)C(=O)c1cc(-c2nnc([C@](C)(N)Cc3ccccc3)o2)cc(N(C)S(C)(=O)=O)c1;Ki;'=';16500.0;nM;4.78;;;UO_0000065;10.47;0.20;1.39;4.01;False;CHEMBL902621;Inhibition of BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1138425;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2007;None
CHEMBL302651;;0;764.09;3;5.18;11;CSCCC(NC(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)C(=O)N[C@@H](CC(C)C)C(O)CC(CC(C)C)C(=O)NC(C(=O)NCc1ccccc1)C(C)C;Ki;'=';10491.0;nM;4.98;;;UO_0000065;6.52;0.13;-0.20;2.85;False;CHEMBL655069;Binding affinity for human brain memapsin 2 beta-Secretase (BACE);B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1144924;1;Scientific Literature;J. Med. Chem.;2003;None
CHEMBL98238;;0;704.91;2;2.27;16;CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C;Ki;'=';5.9;nM;8.23;;;UO_0000065;11.67;0.22;5.96;3.77;True;CHEMBL711471;Binding affinity for human brain memapsin 2;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1134775;1;Scientific Literature;J. Med. Chem.;2001;None
CHEMBL154897;;0;563.69;1;1.81;15;CC(=O)OCC[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)C[C@H](NC(=O)CC(C)C)C(=O)O)C(=O)NCC(C)C;Ki;'=';2700.0;nM;5.57;;;UO_0000065;9.88;0.19;3.76;3.25;False;CHEMBL653517;Tested for inhibition of Beta-secretase 1 (BACE 1) expressed in insect cell using baculovirus;B;BAO_0000019;assay format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1147418;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2004;None
CHEMBL463145;NORARTOCARPETIN;0;286.24;0;2.28;1;O=c1cc(-c2ccc(O)cc2O)oc2cc(O)cc(O)c12;Ki;'=';82600.0;nM;4.08;;;UO_0000065;14.26;0.27;1.80;3.67;False;CHEMBL1771832;Noncompetitive inhibition of human recombinant BACE-1 by Dixon plot analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1770081;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2011;None
CHEMBL387771;;0;701.93;1;3.77;5d, GRL-7234;CC(C)C[C@H](NC(=O)c1cc(C(=O)N[C@H](C)c2ccccc2)cc(N(C)S(C)(=O)=O)c1)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NC(C)C)C(C)C;Ki;'=';1.1;nM;8.96;;;UO_0000065;12.76;0.25;5.19;5.15;False;CHEMBL915132;Inhibition of recombinant memapsin 2;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1139858;1;Scientific Literature;J. Med. Chem.;2007;None
CHEMBL360361;;0;700.88;2;1.67;3a;CC(C)C[C@H](NC(=O)[C@@H]1CC(=O)NC/C=C/COC(=O)N[C@@H](C(C)C)C(=O)N1)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C;Ki;'=';87.2;nM;7.06;;;UO_0000065;10.07;0.19;5.39;3.46;False;CHEMBL828805;Binding affinity for human brain memapsin 2;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1145144;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2005;None
CHEMBL78946;;0;893.01;3;-1.74;1;CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(=O)O)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O;Ki;'=';1.6;nM;8.8;;;UO_0000065;9.85;0.19;10.54;2.34;True;CHEMBL945886;Binding affinity to recombinant memapsin 2;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1141466;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2008;None
CHEMBL591428;;0;582.7;1;3.14;1;C[C@@H](NC(=O)c1cc(NS(C)(=O)=O)cc(C(=O)N[C@@H](Cc2ccccc2)[C@@H](O)CNC2CC2)c1)c1ccc(F)cc1;Ki;'=';10.0;nM;8.0;;;UO_0000065;13.73;0.27;4.86;5.86;False;CHEMBL1045676;Inhibition of human recombinant BACE1 by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1154184;1;Scientific Literature;J. Med. Chem.;2009;None
CHEMBL78946;;0;893.01;3;-1.74;OM99-2;CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(=O)O)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O;Ki;'=';1.6;nM;8.8;;;UO_0000065;9.85;0.19;10.54;2.34;True;CHEMBL827180;Binding affinity against Beta-secretase;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1137865;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2004;None
CHEMBL183214;;0;935.08;3;0.98;OM00-3;CC(C)C[C@H](NC(=O)[C@@H](N)CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)C[C@@H](Cc1ccccc1)C(=O)O)C(C)C;Ki;'=';0.32;nM;9.49;;;UO_0000065;10.15;0.20;8.51;2.65;False;CHEMBL827180;Binding affinity against Beta-secretase;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1137865;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2004;None
CHEMBL66595;;0;622.87;1;4.01;8;CSCCC(NC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(O)CC(C)C(=O)NC(C(=O)NCc1ccccc1)C(C)C;Ki;'=';5808.0;nM;5.24;;;UO_0000065;8.41;0.17;1.23;3.59;False;CHEMBL827180;Binding affinity against Beta-secretase;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1137865;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2004;None
CHEMBL126142;;0;442.38;1;2.53;3;O=C(O[C@H]1Cc2c(O)cc(O)cc2O[C@H]1c1ccc(O)c(O)c1)c1cc(O)c(O)c(O)c1;Ki;'=';5300.0;nM;5.28;;;UO_0000065;11.93;0.23;2.75;2.98;False;CHEMBL653508;Inhibitory activity against recombinant human Beta-secretase 1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1136344;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2003;None
CHEMBL3401340;;0;482.61;1;5.00;2;C[C@@]1(c2ccc3sccc3c2)CC(=O)N(Cc2cccc(C(=O)NCc3ccccc3)c2)C(=N)N1;Ki;'=';3821.0;nM;5.42;;;UO_0000065;11.23;0.21;0.42;6.35;False;CHEMBL3406560;Inhibition of BACE1 (unknown origin);B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3400110;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;None
CHEMBL3627965;;0;462.38;0;3.86;12a;CC(=O)Nc1c(Cl)cc(CN/C(N)=N/C(=O)[C@@H]2CCCN2c2ccc(C)cc2)cc1Cl;Ki;'=';3400.0;nM;5.47;;;UO_0000065;11.83;0.24;1.61;5.48;False;CHEMBL3630426;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 6.4 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL1097336;;0;691.87;1;3.97;3r;CCCN(CCC)C(=O)c1cc(C)cc(C(=O)N[C@@H](Cc2cc(F)cc(F)c2)[C@H](O)[C@H]2CN(S(=O)(=O)c3sc(C)nc3C)CCN2)c1;Ki;'=';240.0;nM;6.62;;;UO_0000065;9.57;0.19;2.65;5.02;False;CHEMBL1109071;Inhibition oh BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157894;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL591371;;0;928.07;2;5.82;2a;CC(C)[C@H](NC(=O)[C@@H](C[C@H](O)[C@H](COc1cc(F)cc(F)c1)NC(=O)c1cc(C(=O)N[C@H](C)c2ccccc2)cc(N(C)S(C)(=O)=O)c1)OCc1ccccc1)C(=O)NCc1ccccc1;Ki;'=';20.0;nM;7.7;;;UO_0000065;8.3;0.16;1.88;4.00;False;CHEMBL1069651;Inhibition of human BACE1 expressed in Escherichia coli BL21(DE3) by resolved fluorescence assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1156935;1;Scientific Literature;Bioorg. Med. Chem.;2010;None
CHEMBL601521;;0;835.97;2;5.28;2g;CO[C@H](CC[C@H](COc1cc(F)cc(F)c1)NC(=O)c1cc(C(=O)N[C@H](C)c2ccccc2)cc(N(C)S(C)(=O)=O)c1)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C;Ki;'=';130.0;nM;6.89;;;UO_0000065;8.24;0.16;1.61;4.00;False;CHEMBL1069651;Inhibition of human BACE1 expressed in Escherichia coli BL21(DE3) by resolved fluorescence assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1156935;1;Scientific Literature;Bioorg. Med. Chem.;2010;None
CHEMBL97631;;0;577.72;2;1.49;5;CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)OC(C)(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)NCc1ccccc1;Ki;'=';22423.0;nM;4.65;;;UO_0000065;8.05;0.15;3.16;2.46;False;CHEMBL1931877;Inhibition of human recombinant BACE1 ectodomain (1 to 460 amino acids) assessed as inhibition of proteolytic cleavage of Rhodamine-EVNLDAEFK-Quencher substrate after 35 mins by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1926578;1;Scientific Literature;J. Med. Chem.;2011;None
CHEMBL2012000;;0;374.27;0;4.26;17a;CN1C(=N)NC(c2cccc(-c3cc(Cl)cc(Cl)c3)c2)(C2CC2)C1=O;Ki;'=';30.0;nM;7.52;;;UO_0000065;20.1;0.41;3.26;13.39;False;CHEMBL2015090;Inhibition of human BACE1 using QSY7EISEVNLDAEFC-Eu-amide as substrate incubated for 30 mins prior to substrate addition measured after 90 mins by FRET analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2010674;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2012;None
CHEMBL2012070;;0;344.42;0;2.72;24;CC#Cc1cncc(-c2cccc([C@@]3(C4CC4)NC(=N)N(C)C3=O)c2)c1;Ki;'=';5.4;nM;8.27;;;UO_0000065;24.0;0.43;5.55;11.97;False;CHEMBL2015090;Inhibition of human BACE1 using QSY7EISEVNLDAEFC-Eu-amide as substrate incubated for 30 mins prior to substrate addition measured after 90 mins by FRET analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2010674;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2012;None
CHEMBL260173;;0;545.68;1;2.40;7;CN(C)c1cccc(CNC[C@@H](O)[C@H](Cc2ccccc2)NC(=O)[C@@H]2CN(CCOc3ccccc3)C(=O)N2)c1;Ki;'=';3514.0;nM;5.45;;;UO_0000065;10.0;0.19;3.05;5.14;False;CHEMBL929344;Inhibition of human BACE1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1145643;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2008;None
CHEMBL78946;;0;893.01;3;-1.74;1;CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(=O)O)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O;Ki;'=';1600.0;nM;;Potential transcription error;;UO_0000065;;;;;True;CHEMBL653514;Binding affinity towards Beta-secretase 1 expressed in HEK293 (Human Embryonic Kidney) cells;B;BAO_0000219;cell-based format;None;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1146698;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2004;CHEMBL3307715
CHEMBL273916;;0;640.84;1;2.30;3;CC(C)C[C@H](NC(=O)[C@H](CS(C)(=O)=O)NC(=O)OC(C)(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C;Ki;'=';1129.0;nM;5.95;;;UO_0000065;9.28;0.18;3.65;3.30;True;CHEMBL942114;Inhibition of BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1140597;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2007;None
CHEMBL2178171;;0;424.89;0;4.20;19c;C=Cc1cc(Cl)cc(CN/C(N)=N/C(=O)c2c(-c3ccc(OC)cc3)noc2C)c1;Ki;'=';430.0;nM;6.37;;;UO_0000065;14.98;0.29;2.17;6.20;False;CHEMBL2187886;Displacement of [3H]BMS-599240 from BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177026;1;Scientific Literature;J. Med. Chem.;2012;CHEMBL3307715
CHEMBL254740;;0;659.85;1;1.90;2;Cc1nc(COC(=O)N[C@@H](CS(C)(=O)=O)C(=O)N[C@@H](CC(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NC(C)(C)C)C(C)C)c(C)o1;Ki;'=';0.12;nM;9.92;;;UO_0000065;15.03;0.30;8.02;4.82;False;CHEMBL945886;Binding affinity to recombinant memapsin 2;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1141466;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2008;None
CHEMBL244342;;0;418.54;0;3.86;1;CN(C(=O)CCN1Cc2cc(C(=O)c3ccccc3)ccc2N=C1N)C1CCCCC1;Ki;'=';900.0;nM;6.05;;;UO_0000065;14.44;0.27;2.19;7.65;False;CHEMBL895728;Inhibition of BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1148753;1;Scientific Literature;J. Med. Chem.;2007;None
CHEMBL182892;;0;728.93;2;2.45;48;CC(C)C[C@H](NC(=O)[C@@H]1CC(=O)NC/C=C/CCCOC(=O)N[C@@H](C(C)C)C(=O)N1)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C;Ki;'=';14.0;nM;7.85;;;UO_0000065;10.77;0.21;5.40;3.85;False;CHEMBL981021;Inhibition of recombinant memapsin 2;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1153435;1;Scientific Literature;J. Med. Chem.;2009;None
CHEMBL293611;;0;722.01;2;4.15;9;CSCCC(NC(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)C(=O)N[C@@H](CC(C)C)C(O)CC(C)C(=O)NC(C(=O)NCc1ccccc1)C(C)C;Ki;'=';2.5;nM;8.6;;;UO_0000065;11.91;0.23;4.45;4.92;False;CHEMBL827180;Binding affinity against Beta-secretase;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1137865;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2004;None
CHEMBL363255;;0;979.1;3;-1.59;BACE Inhibitor 13 OM00-3;CC(C)C[C@H](NC(=O)[C@@H](N)CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)C(O)CN[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C;Ki;'=';0.3;nM;9.52;;;UO_0000065;9.73;0.19;11.11;2.39;False;CHEMBL828263;Binding affinity towards Beta-secretase determined using continuum electrostatics solvation;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1137231;1;Scientific Literature;J. Med. Chem.;2004;None
CHEMBL403269;;0;658.82;1;4.07;25;COc1cccc(CNC[C@@H](O)[C@H](Cc2ccccc2)NC(=O)c2cc(C(=O)N[C@@H](C)c3ccccc3)cc(N(C)S(C)(=O)=O)c2)c1;Ki;'=';617.0;nM;6.21;;;UO_0000065;9.43;0.18;2.14;4.53;False;CHEMBL945886;Binding affinity to recombinant memapsin 2;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1141466;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2008;None
CHEMBL453642;LEACHIANONE A;0;438.52;1;5.61;5;C=C(C)[C@H](CC=C(C)C)Cc1c(O)cc(O)c2c1O[C@H](c1ccc(O)cc1OC)CC2=O;Ki;'=';3900.0;nM;5.41;;;UO_0000065;12.33;0.23;-0.20;5.62;False;CHEMBL946249;Inhibition of human BACE1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1155037;1;Scientific Literature;Bioorg. Med. Chem.;2008;None
CHEMBL1097344;;0;809.96;1;4.06;3z;Cc1cccc(S(=O)(=O)N2CCN[C@@H]([C@@H](O)[C@H](Cc3cc(F)cc(F)c3)NC(=O)c3cc(C(=O)N[C@H](C)c4ccccc4)cc(N4CCCCS4(=O)=O)c3)C2)c1;Ki;'=';1.0;nM;9.0;;;UO_0000065;11.11;0.22;4.94;5.45;False;CHEMBL1109071;Inhibition oh BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157894;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL1097350;;0;671.77;1;2.28;3gg;COC[C@H]1CCCN1C(=O)c1cc(C)cc(C(=O)N[C@@H](Cc2cc(F)cc(F)c2)[C@H](O)[C@H]2CN(S(=O)(=O)c3ccccn3)CCN2)c1;Ki;'=';2.0;nM;8.7;;;UO_0000065;12.95;0.25;6.42;6.16;False;CHEMBL1109071;Inhibition oh BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157894;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL1097342;;0;684.81;1;3.20;3x;COC[C@H]1CCCN1C(=O)c1cc(C)cc(C(=O)N[C@@H](Cc2cc(F)cc(F)c2)[C@H](O)[C@H]2CN(S(=O)(=O)c3cccc(C)c3)CCN2)c1;Ki;'=';0.8;nM;9.1;;;UO_0000065;13.28;0.26;5.90;7.09;False;CHEMBL1109071;Inhibition oh BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157894;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL1097324;;0;691.24;1;4.55;3f;CCCN(CCC)C(=O)c1cc(C)cc(C(=O)N[C@@H](Cc2cc(F)cc(F)c2)[C@H](O)[C@H]2CN(S(=O)(=O)c3cccc(Cl)c3)CCN2)c1;Ki;'=';7.0;nM;8.15;;;UO_0000065;11.8;0.24;3.60;6.85;False;CHEMBL1109071;Inhibition oh BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157894;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL441728;;0;529.69;1;2.91;8;CN(C)c1cccc(CNC[C@@H](O)[C@H](Cc2ccccc2)NC(=O)[C@]2(C)CN(Cc3ccccc3)C(=O)N2)c1;Ki;'=';6768.0;nM;5.17;;;UO_0000065;9.76;0.18;2.26;5.33;False;CHEMBL929344;Inhibition of human BACE1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1145643;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2008;None
CHEMBL1934195;;0;368.43;1;5.62;31;COc1c2occc2c(OC/C=C(\C)CCC=C(C)C)c2ccc(=O)oc12;Ki;'=';13700.0;nM;4.86;;;UO_0000065;13.2;0.25;-0.76;7.87;False;CHEMBL1937035;Inhibition of recombinant human BACE1 assessed as dissociation constant of enzyme-substrate-inhibitor complex using Rh-EVNLDAEFK as substrate by Dixon and Cornish-Bowden plots analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1932923;1;Scientific Literature;Bioorg. Med. Chem.;2012;None
CHEMBL66595;;0;622.87;1;4.01;8;CSCCC(NC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(O)CC(C)C(=O)NC(C(=O)NCc1ccccc1)C(C)C;Ki;'=';5808.0;nM;5.24;;;UO_0000065;8.41;0.17;1.23;3.59;True;CHEMBL655069;Binding affinity for human brain memapsin 2 beta-Secretase (BACE);B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1144924;1;Scientific Literature;J. Med. Chem.;2003;None
CHEMBL2063197;;0;498.63;1;6.38;3c;CN(C(=O)OC[C@@H](c1ccccc1)N1Cc2cc(Oc3ccccc3)ccc2N=C1N)C1CCCCC1;Ki;'=';783.0;nM;6.11;;;UO_0000065;12.25;0.23;-0.27;7.60;False;CHEMBL2067011;Inhibition of recombinant beta-secretase 1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2062429;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2012;None
CHEMBL2063200;;0;506.65;2;5.44;3f;CN(C(=O)OC[C@@H](C1CCCOC1)N1Cc2cc(Oc3ccccc3)ccc2N=C1N)C1CCCCC1;Ki;'=';104.0;nM;6.98;;;UO_0000065;13.78;0.26;1.54;7.79;False;CHEMBL2067011;Inhibition of recombinant beta-secretase 1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2062429;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2012;None
CHEMBL273916;;0;640.84;1;2.30;14;CC(C)C[C@H](NC(=O)[C@H](CS(C)(=O)=O)NC(=O)OC(C)(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C;Ki;'=';1129.0;nM;5.95;;;UO_0000065;9.28;0.18;3.65;3.30;True;CHEMBL711471;Binding affinity for human brain memapsin 2;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1134775;1;Scientific Literature;J. Med. Chem.;2001;None
CHEMBL244347;;0;502.7;2;6.76;3a;CN(C(=O)CC[C@@H](C1CCCCC1)N1Cc2cc(Oc3ccccc3)ccc2N=C1N)C1CCCCC1;Ki;'=';11.0;nM;7.96;;;UO_0000065;15.83;0.29;1.20;11.18;False;CHEMBL895728;Inhibition of BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1148753;1;Scientific Literature;J. Med. Chem.;2007;None
CHEMBL365195;;0;764.09;3;5.18;BACE Inhibitor 11;CSCCC(NC(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)C(=O)N[C@@H](CC(C)C)C(O)CC(CC(C)C)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C;Ki;'=';10491.0;nM;4.98;;;UO_0000065;6.52;0.13;-0.20;2.85;False;CHEMBL828263;Binding affinity towards Beta-secretase determined using continuum electrostatics solvation;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1137231;1;Scientific Literature;J. Med. Chem.;2004;None
CHEMBL2178185;;0;536.44;1;4.51;17k;COc1ccc(-c2noc(C)c2C(=O)/N=C(\N)NCc2cc(Cl)c(NC(=O)CSC)c(Cl)c2)cc1;Ki;'=';50.0;nM;7.3;;;UO_0000065;13.61;0.28;2.79;5.54;False;CHEMBL2187886;Displacement of [3H]BMS-599240 from BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177026;1;Scientific Literature;J. Med. Chem.;2012;CHEMBL3307715
CHEMBL78946;;0;893.01;3;-1.74;1;CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(=O)O)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O;Ki;'=';1.6;nM;8.8;;;UO_0000065;9.85;0.19;10.54;2.34;True;CHEMBL2185575;Inhibition of BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177024;1;Scientific Literature;J. Med. Chem.;2012;None
CHEMBL2179130;;0;649.86;1;4.05;4;CC[C@H](NC[C@H](Cc1ccccc1)NC(=O)c1cc(C(=O)N[C@H](C)c2ccccc2)cc(N(C)S(C)(=O)=O)c1)C(=O)NCC(C)C;Ki;'=';27.12;nM;7.57;;;UO_0000065;11.64;0.22;3.52;5.53;False;CHEMBL2185581;Inhibition of recombinant BACE1 expressed in Escherichia coli using Arg- Glu(EDANS)-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys(Dabcyl)-Arg as substrate by fluorimetric analysis;B;BAO_0000019;assay format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177024;1;Scientific Literature;J. Med. Chem.;2012;None
CHEMBL182892;;0;728.93;2;2.45;3c;CC(C)C[C@H](NC(=O)[C@@H]1CC(=O)NC/C=C/CCCOC(=O)N[C@@H](C(C)C)C(=O)N1)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C;Ki;'=';31.0;nM;7.51;;;UO_0000065;10.3;0.20;5.06;3.68;False;CHEMBL828805;Binding affinity for human brain memapsin 2;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1145144;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2005;None
CHEMBL3896894;;0;470.43;0;1.20;BDBM199111;CN1C(=N)N[C@]2(c3cc(NC(=O)c4cnc(C(F)F)cn4)ccc3F)COC[C@@H]2S1(=O)=O;Ki;'=';999.0;nM;6.0;;354117;UO_0000065;12.76;0.26;4.80;4.37;False;CHEMBL3887768;Homogeneous Time-Resolved FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 u) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886448;37;BindingDB Database;;2015;None
CHEMBL1231280;;0;535.78;2;6.32;1;CCC[C@H]1CN(Cc2ccc(CN3C(=N)N[C@](CCC4CCCCC4)(CC4CCCCC4)C3=O)cc2)C(=O)N1;Ki;'=';27.0;nM;7.57;;;UO_0000065;14.13;0.27;1.25;8.55;False;CHEMBL3386389;Inhibition of purified human BACE1 by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3352601;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2014;None
CHEMBL3354254;;0;452.64;0;4.39;45;CN1C(=N)N[C@](CCC2CCCCC2)(C[C@H]2CCC[C@@H](NC(=O)Cc3ccccc3)C2)C1=O;Ki;'=';585.0;nM;6.23;;;UO_0000065;13.77;0.26;1.84;7.31;False;CHEMBL3386389;Inhibition of purified human BACE1 by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3352601;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2014;None
CHEMBL3354247;;0;416.61;0;3.90;38;CN1C(=N)N[C@](CCC2CCCCC2)(C[C@H]2CCN(C(=O)CC3CCCC3)C2)C1=O;Ki;'=';640.0;nM;6.19;;;UO_0000065;14.87;0.28;2.29;8.10;False;CHEMBL3386389;Inhibition of purified human BACE1 by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3352601;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2014;None
CHEMBL95429;;0;605.78;2;2.13;13;CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)OC(C)(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C;Ki;'=';3134.0;nM;5.5;;;UO_0000065;9.09;0.17;3.37;2.91;True;CHEMBL711471;Binding affinity for human brain memapsin 2;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1134775;1;Scientific Literature;J. Med. Chem.;2001;None
CHEMBL1097352;;0;674.77;1;1.62;3ii;COC[C@H]1CCCN1C(=O)c1cc(C)cc(C(=O)N[C@@H](Cc2cc(F)cc(F)c2)[C@H](O)[C@H]2CN(S(=O)(=O)c3cn(C)cn3)CCN2)c1;Ki;'=';2.0;nM;8.7;;;UO_0000065;12.89;0.25;7.08;5.95;False;CHEMBL1109071;Inhibition oh BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157894;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL187614;;0;722.01;2;4.15;BACE Inhibitor 9;CSCCC(NC(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)C(=O)N[C@@H](CC(C)C)C(O)CC(C)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C;Ki;'=';2.5;nM;8.6;;;UO_0000065;11.91;0.23;4.45;4.92;False;CHEMBL828263;Binding affinity towards Beta-secretase determined using continuum electrostatics solvation;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1137231;1;Scientific Literature;J. Med. Chem.;2004;None
CHEMBL1097281;;0;558.72;2;6.00;Cis-17;NC1=Nc2ccc3cc2CN1[C@H](C1CCCCC1)CCC(=O)N([C@H]1CC[C@@H](C(=O)O)CC1)CCc1cccc(c1)O3;Ki;'=';20.0;nM;7.7;;;UO_0000065;13.78;0.26;1.70;7.10;False;CHEMBL1103872;Inhibition of BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157115;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL603119;;0;830.02;1;4.02;1e;CO[C@H](C[C@H](O)[C@H](COc1ccccc1)NC(=O)c1cc(C(=O)N[C@H](C)c2ccccc2)cc(N(C)CS(C)(=O)=O)c1)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C;Ki;'=';9.0;nM;8.05;;;UO_0000065;9.69;0.19;4.03;4.18;False;CHEMBL1072341;Inhibition of human BACE1 expressed in Escherichia coli cells (BL21(DE3) by TRF assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157542;1;Scientific Literature;J. Med. Chem.;2010;None
CHEMBL253103;;0;580.75;1;3.27;27;CC(C)NC[C@@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc(C(=O)N[C@H](C)c2ccccc2)cc(N(C)S(C)(=O)=O)c1;Ki;'=';425.0;nM;6.37;;;UO_0000065;10.97;0.21;3.10;4.98;False;CHEMBL945886;Binding affinity to recombinant memapsin 2;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1141466;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2008;None
CHEMBL78946;;0;893.01;3;-1.74;OMM99-2;CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(=O)O)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O;Ki;'=';1600.0;nM;;Potential transcription error;;UO_0000065;;;;;True;CHEMBL963290;Inhibition of BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1153267;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2009;None
CHEMBL3931049;;0;523.92;1;4.29;BDBM243002;CN1C(=N)N[C@](C)(c2sc(-c3nnc(-c4ccc(C(F)(F)F)c(F)c4)o3)cc2Cl)CS1(=O)=O;Ki;'=';155.9;nM;6.81;;423883;UO_0000065;12.99;0.28;2.52;6.07;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL1923707;;0;399.47;1;5.89;20;CC(C)(C)Nc1c(-c2ccc(-c3nc4ccc(F)cc4[nH]3)cc2)nc2ccccn12;Ki;'=';2389.0;nM;5.62;;;UO_0000065;14.07;0.26;-0.27;9.69;False;CHEMBL1926456;Inhibition of BACE1 expressing APP Swedish mutant using rhodamine-labeled EVNLDAEFK-quencher as substrate after 60 mins by Michaelis-Menten equation;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1921672;1;Scientific Literature;J. Med. Chem.;2011;None
CHEMBL1923708;;0;411.51;1;5.76;21;COc1ccc2nc(-c3ccc(-c4nc5ccccn5c4NC(C)(C)C)cc3)[nH]c2c1;Ki;'=';2160.0;nM;5.67;;;UO_0000065;13.77;0.25;-0.09;8.43;False;CHEMBL1926456;Inhibition of BACE1 expressing APP Swedish mutant using rhodamine-labeled EVNLDAEFK-quencher as substrate after 60 mins by Michaelis-Menten equation;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1921672;1;Scientific Literature;J. Med. Chem.;2011;None
CHEMBL227758;;0;687.9;1;3.21;5c;CC(C)C[C@H](NC(=O)c1cc(C(=O)NCc2ccccc2)cc(N(C)S(C)(=O)=O)c1)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NC(C)C)C(C)C;Ki;'=';136.0;nM;6.87;;;UO_0000065;9.98;0.20;3.66;3.95;False;CHEMBL915132;Inhibition of recombinant memapsin 2;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1139858;1;Scientific Literature;J. Med. Chem.;2007;None
CHEMBL390456;;0;936.07;3;-0.11;2, OM00-3;CC(C)C[C@H](NC(=O)[C@@H](N)CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C;Ki;'=';0.3;nM;9.52;;;UO_0000065;10.17;0.20;9.63;2.57;True;CHEMBL1931877;Inhibition of human recombinant BACE1 ectodomain (1 to 460 amino acids) assessed as inhibition of proteolytic cleavage of Rhodamine-EVNLDAEFK-Quencher substrate after 35 mins by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1926578;1;Scientific Literature;J. Med. Chem.;2011;None
CHEMBL219601;;0;551.64;1;4.18;1;C[C@@H](NC(=O)c1cc(-c2nnc([C@](C)(N)Cc3ccccc3)o2)cc(N(C)S(C)(=O)=O)c1)c1ccc(F)cc1;Ki;'=';42.4;nM;7.37;;;UO_0000065;13.36;0.26;3.19;5.61;False;CHEMBL902621;Inhibition of BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1138425;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2007;None
CHEMBL362592;;0;730.95;2;2.68;2c;CC(C)C[C@H](NC(=O)[C@@H]1CC(=O)NCCCCCCOC(=O)N[C@@H](C(C)C)C(=O)N1)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C;Ki;'=';25.1;nM;7.6;;;UO_0000065;10.4;0.20;4.92;3.72;False;CHEMBL828805;Binding affinity for human brain memapsin 2;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1145144;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2005;None
CHEMBL361727;;0;622.87;1;4.01;BACE Inhibitor 8;CSCCC(NC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(O)CC(C)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C;Ki;'=';58.8;nM;7.23;;;UO_0000065;11.61;0.23;3.22;4.96;False;CHEMBL828263;Binding affinity towards Beta-secretase determined using continuum electrostatics solvation;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1137231;1;Scientific Literature;J. Med. Chem.;2004;None
CHEMBL456228;;0;496.38;2;4.81;7;Oc1cc(O)cc(Oc2c(O)cc(O)c3c2Oc2c(O)cc(Oc4c(O)cc(O)cc4O)cc2O3)c1;Ki;'=';7200.0;nM;5.14;;;UO_0000065;10.36;0.20;0.33;2.59;False;CHEMBL1117924;Noncompetitive inhibition of human recombinant BACE1 after 60 mins by Dixon plot analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1155522;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL411917;;0;550.65;1;3.86;23;CC(C)c1cccc(CNC[C@@H](O)[C@H](Cc2ccccc2)NC(=O)[C@@H]2CN(Cc3cc(F)cc(F)c3)C(=O)N2)c1;Ki;'=';18.0;nM;7.75;;;UO_0000065;14.06;0.26;3.88;8.27;False;CHEMBL929344;Inhibition of human BACE1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1145643;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2008;None
CHEMBL509210;;0;620.74;1;4.24;1;CCCN(CCC)C(=O)c1cc(C)cc(C(=O)N[C@@H](Cc2cc(F)cc(F)c2)[C@H](O)[C@@H]2NCCN(Cc3ccccc3)C2=O)c1;Ki;'=';3.0;nM;8.52;;;UO_0000065;13.73;0.26;4.28;8.36;False;CHEMBL1109071;Inhibition oh BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157894;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL3797680;;0;431.52;0;1.91;16;CSc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3ccc(C#N)s3)C2)nc(C)c1F;Ki;'=';45.0;nM;7.35;;;UO_0000065;17.03;0.35;5.44;6.74;False;CHEMBL3801550;Inhibition of recombinant human BACE1 preincubated for 30 mins followed QSY7EISEVNLDAEFC-Eu-amide substrate addition measured after 90 mins by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3797133;1;Scientific Literature;J. Med. Chem.;2016;None
CHEMBL1078442;BERGAMOTTIN;0;338.4;1;5.61;18, bergamottin;CC(C)=CCC/C(C)=C/COc1c2ccoc2cc2oc(=O)ccc12;Ki;'=';700.0;nM;6.16;;;UO_0000065;18.19;0.34;0.54;11.71;False;CHEMBL1937035;Inhibition of recombinant human BACE1 assessed as dissociation constant of enzyme-substrate-inhibitor complex using Rh-EVNLDAEFK as substrate by Dixon and Cornish-Bowden plots analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1932923;1;Scientific Literature;Bioorg. Med. Chem.;2012;None
CHEMBL3672920;;0;405.46;0;1.80;BDBM143223;Cc1ccc(C(=O)Nc2ccc(F)c([C@]3(C)CS(=O)(=O)N(C)C(=N)N3)c2)nc1;Ki;'=';3.0;nM;8.52;;279436;UO_0000065;21.02;0.42;6.72;7.40;True;CHEMBL3706083;Homogeneous Time-Resolved FRET Assay: The protocol that was used to determine the recited values isdescribed as follows.BACE1 HTRF FRET AssayReagentsNa+-Acetate pH 5.01% Brij-35GlycerolDimethyl Sulfoxide (DMSO)Recombinant human soluble BACE1 catalytic domain (>95% pure)APP Swedish mutant peptide substrate (QSY7-APPswe-Eu):QSY7-EISEVNLDAEFC-Europium-amideA homogeneous time-resolved FRET assay was used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitored the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contained an N-terminal QSY7 moiety that served as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence was low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638453;37;BindingDB Database;;2015;None
CHEMBL3650845;;0;428.88;0;2.72;BDBM149936;CC1(C)Oc2ccc(NC(=O)c3ccc(Cl)cn3)cc2[C@@]2(COC(N)=N2)C12COC2;Ki;'=';10.3;nM;7.99;;288585;UO_0000065;18.62;0.36;5.27;7.39;True;CHEMBL3705666;Fluorescence Resonance Energy Transfer (FRET) Assay: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638878;37;BindingDB Database;;2015;None
CHEMBL3703233;;0;412.42;0;2.20;BDBM149750;CC1(C)Oc2ccc(NC(=O)c3ccc(F)cn3)cc2C2(COC(N)=N2)C12COC2;Ki;'=';117.0;nM;6.93;;288421;UO_0000065;16.81;0.32;4.73;6.41;True;CHEMBL3705666;Fluorescence Resonance Energy Transfer (FRET) Assay: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638878;37;BindingDB Database;;2015;None
CHEMBL3923725;;0;499.57;0;1.77;BDBM249098;CC#CCOc1ccc(C(=O)Nc2ccc(F)c([C@]3(C)CS(=O)(=O)C4(CN(C)C4)C(=N)N3)c2)nc1;Ki;'=';2.3;nM;8.64;;434636;UO_0000065;17.29;0.34;6.87;6.94;False;CHEMBL3889105;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 ul of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 ul in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window. Inhibitor IC50 values are derived from non-linear regression analysis of concentration response curves. Ki values are then calculated from IC50 values using the Cheng-Prusoff equation using a previously determined um value of 8 uM for the QSY7-APPswe-Eu substrate at BACE1.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886943;37;BindingDB Database;;2016;None
CHEMBL3901537;;0;432.47;0;1.70;BDBM249113;CN1CCC2(CC1)C(=N)N[C@](C)(c1cc(NC(=O)C(F)F)ccc1F)CS2(=O)=O;Ki;'=';1710.0;nM;5.77;;434651;UO_0000065;13.34;0.27;4.07;5.63;False;CHEMBL3889105;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 ul of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 ul in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window. Inhibitor IC50 values are derived from non-linear regression analysis of concentration response curves. Ki values are then calculated from IC50 values using the Cheng-Prusoff equation using a previously determined um value of 8 uM for the QSY7-APPswe-Eu substrate at BACE1.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886943;37;BindingDB Database;;2016;None
CHEMBL2151180;;0;338.44;0;2.78;15;CC#Cc1cncc(-c2cc([C@]3(C)CC(=O)N(C)C(=N)N3)cs2)c1;Ki;'=';47.0;nM;7.33;;;UO_0000065;21.65;0.42;4.55;10.61;False;CHEMBL2155063;Inhibition of human recombinant BACE1 by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2150878;1;Scientific Literature;ACS Med. Chem. Lett.;2012;None
CHEMBL2151140;;0;324.41;0;2.89;12;CN1C(=N)N[C@](C)(c2csc(-c3cccc(C#N)c3)c2)CC1=O;Ki;'=';210.0;nM;6.68;;;UO_0000065;20.58;0.40;3.79;8.35;False;CHEMBL2155063;Inhibition of human recombinant BACE1 by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2150878;1;Scientific Literature;ACS Med. Chem. Lett.;2012;None
CHEMBL603121;;0;732.85;1;3.61;1g;CO[C@H](C[C@H](O)[C@H](COc1cc(F)cc(F)c1)NC(=O)c1cc(C(=O)N[C@H](C)c2ccccc2)cc(N(C)CS(C)(=O)=O)c1)C(=O)NCC(C)C;Ki;'=';400.0;nM;6.4;;;UO_0000065;8.73;0.17;2.79;3.92;False;CHEMBL1072341;Inhibition of human BACE1 expressed in Escherichia coli cells (BL21(DE3) by TRF assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157542;1;Scientific Literature;J. Med. Chem.;2010;None
CHEMBL589644;;0;922.94;1;4.92;1a;CO[C@H](C[C@H](O)[C@H](COCc1ccc(Br)cc1)NC(=O)c1cc(C(=O)N[C@H](C)c2ccccc2)cc(N(C)CS(C)(=O)=O)c1)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C;Ki;'=';60.0;nM;7.22;;;UO_0000065;7.82;0.16;2.30;3.75;False;CHEMBL1072341;Inhibition of human BACE1 expressed in Escherichia coli cells (BL21(DE3) by TRF assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157542;1;Scientific Literature;J. Med. Chem.;2010;None
CHEMBL3946380;;0;434.34;0;4.34;BDBM234460;C[C@]1(F)CC(F)(F)[C@@](C)(c2cc(NC(=O)c3coc(C(F)F)n3)ccc2F)N=C1N;Ki;'=';28.0;nM;7.55;;408776;UO_0000065;17.39;0.34;3.21;8.08;False;CHEMBL3888549;SPA-Based Assay: The binding assay was performed as SPA-based assay using a biotinylated form of human BACE1 recombinantly expressed and subsequently purified from Freestyle HEK293 cells. The binding assay was run in a 50 mM sodium acetate buffer, pH 4.5 containing 50 mM NaCl and 0.03% Tween-20 in white clear bottom 384 plates (Corning #3653). 10 nM (final concentration) radioligand ([3H]-N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N-((R)-1-phenyl-ethyl)-isophthalamide) (TRQ11569 purchased from GE Healthcare) was mixed with test compound at a given concentration, 6 nM (final concentration) human BACE1 and 25 μg Streptavidin coated PVT core SPA beads (RPNQ0007, GE Healthcare Life Sciences) in a total volume of 40 μl.;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886758;37;BindingDB Database;;2016;CHEMBL3307715
CHEMBL3985208;;0;499.4;0;4.30;BDBM190714;C[C@@]1(c2cc(NC(=O)c3ncc(Cl)cc3Cl)ccc2F)CS(=O)(=O)C2(CCCC2)C(=N)N1;Ki;'=';2.7;nM;8.57;;341209;UO_0000065;17.16;0.37;4.27;7.65;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3909483;;0;437.52;0;2.45;BDBM190719;C[C@@]1(c2cc(NC(=O)c3cnsn3)ccc2F)CS(=O)(=O)C2(CCCC2)C(=N)N1;Ki;'=';108.0;nM;6.97;;341214;UO_0000065;15.92;0.33;4.52;5.58;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3912921;;0;443.95;0;3.36;BDBM190757;C[C@@]1(c2sc(-c3cncc(F)c3)cc2Cl)CS(=O)(=O)C2(CCOCC2)C(=N)N1;Ki;'=';260.0;nM;6.58;;341249;UO_0000065;14.83;0.32;3.23;7.15;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3640252;;0;382.44;0;1.60;BDBM102934;CCc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3ccccc3)C2)nc(C)c1F;Ki;'=';61.0;nM;7.21;;220582;UO_0000065;18.86;0.35;5.61;8.23;False;CHEMBL3705045;Time-Resolved FRET Assay: A homogeneous time-resolved FRET assay was used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. The assay monitored the increase of 620nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide).;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638861;37;BindingDB Database;;2013;None
CHEMBL3640271;;0;394.45;0;1.92;BDBM102954;Cc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3ccccc3)C2)nc(C2CC2)c1F;Ki;'=';44.0;nM;7.36;;220585;UO_0000065;18.65;0.35;5.44;8.39;False;CHEMBL3705045;Time-Resolved FRET Assay: A homogeneous time-resolved FRET assay was used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. The assay monitored the increase of 620nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide).;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638861;37;BindingDB Database;;2013;None
CHEMBL3650821;;0;474.32;0;2.22;BDBM149909;CC1(C)Oc2ccc(NC(=O)c3ncc(Br)cn3)cc2C2(COC(N)=N2)C12COC2;Ki;'=';83.5;nM;7.08;;361631;UO_0000065;14.92;0.32;4.86;5.85;False;CHEMBL3887894;Fluorescence Resonance Energy Transfer (FRET) Assay: Test Example 1: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence. The amino acid sequence of the 'core' peptide of the substrate is SEVNLDAEFK (SEQ ID NO:2). The amino terminus was derivatized with (7-methoxycoumarin-4-yl)acetyl (MCA), and the epsilon amine of the lysine side chain of the terminal residue (K in sequence SEVNLDAEFK (SEQ ID NO:2)) was derivatized with 2,4-dinitrophenyl (DNP). Assays were performed in a buffer of 0.1 M sodium acetate, pH 4.4, 0.08% 3-[(3-Cholamidopropyl)dimethylammonio]propanesulfonate (CHAPS), 0.005% Tween80. BACE1 enzyme (final concentration 65 nM) was pre-incubated with test compounds for 15 minutes at room temperature. Fluorescence intensities were measured 60 minutes after addition of the substrate (final concentration 3 uM) by Tecan Safire2.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886493;37;BindingDB Database;;2016;None
CHEMBL559870;DIOXINODEHYDROECKOL;0;370.27;0;4.32;2;Oc1cc(O)c2oc3cc(O)c4oc5cc(O)cc(O)c5oc4c3oc2c1;Ki;'=';8000.0;nM;5.1;;;UO_0000065;13.77;0.26;0.78;3.32;False;CHEMBL1117924;Noncompetitive inhibition of human recombinant BACE1 after 60 mins by Dixon plot analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1155522;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL3939299;;0;299.33;0;0.22;BDBM199117;CN1C(=N)NC2(c3ccccc3F)COCC2S1(=O)=O;Ki;'=';7846.0;nM;5.11;;354120;UO_0000065;17.06;0.35;4.89;6.19;False;CHEMBL3887768;Homogeneous Time-Resolved FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 u) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886448;37;BindingDB Database;;2015;None
CHEMBL3650847;;0;425.45;0;1.47;BDBM149938;COc1cnc(C(=O)Nc2ccc3c(c2)[C@@]2(COC(N)=N2)C2(COC2)C(C)(C)O3)cn1;Ki;'=';42.9;nM;7.37;;288587;UO_0000065;17.32;0.32;5.90;5.66;True;CHEMBL3705666;Fluorescence Resonance Energy Transfer (FRET) Assay: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638878;37;BindingDB Database;;2015;None
CHEMBL3906934;;0;398.36;0;3.71;BDBM234454;Cc1nc(C(=O)Nc2ccc(F)c([C@@]3(C)N=C(N)[C@@](C)(F)CC3(F)F)c2)co1;Ki;'=';33.0;nM;7.48;;408770;UO_0000065;18.78;0.36;3.77;8.00;False;CHEMBL3888549;SPA-Based Assay: The binding assay was performed as SPA-based assay using a biotinylated form of human BACE1 recombinantly expressed and subsequently purified from Freestyle HEK293 cells. The binding assay was run in a 50 mM sodium acetate buffer, pH 4.5 containing 50 mM NaCl and 0.03% Tween-20 in white clear bottom 384 plates (Corning #3653). 10 nM (final concentration) radioligand ([3H]-N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N-((R)-1-phenyl-ethyl)-isophthalamide) (TRQ11569 purchased from GE Healthcare) was mixed with test compound at a given concentration, 6 nM (final concentration) human BACE1 and 25 μg Streptavidin coated PVT core SPA beads (RPNQ0007, GE Healthcare Life Sciences) in a total volume of 40 μl.;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886758;37;BindingDB Database;;2016;CHEMBL3307715
CHEMBL370043;;0;561.53;1;4.89;1;CN(C)c1ccc(NC(=O)Nc2cc(C(F)(F)F)cc(C(F)(F)F)c2)cc1C(=O)NCCCN1CCOCC1;Ki;'=';8100.0;nM;5.09;;;UO_0000065;9.07;0.18;0.20;5.92;False;CHEMBL838759;Predicted binding affinity for beta secretase by linear interaction energy continuum electrostatics;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1144345;1;Scientific Literature;J. Med. Chem.;2005;None
CHEMBL200014;;0;621.87;1;4.90;3;CCCN(CCC)C(=O)c1cccc(C(=O)N[C@@H](CC(C)C)[C@H](N)C[C@@H](C)C(=O)N[C@H](C(=O)NCc2ccccc2)C(C)C)c1;Ki;'=';11300.0;nM;4.95;;;UO_0000065;7.95;0.15;0.05;3.70;False;CHEMBL853557;Inhibition of human BACE1 expressed in Hi5 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;BTI-TN-5B1-4;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1148624;1;Scientific Literature;J. Med. Chem.;2006;CHEMBL3833782
CHEMBL227641;;0;639.86;1;2.42;5a;CCCNC(=O)c1cc(C(=O)N[C@@H](CC(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NC(C)C)C(C)C)cc(N(C)S(C)(=O)=O)c1;Ki;'=';52.5;nM;7.28;;;UO_0000065;11.38;0.23;4.86;4.18;False;CHEMBL915132;Inhibition of recombinant memapsin 2;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1139858;1;Scientific Literature;J. Med. Chem.;2007;None
CHEMBL3703253;;0;352.39;0;1.87;BDBM149770;CC1(C)Oc2ccc(-c3cncnc3)cc2C2(COC(N)=N2)C12COC2;Ki;'=';137.0;nM;6.86;;288441;UO_0000065;19.48;0.36;4.99;7.47;True;CHEMBL3705666;Fluorescence Resonance Energy Transfer (FRET) Assay: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638878;37;BindingDB Database;;2015;None
CHEMBL4092310;;0;711.89;1;3.32;6f;C[C@@H](NC(=O)c1cc(C(=O)N[C@@H](Cc2ccccc2)[C@H](O)[C@@H]2NC[C@@H](Cc3ccccc3)N(C)C2=O)cc(N(C)S(C)(=O)=O)c1)c1ccccc1;Ki;'=';12.0;nM;7.92;;;UO_0000065;11.13;0.21;4.60;5.35;False;CHEMBL4018279;Inhibition of recombinant human BACE1 (Ala8P to Ala326 residues) expressed in Escherichia coli BL21(DE3) using Arg-Glu(EDANS)-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys (Dabcyl)-Arg as substrate by fluorescence assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4017478;1;Scientific Literature;Bioorg Med Chem Lett;2017;None
CHEMBL3640273;;0;418.4;0;0.89;BDBM102956;COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3ccc(F)cc3)C2)nc(OC)c1F;Ki;'=';4.4;nM;8.36;;220588;UO_0000065;19.97;0.38;7.47;7.87;False;CHEMBL3705045;Time-Resolved FRET Assay: A homogeneous time-resolved FRET assay was used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. The assay monitored the increase of 620nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide).;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638861;37;BindingDB Database;;2013;None
CHEMBL3930012;;0;373.82;0;1.62;BDBM190885;C[C@@]1(c2cc([N+](=O)[O-])ccc2Cl)CS(=O)(=O)[C@]2(CCOC2)C(=N)N1;Ki;'=';6692.0;nM;5.17;;341357;UO_0000065;13.84;0.29;3.55;4.23;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3917414;;0;451.96;0;3.44;BDBM242237;Cc1nnc(-c2cccc(-c3cc(Cl)c([C@]4(C)CS(=O)(=O)N(C)C(=N)N4)s3)c2)o1;Ki;'=';129.0;nM;6.89;;422402;UO_0000065;15.24;0.32;3.45;6.14;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3921002;;0;436.95;0;3.74;BDBM242291;CN1C(=N)N[C@](C)(c2sc(-c3ccc(-c4ncco4)cc3)cc2Cl)CS1(=O)=O;Ki;'=';4231.0;nM;5.37;;422418;UO_0000065;12.3;0.26;1.63;5.41;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3913815;;0;434.52;0;2.46;BDBM242294;Cc1cn(-c2cc(-c3cc(F)c([C@]4(C)CS(=O)(=O)N(C)C(=N)N4)s3)ccn2)cn1;Ki;'=';67.2;nM;7.17;;422421;UO_0000065;16.51;0.34;4.71;6.90;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3945243;;0;431.52;0;3.03;BDBM242295;CN1C(=N)N[C@](C)(c2sc(-c3ccnc(-c4ccncc4)c3)cc2F)CS1(=O)=O;Ki;'=';338.0;nM;6.47;;422422;UO_0000065;15.0;0.30;3.44;6.53;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3936335;;0;434.52;0;2.46;BDBM242297;Cc1cnn(-c2cc(-c3cc(F)c([C@]4(C)CS(=O)(=O)N(C)C(=N)N4)s3)ccn2)c1;Ki;'=';2783.0;nM;5.55;;422424;UO_0000065;12.79;0.26;3.10;5.34;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3955090;;0;469.34;0;2.44;BDBM247285;CN1C(=N)N[C@](C)(c2cc(NC(=N)c3ccc(Br)cn3)ccc2F)CS1(=O)=O;Ki;'=';371.0;nM;6.43;;431487;UO_0000065;13.7;0.31;3.99;5.27;False;CHEMBL3889053;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886930;37;BindingDB Database;;2016;None
CHEMBL3985839;;0;536.68;1;2.96;BDBM242307;CN1C(=N)N[C@](C)(c2sc3c(-c4ccc(N5CCS(=O)(=O)CC5)cc4)cccc3c2F)CS1(=O)=O;Ki;'=';6521.0;nM;5.19;;422434;UO_0000065;9.66;0.20;2.23;4.69;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3978589;;0;488.0;0;3.21;BDBM242321;CN1C(=N)N[C@](C)(c2sc3c(-c4ccc(-n5nccn5)cc4)nccc3c2Cl)CS1(=O)=O;Ki;'=';224.0;nM;6.65;;422448;UO_0000065;13.63;0.28;3.44;5.69;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3909833;;0;519.03;1;4.17;BDBM242334;CN1C(=N)N[C@](C)(c2sc3c(-c4ccc(-c5cnn(C)c5)cc4F)nccc3c2Cl)CS1(=O)=O;Ki;'=';290.8;nM;6.54;;422461;UO_0000065;12.59;0.26;2.37;6.29;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3972470;;0;454.92;0;2.31;BDBM247284;CO/N=C(/Nc1ccc(F)c([C@]2(C)CS(=O)(=O)N(C)C(=N)N2)c1)c1ccc(Cl)cn1;Ki;'=';340.0;nM;6.47;;431486;UO_0000065;14.22;0.29;4.16;5.40;False;CHEMBL3889053;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886930;37;BindingDB Database;;2016;None
CHEMBL3920380;;0;440.93;0;3.14;BDBM244045;CNS1(O)C[C@@](C)(c2cc(NC(=O)c3ccc(Cl)cn3)ccc2F)NC(=N)N1C;Ki;'=';5.0;nM;8.3;;425630;UO_0000065;18.83;0.39;5.16;7.32;False;CHEMBL3888967;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window Inhibitor.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886899;37;BindingDB Database;;2016;None
CHEMBL3978379;;0;491.93;0;2.37;BDBM190869;C[C@@]1(c2cc(NC(=O)c3ncc(Cl)cc3C#N)ccc2F)CS(=O)(=O)[C@]2(CCOC2)C(=N)N1;Ki;'=';5.7;nM;8.24;;341348;UO_0000065;16.76;0.34;5.87;5.68;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3934070;;0;297.36;0;1.15;BDBM190871;C[C@@]1(c2cc(N)ccc2F)CS(=O)(=O)C2(CC2)C(=N)N1;Ki;'=';4900.0;nM;5.31;;341349;UO_0000065;17.86;0.36;4.16;5.53;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3627965;;0;462.38;0;3.86;12a;CC(=O)Nc1c(Cl)cc(CN/C(N)=N/C(=O)[C@@H]2CCCN2c2ccc(C)cc2)cc1Cl;Ki;'=';1400.0;nM;5.85;;;UO_0000065;12.66;0.26;1.99;5.86;False;CHEMBL3630425;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 5 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL3627959;;0;448.35;0;3.55;7d;CC(=O)Nc1c(Cl)cc(CN/C(N)=N/C(=O)[C@H]2CCCN2c2ccccc2)cc1Cl;Ki;'=';3100.0;nM;5.51;;;UO_0000065;12.29;0.25;1.96;5.52;False;CHEMBL3630425;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 5 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL3627958;;0;448.35;0;3.55;7c;CC(=O)Nc1c(Cl)cc(CN/C(N)=N/C(=O)[C@@H]2CCCN2c2ccccc2)cc1Cl;Ki;'=';340.0;nM;6.47;;;UO_0000065;14.43;0.29;2.92;6.48;False;CHEMBL3630426;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 6.4 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL3694261;;0;727.88;1;3.28;5d;COc1ccc(CN2CCN[C@@H]([C@@H](O)[C@H](Cc3ccccc3)NC(=O)c3cc(C(=O)N[C@H](C)c4ccccc4)cc(N(C)S(C)(=O)=O)c3)C2=O)cc1;Ki;'=';81.4;nM;7.09;;;UO_0000065;9.74;0.19;3.81;4.50;False;CHEMBL4018279;Inhibition of recombinant human BACE1 (Ala8P to Ala326 residues) expressed in Escherichia coli BL21(DE3) using Arg-Glu(EDANS)-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys (Dabcyl)-Arg as substrate by fluorescence assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4017478;1;Scientific Literature;Bioorg Med Chem Lett;2017;None
CHEMBL262295;;0;893.01;3;-1.74;2;CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)C(NC(=O)[C@H](N)CCC(=O)O)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(=O)O)C(=O)NC(Cc1ccccc1)C(=O)O;Ki;'=';1.6;nM;8.8;;;UO_0000065;9.85;0.19;10.54;2.34;False;CHEMBL711471;Binding affinity for human brain memapsin 2;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1134775;1;Scientific Literature;J. Med. Chem.;2001;None
CHEMBL3703291;;0;457.45;0;3.78;BDBM149815;CC#Cc1cncc(-c2ccc3c(c2)C2(COC(N)=N2)C2(COC2)C(CCC(F)(F)F)O3)c1;Ki;'=';868.0;nM;6.06;;288479;UO_0000065;13.25;0.25;2.28;7.68;True;CHEMBL3705666;Fluorescence Resonance Energy Transfer (FRET) Assay: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638878;37;BindingDB Database;;2015;None
CHEMBL3650778;;0;402.85;0;3.87;BDBM149865;CC1(C)Oc2ccc(-c3cc(F)cc(Cl)c3)cc2C2(COC(N)=N2)C12COC2;Ki;'=';188.0;nM;6.73;;288528;UO_0000065;16.7;0.33;2.86;10.18;True;CHEMBL3705666;Fluorescence Resonance Energy Transfer (FRET) Assay: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638878;37;BindingDB Database;;2015;None
CHEMBL3640256;;0;436.39;0;1.03;BDBM102938;COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3cc(F)ccc3F)C2)nc(OC)c1F;Ki;'=';5.6;nM;8.25;;220590;UO_0000065;18.91;0.36;7.22;7.77;False;CHEMBL3705045;Time-Resolved FRET Assay: A homogeneous time-resolved FRET assay was used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. The assay monitored the increase of 620nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide).;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638861;37;BindingDB Database;;2013;None
CHEMBL3640287;;0;474.37;0;2.04;BDBM102970;COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3ccc(F)cc3F)C2)nc(C(F)(F)F)c1F;Ki;'=';32.0;nM;7.5;;220604;UO_0000065;15.8;0.31;5.45;7.73;False;CHEMBL3705045;Time-Resolved FRET Assay: A homogeneous time-resolved FRET assay was used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. The assay monitored the increase of 620nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide).;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638861;37;BindingDB Database;;2013;None
CHEMBL3902268;;0;412.36;0;3.95;BDBM234448;C[C@]1(F)CC(F)(F)[C@@](C)(c2cc(NC(=O)c3ccc(F)cn3)ccc2F)N=C1N;Ki;'=';83.0;nM;7.08;;408764;UO_0000065;17.17;0.33;3.13;8.81;False;CHEMBL3888549;SPA-Based Assay: The binding assay was performed as SPA-based assay using a biotinylated form of human BACE1 recombinantly expressed and subsequently purified from Freestyle HEK293 cells. The binding assay was run in a 50 mM sodium acetate buffer, pH 4.5 containing 50 mM NaCl and 0.03% Tween-20 in white clear bottom 384 plates (Corning #3653). 10 nM (final concentration) radioligand ([3H]-N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N-((R)-1-phenyl-ethyl)-isophthalamide) (TRQ11569 purchased from GE Healthcare) was mixed with test compound at a given concentration, 6 nM (final concentration) human BACE1 and 25 μg Streptavidin coated PVT core SPA beads (RPNQ0007, GE Healthcare Life Sciences) in a total volume of 40 μl.;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886758;37;BindingDB Database;;2016;CHEMBL3307715
CHEMBL3904873;;0;438.92;0;2.53;BDBM242958;CN1C(=N)N[C@](C)(c2sc(-c3nnc(-c4ccccn4)o3)cc2Cl)CS1(=O)=O;Ki;'=';554.6;nM;6.26;;423839;UO_0000065;14.25;0.31;3.73;5.00;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3893375;;0;419.38;0;3.68;BDBM234451;C[C@]1(F)CC(F)(F)[C@@](C)(c2cc(NC(=O)c3ccc(C#N)cn3)ccc2F)N=C1N;Ki;'=';11.0;nM;7.96;;408767;UO_0000065;18.98;0.36;4.28;7.64;False;CHEMBL3888549;SPA-Based Assay: The binding assay was performed as SPA-based assay using a biotinylated form of human BACE1 recombinantly expressed and subsequently purified from Freestyle HEK293 cells. The binding assay was run in a 50 mM sodium acetate buffer, pH 4.5 containing 50 mM NaCl and 0.03% Tween-20 in white clear bottom 384 plates (Corning #3653). 10 nM (final concentration) radioligand ([3H]-N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N-((R)-1-phenyl-ethyl)-isophthalamide) (TRQ11569 purchased from GE Healthcare) was mixed with test compound at a given concentration, 6 nM (final concentration) human BACE1 and 25 μg Streptavidin coated PVT core SPA beads (RPNQ0007, GE Healthcare Life Sciences) in a total volume of 40 μl.;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886758;37;BindingDB Database;;2016;CHEMBL3307715
CHEMBL3945186;;0;439.41;0;3.52;BDBM234466;COc1cnc(C(=O)Nc2ccc(F)c([C@@]3(C)N=C(N)[C@@](C)(F)CC3(F)F)c2)c(C)n1;Ki;'=';32.0;nM;7.5;;408782;UO_0000065;17.06;0.33;3.97;7.31;False;CHEMBL3888549;SPA-Based Assay: The binding assay was performed as SPA-based assay using a biotinylated form of human BACE1 recombinantly expressed and subsequently purified from Freestyle HEK293 cells. The binding assay was run in a 50 mM sodium acetate buffer, pH 4.5 containing 50 mM NaCl and 0.03% Tween-20 in white clear bottom 384 plates (Corning #3653). 10 nM (final concentration) radioligand ([3H]-N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N-((R)-1-phenyl-ethyl)-isophthalamide) (TRQ11569 purchased from GE Healthcare) was mixed with test compound at a given concentration, 6 nM (final concentration) human BACE1 and 25 μg Streptavidin coated PVT core SPA beads (RPNQ0007, GE Healthcare Life Sciences) in a total volume of 40 μl.;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886758;37;BindingDB Database;;2016;CHEMBL3307715
CHEMBL4113423;;0;433.36;0;4.01;BDBM234470;C[C@@]1(F)CC(F)(F)[C@@](C)(c2cc(NC(=O)c3ccn(C(F)F)n3)ccc2F)N=C1N;Ki;'=';71.0;nM;7.15;;408786;UO_0000065;16.5;0.33;3.14;8.38;False;CHEMBL3888549;SPA-Based Assay: The binding assay was performed as SPA-based assay using a biotinylated form of human BACE1 recombinantly expressed and subsequently purified from Freestyle HEK293 cells. The binding assay was run in a 50 mM sodium acetate buffer, pH 4.5 containing 50 mM NaCl and 0.03% Tween-20 in white clear bottom 384 plates (Corning #3653). 10 nM (final concentration) radioligand ([3H]-N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N-((R)-1-phenyl-ethyl)-isophthalamide) (TRQ11569 purchased from GE Healthcare) was mixed with test compound at a given concentration, 6 nM (final concentration) human BACE1 and 25 μg Streptavidin coated PVT core SPA beads (RPNQ0007, GE Healthcare Life Sciences) in a total volume of 40 μl.;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886758;37;BindingDB Database;;2016;CHEMBL3307715
CHEMBL3703237;;0;384.82;0;2.70;BDBM149754;NC1=NC2(CO1)c1cc(NC(=O)c3ccc(Cl)cn3)ccc1OCC21CC1;Ki;'=';378.0;nM;6.42;;288425;UO_0000065;16.69;0.32;3.72;6.50;True;CHEMBL3705666;Fluorescence Resonance Energy Transfer (FRET) Assay: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638878;37;BindingDB Database;;2015;None
CHEMBL3905233;;0;537.62;1;2.95;BDBM249121;COc1ccc(C(=O)Nc2ccc(F)c([C@]3(C)CS(=O)(=O)C4(CN(Cc5ccccc5)C4)C(=N)N3)c2)nc1;Ki;'=';7.7;nM;8.11;;434659;UO_0000065;15.09;0.29;5.16;6.52;False;CHEMBL3889105;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 ul of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 ul in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window. Inhibitor IC50 values are derived from non-linear regression analysis of concentration response curves. Ki values are then calculated from IC50 values using the Cheng-Prusoff equation using a previously determined um value of 8 uM for the QSY7-APPswe-Eu substrate at BACE1.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886943;37;BindingDB Database;;2016;None
CHEMBL3890282;;0;436.95;0;2.66;BDBM242942;CN1C(=N)N[C@](C)(c2sc(-c3cn(-c4ccccc4)nn3)cc2Cl)CS1(=O)=O;Ki;'=';1985.0;nM;5.7;;423823;UO_0000065;13.05;0.28;3.04;5.48;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3897312;;0;487.44;0;1.89;BDBM199107;CN1C(=N)N[C@]2(c3cc(NC(=O)c4ccc(C(F)(F)F)cn4)ccc3F)COC[C@@H]2S1(=O)=O;Ki;'=';354.0;nM;6.45;;354115;UO_0000065;13.23;0.27;4.56;5.18;False;CHEMBL3887768;Homogeneous Time-Resolved FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 u) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886448;37;BindingDB Database;;2015;None
CHEMBL3929668;;0;440.5;0;2.60;BDBM190739;C[C@@]1(c2cc(-n3cc(-c4cccnc4)nn3)ccc2F)CS(=O)(=O)C2(CCC2)C(=N)N1;Ki;'=';8557.0;nM;5.07;;341233;UO_0000065;11.5;0.22;2.47;4.46;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3942086;;0;439.91;0;1.92;BDBM242964;CN1C(=N)N[C@](C)(c2sc(-c3nnc(-c4cnccn4)o3)cc2Cl)CS1(=O)=O;Ki;'=';682.9;nM;6.17;;423845;UO_0000065;14.02;0.30;4.25;4.47;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3921866;;0;444.95;0;2.59;BDBM242970;CN1C(=N)N[C@](C)(c2sc(-c3nnc(-c4cncs4)o3)cc2Cl)CS1(=O)=O;Ki;'=';863.3;nM;6.06;;423851;UO_0000065;13.63;0.31;3.47;4.85;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3936219;;0;444.95;0;2.59;BDBM242974;CN1C(=N)N[C@](C)(c2sc(-c3nnc(-c4cscn4)o3)cc2Cl)CS1(=O)=O;Ki;'=';662.1;nM;6.18;;423855;UO_0000065;13.89;0.31;3.59;4.94;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3918474;;0;406.4;0;1.55;BDBM242991;CN1C(=N)N[C@](C)(c2cc(-c3nnc(-c4cocn4)o3)ccc2F)CS1(=O)=O;Ki;'=';7548.0;nM;5.12;;423872;UO_0000065;12.6;0.25;3.57;3.71;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3952233;;0;521.02;1;3.26;BDBM243006;CN1C(=N)N[C@](C)(c2sc(-c3nnc(-c4ccc(N5CCCC5=O)cc4)o3)cc2Cl)CS1(=O)=O;Ki;'=';1026.0;nM;5.99;;423887;UO_0000065;11.49;0.24;2.73;4.52;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3949575;;0;509.04;1;4.05;BDBM243009;Cc1nc2cc(-c3nnc(-c4cc(Cl)c([C@]5(C)CS(=O)(=O)N(C)C(=N)N5)s4)o3)ccc2s1;Ki;'=';421.8;nM;6.38;;423890;UO_0000065;12.52;0.27;2.32;5.10;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3976431;;0;506.92;1;3.55;BDBM243012;CN1C(=N)N[C@](C)(c2sc(-c3nnc(-c4ccc(C(F)(F)F)cn4)o3)cc2Cl)CS1(=O)=O;Ki;'=';164.5;nM;6.78;;423893;UO_0000065;13.38;0.29;3.23;5.42;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3932859;;0;510.0;1;2.85;BDBM243017;COC(=O)Cc1ccc(-c2nnc(-c3cc(Cl)c([C@]4(C)CS(=O)(=O)N(C)C(=N)N4)s3)o2)cc1;Ki;'=';137.9;nM;6.86;;423898;UO_0000065;13.45;0.28;4.01;4.95;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3926717;;0;488.54;0;4.52;BDBM243020;CN1C(=N)N[C@](C)(c2sc3c(-c4cnc(-c5ccc(F)cc5)o4)cccc3c2F)CS1(=O)=O;Ki;'=';3177.0;nM;5.5;;423901;UO_0000065;11.25;0.23;0.98;5.54;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3945940;;0;488.99;0;2.61;BDBM242319;CN1C(=N)N[C@](C)(c2sc3c(-c4cnc(-n5cccn5)nc4)nccc3c2Cl)CS1(=O)=O;Ki;'=';61.2;nM;7.21;;422446;UO_0000065;14.75;0.31;4.60;5.56;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3983409;;0;501.04;1;4.03;BDBM242327;CN1C(=N)N[C@](C)(c2sc3c(-c4ccc(-c5nccn5C)cc4)nccc3c2Cl)CS1(=O)=O;Ki;'=';1639.0;nM;5.79;;422454;UO_0000065;11.55;0.24;1.76;5.56;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3911285;;0;519.03;1;4.17;BDBM242333;CN1C(=N)N[C@](C)(c2sc3c(-c4ccc(-c5ccnn5C)cc4F)nccc3c2Cl)CS1(=O)=O;Ki;'=';196.7;nM;6.71;;422460;UO_0000065;12.92;0.27;2.54;6.45;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3898839;;0;526.11;1;3.51;BDBM242344;Cc1nsc(C2CCN(c3nccc4c(Cl)c([C@]5(C)CS(=O)(=O)N(C)C(=N)N5)sc34)CC2)n1;Ki;'=';884.6;nM;6.05;;422471;UO_0000065;11.51;0.25;2.54;5.26;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3980366;;0;464.49;0;2.37;BDBM190726;C[C@@]1(c2cc(NC(=O)c3ccc(F)cn3)ccc2F)CS(=O)(=O)C2(CCOCC2)C(=N)N1;Ki;'=';10.9;nM;7.96;;341221;UO_0000065;17.14;0.34;5.59;6.57;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3913650;;0;515.39;1;3.54;BDBM190727;C[C@@]1(c2cc(NC(=O)c3ncc(Cl)cc3Cl)ccc2F)CS(=O)(=O)C2(CCOCC2)C(=N)N1;Ki;'=';4.1;nM;8.39;;341222;UO_0000065;16.27;0.35;4.85;6.92;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3912550;;0;422.44;0;1.44;BDBM190838;C[C@@]1(c2cc(NC(=O)c3ccno3)ccc2F)CS(=O)(=O)[C@]2(CCOC2)C(=N)N1;Ki;'=';300.0;nM;6.52;;341320;UO_0000065;15.44;0.31;5.08;4.85;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3949563;;0;420.49;0;3.22;BDBM242229;CN1C(=N)N[C@](C)(c2sc(-c3cccc(-c4ncco4)c3)cc2F)CS1(=O)=O;Ki;'=';8.7;nM;8.06;;422356;UO_0000065;19.17;0.39;4.84;8.12;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3934800;;0;420.5;0;2.15;BDBM242298;CN1C(=N)N[C@](C)(c2sc(-c3ccnc(-n4ccnc4)c3)cc2F)CS1(=O)=O;Ki;'=';112.0;nM;6.95;;422425;UO_0000065;16.53;0.34;4.80;6.69;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3984963;;0;480.59;0;4.78;BDBM242306;CN1C(=N)N[C@](C)(c2sc3c(-c4ccc(-c5ccncc5)cc4)cccc3c2F)CS1(=O)=O;Ki;'=';351.0;nM;6.46;;422433;UO_0000065;13.43;0.27;1.67;7.49;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3930419;;0;444.56;0;3.99;BDBM242318;CN1C(=N)N[C@](C)(c2sc3c(-c4ccc(C5CC5)nc4)cccc3c2F)CS1(=O)=O;Ki;'=';327.0;nM;6.49;;422445;UO_0000065;14.59;0.30;2.50;7.53;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL188956;;0;591.75;2;1.74;BACE Inhibitor 2;CC(C)C[C@H](NC(=O)[C@@H](NC(=O)OC(C)(C)C)C(N)=O)C(O)CC(C)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C;Ki;'=';3134.0;nM;5.5;;;UO_0000065;9.3;0.18;3.76;2.91;False;CHEMBL828263;Binding affinity towards Beta-secretase determined using continuum electrostatics solvation;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1137231;1;Scientific Literature;J. Med. Chem.;2004;None
CHEMBL3703233;;0;412.42;0;2.20;BDBM149750;CC1(C)Oc2ccc(NC(=O)c3ccc(F)cn3)cc2C2(COC(N)=N2)C12COC2;Ki;'=';117.0;nM;6.93;;361491;UO_0000065;16.81;0.32;4.73;6.41;False;CHEMBL3887894;Fluorescence Resonance Energy Transfer (FRET) Assay: Test Example 1: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence. The amino acid sequence of the 'core' peptide of the substrate is SEVNLDAEFK (SEQ ID NO:2). The amino terminus was derivatized with (7-methoxycoumarin-4-yl)acetyl (MCA), and the epsilon amine of the lysine side chain of the terminal residue (K in sequence SEVNLDAEFK (SEQ ID NO:2)) was derivatized with 2,4-dinitrophenyl (DNP). Assays were performed in a buffer of 0.1 M sodium acetate, pH 4.4, 0.08% 3-[(3-Cholamidopropyl)dimethylammonio]propanesulfonate (CHAPS), 0.005% Tween80. BACE1 enzyme (final concentration 65 nM) was pre-incubated with test compounds for 15 minutes at room temperature. Fluorescence intensities were measured 60 minutes after addition of the substrate (final concentration 3 uM) by Tecan Safire2.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886493;37;BindingDB Database;;2016;None
CHEMBL294274;;0;739.98;2;2.44;7;CC(C)C[C@H](NC(=O)C(CS(C)(=O)=O)NC(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)C(O)CC(C)C(=O)NC(C(=O)NCc1ccccc1)C(C)C;Ki;'=';9.4;nM;8.03;;;UO_0000065;10.85;0.21;5.59;3.84;True;CHEMBL655069;Binding affinity for human brain memapsin 2 beta-Secretase (BACE);B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1144924;1;Scientific Literature;J. Med. Chem.;2003;None
CHEMBL3961890;;0;429.35;0;3.12;BDBM230867;COc1cnc(C(=O)Nc2ccc(F)c([C@@]3(C(F)F)N=C(N)CCC3(F)F)c2)cn1;Ki;'=';8.5;nM;8.07;;402950;UO_0000065;18.8;0.37;4.95;7.87;False;CHEMBL3888456;BACE1 Binding Assay: The binding assay was performed as SPA-based assay using a biotinylated form of human BACE1 recombinantly expressed and subsequently purified from Freestyle HEK293 cells. The binding assay was run in a 50 mM sodium acetate buffer, pH 4.5 containing 50 mM NaCl and 0.03% Tween-20 in white clear bottom 384 plates (Corning #3653). 10 nM (final concentration) radioligand ([3H]−N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N−((R)-1-phenyl-ethyl)-isophthalamide) (TRQ11569 purchased from GE Healthcare) was mixed with test compound at a given concentration, 6 nM (final concentration) human BACE1 and 25 μg Streptavidin coated PVT core SPA beads (RPNQ0007, GE Healthcare Life Sciences) in a total volume of 40 μl. Several concentrations of each test compound were tested in the assay for IC50 determination. The plates were incubated for one hour at room temperature and counted in a Wallac Trilux counter. Total and non-specific binding were determined using buffer and 1 μM (final concentration) of the high affinity BACE1 reference inhibitor (S)-6-[3-chloro-5-(5-prop-1-ynyl-pyridin-3-yl)-thiophen-2-yl]-2-imino-3,6-dimethyl-tetrahydro-pyrimidin-4-one, respectively.;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886720;37;BindingDB Database;;2016;CHEMBL3307715
CHEMBL95429;;0;605.78;2;2.13;2;CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)OC(C)(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C;Ki;'=';3134.0;nM;5.5;;;UO_0000065;9.09;0.17;3.37;2.91;False;CHEMBL942114;Inhibition of BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1140597;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2007;None
CHEMBL1097330;;0;716.85;1;3.92;3l;CCCN(CCC)C(=O)c1cc(C)cc(C(=O)N[C@@H](Cc2cc(F)cc(F)c2)[C@H](O)[C@H]2CN(S(=O)(=O)c3ccc(OC)c(OC)c3)CCN2)c1;Ki;'=';45.0;nM;7.35;;;UO_0000065;10.25;0.20;3.43;5.34;False;CHEMBL1109071;Inhibition oh BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157894;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL1097322;;0;670.82;1;4.21;3d;CCCN(CCC)C(=O)c1cc(C)cc(C(=O)N[C@@H](Cc2cc(F)cc(F)c2)[C@H](O)[C@H]2CN(S(=O)(=O)c3ccc(C)cc3)CCN2)c1;Ki;'=';60.0;nM;7.22;;;UO_0000065;10.77;0.21;3.01;6.07;False;CHEMBL1109071;Inhibition oh BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157894;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL418329;;0;763.89;2;-1.09;2;CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)C(C)C)C(O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O;Ki;'=';68.0;nM;7.17;;;UO_0000065;9.38;0.18;8.26;2.32;False;CHEMBL653499;Inhibition of human recombinant beta-secretase;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1134505;1;Scientific Literature;J. Med. Chem.;2001;None
CHEMBL3924242;;0;453.88;0;1.52;BDBM199103;CN1C(=N)N[C@]2(c3cc(NC(=O)c4ccc(Cl)cn4)ccc3F)COC[C@@H]2S1(=O)=O;Ki;'=';197.0;nM;6.71;;354113;UO_0000065;14.77;0.31;5.19;5.39;False;CHEMBL3887768;Homogeneous Time-Resolved FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 u) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886448;37;BindingDB Database;;2015;None
CHEMBL3924578;;0;475.57;0;3.31;BDBM190716;C[C@@]1(c2cc(NC(=O)c3cn4ccsc4n3)ccc2F)CS(=O)(=O)C2(CCCC2)C(=N)N1;Ki;'=';82.0;nM;7.09;;341211;UO_0000065;14.9;0.30;3.78;6.09;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3650850;;0;409.45;0;2.23;BDBM149941;COc1cnc(C(=O)Nc2ccc3c(c2)[C@@]2(COC(N)=N2)C2(CC2)C(C)(C)O3)cn1;Ki;'=';61.2;nM;7.21;;288590;UO_0000065;17.62;0.33;4.98;5.96;True;CHEMBL3705666;Fluorescence Resonance Energy Transfer (FRET) Assay: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638878;37;BindingDB Database;;2015;None
CHEMBL3703253;;0;352.39;0;1.87;BDBM149770;CC1(C)Oc2ccc(-c3cncnc3)cc2C2(COC(N)=N2)C12COC2;Ki;'=';137.0;nM;6.86;;361511;UO_0000065;19.48;0.36;4.99;7.47;False;CHEMBL3887894;Fluorescence Resonance Energy Transfer (FRET) Assay: Test Example 1: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence. The amino acid sequence of the 'core' peptide of the substrate is SEVNLDAEFK (SEQ ID NO:2). The amino terminus was derivatized with (7-methoxycoumarin-4-yl)acetyl (MCA), and the epsilon amine of the lysine side chain of the terminal residue (K in sequence SEVNLDAEFK (SEQ ID NO:2)) was derivatized with 2,4-dinitrophenyl (DNP). Assays were performed in a buffer of 0.1 M sodium acetate, pH 4.4, 0.08% 3-[(3-Cholamidopropyl)dimethylammonio]propanesulfonate (CHAPS), 0.005% Tween80. BACE1 enzyme (final concentration 65 nM) was pre-incubated with test compounds for 15 minutes at room temperature. Fluorescence intensities were measured 60 minutes after addition of the substrate (final concentration 3 uM) by Tecan Safire2.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886493;37;BindingDB Database;;2016;None
CHEMBL3979167;;0;488.03;0;4.50;BDBM190792;C[C@@]1(c2sc(-c3ccnc(-c4ccccc4)c3)cc2Cl)CS(=O)(=O)[C@@]2(CCOC2)C(=N)N1;Ki;'=';849.0;nM;6.07;;341284;UO_0000065;12.44;0.26;1.57;6.59;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3918762;;0;478.0;0;4.09;BDBM190793;C[C@@]1(c2sc(-c3ccnc(-c4ccoc4)c3)cc2Cl)CS(=O)(=O)[C@@]2(CCOC2)C(=N)N1;Ki;'=';673.8;nM;6.17;;341285;UO_0000065;12.91;0.27;2.08;5.86;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3664018;;0;602.78;1;3.33;BDBM172749;CC(C)CNC(=O)C(NCC(O)C(Cc1ccccc1)NC(=O)c1cccc(C(=O)N(C)C(C)c2ccccc2)c1)C(C)O;Ki;'=';5812.0;nM;5.24;;317738;UO_0000065;8.69;0.16;1.91;4.00;False;CHEMBL3707552;Inhibition Assay: Previously, one of the following compounds discussed below have been studied in memapsin 2 inhibition (Ghosh et al., 2008), which the others are previously unpublished. Given the closely related substrate specificity for memapsin 1 and memapsin 2, the inventors chose to screen these previously identified memapsin 2 inhibitors for lead compounds as memapsin 1 inhibitors. Recombinant memapsin 1 ectodomain was prepared as described by Turner et al. (2002) and assayed using a commercially purchased fluorescent substrate.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638586;37;BindingDB Database;;2015;None
CHEMBL362592;;0;730.95;2;2.68;3;CC(C)C[C@H](NC(=O)[C@@H]1CC(=O)NCCCCCCOC(=O)N[C@@H](C(C)C)C(=O)N1)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C;Ki;'=';25.0;nM;7.6;;;UO_0000065;10.4;0.20;4.92;3.73;False;CHEMBL2411011;Inhibition of human brain BACE1;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2406987;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2013;None
CHEMBL568035;;0;387.37;0;4.26;14;O=C(Nc1nc2ccc(F)cc2[nH]1)c1ccc2c(c1)Nc1ccccc1NC2=O;Ki;'=';244.0;nM;6.61;;;UO_0000065;17.07;0.31;2.35;6.69;False;CHEMBL1045676;Inhibition of human recombinant BACE1 by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1154184;1;Scientific Literature;J. Med. Chem.;2009;None
CHEMBL2178162;;0;549.48;1;4.23;22e;CCNCC(=O)Nc1c(Cl)cc(CN/C(N)=N/C(=O)c2c(-c3ccc(OC)cc3)nsc2C)cc1Cl;Ki;'=';10.0;nM;8.0;;;UO_0000065;14.56;0.30;3.77;6.12;False;CHEMBL2187886;Displacement of [3H]BMS-599240 from BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177026;1;Scientific Literature;J. Med. Chem.;2012;CHEMBL3307715
CHEMBL2178191;;0;533.42;1;3.71;17q;COc1ccc(-c2noc(C)c2C(=O)/N=C(\N)NCc2cc(Cl)c(NC(=O)CN(C)C)c(Cl)c2)cc1;Ki;'=';50.0;nM;7.3;;;UO_0000065;13.69;0.28;3.59;5.40;False;CHEMBL2187886;Displacement of [3H]BMS-599240 from BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177026;1;Scientific Literature;J. Med. Chem.;2012;CHEMBL3307715
CHEMBL2178203;;0;446.34;0;3.96;8n;COc1ccc(-c2c(C(=O)/N=C(\N)NCc3cc(Cl)cc(Cl)c3)c(C)nn2C)cc1;Ki;'=';4000.0;nM;5.4;;;UO_0000065;12.09;0.25;1.44;5.71;False;CHEMBL2187886;Displacement of [3H]BMS-599240 from BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177026;1;Scientific Literature;J. Med. Chem.;2012;CHEMBL3307715
CHEMBL390456;;0;936.07;3;-0.11;1;CC(C)C[C@H](NC(=O)[C@@H](N)CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C;Ki;'=';1.2;nM;8.92;;;UO_0000065;9.53;0.18;9.03;2.41;False;CHEMBL3592345;Inhibition of human recombinant BACE1 using Mca-SEVNLDAEFK-DNP substrate assessed as substrate hydrolysis after 2 hrs by HPLC-FLU analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3588858;1;Scientific Literature;J. Med. Chem.;2015;None
CHEMBL3589002;;0;1285.41;None;None;5;CC(C)C[C@H](NC(=O)[C@@H](N)CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)C(C)C;Ki;'=';1.7;nM;8.77;;;UO_0000065;6.82;None;None;None;False;CHEMBL3592345;Inhibition of human recombinant BACE1 using Mca-SEVNLDAEFK-DNP substrate assessed as substrate hydrolysis after 2 hrs by HPLC-FLU analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3588858;1;Scientific Literature;J. Med. Chem.;2015;None
CHEMBL390456;;0;936.07;3;-0.11;1;CC(C)C[C@H](NC(=O)[C@@H](N)CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C;Ki;'=';0.31;nM;9.51;;;UO_0000065;10.16;0.20;9.62;2.57;False;CHEMBL3592359;Inhibition of active BACE1 (unknown origin);B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3588858;1;Scientific Literature;J. Med. Chem.;2015;None
CHEMBL405889;;0;551.64;1;2.80;25;CN(C)c1cccc(CNC[C@@H](O)[C@H](Cc2cc(F)cc(F)c2)NC(=O)[C@@H]2CN(Cc3ccccc3)C(=O)N2)c1;Ki;'=';51.0;nM;7.29;;;UO_0000065;13.22;0.25;4.49;7.52;False;CHEMBL929344;Inhibition of human BACE1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1145643;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2008;None
CHEMBL413999;;0;551.64;1;2.80;17;CN(C)c1cccc(CNC[C@@H](O)[C@H](Cc2ccccc2)NC(=O)[C@@H]2CN(Cc3cc(F)cc(F)c3)C(=O)N2)c1;Ki;'=';53.0;nM;7.28;;;UO_0000065;13.19;0.25;4.48;7.51;False;CHEMBL929344;Inhibition of human BACE1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1145643;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2008;None
CHEMBL260174;;0;481.64;0;2.12;5;CCCCN1C[C@@H](C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CNCc2cccc(N(C)C)c2)NC1=O;Ki;'=';39989.0;nM;4.4;;;UO_0000065;9.13;0.17;2.28;4.54;False;CHEMBL929344;Inhibition of human BACE1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1145643;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2008;None
CHEMBL408948;;0;514.67;1;2.68;2;CN(C)c1cccc(CNC[C@@H](O)[C@H](Cc2ccccc2)NC(=O)[C@@H]2CC(Cc3ccccc3)C(=O)N2)c1;Ki;'=';3005.0;nM;5.52;;;UO_0000065;10.73;0.20;2.84;5.89;False;CHEMBL929344;Inhibition of human BACE1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1145643;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2008;None
CHEMBL3939154;;0;485.99;0;4.45;BDBM242935;CC1(C)C(=N)N[C@](C)(c2cc(NC(=O)c3ccc(Cl)cn3)ccc2F)CS1(O)NCCF;Ki;'=';3.0;nM;8.52;;423796;UO_0000065;17.54;0.36;4.07;7.74;False;CHEMBL3888940;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886895;37;BindingDB Database;;2016;None
CHEMBL3891223;;0;452.94;0;3.21;BDBM244052;CCN=S1(=O)C[C@@](C)(c2cc(NC(=O)c3ccc(Cl)cn3)ccc2F)NC(=N)N1C;Ki;'=';8.0;nM;8.1;;425637;UO_0000065;17.88;0.37;4.89;7.32;False;CHEMBL3888967;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window Inhibitor.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886899;37;BindingDB Database;;2016;None
CHEMBL4113087;;0;434.34;0;4.34;BDBM234476;C[C@@]1(F)CC(F)(F)[C@@](C)(c2cc(NC(=O)c3coc(C(F)F)n3)ccc2F)N=C1N;Ki;'=';92.0;nM;7.04;;408792;UO_0000065;16.2;0.32;2.70;7.52;False;CHEMBL3888549;SPA-Based Assay: The binding assay was performed as SPA-based assay using a biotinylated form of human BACE1 recombinantly expressed and subsequently purified from Freestyle HEK293 cells. The binding assay was run in a 50 mM sodium acetate buffer, pH 4.5 containing 50 mM NaCl and 0.03% Tween-20 in white clear bottom 384 plates (Corning #3653). 10 nM (final concentration) radioligand ([3H]-N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N-((R)-1-phenyl-ethyl)-isophthalamide) (TRQ11569 purchased from GE Healthcare) was mixed with test compound at a given concentration, 6 nM (final concentration) human BACE1 and 25 μg Streptavidin coated PVT core SPA beads (RPNQ0007, GE Healthcare Life Sciences) in a total volume of 40 μl.;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886758;37;BindingDB Database;;2016;CHEMBL3307715
CHEMBL3906268;;0;373.45;0;1.42;BDBM244049;CNS1(O)C[C@@](C)(c2cc(NC(=O)COC)ccc2F)NC(=N)N1C;Ki;'=';189.0;nM;6.72;;425634;UO_0000065;18.0;0.37;5.30;6.13;False;CHEMBL3888967;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window Inhibitor.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886899;37;BindingDB Database;;2016;None
CHEMBL3985789;;0;437.93;0;3.13;BDBM242223;CN1C(=N)N[C@](C)(c2sc(-c3cccc(-c4nnco4)c3)cc2Cl)CS1(=O)=O;Ki;'=';1.6;nM;8.8;;422350;UO_0000065;20.09;0.43;5.67;7.84;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3944146;;0;478.0;0;4.01;BDBM242261;CN1C(=N)N[C@](C)(c2sc(-c3cccc(-c4nc(C5CC5)no4)c3)cc2Cl)CS1(=O)=O;Ki;'=';419.0;nM;6.38;;422388;UO_0000065;13.34;0.28;2.37;5.69;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3921775;;0;489.6;0;2.95;BDBM242316;CN1C(=N)N[C@](C)(c2sc3c(-c4ccc(N5CCOCC5)nc4)cccc3c2F)CS1(=O)=O;Ki;'=';1500.0;nM;5.82;;422443;UO_0000065;11.9;0.24;2.87;5.91;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3977064;;0;505.98;1;4.43;BDBM242330;CN1C(=N)N[C@](C)(c2sc3c(-c4ccc(-c5cnco5)cc4F)nccc3c2Cl)CS1(=O)=O;Ki;'=';35.16;nM;7.45;;422457;UO_0000065;14.73;0.31;3.02;6.64;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL293611;;0;722.01;2;4.15;9;CSCCC(NC(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)C(=O)N[C@@H](CC(C)C)C(O)CC(C)C(=O)NC(C(=O)NCc1ccccc1)C(C)C;Ki;'=';2.5;nM;8.6;;;UO_0000065;11.91;0.23;4.45;4.92;True;CHEMBL655069;Binding affinity for human brain memapsin 2 beta-Secretase (BACE);B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1144924;1;Scientific Literature;J. Med. Chem.;2003;None
CHEMBL3959832;;0;470.02;0;3.06;BDBM190779;CC(C)(O)c1cncc(-c2cc(Cl)c([C@]3(C)CS(=O)(=O)[C@]4(CCOC4)C(=N)N3)s2)c1;Ki;'=';2422.0;nM;5.62;;341276;UO_0000065;11.95;0.26;2.56;5.00;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3910091;;0;399.97;0;2.50;BDBM190814;CNCCC#Cc1cc(Cl)c([C@]2(C)CS(=O)(=O)C3(CCC3)C(=N)N2)s1;Ki;'=';104.7;nM;6.98;;341298;UO_0000065;17.45;0.38;4.48;8.51;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3940539;;0;422.44;0;1.44;BDBM190839;C[C@@]1(c2cc(NC(=O)c3cocn3)ccc2F)CS(=O)(=O)[C@]2(CCOC2)C(=N)N1;Ki;'=';180.0;nM;6.75;;341321;UO_0000065;15.97;0.32;5.30;5.02;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3913922;;0;341.36;0;1.87;BDBM190872;C[C@@]1(c2cc([N+](=O)[O-])ccc2F)CS(=O)(=O)C2(CCC2)C(=N)N1;Ki;'=';3630.0;nM;5.44;;341350;UO_0000065;15.94;0.32;3.57;4.81;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3640264;;0;418.86;0;1.70;BDBM102947;COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3ccccc3F)C2)nc(C)c1Cl;Ki;'=';9.3;nM;8.03;;220576;UO_0000065;19.17;0.38;6.33;8.29;False;CHEMBL3705045;Time-Resolved FRET Assay: A homogeneous time-resolved FRET assay was used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. The assay monitored the increase of 620nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide).;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638861;37;BindingDB Database;;2013;None
CHEMBL4112488;;0;476.51;0;2.37;BDBM236614;C[C@]1(C2CC2)C(=N)N[C@@]2(c3cc(NC(=O)c4ccc(F)cn4)ccc3F)COC[C@H]2S1(=O)=O;Ki;'=';62.0;nM;7.21;;412130;UO_0000065;15.13;0.30;4.84;5.94;False;CHEMBL3888701;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886796;37;BindingDB Database;;2016;None
CHEMBL2011999;;0;382.88;0;3.70;13o;CN1C(=N)NC(c2cccc(-c3cccc(Cl)c3)c2)(c2nccs2)C1=O;Ki;'=';1200.0;nM;5.92;;;UO_0000065;15.46;0.31;2.22;8.57;False;CHEMBL2015090;Inhibition of human BACE1 using QSY7EISEVNLDAEFC-Eu-amide as substrate incubated for 30 mins prior to substrate addition measured after 90 mins by FRET analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2010674;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2012;None
CHEMBL601523;;0;876.98;2;5.57;2i;CO[C@H](C[C@H](N=[N+]=[N-])[C@H](COc1cc(F)cc(F)c1)NC(=O)c1cc(C(=O)N[C@H](C)c2ccccc2)cc(N(C)S(C)(=O)=O)c1)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C;Ki;'=';70.0;nM;7.16;;;UO_0000065;8.16;0.16;1.58;3.24;False;CHEMBL1069651;Inhibition of human BACE1 expressed in Escherichia coli BL21(DE3) by resolved fluorescence assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1156935;1;Scientific Literature;Bioorg. Med. Chem.;2010;None
CHEMBL1934195;;0;368.43;1;5.62;31;COc1c2occc2c(OC/C=C(\C)CCC=C(C)C)c2ccc(=O)oc12;Ki;'=';102700.0;nM;;Outside typical range;;UO_0000065;;;;;False;CHEMBL1936883;Inhibition of recombinant human BACE1 assessed as dissociation constant of enzyme-inhibitor complex using Rh-EVNLDAEFK as substrate by Dixon and Cornish-Bowden plots analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1932923;1;Scientific Literature;Bioorg. Med. Chem.;2012;None
CHEMBL1097320;;0;670.82;1;4.21;3b;CCCN(CCC)C(=O)c1cc(C)cc(C(=O)N[C@@H](Cc2cc(F)cc(F)c2)[C@H](O)[C@H]2CN(S(=O)(=O)c3ccccc3C)CCN2)c1;Ki;'=';5.0;nM;8.3;;;UO_0000065;12.37;0.24;4.09;6.97;False;CHEMBL1109071;Inhibition oh BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157894;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL1097331;;0;674.82;1;2.94;3m;CCCN(CCC)C(=O)c1cc(C)cc(C(=O)N[C@@H](Cc2cc(F)cc(F)c2)[C@H](O)[C@H]2CN(S(=O)(=O)c3cnc(C)n3C)CCN2)c1;Ki;'=';3.0;nM;8.52;;;UO_0000065;12.63;0.25;5.58;6.23;False;CHEMBL1109071;Inhibition oh BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157894;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL78946;;0;893.01;3;-1.74;1, OM99-2;CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(=O)O)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O;Ki;'=';1.6;nM;8.8;;;UO_0000065;9.85;0.19;10.54;2.34;True;CHEMBL1931877;Inhibition of human recombinant BACE1 ectodomain (1 to 460 amino acids) assessed as inhibition of proteolytic cleavage of Rhodamine-EVNLDAEFK-Quencher substrate after 35 mins by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1926578;1;Scientific Literature;J. Med. Chem.;2011;None
CHEMBL2151040;;0;385.47;0;3.99;7;COc1cccc(-c2cccc([C@]3(c4ccccc4)CC(=O)N(C)C(=N)N3)c2)c1;Ki;'=';22000.0;nM;4.66;;;UO_0000065;12.08;0.22;0.67;7.12;False;CHEMBL2155063;Inhibition of human recombinant BACE1 by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2150878;1;Scientific Literature;ACS Med. Chem. Lett.;2012;None
CHEMBL3897894;;0;454.96;0;2.80;BDBM190818;COc1cccc(NC(=O)c2cc(Cl)c([C@]3(C)CS(=O)(=O)C4(CC4)C(=N)N3)s2)n1;Ki;'=';74.0;nM;7.13;;341301;UO_0000065;15.67;0.34;4.33;5.88;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3983432;;0;433.47;0;1.62;BDBM190698;COc1cnc(C(=O)Nc2ccc(F)c([C@]3(C)CS(=O)(=O)C4(CC4)C(=N)N3)c2)cn1;Ki;'=';4.2;nM;8.38;;341193;UO_0000065;19.32;0.38;6.76;6.25;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3980201;;0;499.49;0;3.41;BDBM190712;C[C@@]1(c2cc(NC(=O)c3cnc(C(F)(F)F)cn3)ccc2F)CS(=O)(=O)C2(CCCC2)C(=N)N1;Ki;'=';13.0;nM;7.89;;341207;UO_0000065;15.79;0.32;4.48;6.31;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3900066;;0;435.48;0;2.29;BDBM190717;Cc1nc(C(=O)Nc2ccc(F)c([C@]3(C)CS(=O)(=O)C4(CCCC4)C(=N)N3)c2)no1;Ki;'=';13.9;nM;7.86;;341212;UO_0000065;18.04;0.36;5.57;5.69;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3965155;;0;475.55;0;2.79;BDBM190723;COc1cnc(C(=O)Nc2ccc(F)c([C@]3(C)CS(=O)(=O)C4(CCCCC4)C(=N)N3)c2)cn1;Ki;'=';36.0;nM;7.44;;341218;UO_0000065;15.65;0.31;4.65;5.55;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3950248;;0;442.93;0;2.93;BDBM190820;C[C@@]1(c2sc(C(=O)Nc3cccc(F)n3)cc2Cl)CS(=O)(=O)C2(CC2)C(=N)N1;Ki;'=';227.0;nM;6.64;;341303;UO_0000065;15.0;0.32;3.71;5.93;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL455679;KUSHENOL A;0;408.49;1;5.60;6;C=C(C)[C@H](CC=C(C)C)Cc1c(O)cc(O)c2c1O[C@H](c1ccccc1O)CC2=O;Ki;'=';3000.0;nM;5.52;;;UO_0000065;13.52;0.25;-0.08;6.35;False;CHEMBL946249;Inhibition of human BACE1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1155037;1;Scientific Literature;Bioorg. Med. Chem.;2008;None
CHEMBL492828;ISOXANTHOHUMOL;0;354.4;0;4.32;3;COc1cc(O)c(CC=C(C)C)c2c1C(=O)CC(c1ccc(O)cc1)O2;Ki;;;;;;Not Determined;;;;;;False;CHEMBL946249;Inhibition of human BACE1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1155037;1;Scientific Literature;Bioorg. Med. Chem.;2008;None
CHEMBL3973353;;0;436.95;0;2.66;BDBM242289;CN1C(=N)N[C@](C)(c2sc(-c3ccc(-n4nccn4)cc3)cc2Cl)CS1(=O)=O;Ki;'=';2265.0;nM;5.64;;422416;UO_0000065;12.92;0.28;2.98;5.43;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3925463;;0;506.51;1;2.18;BDBM249100;CN1CC2(C1)C(=N)N[C@](C)(c1cc(NC(=O)c3ncc(C#N)cc3C(F)F)ccc1F)CS2(=O)=O;Ki;'=';1.4;nM;8.85;;434638;UO_0000065;17.48;0.35;6.67;6.37;False;CHEMBL3889105;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 ul of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 ul in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window. Inhibitor IC50 values are derived from non-linear regression analysis of concentration response curves. Ki values are then calculated from IC50 values using the Cheng-Prusoff equation using a previously determined um value of 8 uM for the QSY7-APPswe-Eu substrate at BACE1.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886943;37;BindingDB Database;;2016;None
CHEMBL3939154;;0;485.99;0;4.45;BDBM242934;CC1(C)C(=N)N[C@](C)(c2cc(NC(=O)c3ccc(Cl)cn3)ccc2F)CS1(O)NCCF;Ki;'=';3.0;nM;8.52;;423795;UO_0000065;17.54;0.36;4.07;7.74;False;CHEMBL3888940;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886895;37;BindingDB Database;;2016;None
CHEMBL3938450;;0;414.46;0;3.16;BDBM242950;CN1C(=N)N[C@](C)(c2cc(-c3cc(-c4ccccc4)on3)ccc2F)CS1(=O)=O;Ki;'=';910.0;nM;6.04;;423831;UO_0000065;14.58;0.28;2.88;6.08;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3912880;;0;477.96;0;2.78;BDBM242972;CN1C(=N)N[C@](C)(c2sc(-c3nnc(-c4cnn5ccccc45)o3)cc2Cl)CS1(=O)=O;Ki;'=';2374.0;nM;5.62;;423853;UO_0000065;11.77;0.25;2.84;4.34;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3899232;;0;428.88;0;2.12;BDBM242977;CN1C(=N)N[C@](C)(c2sc(-c3nnc(-c4cnco4)o3)cc2Cl)CS1(=O)=O;Ki;'=';250.3;nM;6.6;;423858;UO_0000065;15.39;0.33;4.48;4.78;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3923862;;0;428.88;0;2.12;BDBM242979;CN1C(=N)N[C@](C)(c2sc(-c3nnc(-c4cocn4)o3)cc2Cl)CS1(=O)=O;Ki;'=';924.7;nM;6.03;;423860;UO_0000065;14.07;0.31;3.91;4.37;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3893604;;0;439.91;0;1.92;BDBM242980;CN1C(=N)N[C@](C)(c2sc(-c3nnc(-c4ccncn4)o3)cc2Cl)CS1(=O)=O;Ki;'=';822.5;nM;6.08;;423861;UO_0000065;13.83;0.30;4.16;4.41;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3937213;;0;441.93;0;1.87;BDBM242983;CN1C(=N)N[C@](C)(c2sc(-c3nnc(-c4ccn(C)n4)o3)cc2Cl)CS1(=O)=O;Ki;'=';1139.0;nM;5.94;;423864;UO_0000065;13.45;0.29;4.07;4.57;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3929364;;0;477.96;0;3.01;BDBM242995;CN1C(=N)N[C@](C)(c2sc(-c3nnc(-c4ccc5[nH]cnc5c4)o3)cc2Cl)CS1(=O)=O;Ki;'=';964.3;nM;6.02;;423876;UO_0000065;12.59;0.27;3.01;4.27;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL158203;;0;519.68;1;2.66;12;CCC[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)C[C@H](NC(=O)CC(C)C)C(=O)O)C(=O)NCC(C)C;Ki;'=';69500.0;nM;4.16;;;UO_0000065;8.0;0.15;1.50;2.87;False;CHEMBL653517;Tested for inhibition of Beta-secretase 1 (BACE 1) expressed in insect cell using baculovirus;B;BAO_0000019;assay format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1147418;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2004;None
CHEMBL302833;;0;640.84;1;2.30;3;CC(C)C[C@H](NC(=O)[C@H](CS(C)(=O)=O)NC(=O)OC(C)(C)C)C(O)CC(C)C(=O)NC(C(=O)NCc1ccccc1)C(C)C;Ki;'=';1129.0;nM;5.95;;;UO_0000065;9.28;0.18;3.65;3.30;False;CHEMBL655069;Binding affinity for human brain memapsin 2 beta-Secretase (BACE);B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1144924;1;Scientific Literature;J. Med. Chem.;2003;None
CHEMBL3960086;;0;494.04;0;4.89;BDBM242932;CC1(C)C(=N)N[C@](C)(c2cc(NC(=O)c3ccc(Cl)cn3)ccc2F)CS1(O)NCC1CC1;Ki;'=';4.0;nM;8.4;;423793;UO_0000065;17.0;0.35;3.51;7.63;False;CHEMBL3888940;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886895;37;BindingDB Database;;2016;None
CHEMBL3944720;;0;478.99;0;3.41;BDBM242273;CN1C(=N)N[C@](C)(c2sc(-c3ccnc(-c4nc(C5CC5)no4)c3)cc2Cl)CS1(=O)=O;Ki;'=';127.0;nM;6.9;;422400;UO_0000065;14.4;0.30;3.49;5.51;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3970292;;0;490.01;0;3.19;BDBM242323;CN1C(=N)N[C@](C)(c2sc3c(-c4ccc(C5CC(=O)N5)cc4)nccc3c2Cl)CS1(=O)=O;Ki;'=';959.2;nM;6.02;;422450;UO_0000065;12.28;0.26;2.83;5.22;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3893733;;0;519.03;1;4.26;BDBM242341;Cc1cnn(-c2ccc(-c3nccc4c(Cl)c([C@]5(C)CS(=O)(=O)N(C)C(=N)N5)sc34)c(F)c2)c1;Ki;'=';189.4;nM;6.72;;422468;UO_0000065;12.95;0.27;2.46;6.47;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL1097058;;0;476.62;0;4.61;16;CC(C)[C@@H]1CCC(=O)N(C2CCOCC2)CCc2cccc(c2)Oc2ccc3c(c2)CN1C(N)=N3;Ki;'=';22.0;nM;7.66;;;UO_0000065;16.07;0.30;3.05;9.53;False;CHEMBL1103872;Inhibition of BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157115;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL3800286;;0;477.53;0;2.55;14;COc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3cc(-c4cccc(C#N)c4)cs3)C2)ncc1F;Ki;'=';1.0;nM;9.0;;;UO_0000065;18.85;0.36;6.45;7.61;False;CHEMBL4270026;Inhibition of recombinant human BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4266039;1;Scientific Literature;J Med Chem;2018;None
CHEMBL319881;;0;622.87;1;4.01;19;CSCC[C@H](NC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C;Ki;'=';5808.0;nM;5.24;;;UO_0000065;8.41;0.17;1.23;3.59;False;CHEMBL711471;Binding affinity for human brain memapsin 2;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1134775;1;Scientific Literature;J. Med. Chem.;2001;None
CHEMBL199946;;0;655.88;2;5.10;6;CCCN(CCC)C(=O)c1cccc(C(=O)N[C@@H](Cc2ccccc2)[C@@H](N)C[C@@H](C)C(=O)N[C@H](C(=O)NCc2ccccc2)C(C)C)c1;Ki;'=';33.0;nM;7.48;;;UO_0000065;11.41;0.21;2.38;5.60;False;CHEMBL853557;Inhibition of human BACE1 expressed in Hi5 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;BTI-TN-5B1-4;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1148624;1;Scientific Literature;J. Med. Chem.;2006;CHEMBL3833782
CHEMBL2178143;;0;443.54;0;2.71;45;Cc1cnc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3cc(-c4cccc(C#N)c4)cs3)C2)nc1;Ki;'=';9.0;nM;8.05;;;UO_0000065;18.14;0.34;5.34;7.38;False;CHEMBL2183861;Inhibition of BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177036;1;Scientific Literature;J. Med. Chem.;2012;None
CHEMBL2178719;;0;463.95;0;3.06;44;CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3ncc(Cl)cn3)C[C@H]2C1=O;Ki;'=';7.0;nM;8.15;;;UO_0000065;17.58;0.35;5.09;7.48;False;CHEMBL2183861;Inhibition of BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177036;1;Scientific Literature;J. Med. Chem.;2012;None
CHEMBL97631;;0;577.72;2;1.49;1;CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)OC(C)(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)NCc1ccccc1;Ki;'=';22423.0;nM;4.65;;;UO_0000065;8.05;0.15;3.16;2.46;True;CHEMBL942114;Inhibition of BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1140597;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2007;None
CHEMBL78946;;0;893.01;3;-1.74;OM99-2;CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(=O)O)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O;Ki;'=';1.6;nM;8.8;;;UO_0000065;9.85;0.19;10.54;2.34;True;CHEMBL1045676;Inhibition of human recombinant BACE1 by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1154184;1;Scientific Literature;J. Med. Chem.;2009;None
CHEMBL3945065;;0;465.93;0;3.10;BDBM190849;C[C@@]1(c2cc(NC(=O)c3ccc(Cl)cc3)ccc2F)CS(=O)(=O)[C@]2(CCOC2)C(=N)N1;Ki;'=';82.0;nM;7.09;;341331;UO_0000065;15.21;0.31;3.99;6.54;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3899452;;0;399.44;0;0.78;BDBM190859;COCC(=O)Nc1ccc(F)c([C@]2(C)CS(=O)(=O)[C@]3(CCOC3)C(=N)N2)c1;Ki;'=';429.0;nM;6.37;;341339;UO_0000065;15.94;0.32;5.59;5.42;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3650826;;0;442.9;0;3.02;BDBM149914;Cc1cc(Cl)cnc1C(=O)Nc1ccc2c(c1)C1(COC(N)=N1)C1(COC1)C(C)(C)O2;Ki;'=';64.5;nM;7.19;;361636;UO_0000065;16.23;0.32;4.17;6.65;False;CHEMBL3887894;Fluorescence Resonance Energy Transfer (FRET) Assay: Test Example 1: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence. The amino acid sequence of the 'core' peptide of the substrate is SEVNLDAEFK (SEQ ID NO:2). The amino terminus was derivatized with (7-methoxycoumarin-4-yl)acetyl (MCA), and the epsilon amine of the lysine side chain of the terminal residue (K in sequence SEVNLDAEFK (SEQ ID NO:2)) was derivatized with 2,4-dinitrophenyl (DNP). Assays were performed in a buffer of 0.1 M sodium acetate, pH 4.4, 0.08% 3-[(3-Cholamidopropyl)dimethylammonio]propanesulfonate (CHAPS), 0.005% Tween80. BACE1 enzyme (final concentration 65 nM) was pre-incubated with test compounds for 15 minutes at room temperature. Fluorescence intensities were measured 60 minutes after addition of the substrate (final concentration 3 uM) by Tecan Safire2.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886493;37;BindingDB Database;;2016;None
CHEMBL1097340;;0;594.73;1;2.47;3v;CCCN(CCC)C(=O)c1cc(C)cc(C(=O)N[C@@H](Cc2cc(F)cc(F)c2)[C@H](O)[C@H]2CN(S(C)(=O)=O)CCN2)c1;Ki;'=';73.0;nM;7.14;;;UO_0000065;12.0;0.24;4.67;5.99;False;CHEMBL1109071;Inhibition oh BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157894;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL3907458;;0;455.99;0;3.23;BDBM190755;COc1cncc(-c2cc(Cl)c([C@]3(C)CS(=O)(=O)C4(CCOCC4)C(=N)N3)s2)c1;Ki;'=';555.0;nM;6.26;;341247;UO_0000065;13.72;0.29;3.03;6.17;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3984303;;0;487.09;1;5.40;BDBM190811;C[C@@]1(c2sc(C#CC3(c4ccccc4)CCCC3)cc2Cl)CS(=O)(=O)C2(CCC2)C(=N)N1;Ki;'=';2552.0;nM;5.59;;341295;UO_0000065;11.48;0.24;0.19;7.99;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3899032;;0;498.05;0;4.38;BDBM190827;C[C@@]1(c2sc(C(=O)NCc3ccc(F)cc3)cc2Cl)CS(=O)(=O)C2(CCCCC2)C(=N)N1;Ki;'=';588.0;nM;6.23;;341310;UO_0000065;12.51;0.27;1.85;6.29;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3930380;;0;413.47;0;1.17;BDBM190837;CCOCC(=O)Nc1ccc(F)c([C@]2(C)CS(=O)(=O)[C@]3(CCOC3)C(=N)N2)c1;Ki;'=';4148.0;nM;5.38;;341319;UO_0000065;13.02;0.26;4.21;4.58;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL4113860;;0;477.52;0;1.55;BDBM236593;COc1cnc(C(=O)Nc2ccc(F)c([C@]34COC[C@H]3S(=O)(=O)C(C)(C)C(=N)N4)c2)c(C)n1;Ki;'=';10.0;nM;8.0;;412109;UO_0000065;16.75;0.33;6.45;5.58;False;CHEMBL3888701;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886796;37;BindingDB Database;;2016;None
CHEMBL3895598;;0;450.45;0;0.27;BDBM199099;COc1cnc(C(=O)Nc2ccc(F)c([C@@]34COC[C@@H]3S(=O)(=O)N(C)C(=N)N4)c2)cn1;Ki;'=';1326.0;nM;5.88;;354111;UO_0000065;13.05;0.26;5.61;4.01;False;CHEMBL3887768;Homogeneous Time-Resolved FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 u) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886448;37;BindingDB Database;;2015;None
CHEMBL3650853;;0;428.88;0;2.72;BDBM149944;CC1(C)Oc2ccc(NC(=O)c3ccc(Cl)cn3)cc2[C@]2(COC(N)=N2)C12COC2;Ki;'=';30200.0;nM;4.52;;361663;UO_0000065;10.54;0.21;1.80;4.18;False;CHEMBL3887894;Fluorescence Resonance Energy Transfer (FRET) Assay: Test Example 1: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence. The amino acid sequence of the 'core' peptide of the substrate is SEVNLDAEFK (SEQ ID NO:2). The amino terminus was derivatized with (7-methoxycoumarin-4-yl)acetyl (MCA), and the epsilon amine of the lysine side chain of the terminal residue (K in sequence SEVNLDAEFK (SEQ ID NO:2)) was derivatized with 2,4-dinitrophenyl (DNP). Assays were performed in a buffer of 0.1 M sodium acetate, pH 4.4, 0.08% 3-[(3-Cholamidopropyl)dimethylammonio]propanesulfonate (CHAPS), 0.005% Tween80. BACE1 enzyme (final concentration 65 nM) was pre-incubated with test compounds for 15 minutes at room temperature. Fluorescence intensities were measured 60 minutes after addition of the substrate (final concentration 3 uM) by Tecan Safire2.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886493;37;BindingDB Database;;2016;None
CHEMBL3703289;;0;403.48;0;3.24;BDBM149811;CC#Cc1cncc(-c2ccc3c(c2)C2(COC(N)=N2)C2(COC2)C(CCC)O3)c1;Ki;'=';87.9;nM;7.06;;361545;UO_0000065;17.49;0.32;3.82;8.94;False;CHEMBL3887894;Fluorescence Resonance Energy Transfer (FRET) Assay: Test Example 1: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence. The amino acid sequence of the 'core' peptide of the substrate is SEVNLDAEFK (SEQ ID NO:2). The amino terminus was derivatized with (7-methoxycoumarin-4-yl)acetyl (MCA), and the epsilon amine of the lysine side chain of the terminal residue (K in sequence SEVNLDAEFK (SEQ ID NO:2)) was derivatized with 2,4-dinitrophenyl (DNP). Assays were performed in a buffer of 0.1 M sodium acetate, pH 4.4, 0.08% 3-[(3-Cholamidopropyl)dimethylammonio]propanesulfonate (CHAPS), 0.005% Tween80. BACE1 enzyme (final concentration 65 nM) was pre-incubated with test compounds for 15 minutes at room temperature. Fluorescence intensities were measured 60 minutes after addition of the substrate (final concentration 3 uM) by Tecan Safire2.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886493;37;BindingDB Database;;2016;None
CHEMBL3942552;;0;460.53;0;3.00;BDBM190711;COc1ccc(C(=O)Nc2ccc(F)c([C@]3(C)CS(=O)(=O)C4(CCCC4)C(=N)N3)c2)nc1;Ki;'=';5.2;nM;8.28;;341206;UO_0000065;17.99;0.35;5.28;6.83;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3640272;;0;424.94;0;2.69;BDBM102955;CCc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3ccccc3)C2)nc(C2CC2)c1Cl;Ki;'=';180.0;nM;6.75;;220587;UO_0000065;15.87;0.31;4.05;7.69;False;CHEMBL3705045;Time-Resolved FRET Assay: A homogeneous time-resolved FRET assay was used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. The assay monitored the increase of 620nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide).;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638861;37;BindingDB Database;;2013;None
CHEMBL3672923;;0;422.44;0;0.89;BDBM143228;COc1cnc(C(=O)Nc2ccc(F)c([C@]3(C)CS(=O)(=O)N(C)C(=N)N3)c2)cn1;Ki;'=';1.64;nM;8.79;;279441;UO_0000065;20.8;0.41;7.90;6.40;True;CHEMBL3706083;Homogeneous Time-Resolved FRET Assay: The protocol that was used to determine the recited values isdescribed as follows.BACE1 HTRF FRET AssayReagentsNa+-Acetate pH 5.01% Brij-35GlycerolDimethyl Sulfoxide (DMSO)Recombinant human soluble BACE1 catalytic domain (>95% pure)APP Swedish mutant peptide substrate (QSY7-APPswe-Eu):QSY7-EISEVNLDAEFC-Europium-amideA homogeneous time-resolved FRET assay was used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitored the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contained an N-terminal QSY7 moiety that served as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence was low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638453;37;BindingDB Database;;2015;None
CHEMBL2151134;;0;318.38;0;2.83;5;CN1C(=N)N[C@](C)(c2cccc(-c3cccc(C#N)c3)c2)CC1=O;Ki;'=';350.0;nM;6.46;;;UO_0000065;20.28;0.37;3.63;8.07;False;CHEMBL2155063;Inhibition of human recombinant BACE1 by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2150878;1;Scientific Literature;ACS Med. Chem. Lett.;2012;None
CHEMBL2151141;;0;338.44;0;2.78;13;CC#Cc1cncc(-c2csc([C@]3(C)CC(=O)N(C)C(=N)N3)c2)c1;Ki;'=';7.8;nM;8.11;;;UO_0000065;23.96;0.46;5.33;11.74;False;CHEMBL2155063;Inhibition of human recombinant BACE1 by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2150878;1;Scientific Literature;ACS Med. Chem. Lett.;2012;None
CHEMBL4081377;;0;697.86;1;3.28;5a;C[C@@H](NC(=O)c1cc(C(=O)N[C@@H](Cc2ccccc2)[C@H](O)[C@@H]2NCCN(Cc3ccccc3)C2=O)cc(N(C)S(C)(=O)=O)c1)c1ccccc1;Ki;'=';2.0;nM;8.7;;;UO_0000065;12.47;0.24;5.42;5.87;False;CHEMBL4018279;Inhibition of recombinant human BACE1 (Ala8P to Ala326 residues) expressed in Escherichia coli BL21(DE3) using Arg-Glu(EDANS)-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys (Dabcyl)-Arg as substrate by fluorescence assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4017478;1;Scientific Literature;Bioorg Med Chem Lett;2017;None
CHEMBL3694260;;0;663.84;1;2.73;5b;CC(C)CN1CCN[C@@H]([C@@H](O)[C@H](Cc2ccccc2)NC(=O)c2cc(C(=O)N[C@H](C)c3ccccc3)cc(N(C)S(C)(=O)=O)c2)C1=O;Ki;'=';12.9;nM;7.89;;;UO_0000065;11.88;0.23;5.16;5.33;False;CHEMBL4018279;Inhibition of recombinant human BACE1 (Ala8P to Ala326 residues) expressed in Escherichia coli BL21(DE3) using Arg-Glu(EDANS)-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys (Dabcyl)-Arg as substrate by fluorescence assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4017478;1;Scientific Literature;Bioorg Med Chem Lett;2017;None
CHEMBL187568;;0;563.7;2;1.10;BACE Inhibitor 1;CC(C)C[C@H](NC(=O)[C@@H](NC(=O)OC(C)(C)C)C(N)=O)C(O)CC(C)C(=O)N[C@@H](C)C(=O)NCc1ccccc1;Ki;'=';22423.0;nM;4.65;;;UO_0000065;8.25;0.16;3.55;2.46;False;CHEMBL828263;Binding affinity towards Beta-secretase determined using continuum electrostatics solvation;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1137231;1;Scientific Literature;J. Med. Chem.;2004;None
CHEMBL1923709;;0;381.48;1;5.76;24;CC(C)(C)Nc1c(-c2cccc(-c3nc4ccccc4[nH]3)c2)nc2ccccn12;Ki;'=';495.0;nM;6.3;;;UO_0000065;16.53;0.30;0.55;10.87;False;CHEMBL1926456;Inhibition of BACE1 expressing APP Swedish mutant using rhodamine-labeled EVNLDAEFK-quencher as substrate after 60 mins by Michaelis-Menten equation;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1921672;1;Scientific Literature;J. Med. Chem.;2011;None
CHEMBL603118;;0;908.91;1;4.78;1c;CO[C@H](C[C@H](O)[C@H](COc1ccc(Br)cc1)NC(=O)c1cc(C(=O)N[C@H](C)c2ccccc2)cc(N(C)CS(C)(=O)=O)c1)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C;Ki;'=';75.0;nM;7.12;;;UO_0000065;7.84;0.16;2.34;3.70;False;CHEMBL1072341;Inhibition of human BACE1 expressed in Escherichia coli cells (BL21(DE3) by TRF assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157542;1;Scientific Literature;J. Med. Chem.;2010;None
CHEMBL1412710;;0;338.4;1;5.61;24;CC(C)=CCC/C(C)=C/COc1c2occc2cc2ccc(=O)oc12;Ki;'=';61600.0;nM;4.21;;;UO_0000065;12.44;0.23;-1.40;8.01;False;CHEMBL1936883;Inhibition of recombinant human BACE1 assessed as dissociation constant of enzyme-inhibitor complex using Rh-EVNLDAEFK as substrate by Dixon and Cornish-Bowden plots analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1932923;1;Scientific Literature;Bioorg. Med. Chem.;2012;None
CHEMBL508648;BYAKANGELICIN;0;334.32;0;2.06;34;COc1c2ccoc2c(OC[C@@H](O)C(C)(C)O)c2oc(=O)ccc12;Ki;'=';55000.0;nM;4.26;;;UO_0000065;12.74;0.24;2.20;4.17;False;CHEMBL1936883;Inhibition of recombinant human BACE1 assessed as dissociation constant of enzyme-inhibitor complex using Rh-EVNLDAEFK as substrate by Dixon and Cornish-Bowden plots analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1932923;1;Scientific Literature;Bioorg. Med. Chem.;2012;None
CHEMBL589772;;0;766.86;1;4.15;1h;CO[C@H](C[C@H](O)[C@H](COc1cc(F)cc(F)c1)NC(=O)c1cc(C(=O)N[C@H](C)c2ccccc2)cc(N(C)CS(C)(=O)=O)c1)C(=O)NCc1ccccc1;Ki;'=';1400.0;nM;5.85;;;UO_0000065;7.63;0.15;1.70;3.58;False;CHEMBL1072341;Inhibition of human BACE1 expressed in Escherichia coli cells (BL21(DE3) by TRF assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157542;1;Scientific Literature;J. Med. Chem.;2010;None
CHEMBL589377;;0;752.84;1;4.48;1i;CO[C@H](C[C@H](O)[C@H](COc1cc(F)cc(F)c1)NC(=O)c1cc(C(=O)N[C@H](C)c2ccccc2)cc(N(C)CS(C)(=O)=O)c1)C(=O)Nc1ccccc1;Ki;'=';200.0;nM;6.7;;;UO_0000065;8.9;0.17;2.22;4.10;False;CHEMBL1072341;Inhibition of human BACE1 expressed in Escherichia coli cells (BL21(DE3) by TRF assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157542;1;Scientific Literature;J. Med. Chem.;2010;None
CHEMBL1923705;;0;492.58;0;4.77;14;C[C@H](NC(=O)c1cc(-c2ncc(-c3cccc(F)c3)[nH]2)cc(N(C)S(C)(=O)=O)c1)c1ccccc1;Ki;'=';180.0;nM;6.75;;;UO_0000065;13.69;0.26;1.97;7.09;False;CHEMBL1926456;Inhibition of BACE1 expressing APP Swedish mutant using rhodamine-labeled EVNLDAEFK-quencher as substrate after 60 mins by Michaelis-Menten equation;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1921672;1;Scientific Literature;J. Med. Chem.;2011;None
CHEMBL1923701;;0;478.57;0;4.13;7;COc1ccc2[nH]c(-c3cc(C(=O)N[C@@H](C)c4ccccc4)cc(N(C)S(C)(=O)=O)c3)nc2c1;Ki;'=';525.0;nM;6.28;;;UO_0000065;13.12;0.25;2.15;6.02;False;CHEMBL1926456;Inhibition of BACE1 expressing APP Swedish mutant using rhodamine-labeled EVNLDAEFK-quencher as substrate after 60 mins by Michaelis-Menten equation;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1921672;1;Scientific Literature;J. Med. Chem.;2011;None
CHEMBL1923700;;0;448.55;0;4.12;6;C[C@H](NC(=O)c1cc(-c2nc3ccccc3[nH]2)cc(N(C)S(C)(=O)=O)c1)c1ccccc1;Ki;'=';1041.0;nM;5.98;;;UO_0000065;13.34;0.26;1.86;6.29;False;CHEMBL1926456;Inhibition of BACE1 expressing APP Swedish mutant using rhodamine-labeled EVNLDAEFK-quencher as substrate after 60 mins by Michaelis-Menten equation;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1921672;1;Scientific Literature;J. Med. Chem.;2011;None
CHEMBL509188;;0;763.89;2;-1.09;44, OM-99-1;CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O;Ki;'=';9.6;nM;8.02;;;UO_0000065;10.5;0.20;9.11;2.59;False;CHEMBL981021;Inhibition of recombinant memapsin 2;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1153435;1;Scientific Literature;J. Med. Chem.;2009;None
CHEMBL2011993;;0;353.85;0;4.00;13i;CN1C(=N)NC(CC2CC2)(c2cccc(-c3cccc(Cl)c3)c2)C1=O;Ki;'=';350.0;nM;6.46;;;UO_0000065;18.24;0.35;2.46;11.49;False;CHEMBL2015090;Inhibition of human BACE1 using QSY7EISEVNLDAEFC-Eu-amide as substrate incubated for 30 mins prior to substrate addition measured after 90 mins by FRET analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2010674;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2012;None
CHEMBL318115;;0;754.0;2;2.83;23;CC(C)C[C@H](NC(=O)[C@H](CCS(C)(=O)=O)NC(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C;Ki;'=';8.0;nM;8.1;;;UO_0000065;10.74;0.21;5.27;3.87;False;CHEMBL711471;Binding affinity for human brain memapsin 2;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1134775;1;Scientific Literature;J. Med. Chem.;2001;None
CHEMBL1098734;;0;528.74;2;7.08;12;NC1=Nc2ccc3cc2CN1[C@H](C1CCCCC1)CCC(=O)N(C1CCCCC1)CCCc1cccc(c1)O3;Ki;'=';31.0;nM;7.51;;;UO_0000065;14.2;0.26;0.43;10.55;False;CHEMBL1103872;Inhibition of BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157115;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL200077;;0;560.71;2;5.42;7;CCCN(CCC)C(=O)c1cccc(C(=O)N[C@@H](Cc2ccccc2)[C@@H](N)C[C@@H](C)C(=O)Nc2ccc(F)cc2)c1;Ki;'=';26.0;nM;7.58;;;UO_0000065;13.53;0.25;2.17;7.26;False;CHEMBL853557;Inhibition of human BACE1 expressed in Hi5 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;BTI-TN-5B1-4;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1148624;1;Scientific Literature;J. Med. Chem.;2006;CHEMBL3833782
CHEMBL3916477;;0;477.54;0;2.29;BDBM249102;CN1CCC2(CC1)C(=N)N[C@](C)(c1cc(NC(=O)c3ccc(F)cn3)ccc1F)CS2(=O)=O;Ki;'=';37.0;nM;7.43;;434640;UO_0000065;15.56;0.31;5.14;6.45;False;CHEMBL3889105;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 ul of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 ul in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window. Inhibitor IC50 values are derived from non-linear regression analysis of concentration response curves. Ki values are then calculated from IC50 values using the Cheng-Prusoff equation using a previously determined um value of 8 uM for the QSY7-APPswe-Eu substrate at BACE1.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886943;37;BindingDB Database;;2016;None
CHEMBL3983366;;0;460.38;0;4.41;BDBM234491;C[C@]1(F)CC(F)(F)[C@@](C)(c2cc(NC(=O)c3ccc(OC(F)F)cn3)ccc2F)N=C1N;Ki;'=';14.0;nM;7.85;;408808;UO_0000065;17.06;0.34;3.44;8.77;False;CHEMBL3888549;SPA-Based Assay: The binding assay was performed as SPA-based assay using a biotinylated form of human BACE1 recombinantly expressed and subsequently purified from Freestyle HEK293 cells. The binding assay was run in a 50 mM sodium acetate buffer, pH 4.5 containing 50 mM NaCl and 0.03% Tween-20 in white clear bottom 384 plates (Corning #3653). 10 nM (final concentration) radioligand ([3H]-N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N-((R)-1-phenyl-ethyl)-isophthalamide) (TRQ11569 purchased from GE Healthcare) was mixed with test compound at a given concentration, 6 nM (final concentration) human BACE1 and 25 μg Streptavidin coated PVT core SPA beads (RPNQ0007, GE Healthcare Life Sciences) in a total volume of 40 μl.;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886758;37;BindingDB Database;;2016;CHEMBL3307715
CHEMBL3964692;;0;512.53;1;4.41;BDBM190725;C[C@@]1(c2cc(NC(=O)c3ccc(C(F)(F)F)cn3)ccc2F)CS(=O)(=O)C2(CCCCC2)C(=N)N1;Ki;'=';23.3;nM;7.63;;341220;UO_0000065;14.89;0.30;3.22;6.81;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3912689;;0;411.5;0;3.89;BDBM190734;C[C@@]1(c2cc(-c3cccc(C#N)c3)ccc2F)CS(=O)(=O)C2(CCCC2)C(=N)N1;Ki;'=';1292.0;nM;5.89;;341228;UO_0000065;14.31;0.28;2.00;6.28;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL98239;;0;707.98;2;3.76;6;CSC[C@H](NC(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)C(=O)N[C@@H](CC(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C;Ki;'=';50.1;nM;7.3;;;UO_0000065;10.31;0.20;3.54;4.17;False;CHEMBL942114;Inhibition of BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1140597;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2007;None
CHEMBL3971718;;0;492.97;0;4.85;BDBM190754;C[C@@]1(c2sc(-c3cccc(C(F)(F)F)c3)cc2Cl)CS(=O)(=O)C2(CCOCC2)C(=N)N1;Ki;'=';147.0;nM;6.83;;341246;UO_0000065;13.86;0.30;1.98;8.62;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3927085;;0;498.05;0;4.38;BDBM190826;C[C@@]1(c2sc(C(=O)NCc3cccc(F)c3)cc2Cl)CS(=O)(=O)C2(CCCCC2)C(=N)N1;Ki;'=';5116.0;nM;5.29;;341309;UO_0000065;10.62;0.23;0.91;5.34;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3905817;;0;395.46;0;1.54;BDBM190836;C[C@@]1(c2cc(NC(=O)C3CC3)ccc2F)CS(=O)(=O)[C@]2(CCOC2)C(=N)N1;Ki;'=';5166.0;nM;5.29;;341318;UO_0000065;13.37;0.27;3.75;4.88;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3968905;;0;420.47;0;1.44;BDBM190845;C[C@@]1(c2cc(NC(=O)C3(C#N)CC3)ccc2F)CS(=O)(=O)[C@]2(CCOC2)C(=N)N1;Ki;'=';741.0;nM;6.13;;341327;UO_0000065;14.58;0.29;4.69;4.64;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3984945;;0;510.57;1;1.25;BDBM190862;C[C@@]1(c2cc(NC(=O)c3ccc(S(C)(=O)=O)cn3)ccc2F)CS(=O)(=O)[C@]2(CCOC2)C(=N)N1;Ki;'=';3166.0;nM;5.5;;341342;UO_0000065;10.77;0.22;4.25;3.54;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL66035;;0;878.98;3;-2.13;3;CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O;Ki;'=';10.0;nM;8.0;;;UO_0000065;9.1;0.18;10.13;2.13;False;CHEMBL653499;Inhibition of human recombinant beta-secretase;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1134505;1;Scientific Literature;J. Med. Chem.;2001;None
CHEMBL97631;;0;577.72;2;1.49;12;CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)OC(C)(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)NCc1ccccc1;Ki;'=';22423.0;nM;4.65;;;UO_0000065;8.05;0.15;3.16;2.46;True;CHEMBL711471;Binding affinity for human brain memapsin 2;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1134775;1;Scientific Literature;J. Med. Chem.;2001;None
CHEMBL362078;;0;714.91;2;2.06;3b;CC(C)C[C@H](NC(=O)[C@@H]1CC(=O)NC/C=C/CCOC(=O)N[C@@H](C(C)C)C(=O)N1)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C;Ki;'=';28.4;nM;7.55;;;UO_0000065;10.56;0.20;5.49;3.70;False;CHEMBL828805;Binding affinity for human brain memapsin 2;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1145144;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2005;None
CHEMBL1923703;;0;474.59;0;4.63;12;C[C@H](NC(=O)c1cc(-c2ncc(-c3ccccc3)[nH]2)cc(N(C)S(C)(=O)=O)c1)c1ccccc1;Ki;'=';304.0;nM;6.52;;;UO_0000065;13.73;0.26;1.89;6.85;False;CHEMBL1926456;Inhibition of BACE1 expressing APP Swedish mutant using rhodamine-labeled EVNLDAEFK-quencher as substrate after 60 mins by Michaelis-Menten equation;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1921672;1;Scientific Literature;J. Med. Chem.;2011;None
CHEMBL260621;;0;600.66;1;4.31;26;CC(C)(C)c1cccc(CNC[C@@H](O)[C@H](Cc2cc(F)cc(F)c2)NC(=O)[C@@H]2CN(Cc3cc(F)cc(F)c3)C(=O)N2)c1;Ki;'=';2.0;nM;8.7;;;UO_0000065;14.48;0.28;4.39;9.28;False;CHEMBL929344;Inhibition of human BACE1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1145643;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2008;None
CHEMBL265953;;0;551.64;1;2.80;16;CN(C)c1cccc(CNC[C@@H](O)[C@H](Cc2ccccc2)NC(=O)[C@@H]2CN(Cc3ccc(F)cc3F)C(=O)N2)c1;Ki;'=';867.0;nM;6.06;;;UO_0000065;10.99;0.21;3.26;6.25;False;CHEMBL929344;Inhibition of human BACE1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1145643;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2008;None
CHEMBL273916;;0;640.84;1;2.30;46;CC(C)C[C@H](NC(=O)[C@H](CS(C)(=O)=O)NC(=O)OC(C)(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C;Ki;'=';1129.0;nM;5.95;;;UO_0000065;9.28;0.18;3.65;3.30;False;CHEMBL981021;Inhibition of recombinant memapsin 2;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1153435;1;Scientific Literature;J. Med. Chem.;2009;None
CHEMBL1097353;;0;684.81;1;3.03;3jj;COC[C@H]1CCCN1C(=O)c1cc(C)cc(C(=O)N[C@@H](Cc2cc(F)cc(F)c2)[C@H](O)[C@H]2CN(S(=O)(=O)Cc3ccccc3)CCN2)c1;Ki;'=';1.0;nM;9.0;;;UO_0000065;13.14;0.26;5.97;7.02;False;CHEMBL1109071;Inhibition oh BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157894;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL200116;;0;622.85;1;4.94;1;CCCN(CCC)C(=O)c1cccc(C(=O)N[C@@H](CC(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NCc2ccccc2)C(C)C)c1;Ki;'=';71.0;nM;7.15;;;UO_0000065;11.48;0.22;2.21;5.59;False;CHEMBL853557;Inhibition of human BACE1 expressed in Hi5 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;BTI-TN-5B1-4;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1148624;1;Scientific Literature;J. Med. Chem.;2006;CHEMBL3833782
CHEMBL425031;;0;527.68;2;5.26;4;CCCN(CCC)C(=O)c1cccc(C(=O)N[C@@H](CC(C)C)[C@@H](O)C[C@@H](C)C(=O)Nc2ccc(F)cc2)c1;Ki;'=';1300.0;nM;5.89;;;UO_0000065;11.15;0.21;0.63;5.96;False;CHEMBL853557;Inhibition of human BACE1 expressed in Hi5 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;BTI-TN-5B1-4;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1148624;1;Scientific Literature;J. Med. Chem.;2006;CHEMBL3833782
CHEMBL2178189;;0;495.97;0;4.21;17o;COc1ccc(-c2noc(C)c2C(=O)/N=C(\N)NCc2cc(C)c(NC(=O)C3CC3)c(Cl)c2)cc1;Ki;'=';20.0;nM;7.7;;;UO_0000065;15.52;0.30;3.49;5.84;False;CHEMBL2187886;Displacement of [3H]BMS-599240 from BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177026;1;Scientific Literature;J. Med. Chem.;2012;CHEMBL3307715
CHEMBL2178181;;0;486.0;0;4.29;17g;COc1ccc(-c2nsc(C)c2C(=O)/N=C(\N)NCc2cc(C)c(NC(C)=O)c(Cl)c2)cc1;Ki;'=';20.0;nM;7.7;;;UO_0000065;15.84;0.32;3.41;6.49;False;CHEMBL2187886;Displacement of [3H]BMS-599240 from BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177026;1;Scientific Literature;J. Med. Chem.;2012;CHEMBL3307715
CHEMBL347901;;0;521.66;2;1.24;14;CC(C)CNC(=O)[C@H](CCO)C[C@H](O)[C@H](Cc1ccccc1)NC(=O)C[C@H](NC(=O)CC(C)C)C(=O)O;Ki;'=';1900.0;nM;5.72;;;UO_0000065;10.97;0.21;4.48;3.47;False;CHEMBL653517;Tested for inhibition of Beta-secretase 1 (BACE 1) expressed in insect cell using baculovirus;B;BAO_0000019;assay format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1147418;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2004;None
CHEMBL3628122;;0;460.37;0;3.41;7n;CC(=O)Nc1c(Cl)cc(CN/C(N)=N/C(=O)C2C3CC3CN2c2ccccc2)cc1Cl;Ki;'=';360.0;nM;6.44;;;UO_0000065;14.0;0.28;3.03;6.46;False;CHEMBL3630426;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 6.4 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL253930;;0;745.92;1;3.83;23;C[C@@H](NC(=O)c1cc(C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CNCc2ccc3ccn(S(C)(=O)=O)c3c2)cc(N(C)S(C)(=O)=O)c1)c1ccccc1;Ki;'=';27.0;nM;7.57;;;UO_0000065;10.15;0.20;3.74;4.53;False;CHEMBL945886;Binding affinity to recombinant memapsin 2;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1141466;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2008;None
CHEMBL2299407;;0;754.0;2;2.48;9;CC(C)C[C@H](NCC(=O)[C@H](CS(C)(=O)=O)NC(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C(=O)NCc1ccccc1)C(C)C;Ki;'=';9397.23;nM;5.03;;;UO_0000065;6.67;0.13;2.55;2.40;False;CHEMBL3075361;Inhibition of BACE (unknown origin);B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3045025;1;Scientific Literature;Med Chem Res;2013;None
CHEMBL97603;;0;764.09;3;5.18;11;CSCC[C@H](NC(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)C(=O)N[C@@H](CC(C)C)[C@@H](O)C[C@@H](CC(C)C)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C;Ki;'=';10491.0;nM;4.98;;;UO_0000065;6.52;0.13;-0.20;2.85;False;CHEMBL942114;Inhibition of BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1140597;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2007;None
CHEMBL97603;;0;764.09;3;5.18;24;CSCC[C@H](NC(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)C(=O)N[C@@H](CC(C)C)[C@@H](O)C[C@@H](CC(C)C)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C;Ki;'=';10491.0;nM;4.98;;;UO_0000065;6.52;0.13;-0.20;2.85;True;CHEMBL711471;Binding affinity for human brain memapsin 2;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1134775;1;Scientific Literature;J. Med. Chem.;2001;None
CHEMBL253931;;0;624.8;1;3.88;26;COc1cccc(CNC[C@@H](O)[C@H](CC(C)C)NC(=O)c2cc(C(=O)N[C@H](C)c3ccccc3)cc(N(C)S(C)(=O)=O)c2)c1;Ki;'=';916.0;nM;6.04;;;UO_0000065;9.66;0.19;2.16;4.41;False;CHEMBL945886;Binding affinity to recombinant memapsin 2;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1141466;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2008;None
CHEMBL294274;;0;739.98;2;2.44;7;CC(C)C[C@H](NC(=O)C(CS(C)(=O)=O)NC(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)C(O)CC(C)C(=O)NC(C(=O)NCc1ccccc1)C(C)C;Ki;'=';9.4;nM;8.03;;;UO_0000065;10.85;0.21;5.59;3.84;False;CHEMBL827180;Binding affinity against Beta-secretase;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1137865;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2004;None
CHEMBL3361306;;0;736.01;2;3.61;3d;Cc1cc(C)n(C[C@@H](C(=O)N[C@@H](CNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NCC(C)C)C(C)C)C(C)C)n1;Ki;'=';471.0;nM;6.33;;;UO_0000065;8.6;0.17;2.72;3.28;False;CHEMBL3380862;Inhibition of recombinant BACE1 (unknown origin);B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3351680;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;None
CHEMBL2011979;;0;360.39;0;3.13;4o;CN1C(=N)NC(c2ccccc2)(c2cccc(-c3cncc(F)c3)c2)C1=O;Ki;'=';290.0;nM;6.54;;;UO_0000065;18.14;0.33;3.41;9.46;False;CHEMBL2015090;Inhibition of human BACE1 using QSY7EISEVNLDAEFC-Eu-amide as substrate incubated for 30 mins prior to substrate addition measured after 90 mins by FRET analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2010674;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2012;None
CHEMBL2011981;;0;371.44;0;3.60;6a;COc1cccc(-c2cccc([C@@]3(c4ccccc4)NC(=N)N(C)C3=O)c2)c1;Ki;'=';80.0;nM;7.1;;;UO_0000065;19.11;0.35;3.50;10.85;False;CHEMBL2015090;Inhibition of human BACE1 using QSY7EISEVNLDAEFC-Eu-amide as substrate incubated for 30 mins prior to substrate addition measured after 90 mins by FRET analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2010674;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2012;None
CHEMBL2011986;;0;327.82;0;3.61;13b;CCC1(c2cccc(-c3cccc(Cl)c3)c2)NC(=N)N(C)C1=O;Ki;'=';450.0;nM;6.35;;;UO_0000065;19.36;0.38;2.74;11.30;False;CHEMBL2015090;Inhibition of human BACE1 using QSY7EISEVNLDAEFC-Eu-amide as substrate incubated for 30 mins prior to substrate addition measured after 90 mins by FRET analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2010674;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2012;None
CHEMBL2011987;;0;341.84;0;3.85;13c;CC(C)C1(c2cccc(-c3cccc(Cl)c3)c2)NC(=N)N(C)C1=O;Ki;'=';320.0;nM;6.5;;;UO_0000065;19.0;0.37;2.64;11.56;False;CHEMBL2015090;Inhibition of human BACE1 using QSY7EISEVNLDAEFC-Eu-amide as substrate incubated for 30 mins prior to substrate addition measured after 90 mins by FRET analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2010674;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2012;None
CHEMBL2011988;;0;339.83;0;3.61;13d;CN1C(=N)NC(c2cccc(-c3cccc(Cl)c3)c2)(C2CC2)C1=O;Ki;'=';47.0;nM;7.33;;;UO_0000065;21.56;0.42;3.72;13.04;False;CHEMBL2015090;Inhibition of human BACE1 using QSY7EISEVNLDAEFC-Eu-amide as substrate incubated for 30 mins prior to substrate addition measured after 90 mins by FRET analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2010674;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2012;None
CHEMBL3961621;;0;496.01;0;3.92;BDBM242997;CC(C)Oc1ccc(-c2nnc(-c3cc(Cl)c([C@]4(C)CS(=O)(=O)N(C)C(=N)N4)s3)o2)cc1;Ki;'=';204.9;nM;6.69;;423878;UO_0000065;13.48;0.29;2.77;5.51;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3973836;;0;497.04;0;2.67;BDBM190775;C[C@@]1(c2sc(-c3cncc(N4CCOCC4)c3)cc2Cl)CS(=O)(=O)[C@]2(CCOC2)C(=N)N1;Ki;'=';1662.0;nM;5.78;;341272;UO_0000065;11.63;0.25;3.11;5.52;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL1770312;KUWANON A;0;420.46;1;5.27;4;CC(C)=CCc1c(-c2ccc(O)c3c2OC(C)(C)C=C3)oc2cc(O)cc(O)c2c1=O;Ki;'=';10600.0;nM;4.97;;;UO_0000065;11.83;0.22;-0.30;4.97;False;CHEMBL1771832;Noncompetitive inhibition of human recombinant BACE-1 by Dixon plot analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1770081;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2011;None
CHEMBL3627961;;0;422.32;0;3.83;11b;CC(=O)Nc1c(Cl)cc(CN/C(N)=N/C(=O)N[C@@H](C)c2ccccc2)cc1Cl;Ki;'=';2400.0;nM;5.62;;;UO_0000065;13.31;0.27;1.79;5.17;False;CHEMBL3630426;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 6.4 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL3628125;;0;545.47;1;3.46;20b;N/C1=N\C(=O)[C@@H]2CCCN2c2ccc(cc2)OC/C=C/CCNCC(=O)Nc2c(Cl)cc(cc2Cl)CN1;Ki;'=';110.0;nM;6.96;;;UO_0000065;12.76;0.26;3.50;5.75;False;CHEMBL3630426;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 6.4 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL1097346;;0;679.81;1;2.47;3bb;CCNc1cc(C(=O)N[C@@H](Cc2cc(F)cc(F)c2)[C@H](O)[C@H]2CN(S(=O)(=O)c3cccc(C)c3)CCN2)cc(N(C)S(C)(=O)=O)c1;Ki;'=';1.0;nM;9.0;;;UO_0000065;13.24;0.27;6.53;6.07;False;CHEMBL1109071;Inhibition oh BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157894;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL1097355;;0;608.71;1;1.46;3ll;COC[C@H]1CCCN1C(=O)c1cc(C)cc(C(=O)N[C@@H](Cc2cc(F)cc(F)c2)[C@H](O)[C@H]2CN(S(C)(=O)=O)CCN2)c1;Ki;'=';13.0;nM;7.89;;;UO_0000065;12.96;0.26;6.43;6.15;False;CHEMBL1109071;Inhibition oh BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157894;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL573162;;0;413.41;0;4.78;12;O=C(Nc1ncc(-c2ccc(F)cc2)[nH]1)c1ccc2c(c1)Nc1ccccc1NC2=O;Ki;'=';293.0;nM;6.53;;;UO_0000065;15.8;0.29;1.75;6.61;False;CHEMBL1045676;Inhibition of human recombinant BACE1 by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1154184;1;Scientific Literature;J. Med. Chem.;2009;None
CHEMBL1097339;;0;657.78;1;3.30;3u;CCCN(CCC)C(=O)c1cc(C)cc(C(=O)N[C@@H](Cc2cc(F)cc(F)c2)[C@H](O)[C@H]2CN(S(=O)(=O)c3cccnc3)CCN2)c1;Ki;'=';5800.0;nM;5.24;;;UO_0000065;7.96;0.16;1.94;3.97;False;CHEMBL1109071;Inhibition oh BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157894;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL2011984;;0;342.4;0;2.99;7b;CN1C(=N)N[C@@](c2ccccc2)(c2cccc(-c3cccnc3)c2)C1=O;Ki;'=';1700.0;nM;5.77;;;UO_0000065;16.85;0.30;2.78;8.35;False;CHEMBL2015090;Inhibition of human BACE1 using QSY7EISEVNLDAEFC-Eu-amide as substrate incubated for 30 mins prior to substrate addition measured after 90 mins by FRET analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2010674;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2012;None
CHEMBL2012006;;0;324.36;0;2.49;17g;CN1C(=N)NC(c2cccc(-c3cncc(F)c3)c2)(C2CC2)C1=O;Ki;'=';160.0;nM;6.8;;;UO_0000065;20.95;0.39;4.31;9.84;False;CHEMBL2015090;Inhibition of human BACE1 using QSY7EISEVNLDAEFC-Eu-amide as substrate incubated for 30 mins prior to substrate addition measured after 90 mins by FRET analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2010674;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2012;None
CHEMBL455667;KURARINOL;0;456.54;0;4.80;7;C=C(C)[C@H](CCC(C)(C)O)Cc1c(O)cc(OC)c2c1O[C@H](c1ccc(O)cc1O)CC2=O;Ki;;;;;;Not Determined;;;;;;False;CHEMBL946249;Inhibition of human BACE1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1155037;1;Scientific Literature;Bioorg. Med. Chem.;2008;None
CHEMBL2179138;;0;653.89;1;3.99;20;CCC[C@H](O)[C@H](NC[C@H](Cc1ccccc1)NC(=O)c1cc2c3c(c1)c(CC)cn3CC(C)(C)S(=O)(=O)N2C)C(=O)NCC(C)C;Ki;'=';0.036000000000000004;nM;10.44;;;UO_0000065;15.97;0.31;6.45;7.87;False;CHEMBL2185581;Inhibition of recombinant BACE1 expressed in Escherichia coli using Arg- Glu(EDANS)-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys(Dabcyl)-Arg as substrate by fluorimetric analysis;B;BAO_0000019;assay format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177024;1;Scientific Literature;J. Med. Chem.;2012;None
CHEMBL185777;;0;754.0;2;2.83;BACE Inhibitor 10;CC(C)C[C@H](NC(=O)C(CCS(C)(=O)=O)NC(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)C(O)CC(C)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C;Ki;'=';8.0;nM;8.1;;;UO_0000065;10.74;0.21;5.27;3.87;False;CHEMBL828263;Binding affinity towards Beta-secretase determined using continuum electrostatics solvation;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1137231;1;Scientific Literature;J. Med. Chem.;2004;None
CHEMBL189141;;0;936.03;3;-3.22;BACE Inhibitor 12 OM99-2;CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(=O)O)C(C)C)C(=O)C(O)CN[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O;Ki;'=';1.6;nM;8.8;;;UO_0000065;9.4;0.18;12.02;2.17;False;CHEMBL828263;Binding affinity towards Beta-secretase determined using continuum electrostatics solvation;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1137231;1;Scientific Literature;J. Med. Chem.;2004;None
CHEMBL95430;;0;739.98;2;2.44;18;CC(C)C[C@H](NC(=O)[C@H](CS(C)(=O)=O)NC(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C;Ki;'=';9.4;nM;8.03;;;UO_0000065;10.85;0.21;5.59;3.84;True;CHEMBL711471;Binding affinity for human brain memapsin 2;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1134775;1;Scientific Literature;J. Med. Chem.;2001;None
CHEMBL360362;;0;702.89;2;1.90;2a;CC(C)C[C@H](NC(=O)[C@@H]1CC(=O)NCCCCOC(=O)N[C@@H](C(C)C)C(=O)N1)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C;Ki;'=';217.6;nM;6.66;;;UO_0000065;9.48;0.18;4.76;3.26;False;CHEMBL828805;Binding affinity for human brain memapsin 2;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1145144;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2005;None
CHEMBL3353630;;0;420.6;0;4.12;25;CN1C(=N)N[C@](CCC2CCCCC2)(C[C@@H]2CCCN(C(=O)OC(C)(C)C)C2)C1=O;Ki;'=';41000.0;nM;4.39;;;UO_0000065;10.43;0.20;0.27;5.12;False;CHEMBL3386389;Inhibition of purified human BACE1 by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3352601;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2014;None
CHEMBL3354262;;0;504.68;2;5.40;53;CN1C(=N)N[C@](CCC2CCCCC2)(C[C@H]2CCC[C@@H](NC(=O)Nc3ccc4ccccc4n3)C2)C1=O;Ki;'=';22.0;nM;7.66;;;UO_0000065;15.17;0.28;2.26;6.95;False;CHEMBL3386389;Inhibition of purified human BACE1 by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3352601;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2014;None
CHEMBL3354243;;0;430.64;0;4.29;34;CN1C(=N)N[C@](CCC2CCCCC2)(C[C@H]2CCCN(C(=O)CC3CCCC3)C2)C1=O;Ki;'=';970.0;nM;6.01;;;UO_0000065;13.96;0.26;1.72;7.86;False;CHEMBL3386389;Inhibition of purified human BACE1 by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3352601;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2014;None
CHEMBL390159;;0;720.93;1;3.38;5g;Cc1nc(C(C)NC(=O)c2cc(C(=O)N[C@@H](CC(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NC(C)C)C(C)C)cc(N(C)S(C)(=O)=O)c2)c(C)o1;Ki;'=';27.0;nM;7.57;;;UO_0000065;10.5;0.21;4.19;3.78;False;CHEMBL915132;Inhibition of recombinant memapsin 2;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1139858;1;Scientific Literature;J. Med. Chem.;2007;None
CHEMBL375678;;0;532.73;1;3.02;22;CCCNC(=O)c1cccc(C(=O)N[C@@H](CC(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NC(C)C)C(C)C)c1;Ki;'=';788.0;nM;6.1;;;UO_0000065;11.46;0.22;3.08;4.47;False;CHEMBL915132;Inhibition of recombinant memapsin 2;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1139858;1;Scientific Literature;J. Med. Chem.;2007;None
CHEMBL3901897;;0;435.51;0;2.93;BDBM242238;Cc1nnc(-c2cccc(-c3cc(F)c([C@]4(C)CS(=O)(=O)N(C)C(=N)N4)s3)c2)o1;Ki;'=';232.0;nM;6.63;;422365;UO_0000065;15.23;0.31;3.70;5.91;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3920356;;0;503.07;1;2.32;BDBM242283;CN1C(=N)N[C@](C)(c2sc(-c3cccc(N4CCS(=O)(=O)CC4)c3)cc2Cl)CS1(=O)=O;Ki;'=';693.0;nM;6.16;;422410;UO_0000065;12.24;0.27;3.84;5.57;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3902345;;0;455.99;0;2.31;BDBM242288;CN1C(=N)N[C@](C)(c2sc(-c3ccc(N4CCOCC4)nc3)cc2Cl)CS1(=O)=O;Ki;'=';5904.0;nM;5.23;;422415;UO_0000065;11.47;0.25;2.92;5.30;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3893399;;0;462.53;0;2.89;BDBM242274;CN1C(=N)N[C@](C)(c2sc(-c3ccnc(-c4nc(C5CC5)no4)c3)cc2F)CS1(=O)=O;Ki;'=';498.0;nM;6.3;;422401;UO_0000065;13.63;0.28;3.41;5.04;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3923790;;0;434.47;0;2.75;BDBM190704;C[C@@]1(c2cc(NC(=O)c3ccc(F)cn3)ccc2F)CS(=O)(=O)C2(CCC2)C(=N)N1;Ki;'=';17.1;nM;7.77;;341199;UO_0000065;17.88;0.35;5.02;6.93;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3986161;;0;498.5;0;4.02;BDBM190710;C[C@@]1(c2cc(NC(=O)c3ccc(C(F)(F)F)cn3)ccc2F)CS(=O)(=O)C2(CCCC2)C(=N)N1;Ki;'=';2.2;nM;8.66;;341205;UO_0000065;17.37;0.35;4.64;7.73;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3966558;;0;410.95;0;3.38;BDBM190743;C[C@@]1(c2sc(-c3cncnc3)cc2Cl)CS(=O)(=O)C2(CCCC2)C(=N)N1;Ki;'=';73.1;nM;7.14;;341235;UO_0000065;17.36;0.37;3.76;7.45;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3984050;;0;396.93;0;2.99;BDBM190763;C[C@@]1(c2sc(-c3cncnc3)cc2Cl)CS(=O)(=O)C2(CCC2)C(=N)N1;Ki;'=';374.0;nM;6.43;;341255;UO_0000065;16.19;0.35;3.44;6.71;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3896325;;0;457.49;0;2.39;BDBM190771;[C-]#[N+]c1ccc(C(=O)Nc2ccc(F)c([C@]3(C)CS(=O)(=O)[C@]4(CCOC4)C(=N)N3)c2)nc1;Ki;'=';6.1;nM;8.21;;341263;UO_0000065;17.96;0.35;5.82;6.54;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3904536;;0;482.03;0;3.03;BDBM190825;C[C@@]1(c2sc(C(=O)NCc3ccncn3)cc2Cl)CS(=O)(=O)C2(CCCCC2)C(=N)N1;Ki;'=';4154.0;nM;5.38;;341308;UO_0000065;11.16;0.24;2.35;4.31;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3890098;;0;449.46;0;0.88;BDBM199095;COc1ccc(C(=O)Nc2ccc(F)c([C@@]34COC[C@@H]3S(=O)(=O)N(C)C(=N)N4)c2)nc1;Ki;'=';871.5;nM;6.06;;354109;UO_0000065;13.48;0.27;5.18;4.53;False;CHEMBL3887768;Homogeneous Time-Resolved FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 u) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886448;37;BindingDB Database;;2015;None
CHEMBL3640269;;0;368.42;0;1.35;BDBM102952;Cc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3ccccc3)C2)nc(C)c1F;Ki;'=';154.0;nM;6.81;;220580;UO_0000065;18.49;0.34;5.46;7.77;False;CHEMBL3705045;Time-Resolved FRET Assay: A homogeneous time-resolved FRET assay was used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. The assay monitored the increase of 620nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide).;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638861;37;BindingDB Database;;2013;None
CHEMBL3703255;;0;361.4;0;2.07;BDBM149773;CC#Cc1cncc(-c2ccc3c(c2)C2(COC(N)=N2)C2(COC2)CO3)c1;Ki;'=';123.0;nM;6.91;;288443;UO_0000065;19.12;0.35;4.84;8.75;True;CHEMBL3705666;Fluorescence Resonance Energy Transfer (FRET) Assay: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638878;37;BindingDB Database;;2015;None
CHEMBL3920380;;0;440.93;0;3.14;BDBM244046;CNS1(O)C[C@@](C)(c2cc(NC(=O)c3ccc(Cl)cn3)ccc2F)NC(=N)N1C;Ki;'=';1.0;nM;9.0;;425631;UO_0000065;20.41;0.42;5.86;7.94;False;CHEMBL3888967;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window Inhibitor.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886899;37;BindingDB Database;;2016;None
CHEMBL3903739;;0;424.48;0;2.62;BDBM244050;CNS1(O)C[C@@](C)(c2cc(NC(=O)c3ccc(F)cn3)ccc2F)NC(=N)N1C;Ki;'=';2.0;nM;8.7;;425636;UO_0000065;20.49;0.41;6.08;7.67;False;CHEMBL3888967;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window Inhibitor.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886899;37;BindingDB Database;;2016;None
CHEMBL2063199;;0;490.65;1;6.25;3e;NC1=Nc2ccc(Oc3ccccc3)cc2CN1[C@@H](COC(=O)NC1CCCCC1)C1CCCCC1;Ki;'=';60.0;nM;7.22;;;UO_0000065;14.72;0.27;0.97;8.10;False;CHEMBL2067011;Inhibition of recombinant beta-secretase 1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2062429;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2012;None
CHEMBL3950129;;0;449.0;0;4.25;BDBM190747;C[C@@]1(c2sc(-c3cncc(C#N)c3)cc2Cl)CS(=O)(=O)C2(CCCCC2)C(=N)N1;Ki;'=';114.0;nM;6.94;;341239;UO_0000065;15.46;0.33;2.69;6.51;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3941251;;0;439.99;0;3.40;BDBM190790;CCc1cncc(-c2cc(Cl)c([C@]3(C)CS(=O)(=O)[C@@]4(CCOC4)C(=N)N3)s2)c1;Ki;'=';1776.0;nM;5.75;;341282;UO_0000065;13.07;0.28;2.35;6.24;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3982624;;0;438.51;0;1.90;BDBM190856;C[C@@]1(c2cc(NC(=O)c3cncs3)ccc2F)CS(=O)(=O)[C@]2(CCOC2)C(=N)N1;Ki;'=';1945.0;nM;5.71;;341337;UO_0000065;13.02;0.27;3.81;4.71;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3640253;;0;398.44;0;1.31;BDBM102935;CCc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3ccccc3)C2)nc(OC)c1F;Ki;'=';16.0;nM;7.8;;220583;UO_0000065;19.57;0.37;6.49;8.04;False;CHEMBL3705045;Time-Resolved FRET Assay: A homogeneous time-resolved FRET assay was used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. The assay monitored the increase of 620nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide).;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638861;37;BindingDB Database;;2013;None
CHEMBL3650771;;0;384.86;0;3.73;BDBM149858;CC1(C)Oc2ccc(-c3cccc(Cl)c3)cc2C2(COC(N)=N2)C12COC2;Ki;'=';215.0;nM;6.67;;288521;UO_0000065;17.32;0.34;2.94;10.09;True;CHEMBL3705666;Fluorescence Resonance Energy Transfer (FRET) Assay: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638878;37;BindingDB Database;;2015;None
CHEMBL3918096;;0;428.88;0;2.12;BDBM242981;CN1C(=N)N[C@](C)(c2sc(-c3nnc(-c4ccon4)o3)cc2Cl)CS1(=O)=O;Ki;'=';1336.0;nM;5.87;;423862;UO_0000065;13.7;0.30;3.75;4.25;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3969645;;0;521.07;1;4.12;BDBM243005;CN1C(=N)N[C@](C)(c2sc(-c3nnc(-c4ccc(N5CCCCC5)cc4)o3)cc2Cl)CS1(=O)=O;Ki;'=';5362.0;nM;5.27;;423886;UO_0000065;10.12;0.21;1.15;4.57;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3961870;;0;522.05;1;4.89;BDBM242335;CN1C(=N)N[C@](C)(c2sc3c(-c4ccc(-c5cncs5)cc4F)nccc3c2Cl)CS1(=O)=O;Ki;'=';105.0;nM;6.98;;422462;UO_0000065;13.37;0.29;2.09;7.05;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL78946;;0;893.01;3;-1.74;OM99-2;CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(=O)O)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O;Ki;'=';1.2;nM;8.92;;;UO_0000065;9.99;0.19;10.66;2.37;False;CHEMBL830203;Binding affinity for hamster memapsin 2;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1145144;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2005;None
CHEMBL2178180;;0;506.42;1;4.64;17f;COc1ccc(-c2nsc(C)c2C(=O)/N=C(\N)NCc2cc(Cl)c(NC(C)=O)c(Cl)c2)cc1;Ki;'=';5.0;nM;8.3;;;UO_0000065;16.39;0.34;3.66;6.99;False;CHEMBL2187886;Displacement of [3H]BMS-599240 from BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177026;1;Scientific Literature;J. Med. Chem.;2012;CHEMBL3307715
CHEMBL2178167;;0;477.75;0;4.32;8r;COc1ccc(-c2noc(C)c2C(=O)/N=C(\N)NCc2cc(Cl)cc(Br)c2)cc1;Ki;'=';270.0;nM;6.57;;;UO_0000065;13.75;0.31;2.25;6.39;False;CHEMBL2187886;Displacement of [3H]BMS-599240 from BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177026;1;Scientific Literature;J. Med. Chem.;2012;CHEMBL3307715
CHEMBL3628127;;0;559.5;1;3.85;20c;N/C1=N\C(=O)[C@@H]2CCCN2c2ccc(cc2)OC/C=C/CCCNCC(=O)Nc2c(Cl)cc(cc2Cl)CN1;Ki;'=';59.0;nM;7.23;;;UO_0000065;12.92;0.26;3.38;5.97;False;CHEMBL3630426;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 6.4 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL602914;;0;880.02;1;4.43;1b;CO[C@H](C[C@H](O)[C@H](COCc1cc(F)cc(F)c1)NC(=O)c1cc(C(=O)N[C@H](C)c2ccccc2)cc(N(C)CS(C)(=O)=O)c1)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C;Ki;'=';80.0;nM;7.1;;;UO_0000065;8.06;0.16;2.67;3.69;False;CHEMBL1072341;Inhibition of human BACE1 expressed in Escherichia coli cells (BL21(DE3) by TRF assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157542;1;Scientific Literature;J. Med. Chem.;2010;None
CHEMBL243148;SOPHORAFLAVANONE G;0;424.49;1;5.31;1;C=C(C)[C@H](CC=C(C)C)Cc1c(O)cc(O)c2c1O[C@H](c1ccc(O)cc1O)CC2=O;Ki;'=';1100.0;nM;5.96;;;UO_0000065;14.04;0.26;0.65;5.56;False;CHEMBL946249;Inhibition of human BACE1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1155037;1;Scientific Literature;Bioorg. Med. Chem.;2008;None
CHEMBL498456;BOERAVINONE D;0;342.3;0;2.92;1;COC1Oc2cc(O)ccc2-c2c1oc1cc(O)c(C)c(O)c1c2=O;Ki;'=';5010.0;nM;5.3;;;UO_0000065;15.48;0.29;2.38;4.85;False;CHEMBL3293239;Non-competitive inhibition of BACE1 (unknown origin) by Dixon plot analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3286369;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2014;None
CHEMBL2151182;;0;372.88;0;3.44;17;CC#Cc1cncc(-c2cc([C@]3(C)CC(=O)N(C)C(=N)N3)c(Cl)s2)c1;Ki;'=';8.0;nM;8.1;;;UO_0000065;21.71;0.44;4.66;11.72;False;CHEMBL2155063;Inhibition of human recombinant BACE1 by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2150878;1;Scientific Literature;ACS Med. Chem. Lett.;2012;None
CHEMBL2151135;;0;294.36;0;2.35;6;CN1C(=N)N[C@](C)(c2cccc(-c3cccnc3)c2)CC1=O;Ki;'=';670.0;nM;6.17;;;UO_0000065;20.97;0.38;3.82;8.94;False;CHEMBL2155063;Inhibition of human recombinant BACE1 by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2150878;1;Scientific Literature;ACS Med. Chem. Lett.;2012;None
CHEMBL157575;;0;549.67;2;1.72;17;CC(C)CNC(=O)[C@H](CCC(=O)O)C[C@H](O)[C@H](Cc1ccccc1)NC(=O)C[C@H](NC(=O)CC(C)C)C(=O)O;Ki;'=';1700.0;nM;5.77;;;UO_0000065;10.5;0.20;4.05;3.17;False;CHEMBL653517;Tested for inhibition of Beta-secretase 1 (BACE 1) expressed in insect cell using baculovirus;B;BAO_0000019;assay format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1147418;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2004;None
CHEMBL3694261;;0;727.88;1;3.28;BDBM120273;COc1ccc(CN2CCN[C@@H]([C@@H](O)[C@H](Cc3ccccc3)NC(=O)c3cc(C(=O)N[C@H](C)c4ccccc4)cc(N(C)S(C)(=O)=O)c3)C2=O)cc1;Ki;'<';1000.0;nM;;;248249;UO_0000065;;;;;False;CHEMBL3706207;Inhibition Assay: The potencies of compounds were determined by measurement of their inhibition of memapsin 2 catalytic activity toward a fluorescent substrate. Kinetic inhibition experiments were performed using the procedure as described in Ermolieff, et al. Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety. Briefly, assays were performed at pH 4, 37° C., by pre-incubation of memapsin 2 enzyme with compound for 20 minutes. Activity measure was initiated by addition of a fluorogenic substrate FS-2 (Bachem Americas, Torrance, Calif.).;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3639069;37;BindingDB Database;;2014;None
CHEMBL3921902;;0;449.99;0;3.70;BDBM190751;C[C@@]1(c2sc(-c3cccc(C#N)c3)cc2Cl)CS(=O)(=O)C2(CCOCC2)C(=N)N1;Ki;'=';113.0;nM;6.95;;341243;UO_0000065;15.44;0.33;3.25;6.74;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3910429;;0;469.54;0;3.26;BDBM190724;C[C@@]1(c2cc(NC(=O)c3ccc(C#N)cn3)ccc2F)CS(=O)(=O)C2(CCCCC2)C(=N)N1;Ki;'=';10.6;nM;7.97;;341219;UO_0000065;16.98;0.33;4.71;5.87;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3986687;;0;409.48;0;1.93;BDBM190843;C[C@@]1(c2cc(NC(=O)CC3CC3)ccc2F)CS(=O)(=O)[C@]2(CCOC2)C(=N)N1;Ki;'=';2960.0;nM;5.53;;341325;UO_0000065;13.5;0.27;3.60;5.10;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL243796;KURARINONE;0;438.52;1;5.61;2;C=C(C)C(CC=C(C)C)Cc1c(O)cc(OC)c2c1O[C@H](c1ccc(O)cc1O)CC2=O;Ki;'=';7200.0;nM;5.14;;;UO_0000065;11.73;0.22;-0.47;5.34;False;CHEMBL946249;Inhibition of human BACE1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1155037;1;Scientific Literature;Bioorg. Med. Chem.;2008;None
CHEMBL3983037;;0;450.47;0;1.98;BDBM190768;C[C@@]1(c2cc(NC(=O)c3ccc(F)cn3)ccc2F)CS(=O)(=O)[C@]2(CCOC2)C(=N)N1;Ki;'=';24.0;nM;7.62;;341260;UO_0000065;16.92;0.34;5.64;6.28;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL1083394;TRIPHLOROETHOL A;0;374.3;1;3.21;6;Oc1cc(O)cc(Oc2c(O)cc(O)cc2Oc2c(O)cc(O)cc2O)c1;Ki;'=';12100.0;nM;4.92;;;UO_0000065;13.14;0.25;1.71;3.07;False;CHEMBL1117924;Noncompetitive inhibition of human recombinant BACE1 after 60 mins by Dixon plot analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1155522;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL4278329;;0;477.53;0;2.55;5;COc1cc(C#N)cc(-c2csc([C@]34CN(c5ncc(F)cn5)C[C@H]3C(=O)N(C)C(=N)N4)c2)c1;Ki;'=';1.0;nM;9.0;;;UO_0000065;18.85;0.36;6.45;7.61;False;CHEMBL4270026;Inhibition of recombinant human BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4266039;1;Scientific Literature;J Med Chem;2018;None
CHEMBL78946;;0;893.01;3;-1.74;OM99-2;CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(=O)O)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O;Ki;'=';1.6;nM;8.8;;;UO_0000065;9.85;0.19;10.54;2.34;True;CHEMBL1113137;Inhibition of BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1154387;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2009;None
CHEMBL78946;;0;893.01;3;-1.74;OM99-2;CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(=O)O)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O;Ki;'=';1.6;nM;8.8;;;UO_0000065;9.85;0.19;10.54;2.34;True;CHEMBL828805;Binding affinity for human brain memapsin 2;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1145144;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2005;None
CHEMBL3353633;;0;320.48;0;2.47;28;CN1C(=N)N[C@](CCC2CCCCC2)(C[C@H]2CCCNC2)C1=O;Ki;'=';8500.0;nM;5.07;;;UO_0000065;15.82;0.30;2.60;7.43;False;CHEMBL3386389;Inhibition of purified human BACE1 by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3352601;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2014;None
CHEMBL508791;DIECKOL;0;742.55;4;7.62;5;Oc1cc(O)cc(Oc2c(O)cc(O)c3c2Oc2c(O)cc(Oc4c(O)cc(Oc5c(O)cc(O)c6c5Oc5c(O)cc(O)cc5O6)cc4O)cc2O3)c1;Ki;'=';1500.0;nM;5.82;;;UO_0000065;7.84;0.15;-1.80;2.03;False;CHEMBL1117924;Noncompetitive inhibition of human recombinant BACE1 after 60 mins by Dixon plot analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1155522;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL3896640;;0;443.38;0;3.43;BDBM230874;COc1cnc(C(=O)Nc2ccc(F)c([C@@]3(C(F)F)N=C(N)CCC3(F)F)c2)c(C)n1;Ki;'=';16.0;nM;7.8;;402957;UO_0000065;17.58;0.34;4.37;7.61;False;CHEMBL3888456;BACE1 Binding Assay: The binding assay was performed as SPA-based assay using a biotinylated form of human BACE1 recombinantly expressed and subsequently purified from Freestyle HEK293 cells. The binding assay was run in a 50 mM sodium acetate buffer, pH 4.5 containing 50 mM NaCl and 0.03% Tween-20 in white clear bottom 384 plates (Corning #3653). 10 nM (final concentration) radioligand ([3H]−N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N−((R)-1-phenyl-ethyl)-isophthalamide) (TRQ11569 purchased from GE Healthcare) was mixed with test compound at a given concentration, 6 nM (final concentration) human BACE1 and 25 μg Streptavidin coated PVT core SPA beads (RPNQ0007, GE Healthcare Life Sciences) in a total volume of 40 μl. Several concentrations of each test compound were tested in the assay for IC50 determination. The plates were incubated for one hour at room temperature and counted in a Wallac Trilux counter. Total and non-specific binding were determined using buffer and 1 μM (final concentration) of the high affinity BACE1 reference inhibitor (S)-6-[3-chloro-5-(5-prop-1-ynyl-pyridin-3-yl)-thiophen-2-yl]-2-imino-3,6-dimethyl-tetrahydro-pyrimidin-4-one, respectively.;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886720;37;BindingDB Database;;2016;CHEMBL3307715
CHEMBL3969624;;0;428.36;0;3.73;BDBM230869;COc1ccc(C(=O)Nc2ccc(F)c([C@@]3(C(F)F)N=C(N)CCC3(F)F)c2)nc1;Ki;'=';14.0;nM;7.85;;402960;UO_0000065;18.33;0.36;4.12;8.77;False;CHEMBL3888456;BACE1 Binding Assay: The binding assay was performed as SPA-based assay using a biotinylated form of human BACE1 recombinantly expressed and subsequently purified from Freestyle HEK293 cells. The binding assay was run in a 50 mM sodium acetate buffer, pH 4.5 containing 50 mM NaCl and 0.03% Tween-20 in white clear bottom 384 plates (Corning #3653). 10 nM (final concentration) radioligand ([3H]−N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N−((R)-1-phenyl-ethyl)-isophthalamide) (TRQ11569 purchased from GE Healthcare) was mixed with test compound at a given concentration, 6 nM (final concentration) human BACE1 and 25 μg Streptavidin coated PVT core SPA beads (RPNQ0007, GE Healthcare Life Sciences) in a total volume of 40 μl. Several concentrations of each test compound were tested in the assay for IC50 determination. The plates were incubated for one hour at room temperature and counted in a Wallac Trilux counter. Total and non-specific binding were determined using buffer and 1 μM (final concentration) of the high affinity BACE1 reference inhibitor (S)-6-[3-chloro-5-(5-prop-1-ynyl-pyridin-3-yl)-thiophen-2-yl]-2-imino-3,6-dimethyl-tetrahydro-pyrimidin-4-one, respectively.;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886720;37;BindingDB Database;;2016;CHEMBL3307715
CHEMBL3650852;;0;425.45;0;1.47;BDBM149943;COc1cnc(C(=O)Nc2ccc3c(c2)C2(COC(N)=N2)C2(COC2)C(C)(C)O3)cn1;Ki;'=';79.2;nM;7.1;;288592;UO_0000065;16.69;0.31;5.63;5.45;True;CHEMBL3705666;Fluorescence Resonance Energy Transfer (FRET) Assay: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638878;37;BindingDB Database;;2015;None
CHEMBL1923749;;0;399.47;1;5.89;25;CC(C)(C)Nc1c(-c2cccc(-c3nc4ccc(F)cc4[nH]3)c2)nc2ccccn12;Ki;'=';301.0;nM;6.52;;;UO_0000065;16.33;0.30;0.63;11.24;False;CHEMBL1926456;Inhibition of BACE1 expressing APP Swedish mutant using rhodamine-labeled EVNLDAEFK-quencher as substrate after 60 mins by Michaelis-Menten equation;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1921672;1;Scientific Literature;J. Med. Chem.;2011;None
CHEMBL3672920;;0;405.46;0;1.80;BDBM143223;Cc1ccc(C(=O)Nc2ccc(F)c([C@]3(C)CS(=O)(=O)N(C)C(=N)N3)c2)nc1;Ki;'=';3.0;nM;8.52;;300573;UO_0000065;21.02;0.42;6.72;7.40;False;CHEMBL3705433;HTRF FRET Assay: A homogeneous time-resolved FRET assay was used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitored the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contained an N-terminal QSY7 moiety that served as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence was low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors was manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul were preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30 C. in reaction buffer containing 20 mM Na-Acetate pH 5.0.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638621;37;BindingDB Database;;2015;None
CHEMBL3984274;;0;436.95;0;2.66;BDBM242290;CN1C(=N)N[C@](C)(c2sc(-c3cccc(-n4ccnc4)n3)cc2Cl)CS1(=O)=O;Ki;'=';429.0;nM;6.37;;422417;UO_0000065;14.57;0.31;3.71;6.12;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL4110744;;0;501.46;1;2.25;BDBM236590;CC1(C)C(=N)N[C@@]2(c3cc(NC(=O)c4cnc(C(F)(F)F)cn4)ccc3F)COC[C@H]2S1(=O)=O;Ki;'=';13.0;nM;7.89;;412106;UO_0000065;15.73;0.32;5.64;5.88;False;CHEMBL3888701;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886796;37;BindingDB Database;;2016;None
CHEMBL4112828;;0;486.53;0;1.85;BDBM236598;C#CCOc1ccc(C(=O)Nc2ccc(F)c([C@]34COC[C@H]3S(=O)(=O)C(C)(C)C(=N)N4)c2)nc1;Ki;'=';1.0;nM;9.0;;412114;UO_0000065;18.5;0.36;7.15;6.90;False;CHEMBL3888701;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886796;37;BindingDB Database;;2016;None
CHEMBL3985039;;0;478.0;0;4.09;BDBM190778;C[C@@]1(c2sc(-c3ccnc(-c4ccco4)c3)cc2Cl)CS(=O)(=O)[C@]2(CCOC2)C(=N)N1;Ki;'=';45.3;nM;7.34;;341275;UO_0000065;15.36;0.32;3.25;6.98;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL4112977;;0;436.95;0;2.70;BDBM190786;CC1(c2sc(-c3cncc(C#N)c3)cc2Cl)CS(=O)(=O)[C@@]2(CCOC2)C(=N)N1;Ki;'=';192.0;nM;6.72;;341278;UO_0000065;15.37;0.33;4.02;5.79;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL2178201;;0;433.3;0;4.21;8l;COc1ccc(-c2onc(C)c2C(=O)/N=C(\N)NCc2cc(Cl)cc(Cl)c2)cc1;Ki;'=';860.0;nM;6.07;;;UO_0000065;14.0;0.29;1.86;5.90;False;CHEMBL2187886;Displacement of [3H]BMS-599240 from BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177026;1;Scientific Literature;J. Med. Chem.;2012;CHEMBL3307715
CHEMBL3905786;;0;433.36;0;4.01;BDBM234453;C[C@]1(F)CC(F)(F)[C@@](C)(c2cc(NC(=O)c3ccn(C(F)F)n3)ccc2F)N=C1N;Ki;'=';19.0;nM;7.72;;408769;UO_0000065;17.82;0.35;3.71;9.05;False;CHEMBL3888549;SPA-Based Assay: The binding assay was performed as SPA-based assay using a biotinylated form of human BACE1 recombinantly expressed and subsequently purified from Freestyle HEK293 cells. The binding assay was run in a 50 mM sodium acetate buffer, pH 4.5 containing 50 mM NaCl and 0.03% Tween-20 in white clear bottom 384 plates (Corning #3653). 10 nM (final concentration) radioligand ([3H]-N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N-((R)-1-phenyl-ethyl)-isophthalamide) (TRQ11569 purchased from GE Healthcare) was mixed with test compound at a given concentration, 6 nM (final concentration) human BACE1 and 25 μg Streptavidin coated PVT core SPA beads (RPNQ0007, GE Healthcare Life Sciences) in a total volume of 40 μl.;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886758;37;BindingDB Database;;2016;CHEMBL3307715
CHEMBL4111993;;0;432.42;0;4.34;BDBM234478;C[C@@]1(F)CC(F)(F)[C@@](C)(c2cc(NC(=O)c3nc(CF)cs3)ccc2F)N=C1N;Ki;'=';92.0;nM;7.04;;408794;UO_0000065;16.27;0.33;2.70;8.75;False;CHEMBL3888549;SPA-Based Assay: The binding assay was performed as SPA-based assay using a biotinylated form of human BACE1 recombinantly expressed and subsequently purified from Freestyle HEK293 cells. The binding assay was run in a 50 mM sodium acetate buffer, pH 4.5 containing 50 mM NaCl and 0.03% Tween-20 in white clear bottom 384 plates (Corning #3653). 10 nM (final concentration) radioligand ([3H]-N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N-((R)-1-phenyl-ethyl)-isophthalamide) (TRQ11569 purchased from GE Healthcare) was mixed with test compound at a given concentration, 6 nM (final concentration) human BACE1 and 25 μg Streptavidin coated PVT core SPA beads (RPNQ0007, GE Healthcare Life Sciences) in a total volume of 40 μl.;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886758;37;BindingDB Database;;2016;CHEMBL3307715
CHEMBL4115391;;0;428.82;0;4.47;BDBM234480;C[C@@]1(F)CC(F)(F)[C@@](C)(c2cc(NC(=O)c3ccc(Cl)cn3)ccc2F)N=C1N;Ki;'=';62.0;nM;7.21;;408796;UO_0000065;16.81;0.34;2.74;8.97;False;CHEMBL3888549;SPA-Based Assay: The binding assay was performed as SPA-based assay using a biotinylated form of human BACE1 recombinantly expressed and subsequently purified from Freestyle HEK293 cells. The binding assay was run in a 50 mM sodium acetate buffer, pH 4.5 containing 50 mM NaCl and 0.03% Tween-20 in white clear bottom 384 plates (Corning #3653). 10 nM (final concentration) radioligand ([3H]-N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N-((R)-1-phenyl-ethyl)-isophthalamide) (TRQ11569 purchased from GE Healthcare) was mixed with test compound at a given concentration, 6 nM (final concentration) human BACE1 and 25 μg Streptavidin coated PVT core SPA beads (RPNQ0007, GE Healthcare Life Sciences) in a total volume of 40 μl.;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886758;37;BindingDB Database;;2016;CHEMBL3307715
CHEMBL3960350;;0;421.93;0;4.06;BDBM190735;C[C@@]1(c2cc(-c3cncc(Cl)c3)ccc2F)CS(=O)(=O)C2(CCCC2)C(=N)N1;Ki;'=';459.0;nM;6.34;;341229;UO_0000065;15.02;0.31;2.28;7.64;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3893492;;0;386.49;0;2.40;BDBM242925;CNS1(O)C[C@@](C)(c2cc(NC(=O)COC)ccc2F)NC(=N)C1(C)C;Ki;'=';167.0;nM;6.78;;423786;UO_0000065;17.54;0.36;4.38;6.37;False;CHEMBL3888940;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886895;37;BindingDB Database;;2016;None
CHEMBL3985262;;0;458.56;0;3.72;BDBM242930;CCNS1(O)C[C@@](C)(c2cc(NC(=O)c3ccc(C#N)cn3)ccc2F)NC(=N)C1(C)C;Ki;'=';4.0;nM;8.4;;423791;UO_0000065;18.31;0.36;4.68;6.27;False;CHEMBL3888940;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886895;37;BindingDB Database;;2016;None
CHEMBL3967197;;0;437.93;0;3.13;BDBM242957;CN1C(=N)N[C@](C)(c2sc(-c3nnc(-c4ccccc4)o3)cc2Cl)CS1(=O)=O;Ki;'=';105.8;nM;6.98;;423838;UO_0000065;15.93;0.34;3.85;6.22;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3899548;;0;449.9;0;3.21;BDBM242962;CN1C(=N)N[C@](C)(c2cc(-c3nnc(-c4ccc(Cl)cc4)o3)ccc2F)CS1(=O)=O;Ki;'=';2592.0;nM;5.59;;423843;UO_0000065;12.42;0.25;2.38;4.98;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL2179131;;0;665.86;1;3.03;5;CC(C)CNC(=O)[C@@H](NC[C@H](Cc1ccccc1)NC(=O)c1cc(C(=O)N[C@H](C)c2ccccc2)cc(N(C)S(C)(=O)=O)c1)[C@H](C)O;Ki;'=';0.017;nM;10.77;;;UO_0000065;16.17;0.31;7.74;6.86;False;CHEMBL2185581;Inhibition of recombinant BACE1 expressed in Escherichia coli using Arg- Glu(EDANS)-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys(Dabcyl)-Arg as substrate by fluorimetric analysis;B;BAO_0000019;assay format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177024;1;Scientific Literature;J. Med. Chem.;2012;None
CHEMBL182892;;0;728.93;2;2.45;3c;CC(C)C[C@H](NC(=O)[C@@H]1CC(=O)NC/C=C/CCCOC(=O)N[C@@H](C(C)C)C(=O)N1)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C;Ki;'=';14.2;nM;7.85;;;UO_0000065;10.77;0.21;5.40;3.85;False;CHEMBL828805;Binding affinity for human brain memapsin 2;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1145144;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2005;None
CHEMBL3650823;;0;409.83;0;2.57;BDBM149911;N#Cc1cnc(C(=O)Nc2ccc3c(c2)C2(COC(N)=N2)C2(CC2)CO3)c(Cl)c1;Ki;'=';280.0;nM;6.55;;288563;UO_0000065;15.99;0.31;3.98;5.34;True;CHEMBL3705666;Fluorescence Resonance Energy Transfer (FRET) Assay: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638878;37;BindingDB Database;;2015;None
CHEMBL3650831;;0;414.47;0;2.70;BDBM149919;NC1=NC2(CO1)c1cc(-c3cncnc3)ccc1OC(Cc1ccccc1)C21COC1;Ki;'=';113.0;nM;6.95;;288573;UO_0000065;16.76;0.31;4.25;7.56;True;CHEMBL3705666;Fluorescence Resonance Energy Transfer (FRET) Assay: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638878;37;BindingDB Database;;2015;None
CHEMBL3694263;;0;727.88;1;3.28;BDBM120276;COc1cccc(CN2CCN[C@@H]([C@@H](O)[C@H](Cc3ccccc3)NC(=O)c3cc(C(=O)N[C@H](C)c4ccccc4)cc(N(C)S(C)(=O)=O)c3)C2=O)c1;Ki;'<';1000.0;nM;;;248251;UO_0000065;;;;;False;CHEMBL3706207;Inhibition Assay: The potencies of compounds were determined by measurement of their inhibition of memapsin 2 catalytic activity toward a fluorescent substrate. Kinetic inhibition experiments were performed using the procedure as described in Ermolieff, et al. Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety. Briefly, assays were performed at pH 4, 37° C., by pre-incubation of memapsin 2 enzyme with compound for 20 minutes. Activity measure was initiated by addition of a fluorogenic substrate FS-2 (Bachem Americas, Torrance, Calif.).;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3639069;37;BindingDB Database;;2014;None
CHEMBL3798760;;0;452.94;0;2.62;14;CCCc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3ccc(Cl)s3)C2)nc(OC)c1F;Ki;'=';15.0;nM;7.82;;;UO_0000065;17.27;0.36;5.20;8.28;False;CHEMBL3801550;Inhibition of recombinant human BACE1 preincubated for 30 mins followed QSY7EISEVNLDAEFC-Eu-amide substrate addition measured after 90 mins by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3797133;1;Scientific Literature;J. Med. Chem.;2016;None
CHEMBL3800447;;0;401.43;0;0.89;10;COc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3ccc(C#N)s3)C2)ncc1F;Ki;'=';57.0;nM;7.24;;;UO_0000065;18.05;0.35;6.35;6.13;False;CHEMBL3801550;Inhibition of recombinant human BACE1 preincubated for 30 mins followed QSY7EISEVNLDAEFC-Eu-amide substrate addition measured after 90 mins by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3797133;1;Scientific Literature;J. Med. Chem.;2016;None
CHEMBL202507;;0;621.87;1;4.90;2;CCCN(CCC)C(=O)c1cccc(C(=O)N[C@@H](CC(C)C)[C@@H](N)C[C@@H](C)C(=O)N[C@H](C(=O)NCc2ccccc2)C(C)C)c1;Ki;'=';120.0;nM;6.92;;;UO_0000065;11.13;0.21;2.02;5.18;False;CHEMBL853557;Inhibition of human BACE1 expressed in Hi5 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;BTI-TN-5B1-4;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1148624;1;Scientific Literature;J. Med. Chem.;2006;CHEMBL3833782
CHEMBL304010;;0;704.91;2;2.27;5;CC(C)C[C@H](NC(=O)C(CC(N)=O)NC(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)C(O)CC(C)C(=O)NC(C(=O)NCc1ccccc1)C(C)C;Ki;'=';5.9;nM;8.23;;;UO_0000065;11.67;0.22;5.96;3.77;True;CHEMBL655069;Binding affinity for human brain memapsin 2 beta-Secretase (BACE);B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1144924;1;Scientific Literature;J. Med. Chem.;2003;None
CHEMBL3915809;;0;477.23;0;4.48;BDBM230876;NC1=N[C@@](c2cc(NC(=O)c3ccc(Br)cn3)ccc2F)(C(F)F)C(F)(F)CC1;Ki;'=';6.1;nM;8.21;;402959;UO_0000065;17.21;0.39;3.73;10.22;False;CHEMBL3888456;BACE1 Binding Assay: The binding assay was performed as SPA-based assay using a biotinylated form of human BACE1 recombinantly expressed and subsequently purified from Freestyle HEK293 cells. The binding assay was run in a 50 mM sodium acetate buffer, pH 4.5 containing 50 mM NaCl and 0.03% Tween-20 in white clear bottom 384 plates (Corning #3653). 10 nM (final concentration) radioligand ([3H]−N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N−((R)-1-phenyl-ethyl)-isophthalamide) (TRQ11569 purchased from GE Healthcare) was mixed with test compound at a given concentration, 6 nM (final concentration) human BACE1 and 25 μg Streptavidin coated PVT core SPA beads (RPNQ0007, GE Healthcare Life Sciences) in a total volume of 40 μl. Several concentrations of each test compound were tested in the assay for IC50 determination. The plates were incubated for one hour at room temperature and counted in a Wallac Trilux counter. Total and non-specific binding were determined using buffer and 1 μM (final concentration) of the high affinity BACE1 reference inhibitor (S)-6-[3-chloro-5-(5-prop-1-ynyl-pyridin-3-yl)-thiophen-2-yl]-2-imino-3,6-dimethyl-tetrahydro-pyrimidin-4-one, respectively.;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886720;37;BindingDB Database;;2016;CHEMBL3307715
CHEMBL3915968;;0;497.5;0;1.97;BDBM249093;CN1CC2(C1)C(=N)N[C@](C)(c1cc(NC(=O)c3ccc(OC(F)F)cn3)ccc1F)CS2(=O)=O;Ki;'=';2.7;nM;8.57;;434631;UO_0000065;17.22;0.34;6.60;6.88;False;CHEMBL3889105;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 ul of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 ul in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window. Inhibitor IC50 values are derived from non-linear regression analysis of concentration response curves. Ki values are then calculated from IC50 values using the Cheng-Prusoff equation using a previously determined um value of 8 uM for the QSY7-APPswe-Eu substrate at BACE1.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886943;37;BindingDB Database;;2016;None
CHEMBL3926065;;0;476.53;0;1.08;BDBM249096;COc1cnc(C(=O)Nc2ccc(F)c([C@]3(C)CS(=O)(=O)C4(CN(C)C4)C(=N)N3)c2)c(C)n1;Ki;'=';10.4;nM;7.98;;434634;UO_0000065;16.75;0.33;6.90;5.81;False;CHEMBL3889105;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 ul of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 ul in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window. Inhibitor IC50 values are derived from non-linear regression analysis of concentration response curves. Ki values are then calculated from IC50 values using the Cheng-Prusoff equation using a previously determined um value of 8 uM for the QSY7-APPswe-Eu substrate at BACE1.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886943;37;BindingDB Database;;2016;None
CHEMBL3922651;;0;470.53;0;1.55;BDBM249097;Cc1cc(C#N)cnc1C(=O)Nc1ccc(F)c([C@]2(C)CS(=O)(=O)C3(CN(C)C3)C(=N)N2)c1;Ki;'=';1.3;nM;8.89;;434635;UO_0000065;18.89;0.37;7.34;6.39;False;CHEMBL3889105;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 ul of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 ul in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window. Inhibitor IC50 values are derived from non-linear regression analysis of concentration response curves. Ki values are then calculated from IC50 values using the Cheng-Prusoff equation using a previously determined um value of 8 uM for the QSY7-APPswe-Eu substrate at BACE1.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886943;37;BindingDB Database;;2016;None
CHEMBL3986242;;0;489.57;0;2.16;BDBM249103;COc1ccc(C(=O)Nc2ccc(F)c([C@]3(C)CS(=O)(=O)C4(CCN(C)CC4)C(=N)N3)c2)nc1;Ki;'=';35.0;nM;7.46;;434641;UO_0000065;15.23;0.30;5.30;5.99;False;CHEMBL3889105;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 ul of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 ul in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window. Inhibitor IC50 values are derived from non-linear regression analysis of concentration response curves. Ki values are then calculated from IC50 values using the Cheng-Prusoff equation using a previously determined um value of 8 uM for the QSY7-APPswe-Eu substrate at BACE1.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886943;37;BindingDB Database;;2016;None
CHEMBL3915974;;0;456.5;0;1.21;BDBM249117;Cc1cc(C#N)cnc1C(=O)Nc1ccc(F)c([C@]2(C)CS(=O)(=O)C3(CNC3)C(=N)N2)c1;Ki;'=';4.1;nM;8.39;;434655;UO_0000065;18.37;0.36;7.18;5.67;False;CHEMBL3889105;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 ul of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 ul in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window. Inhibitor IC50 values are derived from non-linear regression analysis of concentration response curves. Ki values are then calculated from IC50 values using the Cheng-Prusoff equation using a previously determined um value of 8 uM for the QSY7-APPswe-Eu substrate at BACE1.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886943;37;BindingDB Database;;2016;None
CHEMBL3972708;;0;459.38;0;3.45;BDBM190819;C[C@@]1(c2sc(C(=O)Nc3cccc(Cl)n3)cc2Cl)CS(=O)(=O)C2(CC2)C(=N)N1;Ki;'=';17.0;nM;7.77;;341302;UO_0000065;16.91;0.38;4.32;6.94;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3915937;;0;487.07;0;3.70;BDBM190833;C[C@@]1(c2sc(C(=O)NCc3ccsn3)cc2Cl)CS(=O)(=O)C2(CCCCC2)C(=N)N1;Ki;'=';121.0;nM;6.92;;341315;UO_0000065;14.2;0.31;3.22;6.18;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3943085;;0;425.48;0;1.17;BDBM190852;CC1(C(=O)Nc2ccc(F)c([C@]3(C)CS(=O)(=O)[C@]4(CCOC4)C(=N)N3)c2)COC1;Ki;'=';4185.0;nM;5.38;;341334;UO_0000065;12.64;0.25;4.21;4.57;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3944871;;0;369.42;0;1.15;BDBM190860;CC(=O)Nc1ccc(F)c([C@]2(C)CS(=O)(=O)[C@]3(CCOC3)C(=N)N2)c1;Ki;'=';1522.0;nM;5.82;;341340;UO_0000065;15.75;0.32;4.67;5.37;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3910252;;0;446.5;0;2.15;BDBM190861;Cc1ccc(C(=O)Nc2ccc(F)c([C@]3(C)CS(=O)(=O)[C@]4(CCOC4)C(=N)N3)c2)nc1;Ki;'=';41.0;nM;7.39;;341341;UO_0000065;16.54;0.33;5.24;6.09;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3943076;;0;325.41;0;1.93;BDBM190875;C[C@@]1(c2cc(N)ccc2F)CS(=O)(=O)C2(CCCC2)C(=N)N1;Ki;'=';4126.0;nM;5.38;;341351;UO_0000065;16.55;0.33;3.45;5.61;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3936701;;0;383.72;0;2.91;BDBM190889;C[C@@]1(c2sc(Br)cc2Cl)CS(=O)(=O)C2(CC2)C(=N)N1;Ki;'=';912.0;nM;6.04;;341359;UO_0000065;15.74;0.43;3.13;8.63;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3933481;;0;486.62;0;4.85;BDBM242313;CN1C(=N)N[C@](C)(c2sc3c(-c4ccc(-c5nccs5)cc4)cccc3c2F)CS1(=O)=O;Ki;'=';797.0;nM;6.1;;422440;UO_0000065;12.53;0.26;1.25;7.08;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3640285;;0;454.84;0;1.98;BDBM102968;COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3ccc(F)c(Cl)c3F)C2)nc(C)c1F;Ki;'=';9.2;nM;8.04;;220607;UO_0000065;17.67;0.35;6.06;8.29;False;CHEMBL3705045;Time-Resolved FRET Assay: A homogeneous time-resolved FRET assay was used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. The assay monitored the increase of 620nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide).;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638861;37;BindingDB Database;;2013;None
CHEMBL3640282;;0;409.43;0;0.92;BDBM102965;COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3cccc(C#N)c3)C2)nc(C)c1F;Ki;'=';14.0;nM;7.85;;220608;UO_0000065;19.18;0.36;6.93;6.51;False;CHEMBL3705045;Time-Resolved FRET Assay: A homogeneous time-resolved FRET assay was used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. The assay monitored the increase of 620nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide).;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638861;37;BindingDB Database;;2013;None
CHEMBL3938450;;0;414.46;0;3.16;BDBM242950;CN1C(=N)N[C@](C)(c2cc(-c3cc(-c4ccccc4)on3)ccc2F)CS1(=O)=O;Ki;'=';326.0;nM;6.49;;423833;UO_0000065;15.65;0.31;3.33;6.53;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3952594;;0;467.96;0;3.14;BDBM242954;COc1ccc(-c2nnc(-c3cc(Cl)c([C@]4(C)CS(=O)(=O)N(C)C(=N)N4)s3)o2)cc1;Ki;'=';38.62;nM;7.41;;423835;UO_0000065;15.84;0.34;4.27;6.11;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3921501;;0;422.47;0;2.01;BDBM242986;CN1C(=N)N[C@](C)(c2cc(-c3nnc(-c4nccs4)o3)ccc2F)CS1(=O)=O;Ki;'=';4002.0;nM;5.4;;423867;UO_0000065;12.78;0.26;3.39;4.32;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3672919;;0;440.43;0;1.03;BDBM143222;COc1cnc(C(=O)Nc2cc(F)c(F)c([C@]3(C)CS(=O)(=O)N(C)C(=N)N3)c2)cn1;Ki;'=';1.05;nM;8.98;;300572;UO_0000065;20.39;0.41;7.95;6.54;True;CHEMBL3705433;HTRF FRET Assay: A homogeneous time-resolved FRET assay was used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitored the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contained an N-terminal QSY7 moiety that served as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence was low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors was manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul were preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30 C. in reaction buffer containing 20 mM Na-Acetate pH 5.0.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638621;37;BindingDB Database;;2015;None
CHEMBL3650771;;0;384.86;0;3.73;BDBM149858;CC1(C)Oc2ccc(-c3cccc(Cl)c3)cc2C2(COC(N)=N2)C12COC2;Ki;'=';215.0;nM;6.67;;361591;UO_0000065;17.32;0.34;2.94;10.09;False;CHEMBL3887894;Fluorescence Resonance Energy Transfer (FRET) Assay: Test Example 1: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence. The amino acid sequence of the 'core' peptide of the substrate is SEVNLDAEFK (SEQ ID NO:2). The amino terminus was derivatized with (7-methoxycoumarin-4-yl)acetyl (MCA), and the epsilon amine of the lysine side chain of the terminal residue (K in sequence SEVNLDAEFK (SEQ ID NO:2)) was derivatized with 2,4-dinitrophenyl (DNP). Assays were performed in a buffer of 0.1 M sodium acetate, pH 4.4, 0.08% 3-[(3-Cholamidopropyl)dimethylammonio]propanesulfonate (CHAPS), 0.005% Tween80. BACE1 enzyme (final concentration 65 nM) was pre-incubated with test compounds for 15 minutes at room temperature. Fluorescence intensities were measured 60 minutes after addition of the substrate (final concentration 3 uM) by Tecan Safire2.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886493;37;BindingDB Database;;2016;None
CHEMBL3957619;;0;437.52;0;2.03;BDBM247277;COc1ccc(C(=S)Nc2ccc(F)c([C@]3(C)CS(=O)(=O)N(C)C(=N)N3)c2)nc1;Ki;'=';57.0;nM;7.24;;431480;UO_0000065;16.56;0.34;5.21;6.74;False;CHEMBL3889053;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886930;37;BindingDB Database;;2016;None
CHEMBL3922951;;0;475.49;0;3.04;BDBM247280;CN1C(=N)N[C@](C)(c2cc(NC(=S)c3ccc(C(F)(F)F)cn3)ccc2F)CS1(=O)=O;Ki;'=';18.0;nM;7.75;;431483;UO_0000065;16.29;0.34;4.70;7.89;False;CHEMBL3889053;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886930;37;BindingDB Database;;2016;None
CHEMBL3971668;;0;438.92;0;2.53;BDBM242965;CN1C(=N)N[C@](C)(c2sc(-c3nnc(-c4ccncc4)o3)cc2Cl)CS1(=O)=O;Ki;'=';558.3;nM;6.25;;423846;UO_0000065;14.25;0.31;3.72;5.00;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3925667;;0;544.06;1;4.71;BDBM243000;CN1C(=N)N[C@](C)(c2sc(-c3nnc(-c4ccc(OCc5ccccc5)cc4)o3)cc2Cl)CS1(=O)=O;Ki;'=';226.9;nM;6.64;;423881;UO_0000065;12.21;0.25;1.93;5.47;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3898147;;0;524.07;1;4.70;BDBM243001;CCCCCOc1ccc(-c2nnc(-c3cc(Cl)c([C@]4(C)CS(=O)(=O)N(C)C(=N)N4)s3)o2)cc1;Ki;'=';160.1;nM;6.8;;423882;UO_0000065;12.97;0.27;2.10;5.60;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3971426;;0;573.97;1;4.20;BDBM243014;CN1C(=N)N[C@](C)(c2sc(-c3nnc(-c4ccc(-c5noc(C(F)(F)F)n5)cc4)o3)cc2Cl)CS1(=O)=O;Ki;'=';257.9;nM;6.59;;423895;UO_0000065;11.48;0.24;2.39;4.36;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3894501;;0;469.57;0;3.91;BDBM243018;CN1C(=N)N[C@](C)(c2sc3c(-c4cnn(-c5ccccc5)c4)cccc3c2F)CS1(=O)=O;Ki;'=';1462.0;nM;5.83;;423899;UO_0000065;12.43;0.25;1.93;6.41;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3703255;;0;361.4;0;2.07;BDBM149773;CC#Cc1cncc(-c2ccc3c(c2)C2(COC(N)=N2)C2(COC2)CO3)c1;Ki;'=';123.0;nM;6.91;;361513;UO_0000065;19.12;0.35;4.84;8.75;False;CHEMBL3887894;Fluorescence Resonance Energy Transfer (FRET) Assay: Test Example 1: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence. The amino acid sequence of the 'core' peptide of the substrate is SEVNLDAEFK (SEQ ID NO:2). The amino terminus was derivatized with (7-methoxycoumarin-4-yl)acetyl (MCA), and the epsilon amine of the lysine side chain of the terminal residue (K in sequence SEVNLDAEFK (SEQ ID NO:2)) was derivatized with 2,4-dinitrophenyl (DNP). Assays were performed in a buffer of 0.1 M sodium acetate, pH 4.4, 0.08% 3-[(3-Cholamidopropyl)dimethylammonio]propanesulfonate (CHAPS), 0.005% Tween80. BACE1 enzyme (final concentration 65 nM) was pre-incubated with test compounds for 15 minutes at room temperature. Fluorescence intensities were measured 60 minutes after addition of the substrate (final concentration 3 uM) by Tecan Safire2.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886493;37;BindingDB Database;;2016;None
CHEMBL3905648;;0;432.48;0;2.22;BDBM190701;COc1ccc(C(=O)Nc2ccc(F)c([C@]3(C)CS(=O)(=O)C4(CC4)C(=N)N3)c2)nc1;Ki;'=';3.4;nM;8.47;;341196;UO_0000065;19.58;0.39;6.25;6.98;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL264004;;0;739.98;2;2.44;BACE Inhibitor 7;CC(C)C[C@H](NC(=O)C(CS(C)(=O)=O)NC(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)C(O)CC(C)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C;Ki;'=';9.4;nM;8.03;;;UO_0000065;10.85;0.21;5.59;3.84;False;CHEMBL828263;Binding affinity towards Beta-secretase determined using continuum electrostatics solvation;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1137231;1;Scientific Literature;J. Med. Chem.;2004;None
CHEMBL4107633;;0;495.51;0;1.58;BDBM236605;COc1cnc(C(=O)Nc2ccc(F)c([C@]34COC(CF)[C@H]3S(=O)(=O)C(C)(C)C(=N)N4)c2)cn1;Ki;'=';4.0;nM;8.4;;412121;UO_0000065;16.95;0.34;6.82;5.86;False;CHEMBL3888701;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886796;37;BindingDB Database;;2016;None
CHEMBL3640259;;0;384.42;0;1.05;18;COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3ccccc3)C2)nc(C)c1F;Ki;'=';36.0;nM;7.44;;;UO_0000065;19.36;0.36;6.39;7.68;False;CHEMBL3801550;Inhibition of recombinant human BACE1 preincubated for 30 mins followed QSY7EISEVNLDAEFC-Eu-amide substrate addition measured after 90 mins by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3797133;1;Scientific Literature;J. Med. Chem.;2016;None
CHEMBL3799339;;0;429.48;0;1.58;15;CCOc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3ccc(C#N)s3)C2)nc(C)c1F;Ki;'=';48.0;nM;7.32;;;UO_0000065;17.04;0.33;5.74;6.19;False;CHEMBL3801550;Inhibition of recombinant human BACE1 preincubated for 30 mins followed QSY7EISEVNLDAEFC-Eu-amide substrate addition measured after 90 mins by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3797133;1;Scientific Literature;J. Med. Chem.;2016;None
CHEMBL3798544;;0;415.45;0;1.19;11;COc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3ccc(C#N)s3)C2)nc(C)c1F;Ki;'=';15.0;nM;7.82;;;UO_0000065;18.83;0.37;6.63;6.62;False;CHEMBL3801550;Inhibition of recombinant human BACE1 preincubated for 30 mins followed QSY7EISEVNLDAEFC-Eu-amide substrate addition measured after 90 mins by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3797133;1;Scientific Literature;J. Med. Chem.;2016;None
CHEMBL2178713;;0;453.53;0;2.88;7;CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3ncccc3C#N)C[C@H]2C1=O;Ki;'=';6.0;nM;8.22;;;UO_0000065;18.13;0.34;5.34;6.86;False;CHEMBL3801550;Inhibition of recombinant human BACE1 preincubated for 30 mins followed QSY7EISEVNLDAEFC-Eu-amide substrate addition measured after 90 mins by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3797133;1;Scientific Literature;J. Med. Chem.;2016;None
CHEMBL3904537;;0;438.51;0;1.90;BDBM190857;C[C@@]1(c2cc(NC(=O)c3cscn3)ccc2F)CS(=O)(=O)[C@]2(CCOC2)C(=N)N1;Ki;'=';433.0;nM;6.36;;341338;UO_0000065;14.51;0.30;4.46;5.25;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3960086;;0;494.04;0;4.89;BDBM242931;CC1(C)C(=N)N[C@](C)(c2cc(NC(=O)c3ccc(Cl)cn3)ccc2F)CS1(O)NCC1CC1;Ki;'=';3.0;nM;8.52;;423792;UO_0000065;17.25;0.35;3.63;7.74;False;CHEMBL3888940;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886895;37;BindingDB Database;;2016;None
CHEMBL3918315;;0;427.94;0;2.19;BDBM242943;CN1C(=N)N[C@](C)(c2sc(-c3ccc(C4=NCCO4)[nH]3)cc2Cl)CS1(=O)=O;Ki;'=';270.0;nM;6.57;;423824;UO_0000065;15.35;0.33;4.38;5.94;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3947380;;0;438.92;0;2.53;BDBM242966;CN1C(=N)N[C@](C)(c2sc(-c3nnc(-c4cccnc4)o3)cc2Cl)CS1(=O)=O;Ki;'=';1046.0;nM;5.98;;423847;UO_0000065;13.63;0.29;3.45;4.78;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3979775;;0;477.96;0;2.78;BDBM242967;CN1C(=N)N[C@](C)(c2sc(-c3nnc(-c4cc5ccccn5n4)o3)cc2Cl)CS1(=O)=O;Ki;'=';260.0;nM;6.58;;423848;UO_0000065;13.78;0.29;3.81;5.09;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3903123;;0;406.4;0;1.55;BDBM242992;CN1C(=N)N[C@](C)(c2cc(-c3nnc(-c4ccon4)o3)ccc2F)CS1(=O)=O;Ki;'=';4940.0;nM;5.31;;423873;UO_0000065;13.06;0.26;3.76;3.84;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3977296;;0;480.02;0;4.26;BDBM242993;CC(C)c1ccc(-c2nnc(-c3cc(Cl)c([C@]4(C)CS(=O)(=O)N(C)C(=N)N4)s3)o2)cc1;Ki;'=';358.6;nM;6.45;;423874;UO_0000065;13.43;0.28;2.19;5.75;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL4106803;;0;456.45;0;1.09;BDBM182830;COc1nc(N2CC3[C@](c4ccc(F)cc4F)(C2)NC(=N)N(C)S3(=O)=O)nc(C)c1F;Ki;'=';30.0;nM;7.52;;330378;UO_0000065;16.48;0.33;6.43;6.75;False;CHEMBL3887312;BACE1 HTRF FRET Assay: A homogeneous time-resolved FRET assay was used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitored the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contained an N-terminal QSY7 moiety that served as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence was low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors was manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul were preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886269;37;BindingDB Database;;2015;None
CHEMBL4106980;;0;576.56;1;1.74;BDBM182843;COc1nc(N2CC3[C@](c4cc(NC(=O)c5ccc(F)cn5)ccc4F)(C2)NC(=N)N(C)S3(=O)=O)nc(C)c1F;Ki;'=';1.2;nM;8.92;;330391;UO_0000065;15.47;0.30;7.18;5.81;False;CHEMBL3887312;BACE1 HTRF FRET Assay: A homogeneous time-resolved FRET assay was used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitored the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contained an N-terminal QSY7 moiety that served as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence was low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors was manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul were preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886269;37;BindingDB Database;;2015;None
CHEMBL252910;;0;602.71;1;1.82;31;COc1cccc(CNC[C@@H](O)[C@H](Cc2ccccc2)NC(=O)[C@H](CS(C)(=O)=O)NC(=O)OCc2nc(C)oc2C)c1;Ki;'=';15000.0;nM;4.82;;;UO_0000065;8.0;0.16;3.00;2.85;False;CHEMBL945886;Binding affinity to recombinant memapsin 2;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1141466;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2008;None
CHEMBL3919017;;0;398.98;0;3.93;BDBM190812;CC(C)(C)C#Cc1cc(Cl)c([C@]2(C)CS(=O)(=O)C3(CCC3)C(=N)N2)s1;Ki;'=';165.4;nM;6.78;;341296;UO_0000065;17.0;0.37;2.85;9.69;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL1162067;;0;456.57;0;3.39;2;CC(C)C(=O)c1cc(-c2nnc([C@](C)(N)Cc3ccccc3)o2)cc(N(C)S(C)(=O)=O)c1;Ki;'=';15848.93;nM;4.8;;;UO_0000065;10.51;0.20;1.41;4.02;False;CHEMBL902621;Inhibition of BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1138425;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2007;None
CHEMBL3361307;;0;750.04;2;4.00;3e;Cc1cc(C)n(C[C@H](CC(C)C)C(=O)N[C@@H](CNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NCC(C)C)C(C)C)n1;Ki;'=';147.7;nM;6.83;;;UO_0000065;9.11;0.18;2.83;3.54;False;CHEMBL3380862;Inhibition of recombinant BACE1 (unknown origin);B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3351680;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;None
CHEMBL4294969;;0;481.94;0;3.20;3;CN1C(=N)N[C@@]2(c3cc(-c4ccc(Cl)c(C#N)c4)cs3)CN(c3ncc(F)cn3)C[C@H]2C1=O;Ki;'=';10.0;nM;8.0;;;UO_0000065;16.6;0.33;4.80;7.34;False;CHEMBL4270026;Inhibition of recombinant human BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4266039;1;Scientific Literature;J Med Chem;2018;None
CHEMBL2179136;;0;597.78;1;2.44;18;CCc1cn2c3c(cc(C(=O)N[C@H](CN[C@H](C(=O)NCC(C)C)[C@H](C)O)Cc4ccccc4)cc13)N(C)S(=O)(=O)CC2;Ki;'=';7.3;nM;8.14;;;UO_0000065;13.61;0.26;5.70;6.13;False;CHEMBL2185581;Inhibition of recombinant BACE1 expressed in Escherichia coli using Arg- Glu(EDANS)-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys(Dabcyl)-Arg as substrate by fluorimetric analysis;B;BAO_0000019;assay format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177024;1;Scientific Literature;J. Med. Chem.;2012;None
CHEMBL4064412;;0;424.58;1;6.61;3;CC(C)=CCC/C(=C/CC/C(C)=C/CC/C(C)=C/CC1=CC(=O)C=C(C)C1=O)C(=O)O;Ki;'=';4000.0;nM;5.4;;;UO_0000065;12.71;0.24;-1.21;7.56;False;CHEMBL4055496;Mixed type inhibition of recombinant human BACE1 using Rh-EVNLDAEFK-Quencher as substrate after 60 mins by Dixon plot analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4052658;1;Scientific Literature;Bioorg Med Chem;2017;None
CHEMBL3650834;;0;415.49;0;3.24;BDBM149924;CC#Cc1cncc(-c2ccc3c(c2)C2(COC(N)=N2)C2(COC2)C(CC2CC2)O3)c1;Ki;'=';82.5;nM;7.08;;361646;UO_0000065;17.05;0.31;3.84;8.97;False;CHEMBL3887894;Fluorescence Resonance Energy Transfer (FRET) Assay: Test Example 1: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence. The amino acid sequence of the 'core' peptide of the substrate is SEVNLDAEFK (SEQ ID NO:2). The amino terminus was derivatized with (7-methoxycoumarin-4-yl)acetyl (MCA), and the epsilon amine of the lysine side chain of the terminal residue (K in sequence SEVNLDAEFK (SEQ ID NO:2)) was derivatized with 2,4-dinitrophenyl (DNP). Assays were performed in a buffer of 0.1 M sodium acetate, pH 4.4, 0.08% 3-[(3-Cholamidopropyl)dimethylammonio]propanesulfonate (CHAPS), 0.005% Tween80. BACE1 enzyme (final concentration 65 nM) was pre-incubated with test compounds for 15 minutes at room temperature. Fluorescence intensities were measured 60 minutes after addition of the substrate (final concentration 3 uM) by Tecan Safire2.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886493;37;BindingDB Database;;2016;None
CHEMBL3650845;;0;428.88;0;2.72;BDBM149936;CC1(C)Oc2ccc(NC(=O)c3ccc(Cl)cn3)cc2[C@@]2(COC(N)=N2)C12COC2;Ki;'=';10.3;nM;7.99;;361655;UO_0000065;18.62;0.36;5.27;7.39;False;CHEMBL3887894;Fluorescence Resonance Energy Transfer (FRET) Assay: Test Example 1: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence. The amino acid sequence of the 'core' peptide of the substrate is SEVNLDAEFK (SEQ ID NO:2). The amino terminus was derivatized with (7-methoxycoumarin-4-yl)acetyl (MCA), and the epsilon amine of the lysine side chain of the terminal residue (K in sequence SEVNLDAEFK (SEQ ID NO:2)) was derivatized with 2,4-dinitrophenyl (DNP). Assays were performed in a buffer of 0.1 M sodium acetate, pH 4.4, 0.08% 3-[(3-Cholamidopropyl)dimethylammonio]propanesulfonate (CHAPS), 0.005% Tween80. BACE1 enzyme (final concentration 65 nM) was pre-incubated with test compounds for 15 minutes at room temperature. Fluorescence intensities were measured 60 minutes after addition of the substrate (final concentration 3 uM) by Tecan Safire2.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886493;37;BindingDB Database;;2016;None
CHEMBL3627959;;0;448.35;0;3.55;7d;CC(=O)Nc1c(Cl)cc(CN/C(N)=N/C(=O)[C@H]2CCCN2c2ccccc2)cc1Cl;Ki;'=';2500.0;nM;5.6;;;UO_0000065;12.49;0.26;2.05;5.61;False;CHEMBL3630426;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 6.4 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL3627970;;0;478.38;0;3.56;12f;COc1cccc(N2CCC[C@H]2C(=O)/N=C(\N)NCc2cc(Cl)c(NC(C)=O)c(Cl)c2)c1;Ki;'=';630.0;nM;6.2;;;UO_0000065;12.96;0.26;2.64;5.69;False;CHEMBL3630426;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 6.4 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL3628125;;0;545.47;1;3.46;20b;N/C1=N\C(=O)[C@@H]2CCCN2c2ccc(cc2)OC/C=C/CCNCC(=O)Nc2c(Cl)cc(cc2Cl)CN1;Ki;'=';20.0;nM;7.7;;;UO_0000065;14.11;0.28;4.24;6.36;False;CHEMBL3630425;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 5 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL3628124;;0;531.44;1;3.07;20a;N/C1=N\C(=O)[C@@H]2CCCN2c2ccc(cc2)OC/C=C/CNCC(=O)Nc2c(Cl)cc(cc2Cl)CN1;Ki;'=';220.0;nM;6.66;;;UO_0000065;12.53;0.25;3.59;5.50;False;CHEMBL3630425;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 5 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL3929629;;0;445.46;0;2.18;BDBM190851;C[C@@]1(c2cc(NC(=O)C3CCC3(F)F)ccc2F)CS(=O)(=O)[C@]2(CCOC2)C(=N)N1;Ki;'=';3709.0;nM;5.43;;341333;UO_0000065;12.19;0.25;3.25;5.01;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3627957;;0;444.32;0;3.99;7b;CC(=O)Nc1c(Cl)cc(CN/C(N)=N/C(=O)c2cccn2-c2ccccc2)cc1Cl;Ki;'=';4000.0;nM;5.4;;;UO_0000065;12.15;0.25;1.41;5.32;False;CHEMBL3630426;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 6.4 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL605967;;0;575.65;1;3.45;1l;CCCN(CCC)C(=O)c1cccc(C(=O)N[C@@H](COc2cc(F)cc(F)c2)[C@@H](O)C[C@@H](OC)C(=O)NC2CC2)c1;Ki;'=';220.0;nM;6.66;;;UO_0000065;11.57;0.22;3.21;5.68;False;CHEMBL1072341;Inhibition of human BACE1 expressed in Escherichia coli cells (BL21(DE3) by TRF assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157542;1;Scientific Literature;J. Med. Chem.;2010;None
CHEMBL3930338;;0;425.39;0;3.22;BDBM234452;COc1cnc(C(=O)Nc2ccc(F)c([C@@]3(C)N=C(N)[C@@](C)(F)CC3(F)F)c2)cn1;Ki;'=';18.0;nM;7.75;;408768;UO_0000065;18.21;0.35;4.52;7.56;False;CHEMBL3888549;SPA-Based Assay: The binding assay was performed as SPA-based assay using a biotinylated form of human BACE1 recombinantly expressed and subsequently purified from Freestyle HEK293 cells. The binding assay was run in a 50 mM sodium acetate buffer, pH 4.5 containing 50 mM NaCl and 0.03% Tween-20 in white clear bottom 384 plates (Corning #3653). 10 nM (final concentration) radioligand ([3H]-N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N-((R)-1-phenyl-ethyl)-isophthalamide) (TRQ11569 purchased from GE Healthcare) was mixed with test compound at a given concentration, 6 nM (final concentration) human BACE1 and 25 μg Streptavidin coated PVT core SPA beads (RPNQ0007, GE Healthcare Life Sciences) in a total volume of 40 μl.;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886758;37;BindingDB Database;;2016;CHEMBL3307715
CHEMBL3977552;;0;400.4;0;3.87;BDBM234455;C[C@]1(F)CC(F)(F)[C@@](C)(c2cc(NC(=O)c3nccs3)ccc2F)N=C1N;Ki;'=';66.0;nM;7.18;;408771;UO_0000065;17.93;0.36;3.31;8.93;False;CHEMBL3888549;SPA-Based Assay: The binding assay was performed as SPA-based assay using a biotinylated form of human BACE1 recombinantly expressed and subsequently purified from Freestyle HEK293 cells. The binding assay was run in a 50 mM sodium acetate buffer, pH 4.5 containing 50 mM NaCl and 0.03% Tween-20 in white clear bottom 384 plates (Corning #3653). 10 nM (final concentration) radioligand ([3H]-N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N-((R)-1-phenyl-ethyl)-isophthalamide) (TRQ11569 purchased from GE Healthcare) was mixed with test compound at a given concentration, 6 nM (final concentration) human BACE1 and 25 μg Streptavidin coated PVT core SPA beads (RPNQ0007, GE Healthcare Life Sciences) in a total volume of 40 μl.;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886758;37;BindingDB Database;;2016;CHEMBL3307715
CHEMBL3982347;;0;414.43;0;4.18;BDBM234457;Cc1csc(C(=O)Nc2ccc(F)c([C@@]3(C)N=C(N)[C@@](C)(F)CC3(F)F)c2)n1;Ki;'=';44.0;nM;7.36;;408773;UO_0000065;17.75;0.36;3.18;9.15;False;CHEMBL3888549;SPA-Based Assay: The binding assay was performed as SPA-based assay using a biotinylated form of human BACE1 recombinantly expressed and subsequently purified from Freestyle HEK293 cells. The binding assay was run in a 50 mM sodium acetate buffer, pH 4.5 containing 50 mM NaCl and 0.03% Tween-20 in white clear bottom 384 plates (Corning #3653). 10 nM (final concentration) radioligand ([3H]-N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N-((R)-1-phenyl-ethyl)-isophthalamide) (TRQ11569 purchased from GE Healthcare) was mixed with test compound at a given concentration, 6 nM (final concentration) human BACE1 and 25 μg Streptavidin coated PVT core SPA beads (RPNQ0007, GE Healthcare Life Sciences) in a total volume of 40 μl.;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886758;37;BindingDB Database;;2016;CHEMBL3307715
CHEMBL3640292;;0;436.85;0;2.05;BDBM9649;COc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3cc(Cl)ccc3F)C2)nc(C)c1F;Ki;'=';13.0;nM;7.89;;26899;UO_0000065;18.05;0.36;5.84;8.35;False;CHEMBL3705045;Time-Resolved FRET Assay: A homogeneous time-resolved FRET assay was used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. The assay monitored the increase of 620nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide).;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638861;37;BindingDB Database;;2013;None
CHEMBL4112573;;0;530.53;1;3.26;BDBM236610;C[C@@]1(c2ccc(F)cc2)C(=N)N[C@@]2(c3cc(NC(=O)c4ccc(F)cn4)ccc3F)COC[C@H]2S1(=O)=O;Ki;'=';1.0;nM;9.0;;412126;UO_0000065;16.96;0.33;5.74;7.42;False;CHEMBL3888701;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886796;37;BindingDB Database;;2016;None
CHEMBL98239;;0;707.98;2;3.76;17;CSC[C@H](NC(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)C(=O)N[C@@H](CC(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C;Ki;'=';50.1;nM;7.3;;;UO_0000065;10.31;0.20;3.54;4.17;True;CHEMBL711471;Binding affinity for human brain memapsin 2;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1134775;1;Scientific Literature;J. Med. Chem.;2001;None
CHEMBL3354253;;0;439.6;0;3.86;44;CN1C(=N)N[C@](CCC2CCCCC2)(C[C@H]2CCC[C@@H](NC(=O)c3ccncc3)C2)C1=O;Ki;'=';39.0;nM;7.41;;;UO_0000065;16.85;0.32;3.55;7.55;False;CHEMBL3386389;Inhibition of purified human BACE1 by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3352601;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2014;None
CHEMBL3353637;;0;404.6;0;3.90;32;CCCCC(=O)N1CCC[C@H](C[C@@]2(CCC3CCCCC3)NC(=N)N(C)C2=O)C1;Ki;'=';3200.0;nM;5.5;;;UO_0000065;13.58;0.26;1.59;7.18;False;CHEMBL3386389;Inhibition of purified human BACE1 by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3352601;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2014;None
CHEMBL3353634;;0;390.62;0;4.37;29;CCCCCN1CCC[C@H](C[C@@]2(CCC3CCCCC3)NC(=N)N(C)C2=O)C1;Ki;'=';7600.0;nM;5.12;;;UO_0000065;13.11;0.25;0.75;8.61;False;CHEMBL3386389;Inhibition of purified human BACE1 by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3352601;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2014;None
CHEMBL2151181;;0;372.88;0;3.44;35;CC#Cc1cncc(-c2cc(Cl)c([C@]3(C)CC(=O)N(C)C(=N)N3)s2)c1;Ki;'=';1.7;nM;8.77;;;UO_0000065;23.52;0.48;5.33;12.69;False;CHEMBL3268101;Inhibition of recombinant soluble human BACE1 catalytic domain using QSY7-EISEVNLDAEFC-Europium-amide as substrate preincubated for 10 mins followed by substrate addition measured after 1.5 hrs by time-resolved FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3259716;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2014;None
CHEMBL2011970;;0;283.31;0;2.07;4e;CN1C(=N)NC(c2ccccc2)(c2cccc(F)c2)C1=O;Ki;'=';720.0;nM;6.14;;;UO_0000065;21.68;0.40;4.07;10.93;False;CHEMBL2015090;Inhibition of human BACE1 using QSY7EISEVNLDAEFC-Eu-amide as substrate incubated for 30 mins prior to substrate addition measured after 90 mins by FRET analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2010674;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2012;None
CHEMBL3361304;;0;707.96;2;2.98;3b;Cc1cc(C)n(C[C@@H](C)C(=O)N[C@@H](CNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NCC(C)C)C(C)C)n1;Ki;'=';1640.0;nM;5.79;;;UO_0000065;8.17;0.16;2.81;3.00;False;CHEMBL3380862;Inhibition of recombinant BACE1 (unknown origin);B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3351680;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;None
CHEMBL3361305;;0;721.99;2;3.37;3c;CC[C@@H](Cn1nc(C)cc1C)C(=O)N[C@@H](CNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NCC(C)C)C(C)C;Ki;'=';63.1;nM;7.2;;;UO_0000065;9.97;0.19;3.83;3.73;False;CHEMBL3380862;Inhibition of recombinant BACE1 (unknown origin);B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3351680;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;None
CHEMBL3361313;;0;725.01;2;3.86;4d;CC[C@@H](Cc1nc(C)cs1)C(=O)N[C@@H](CNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NCC(C)C)C(C)C;Ki;'=';10.8;nM;7.97;;;UO_0000065;10.99;0.22;4.11;4.24;False;CHEMBL3380862;Inhibition of recombinant BACE1 (unknown origin);B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3351680;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;None
CHEMBL3961769;;0;419.43;0;1.79;BDBM190866;CC(F)(F)C(=O)Nc1ccc(F)c([C@]2(C)CS(=O)(=O)[C@]3(CCOC3)C(=N)N2)c1;Ki;'=';313.0;nM;6.5;;341345;UO_0000065;15.51;0.32;4.71;6.00;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3904196;;0;427.77;0;2.92;BDBM190883;C[C@@]1(c2sc(Br)cc2Cl)CS(=O)(=O)C2(CCOCC2)C(=N)N1;Ki;'=';2367.0;nM;5.63;;341355;UO_0000065;13.15;0.35;2.71;7.10;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL2178184;;0;548.07;2;5.59;17j;COc1ccc(-c2nsc(C)c2C(=O)/N=C(\N)NCc2cc(C)c(NC(=O)c3ccccc3)c(Cl)c2)cc1;Ki;'=';30.0;nM;7.52;;;UO_0000065;13.73;0.27;1.93;6.34;False;CHEMBL2187886;Displacement of [3H]BMS-599240 from BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177026;1;Scientific Literature;J. Med. Chem.;2012;CHEMBL3307715
CHEMBL2178718;;0;447.5;0;2.54;43;CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3ncc(F)cn3)C[C@H]2C1=O;Ki;'=';4.0;nM;8.4;;;UO_0000065;18.77;0.36;5.86;7.70;True;CHEMBL2183861;Inhibition of BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177036;1;Scientific Literature;J. Med. Chem.;2012;None
CHEMBL2178150;;0;445.52;0;3.75;33;CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3ccc(F)cc3)C[C@H]2C1=O;Ki;'=';26.0;nM;7.58;;;UO_0000065;17.03;0.32;3.84;9.11;True;CHEMBL2183861;Inhibition of BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177036;1;Scientific Literature;J. Med. Chem.;2012;None
CHEMBL2178147;;0;487.56;0;3.28;28;CC#Cc1cncc(-c2csc([C@]34CN(C(=O)c5cccc(F)c5)C[C@H]3C(=O)N(C)C(=N)N4)c2)c1;Ki;'=';1.0;nM;9.0;;;UO_0000065;18.46;0.35;5.72;10.07;False;CHEMBL2183861;Inhibition of BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177036;1;Scientific Literature;J. Med. Chem.;2012;None
CHEMBL2178146;;0;491.52;0;3.53;27;CN1C(=N)N[C@@]2(c3cc(-c4ccc(F)c(C#N)c4)cs3)CN(C(=O)c3cccc(F)c3)C[C@H]2C1=O;Ki;'=';2.0;nM;8.7;;;UO_0000065;17.7;0.34;5.17;8.67;False;CHEMBL2183861;Inhibition of BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177036;1;Scientific Literature;J. Med. Chem.;2012;None
CHEMBL78946;;0;893.01;3;-1.74;1;CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(=O)O)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O;Ki;'=';1.6;nM;8.8;;;UO_0000065;9.85;0.19;10.54;2.34;True;CHEMBL2067011;Inhibition of recombinant beta-secretase 1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2062429;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2012;None
CHEMBL2063209;;0;582.79;2;7.36;4i;Cc1[nH]ncc1CN(C(=O)CC[C@@H](C1CCCCC1)N1Cc2cc(Oc3ccccc3)ccc2N=C1N)C1CCCCC1;Ki;'=';39.0;nM;7.41;;;UO_0000065;12.71;0.24;0.05;7.42;False;CHEMBL2067011;Inhibition of recombinant beta-secretase 1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2062429;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2012;None
CHEMBL2178713;;0;453.53;0;2.88;38;CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3ncccc3C#N)C[C@H]2C1=O;Ki;'=';6.0;nM;8.22;;;UO_0000065;18.13;0.34;5.34;6.86;True;CHEMBL2183861;Inhibition of BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177036;1;Scientific Literature;J. Med. Chem.;2012;None
CHEMBL78946;;0;893.01;3;-1.74;1, OM99-2;CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(=O)O)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O;Ki;'=';1.6;nM;8.8;;;UO_0000065;9.85;0.19;10.54;2.34;True;CHEMBL2399171;Inhibition of human BACE1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2396519;1;Scientific Literature;J. Med. Chem.;2013;None
CHEMBL2178153;;0;428.52;0;3.01;36;CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3ccccn3)C[C@H]2C1=O;Ki;'=';8.0;nM;8.1;;;UO_0000065;18.9;0.36;5.09;8.42;False;CHEMBL2183861;Inhibition of BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177036;1;Scientific Literature;J. Med. Chem.;2012;None
CHEMBL3354245;;0;390.57;0;3.51;36;CCCCC(=O)N1CC[C@H](C[C@@]2(CCC3CCCCC3)NC(=N)N(C)C2=O)C1;Ki;'=';490.0;nM;6.31;;;UO_0000065;16.16;0.31;2.80;8.25;False;CHEMBL3386389;Inhibition of purified human BACE1 by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3352601;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2014;None
CHEMBL4278011;;0;505.58;1;3.33;16;CCCOc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3cc(-c4cccc(C#N)c4)cs3)C2)ncc1F;Ki;'=';1.0;nM;9.0;;;UO_0000065;17.8;0.34;5.67;7.61;False;CHEMBL4270026;Inhibition of recombinant human BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4266039;1;Scientific Literature;J Med Chem;2018;None
CHEMBL2178717;;0;429.51;0;2.40;11;CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3ncccn3)C[C@H]2C1=O;Ki;'=';11.0;nM;7.96;;;UO_0000065;18.53;0.35;5.56;7.30;False;CHEMBL4270026;Inhibition of recombinant human BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4266039;1;Scientific Literature;J Med Chem;2018;None
CHEMBL3800286;;0;477.53;0;2.55;8;COc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3cc(-c4cccc(C#N)c4)cs3)C2)ncc1F;Ki;'=';1.4;nM;8.85;;;UO_0000065;18.54;0.36;6.30;7.49;False;CHEMBL3801550;Inhibition of recombinant human BACE1 preincubated for 30 mins followed QSY7EISEVNLDAEFC-Eu-amide substrate addition measured after 90 mins by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3797133;1;Scientific Literature;J. Med. Chem.;2016;None
CHEMBL2178718;;0;447.5;0;2.54;6;CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3ncc(F)cn3)C[C@H]2C1=O;Ki;'=';4.0;nM;8.4;;;UO_0000065;18.77;0.36;5.86;7.70;True;CHEMBL3801550;Inhibition of recombinant human BACE1 preincubated for 30 mins followed QSY7EISEVNLDAEFC-Eu-amide substrate addition measured after 90 mins by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3797133;1;Scientific Literature;J. Med. Chem.;2016;None
CHEMBL4203158;;0;508.62;2;6.12;8c;Cc1cccc2nc(-c3ccc(OCCCN4C(=O)c5ccccc5C4=O)cc3)c(NC3CCCCC3)n12;Ki;'=';1.37;nM;8.86;;;UO_0000065;17.43;0.32;2.74;11.67;False;CHEMBL4192781;Inhibition of human BACE1 (1 to 460 residues) expressed in baculovirus expression system using Rh-EVNLDAEFK-quencher as substrate after 90 mins by FRET assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4190277;1;Scientific Literature;Eur J Med Chem;2017;None
CHEMBL4208354;;0;559.07;2;6.47;8i;COc1cc(-c2nc3ccc(Cl)cn3c2NC2CCCCC2)ccc1OCCCN1C(=O)c2ccccc2C1=O;Ki;'=';5.03;nM;8.3;;;UO_0000065;14.84;0.28;1.83;9.74;False;CHEMBL4192781;Inhibition of human BACE1 (1 to 460 residues) expressed in baculovirus expression system using Rh-EVNLDAEFK-quencher as substrate after 90 mins by FRET assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4190277;1;Scientific Literature;Eur J Med Chem;2017;None
CHEMBL4238400;;0;613.82;1;1.41;3b;CSC[C@H](NC(=O)C1=NO[C@H]2OCC[C@@H]12)C(=O)N[C@@H](CC(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NCC(C)C)C(C)C;Ki;'=';553.7;nM;6.26;;;UO_0000065;10.19;0.20;4.85;3.74;False;CHEMBL4233526;Inhibition of recombinant BACE1 (unknown origin) using fluorogenic substrate;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4229428;1;Scientific Literature;Bioorg Med Chem Lett;2018;None
CHEMBL2178150;;0;445.52;0;3.75;10;CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3ccc(F)cc3)C[C@H]2C1=O;Ki;'=';26.0;nM;7.58;;;UO_0000065;17.03;0.32;3.84;9.11;False;CHEMBL4270026;Inhibition of recombinant human BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4266039;1;Scientific Literature;J Med Chem;2018;None
CHEMBL3797321;;0;438.92;0;2.23;13;CCc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3ccc(Cl)s3)C2)nc(OC)c1F;Ki;'=';11.0;nM;7.96;;;UO_0000065;18.13;0.37;5.73;8.43;False;CHEMBL3801550;Inhibition of recombinant human BACE1 preincubated for 30 mins followed QSY7EISEVNLDAEFC-Eu-amide substrate addition measured after 90 mins by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3797133;1;Scientific Literature;J. Med. Chem.;2016;None
CHEMBL2178190;;0;521.96;1;4.71;17p;COc1ccc(-c2noc(C)c2C(=O)/N=C(\N)NCc2cc(C)c(NC(=O)c3ccco3)c(Cl)c2)cc1;Ki;'=';60.0;nM;7.22;;;UO_0000065;13.84;0.27;2.51;4.98;False;CHEMBL2187886;Displacement of [3H]BMS-599240 from BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177026;1;Scientific Literature;J. Med. Chem.;2012;CHEMBL3307715
CHEMBL2178188;;0;516.39;1;4.56;17n;COc1ccc(-c2noc(C)c2C(=O)/N=C(\N)NCc2cc(Cl)c(NC(=O)C3CC3)c(Cl)c2)cc1;Ki;'=';50.0;nM;7.3;;;UO_0000065;14.14;0.28;2.74;5.54;False;CHEMBL2187886;Displacement of [3H]BMS-599240 from BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177026;1;Scientific Literature;J. Med. Chem.;2012;CHEMBL3307715
CHEMBL2178187;;0;568.44;1;3.19;17m;COc1ccc(-c2noc(C)c2C(=O)/N=C(\N)NCc2cc(Cl)c(NC(=O)CS(C)(=O)=O)c(Cl)c2)cc1;Ki;'=';30.0;nM;7.52;;;UO_0000065;13.23;0.28;4.33;4.53;False;CHEMBL2187886;Displacement of [3H]BMS-599240 from BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177026;1;Scientific Literature;J. Med. Chem.;2012;CHEMBL3307715
CHEMBL2178202;;0;432.31;0;3.95;8m;COc1ccc(-c2n[nH]c(C)c2C(=O)/N=C(\N)NCc2cc(Cl)cc(Cl)c2)cc1;Ki;'=';210.0;nM;6.68;;;UO_0000065;15.45;0.31;2.73;6.34;False;CHEMBL2187886;Displacement of [3H]BMS-599240 from BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177026;1;Scientific Literature;J. Med. Chem.;2012;CHEMBL3307715
CHEMBL2178752;;0;403.27;0;4.20;8f;Cc1onc(-c2ccccc2)c1C(=O)/N=C(\N)NCc1ccc(Cl)c(Cl)c1;Ki;'=';8800.0;nM;5.06;;;UO_0000065;12.54;0.26;0.86;5.41;False;CHEMBL2187886;Displacement of [3H]BMS-599240 from BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177026;1;Scientific Literature;J. Med. Chem.;2012;CHEMBL3307715
CHEMBL2178714;;0;446.51;0;3.15;39;CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3ccc(F)cn3)C[C@H]2C1=O;Ki;'=';6.0;nM;8.22;;;UO_0000065;18.41;0.35;5.07;8.55;True;CHEMBL2183861;Inhibition of BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177036;1;Scientific Literature;J. Med. Chem.;2012;None
CHEMBL3361309;;0;638.92;1;2.81;3g;CSC[C@H](NC(=O)[C@@H](C)Cn1nc(C)cc1C)C(=O)N[C@@H](CC(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NCC(C)C)C(C)C;Ki;'=';64.2;nM;7.19;;;UO_0000065;11.26;0.22;4.38;4.66;False;CHEMBL3380862;Inhibition of recombinant BACE1 (unknown origin);B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3351680;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;None
CHEMBL2179134;;0;679.88;1;3.68;8;CO[C@@H](C)[C@H](NC[C@H](Cc1ccccc1)NC(=O)c1cc(C(=O)N[C@H](C)c2ccccc2)cc(N(C)S(C)(=O)=O)c1)C(=O)NCC(C)C;Ki;'=';25.0;nM;7.6;;;UO_0000065;11.18;0.22;3.92;5.21;False;CHEMBL2185581;Inhibition of recombinant BACE1 expressed in Escherichia coli using Arg- Glu(EDANS)-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys(Dabcyl)-Arg as substrate by fluorimetric analysis;B;BAO_0000019;assay format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177024;1;Scientific Literature;J. Med. Chem.;2012;None
CHEMBL2151181;;0;372.88;0;3.44;16;CC#Cc1cncc(-c2cc(Cl)c([C@]3(C)CC(=O)N(C)C(=N)N3)s2)c1;Ki;'=';1.7;nM;8.77;;;UO_0000065;23.52;0.48;5.33;12.69;True;CHEMBL2155063;Inhibition of human recombinant BACE1 by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2150878;1;Scientific Literature;ACS Med. Chem. Lett.;2012;None
CHEMBL2151139;;0;324.41;0;2.89;11;CN1C(=N)N[C@](C)(c2ccc(-c3cccc(C#N)c3)s2)CC1=O;Ki;'=';88.0;nM;7.06;;;UO_0000065;21.75;0.42;4.17;8.82;False;CHEMBL2155063;Inhibition of human recombinant BACE1 by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2150878;1;Scientific Literature;ACS Med. Chem. Lett.;2012;None
CHEMBL3927942;;0;426.39;0;4.26;BDBM234494;Cc1cc(F)cnc1C(=O)Nc1ccc(F)c([C@@]2(C)N=C(N)[C@@](C)(F)CC2(F)F)c1;Ki;'=';60.0;nM;7.22;;408812;UO_0000065;16.94;0.33;2.96;8.99;False;CHEMBL3888549;SPA-Based Assay: The binding assay was performed as SPA-based assay using a biotinylated form of human BACE1 recombinantly expressed and subsequently purified from Freestyle HEK293 cells. The binding assay was run in a 50 mM sodium acetate buffer, pH 4.5 containing 50 mM NaCl and 0.03% Tween-20 in white clear bottom 384 plates (Corning #3653). 10 nM (final concentration) radioligand ([3H]-N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N-((R)-1-phenyl-ethyl)-isophthalamide) (TRQ11569 purchased from GE Healthcare) was mixed with test compound at a given concentration, 6 nM (final concentration) human BACE1 and 25 μg Streptavidin coated PVT core SPA beads (RPNQ0007, GE Healthcare Life Sciences) in a total volume of 40 μl.;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886758;37;BindingDB Database;;2016;CHEMBL3307715
CHEMBL3930021;;0;510.04;1;4.31;BDBM242998;CCCCOc1ccc(-c2nnc(-c3cc(Cl)c([C@]4(C)CS(=O)(=O)N(C)C(=N)N4)s3)o2)cc1;Ki;'=';100.2;nM;7.0;;423879;UO_0000065;13.72;0.29;2.69;5.76;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3975362;;0;449.48;0;1.51;BDBM249088;CN1CC2(C1)C(=N)N[C@](C)(c1cc(NC(=O)c3ccc(F)cn3)ccc1F)CS2(=O)=O;Ki;'=';6.1;nM;8.21;;434626;UO_0000065;18.28;0.36;6.70;7.13;False;CHEMBL3889105;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 ul of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 ul in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window. Inhibitor IC50 values are derived from non-linear regression analysis of concentration response curves. Ki values are then calculated from IC50 values using the Cheng-Prusoff equation using a previously determined um value of 8 uM for the QSY7-APPswe-Eu substrate at BACE1.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886943;37;BindingDB Database;;2016;None
CHEMBL3943424;;0;525.55;1;2.75;BDBM249107;CN1CCC2(CC1)C(=N)N[C@](C)(c1cc(NC(=O)c3ccc(OC(F)F)cn3)ccc1F)CS2(=O)=O;Ki;'=';11.0;nM;7.96;;434645;UO_0000065;15.14;0.30;5.21;6.39;False;CHEMBL3889105;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 ul of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 ul in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window. Inhibitor IC50 values are derived from non-linear regression analysis of concentration response curves. Ki values are then calculated from IC50 values using the Cheng-Prusoff equation using a previously determined um value of 8 uM for the QSY7-APPswe-Eu substrate at BACE1.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886943;37;BindingDB Database;;2016;None
CHEMBL3965266;;0;441.93;0;1.87;BDBM242982;CN1C(=N)N[C@](C)(c2sc(-c3nnc(-c4cnn(C)c4)o3)cc2Cl)CS1(=O)=O;Ki;'=';406.6;nM;6.39;;423863;UO_0000065;14.46;0.31;4.52;4.92;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL78946;;0;893.01;3;-1.74;OM99-2;CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(=O)O)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O;Ki;'=';1.4;nM;8.85;;;UO_0000065;9.91;0.19;10.59;2.36;False;CHEMBL3592359;Inhibition of active BACE1 (unknown origin);B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3588858;1;Scientific Literature;J. Med. Chem.;2015;None
CHEMBL2063196;;0;496.66;1;6.55;3b;CN(C(=O)CC[C@@H](c1ccccc1)N1Cc2cc(Oc3ccccc3)ccc2N=C1N)C1CCCCC1;Ki;'=';163.8;nM;6.79;;;UO_0000065;13.66;0.25;0.24;9.54;False;CHEMBL2067011;Inhibition of recombinant beta-secretase 1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2062429;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2012;None
CHEMBL2063201;;0;504.68;2;5.61;3g;CN(C(=O)CC[C@@H](C1CCCOC1)N1Cc2cc(Oc3ccccc3)ccc2N=C1N)C1CCCCC1;Ki;'=';122.0;nM;6.91;;;UO_0000065;13.7;0.26;1.30;8.60;False;CHEMBL2067011;Inhibition of recombinant beta-secretase 1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2062429;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2012;None
CHEMBL3913008;;0;469.49;0;3.19;BDBM190718;C[C@@]1(c2cc(NC(=O)c3ccn(C(F)F)n3)ccc2F)CS(=O)(=O)C2(CCCC2)C(=N)N1;Ki;'=';12.7;nM;7.9;;341213;UO_0000065;16.82;0.34;4.71;6.75;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3261079;;0;478.98;0;4.04;BDBM190720;C[C@@]1(c2cc(NC(=O)c3ccc(Cl)cn3)ccc2F)CS(=O)(=O)C2(CCCCC2)C(=N)N1;Ki;'=';8.4;nM;8.08;;341215;UO_0000065;16.86;0.34;4.04;7.21;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3983399;;0;480.95;0;2.89;BDBM190729;C[C@@]1(c2cc(NC(=O)c3ccc(Cl)cn3)ccc2F)CS(=O)(=O)C2(CCOCC2)C(=N)N1;Ki;'=';6.1;nM;8.21;;341224;UO_0000065;17.08;0.35;5.32;6.78;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3913400;;0;424.98;0;3.77;BDBM190748;C[C@@]1(c2sc(-c3cncnc3)cc2Cl)CS(=O)(=O)C2(CCCCC2)C(=N)N1;Ki;'=';545.0;nM;6.26;;341240;UO_0000065;14.74;0.32;2.49;6.54;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3941512;;0;471.0;0;3.23;BDBM190822;C[C@@]1(c2sc(C(=O)NCc3cnoc3)cc2Cl)CS(=O)(=O)C2(CCCCC2)C(=N)N1;Ki;'=';249.0;nM;6.6;;341305;UO_0000065;14.02;0.30;3.37;5.28;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL2011995;;0;376.85;0;3.64;13k;CN1C(=N)NC(c2cccnc2)(c2cccc(-c3cccc(Cl)c3)c2)C1=O;Ki;'=';170.0;nM;6.77;;;UO_0000065;17.96;0.34;3.13;9.80;False;CHEMBL2015090;Inhibition of human BACE1 using QSY7EISEVNLDAEFC-Eu-amide as substrate incubated for 30 mins prior to substrate addition measured after 90 mins by FRET analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2010674;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2012;None
CHEMBL3973607;;0;436.9;0;2.87;BDBM190697;C[C@@]1(c2cc(NC(=O)c3ccc(Cl)cn3)ccc2F)CS(=O)(=O)C2(CC2)C(=N)N1;Ki;'=';1.6;nM;8.8;;341192;UO_0000065;20.13;0.41;5.93;7.85;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL4106945;;0;413.47;0;1.17;BDBM236589;CO[C@H](C)C(=O)Nc1ccc(F)c([C@]23COC[C@H]2S(=O)(=O)C(C)(C)C(=N)N3)c1;Ki;'=';151.0;nM;6.82;;412105;UO_0000065;16.5;0.33;5.65;5.80;False;CHEMBL3888701;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886796;37;BindingDB Database;;2016;None
CHEMBL3935845;;0;437.42;0;2.09;BDBM190854;C[C@@]1(c2cc(NC(=O)CC(F)(F)F)ccc2F)CS(=O)(=O)[C@]2(CCOC2)C(=N)N1;Ki;'=';3169.0;nM;5.5;;341335;UO_0000065;12.57;0.26;3.41;5.08;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL4100832;;0;419.52;0;3.91;21;[2H]C1([2H])OC(N)=N[C@]12c1cc(-c3cc(C#N)cc(OC)c3)ccc1C[C@]21CC[C@@H](OC)CC1;Ki;'=';23.0;nM;7.64;;;UO_0000065;18.29;0.34;3.73;8.50;False;CHEMBL4049274;Inhibition of human BACE1 (1 to 460 residues) fused with Fc domain of IgG1 expressed in HEK293 cells preincubated for 10 mins followed by substrate addition measured after 17 mins by TR-FRET assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4043307;1;Scientific Literature;J Med Chem;2018;CHEMBL3307715
CHEMBL3892420;;0;451.96;0;3.44;BDBM242263;Cc1nc(-c2cccc(-c3cc(Cl)c([C@]4(C)CS(=O)(=O)N(C)C(=N)N4)s3)c2)no1;Ki;'=';13.4;nM;7.87;;422390;UO_0000065;17.42;0.37;4.43;7.02;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3628121;;0;462.38;0;3.94;7m;CC(=O)Nc1c(Cl)cc(CN/C(N)=N/C(=O)C2CCCCN2c2ccccc2)cc1Cl;Ki;'=';230.0;nM;6.64;;;UO_0000065;14.36;0.29;2.70;6.65;False;CHEMBL3630425;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 5 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL3628120;;0;474.39;0;3.94;7l;CC(=O)Nc1c(Cl)cc(CN/C(N)=N/C(=O)C2[C@H]3CC[C@H](C3)N2c2ccccc2)cc1Cl;Ki;'=';560.0;nM;6.25;;;UO_0000065;13.18;0.27;2.31;6.26;False;CHEMBL3630425;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 5 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL3627964;;0;448.35;0;4.14;11e;CC(=O)Nc1c(Cl)cc(CN/C(N)=N/C(=O)N[C@H]2CCCc3ccccc32)cc1Cl;Ki;'=';13000.0;nM;4.89;;;UO_0000065;10.9;0.22;0.75;4.50;False;CHEMBL3630425;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 5 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL3627971;;0;464.35;0;2.52;7e;CC(=O)Nc1c(Cl)cc(CN/C(N)=N/C(=O)[C@@H]2C[C@H](O)CN2c2ccccc2)cc1Cl;Ki;'=';790.0;nM;6.1;;;UO_0000065;13.14;0.27;3.58;5.08;False;CHEMBL3630425;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 5 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL3361308;;0;693.93;2;2.67;3f;Cc1ccn(C[C@H](C)C(=O)N[C@@H](CNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NCC(C)C)C(C)C)n1;Ki;'=';201.0;nM;6.7;;;UO_0000065;9.65;0.19;4.03;3.47;False;CHEMBL3380862;Inhibition of recombinant BACE1 (unknown origin);B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3351680;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;None
CHEMBL4110452;;0;436.47;0;1.74;BDBM236579;Cc1cc(C(=O)Nc2ccc(F)c([C@]34COC[C@H]3S(=O)(=O)C(C)(C)C(=N)N4)c2)no1;Ki;'=';201.0;nM;6.7;;412095;UO_0000065;15.34;0.30;4.96;4.98;False;CHEMBL3888701;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886796;37;BindingDB Database;;2016;None
CHEMBL2012002;;0;330.39;0;2.83;17c;CN1C(=N)NC(c2cccc(-c3cccc(C#N)c3)c2)(C2CC2)C1=O;Ki;'=';130.0;nM;6.89;;;UO_0000065;20.84;0.38;4.06;8.61;False;CHEMBL2015090;Inhibition of human BACE1 using QSY7EISEVNLDAEFC-Eu-amide as substrate incubated for 30 mins prior to substrate addition measured after 90 mins by FRET analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2010674;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2012;None
CHEMBL2012004;;0;336.4;0;2.36;17e;COc1cncc(-c2cccc(C3(C4CC4)NC(=N)N(C)C3=O)c2)c1;Ki;'=';100.0;nM;7.0;;;UO_0000065;20.81;0.38;4.64;8.94;False;CHEMBL2015090;Inhibition of human BACE1 using QSY7EISEVNLDAEFC-Eu-amide as substrate incubated for 30 mins prior to substrate addition measured after 90 mins by FRET analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2010674;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2012;None
CHEMBL2011989;;0;353.85;0;4.00;13e;CN1C(=N)NC(c2cccc(-c3cccc(Cl)c3)c2)(C2CCC2)C1=O;Ki;'=';110.0;nM;6.96;;;UO_0000065;19.67;0.38;2.96;12.38;False;CHEMBL2015090;Inhibition of human BACE1 using QSY7EISEVNLDAEFC-Eu-amide as substrate incubated for 30 mins prior to substrate addition measured after 90 mins by FRET analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2010674;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2012;None
CHEMBL3672917;;0;459.43;0;2.51;BDBM143219;CN1C(=N)N[C@](C)(c2cc(NC(=O)c3ccc(C(F)(F)F)cn3)ccc2F)CS1(=O)=O;Ki;'=';1.261;nM;8.9;;300569;UO_0000065;19.37;0.39;6.39;7.72;True;CHEMBL3705433;HTRF FRET Assay: A homogeneous time-resolved FRET assay was used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitored the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contained an N-terminal QSY7 moiety that served as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence was low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors was manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul were preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30 C. in reaction buffer containing 20 mM Na-Acetate pH 5.0.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638621;37;BindingDB Database;;2015;None
CHEMBL3901129;;0;425.39;0;3.22;BDBM234459;COc1cnc(C(=O)Nc2ccc(F)c([C@@]3(C)N=C(N)[C@@](C)(F)CC3(F)F)c2)nc1;Ki;'=';29.0;nM;7.54;;408775;UO_0000065;17.72;0.34;4.32;7.35;False;CHEMBL3888549;SPA-Based Assay: The binding assay was performed as SPA-based assay using a biotinylated form of human BACE1 recombinantly expressed and subsequently purified from Freestyle HEK293 cells. The binding assay was run in a 50 mM sodium acetate buffer, pH 4.5 containing 50 mM NaCl and 0.03% Tween-20 in white clear bottom 384 plates (Corning #3653). 10 nM (final concentration) radioligand ([3H]-N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N-((R)-1-phenyl-ethyl)-isophthalamide) (TRQ11569 purchased from GE Healthcare) was mixed with test compound at a given concentration, 6 nM (final concentration) human BACE1 and 25 μg Streptavidin coated PVT core SPA beads (RPNQ0007, GE Healthcare Life Sciences) in a total volume of 40 μl.;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886758;37;BindingDB Database;;2016;CHEMBL3307715
CHEMBL4112057;;0;427.83;1;5.07;BDBM234490;C[C@@]1(F)CC(F)(F)[C@@](C)(c2cc(NC(=O)c3ccc(Cl)cc3)ccc2F)N=C1N;Ki;'=';740.0;nM;6.13;;408807;UO_0000065;14.33;0.29;1.06;9.09;False;CHEMBL3888549;SPA-Based Assay: The binding assay was performed as SPA-based assay using a biotinylated form of human BACE1 recombinantly expressed and subsequently purified from Freestyle HEK293 cells. The binding assay was run in a 50 mM sodium acetate buffer, pH 4.5 containing 50 mM NaCl and 0.03% Tween-20 in white clear bottom 384 plates (Corning #3653). 10 nM (final concentration) radioligand ([3H]-N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N-((R)-1-phenyl-ethyl)-isophthalamide) (TRQ11569 purchased from GE Healthcare) was mixed with test compound at a given concentration, 6 nM (final concentration) human BACE1 and 25 μg Streptavidin coated PVT core SPA beads (RPNQ0007, GE Healthcare Life Sciences) in a total volume of 40 μl.;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886758;37;BindingDB Database;;2016;CHEMBL3307715
CHEMBL78946;;0;893.01;3;-1.74;OM99-2;CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(=O)O)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O;Ki;'=';1.6;nM;8.8;;;UO_0000065;9.85;0.19;10.54;2.34;False;CHEMBL2411013;Inhibition of BACE1 (unknown origin) by fluorescence spectrophotometric analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2406987;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2013;None
CHEMBL2151136;;0;380.45;0;3.86;8;CN1C(=N)N[C@](c2ccccc2)(c2cccc(-c3cccc(C#N)c3)c2)CC1=O;Ki;'=';9500.0;nM;5.02;;;UO_0000065;13.2;0.24;1.16;6.28;False;CHEMBL2155063;Inhibition of human recombinant BACE1 by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2150878;1;Scientific Literature;ACS Med. Chem. Lett.;2012;None
CHEMBL2011969;;0;385.47;0;3.99;4d;CCOc1cccc(-c2cccc(C3(c4ccccc4)NC(=N)N(C)C3=O)c2)c1;Ki;'=';460.0;nM;6.34;;;UO_0000065;16.44;0.30;2.35;9.69;False;CHEMBL2015090;Inhibition of human BACE1 using QSY7EISEVNLDAEFC-Eu-amide as substrate incubated for 30 mins prior to substrate addition measured after 90 mins by FRET analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2010674;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2012;None
CHEMBL2179140;;0;637.85;1;3.50;22;CCC[C@H](O)[C@H](NC[C@H](Cc1ccccc1)NC(=O)c1cc2c3c(c1)c(CC)cn3CC1(CC1)S(=O)(=O)N2C)C(=O)NC(C)C;Ki;'=';0.47;nM;9.33;;;UO_0000065;14.62;0.28;5.83;7.03;False;CHEMBL2185581;Inhibition of recombinant BACE1 expressed in Escherichia coli using Arg- Glu(EDANS)-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys(Dabcyl)-Arg as substrate by fluorimetric analysis;B;BAO_0000019;assay format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177024;1;Scientific Literature;J. Med. Chem.;2012;None
CHEMBL2179137;;0;625.84;1;3.22;19;CCC[C@H](O)[C@H](NC[C@H](Cc1ccccc1)NC(=O)c1cc2c3c(c1)c(CC)cn3CCS(=O)(=O)N2C)C(=O)NCC(C)C;Ki;'=';0.4;nM;9.4;;;UO_0000065;15.02;0.29;6.18;7.08;False;CHEMBL2185581;Inhibition of recombinant BACE1 expressed in Escherichia coli using Arg- Glu(EDANS)-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys(Dabcyl)-Arg as substrate by fluorimetric analysis;B;BAO_0000019;assay format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177024;1;Scientific Literature;J. Med. Chem.;2012;None
CHEMBL78946;;0;893.01;3;-1.74;1;CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(=O)O)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O;Ki;'=';1.6;nM;8.8;;;UO_0000065;9.85;0.19;10.54;2.34;True;CHEMBL653500;Inhibitory activity against human brain beta-APP (amyloid precursor protein) cleaving enzyme Beta-secretase;B;BAO_0000019;assay format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1145754;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2003;None
CHEMBL50;QUERCETIN;3;302.24;0;1.99;Quercetin;O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12;Ki;'=';14000.0;nM;4.85;;;UO_0000065;16.06;0.30;2.86;3.70;False;CHEMBL1117924;Noncompetitive inhibition of human recombinant BACE1 after 60 mins by Dixon plot analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1155522;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL3640286;;0;438.39;0;1.47;24;COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3c(F)ccc(F)c3F)C2)nc(C)c1F;Ki;'=';53.0;nM;7.28;;;UO_0000065;16.6;0.32;5.81;7.51;False;CHEMBL3801550;Inhibition of recombinant human BACE1 preincubated for 30 mins followed QSY7EISEVNLDAEFC-Eu-amide substrate addition measured after 90 mins by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3797133;1;Scientific Literature;J. Med. Chem.;2016;None
CHEMBL3650852;;0;425.45;0;1.47;BDBM149943;COc1cnc(C(=O)Nc2ccc3c(c2)C2(COC(N)=N2)C2(COC2)C(C)(C)O3)cn1;Ki;'=';79.2;nM;7.1;;361662;UO_0000065;16.69;0.31;5.63;5.45;False;CHEMBL3887894;Fluorescence Resonance Energy Transfer (FRET) Assay: Test Example 1: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence. The amino acid sequence of the 'core' peptide of the substrate is SEVNLDAEFK (SEQ ID NO:2). The amino terminus was derivatized with (7-methoxycoumarin-4-yl)acetyl (MCA), and the epsilon amine of the lysine side chain of the terminal residue (K in sequence SEVNLDAEFK (SEQ ID NO:2)) was derivatized with 2,4-dinitrophenyl (DNP). Assays were performed in a buffer of 0.1 M sodium acetate, pH 4.4, 0.08% 3-[(3-Cholamidopropyl)dimethylammonio]propanesulfonate (CHAPS), 0.005% Tween80. BACE1 enzyme (final concentration 65 nM) was pre-incubated with test compounds for 15 minutes at room temperature. Fluorescence intensities were measured 60 minutes after addition of the substrate (final concentration 3 uM) by Tecan Safire2.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886493;37;BindingDB Database;;2016;None
CHEMBL3900282;;0;445.55;0;1.51;BDBM182835;CCOCc1cc(OC)nc(N2CC3C(c4ccccc4)(C2)NC(=N)N(C)S3(=O)=O)c1;Ki;'=';61.0;nM;7.21;;330383;UO_0000065;16.19;0.32;5.70;6.69;False;CHEMBL3887312;BACE1 HTRF FRET Assay: A homogeneous time-resolved FRET assay was used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitored the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contained an N-terminal QSY7 moiety that served as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence was low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors was manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul were preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886269;37;BindingDB Database;;2015;None
CHEMBL4112190;;0;450.49;0;2.05;BDBM236585;Cc1nc(C(=O)Nc2ccc(F)c([C@]34COC[C@H]3S(=O)(=O)C(C)(C)C(=N)N4)c2)c(C)o1;Ki;'=';6.0;nM;8.22;;412101;UO_0000065;18.25;0.36;6.17;6.12;False;CHEMBL3888701;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886796;37;BindingDB Database;;2016;None
CHEMBL4113267;;0;476.53;0;2.16;BDBM236592;COc1cnc(C(=O)Nc2ccc(F)c([C@]34COC[C@H]3S(=O)(=O)C(C)(C)C(=N)N4)c2)c(C)c1;Ki;'=';4.0;nM;8.4;;412108;UO_0000065;17.62;0.35;6.24;6.44;False;CHEMBL3888701;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886796;37;BindingDB Database;;2016;None
CHEMBL3895779;;0;537.07;1;4.22;BDBM242940;CN1/C(=N\C(=O)OC(C)(C)C)N[C@](C)(c2sc(-c3ncc(-c4ccccn4)[nH]3)cc2Cl)CS1(=O)=O;Ki;'=';470.0;nM;6.33;;423821;UO_0000065;11.78;0.25;2.11;4.88;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3927262;;0;435.96;0;3.47;BDBM242941;CN1C(=N)N[C@](C)(c2sc(-c3[nH]cnc3-c3ccccc3)cc2Cl)CS1(=O)=O;Ki;'=';9034.0;nM;5.04;;423822;UO_0000065;11.57;0.25;1.57;4.95;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3954987;;0;428.88;0;2.12;BDBM242978;CN1C(=N)N[C@](C)(c2sc(-c3nnc(-c4ncco4)o3)cc2Cl)CS1(=O)=O;Ki;'=';440.8;nM;6.36;;423859;UO_0000065;14.82;0.32;4.24;4.60;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3910515;;0;436.95;0;3.74;BDBM242951;CN1C(=N)N[C@](C)(c2sc(-c3cc(-c4ccccc4)no3)cc2Cl)CS1(=O)=O;Ki;'=';943.0;nM;6.03;;423832;UO_0000065;13.79;0.29;2.29;6.07;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL1097329;;0;725.69;2;5.21;3k;CCCN(CCC)C(=O)c1cc(C)cc(C(=O)N[C@@H](Cc2cc(F)cc(F)c2)[C@H](O)[C@H]2CN(S(=O)(=O)c3ccc(Cl)c(Cl)c3)CCN2)c1;Ki;'=';73.0;nM;7.14;;;UO_0000065;9.83;0.20;1.93;5.99;False;CHEMBL1109071;Inhibition oh BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157894;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL1097341;;0;622.78;1;3.25;3w;CCCN(CCC)C(=O)c1cc(C)cc(C(=O)N[C@@H](Cc2cc(F)cc(F)c2)[C@H](O)[C@H]2CN(S(=O)(=O)CCC)CCN2)c1;Ki;'=';95.0;nM;7.02;;;UO_0000065;11.28;0.22;3.77;5.90;False;CHEMBL1109071;Inhibition oh BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157894;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL3627974;;0;524.45;1;4.95;7h;CC(=O)Nc1c(Cl)cc(CN/C(N)=N/C(=O)[C@@H]2C[C@H](c3ccccc3)CN2c2ccccc2)cc1Cl;Ki;'=';530.0;nM;6.28;;;UO_0000065;11.97;0.24;1.33;6.29;False;CHEMBL3630425;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 5 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL3361314;;0;739.04;2;4.11;4e;Cc1csc(C[C@@H](C(=O)N[C@@H](CNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NCC(C)C)C(C)C)C(C)C)n1;Ki;'=';28.9;nM;7.54;;;UO_0000065;10.2;0.20;3.43;4.01;False;CHEMBL3380862;Inhibition of recombinant BACE1 (unknown origin);B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3351680;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;None
CHEMBL2063203;;0;599.85;2;8.10;4b;Cc1nc(CN(C(=O)CC[C@@H](C2CCCCC2)N2Cc3cc(Oc4ccccc4)ccc3N=C2N)C2CCCCC2)cs1;Ki;'=';79.0;nM;7.1;;;UO_0000065;11.84;0.23;-1.00;8.45;False;CHEMBL2067011;Inhibition of recombinant beta-secretase 1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2062429;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2012;None
CHEMBL2063206;;0;629.87;2;7.93;4f;COCc1nc(CN(C(=O)CC[C@@H](C2CCCCC2)N2Cc3cc(Oc4ccccc4)ccc3N=C2N)C2CCCCC2)cs1;Ki;'=';13.0;nM;7.89;;;UO_0000065;12.52;0.24;-0.04;8.45;False;CHEMBL2067011;Inhibition of recombinant beta-secretase 1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2062429;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2012;None
CHEMBL338988;;0;458.38;2;2.23;2;O=C(O[C@H]1Cc2c(O)cc(O)cc2O[C@H]1c1cc(O)c(O)c(O)c1)c1cc(O)c(O)c(O)c1;Ki;'=';210.0;nM;6.68;;;UO_0000065;14.57;0.28;4.45;3.38;False;CHEMBL653508;Inhibitory activity against recombinant human Beta-secretase 1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1136344;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2003;None
CHEMBL3354244;;0;430.64;0;4.29;35;CN1C(=N)N[C@](CCC2CCCCC2)(C[C@@H]2CCCN(C(=O)CC3CCCC3)C2)C1=O;Ki;'=';12400.0;nM;4.91;;;UO_0000065;11.39;0.22;0.62;6.41;False;CHEMBL3386389;Inhibition of purified human BACE1 by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3352601;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2014;None
CHEMBL2151179;;0;338.44;0;2.78;14;CC#Cc1cncc(-c2ccc([C@]3(C)CC(=O)N(C)C(=N)N3)s2)c1;Ki;'=';33.0;nM;7.48;;;UO_0000065;22.11;0.43;4.70;10.83;False;CHEMBL2155063;Inhibition of human recombinant BACE1 by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2150878;1;Scientific Literature;ACS Med. Chem. Lett.;2012;None
CHEMBL2011983;;0;342.4;0;2.99;7a;CN1C(=N)N[C@](c2ccccc2)(c2cccc(-c3cccnc3)c2)C1=O;Ki;'=';110.0;nM;6.96;;;UO_0000065;20.32;0.37;3.97;10.07;False;CHEMBL2015090;Inhibition of human BACE1 using QSY7EISEVNLDAEFC-Eu-amide as substrate incubated for 30 mins prior to substrate addition measured after 90 mins by FRET analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2010674;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2012;None
CHEMBL410865;;0;569.63;1;2.94;18;CN(C)c1cccc(CNC[C@@H](O)[C@H](Cc2ccccc2)NC(=O)[C@@H]2CN(Cc3cc(F)c(F)cc3F)C(=O)N2)c1;Ki;'=';260.0;nM;6.58;;;UO_0000065;11.56;0.22;3.65;6.79;False;CHEMBL929344;Inhibition of human BACE1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1145643;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2008;None
CHEMBL405204;;0;575.71;1;2.54;13;COc1cc(CN2C[C@@H](C(=O)N[C@@H](Cc3ccccc3)[C@H](O)CNCc3cccc(N(C)C)c3)NC2=O)cc(OC)c1;Ki;'=';662.0;nM;6.18;;;UO_0000065;10.73;0.20;3.64;5.35;False;CHEMBL929344;Inhibition of human BACE1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1145643;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2008;None
CHEMBL244347;;0;502.7;2;6.76;7;CN(C(=O)CC[C@@H](C1CCCCC1)N1Cc2cc(Oc3ccccc3)ccc2N=C1N)C1CCCCC1;Ki;'=';8.0;nM;8.1;;;UO_0000065;16.11;0.30;1.34;11.38;False;CHEMBL1227788;Inhibition of human BACE1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1221253;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL2178716;;0;496.52;0;4.03;41;CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3cccc(C(F)(F)F)n3)C[C@H]2C1=O;Ki;'=';64.0;nM;7.19;;;UO_0000065;14.49;0.28;3.16;7.48;False;CHEMBL2183861;Inhibition of BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177036;1;Scientific Literature;J. Med. Chem.;2012;None
CHEMBL2178149;;0;463.51;0;3.89;32;CN1C(=N)N[C@@]2(c3ccc(-c4ccc(F)c(C#N)c4)s3)CN(c3ccc(F)cc3)C[C@H]2C1=O;Ki;'=';132.0;nM;6.88;;;UO_0000065;14.84;0.28;2.99;8.27;False;CHEMBL2183861;Inhibition of BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177036;1;Scientific Literature;J. Med. Chem.;2012;None
CHEMBL2178712;;0;458.55;0;3.02;37;COc1cccnc1N1C[C@H]2C(=O)N(C)C(=N)N[C@@]2(c2cc(-c3cccc(C#N)c3)cs2)C1;Ki;'=';3.0;nM;8.52;;;UO_0000065;18.59;0.35;5.50;8.09;False;CHEMBL2183861;Inhibition of BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177036;1;Scientific Literature;J. Med. Chem.;2012;None
CHEMBL3650828;;0;419.44;0;1.93;BDBM149916;CC1(C)Oc2ccc(NC(=O)c3ccc(C#N)cn3)cc2C2(COC(N)=N2)C12COC2;Ki;'=';72.0;nM;7.14;;288568;UO_0000065;17.03;0.31;5.21;5.42;True;CHEMBL3705666;Fluorescence Resonance Energy Transfer (FRET) Assay: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638878;37;BindingDB Database;;2015;None
CHEMBL3898837;;0;446.99;0;4.15;BDBM242287;CN1C(=N)N[C@](C)(c2sc(-c3ccc(-c4ccccn4)cc3)cc2Cl)CS1(=O)=O;Ki;'=';3520.0;nM;5.45;;422414;UO_0000065;12.2;0.26;1.30;6.33;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3894278;;0;453.01;0;4.21;BDBM242292;CN1C(=N)N[C@](C)(c2sc(-c3ccc(-c4nccs4)cc3)cc2Cl)CS1(=O)=O;Ki;'=';827.0;nM;6.08;;422419;UO_0000065;13.43;0.30;1.87;7.06;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3703234;;0;402.81;0;2.84;BDBM149751;NC1=NC2(CO1)c1cc(NC(=O)c3ncc(Cl)cc3F)ccc1OCC21CC1;Ki;'=';240.0;nM;6.62;;361492;UO_0000065;16.43;0.32;3.78;6.70;False;CHEMBL3887894;Fluorescence Resonance Energy Transfer (FRET) Assay: Test Example 1: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence. The amino acid sequence of the 'core' peptide of the substrate is SEVNLDAEFK (SEQ ID NO:2). The amino terminus was derivatized with (7-methoxycoumarin-4-yl)acetyl (MCA), and the epsilon amine of the lysine side chain of the terminal residue (K in sequence SEVNLDAEFK (SEQ ID NO:2)) was derivatized with 2,4-dinitrophenyl (DNP). Assays were performed in a buffer of 0.1 M sodium acetate, pH 4.4, 0.08% 3-[(3-Cholamidopropyl)dimethylammonio]propanesulfonate (CHAPS), 0.005% Tween80. BACE1 enzyme (final concentration 65 nM) was pre-incubated with test compounds for 15 minutes at room temperature. Fluorescence intensities were measured 60 minutes after addition of the substrate (final concentration 3 uM) by Tecan Safire2.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886493;37;BindingDB Database;;2016;None
CHEMBL3893407;;0;497.04;0;3.97;BDBM190834;COc1cccc(NC(=O)c2cc(Cl)c([C@]3(C)CS(=O)(=O)C4(CCCCC4)C(=N)N3)s2)n1;Ki;'=';207.0;nM;6.68;;341316;UO_0000065;13.45;0.29;2.71;5.51;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3650823;;0;409.83;0;2.57;BDBM149911;N#Cc1cnc(C(=O)Nc2ccc3c(c2)C2(COC(N)=N2)C2(CC2)CO3)c(Cl)c1;Ki;'=';280.0;nM;6.55;;361633;UO_0000065;15.99;0.31;3.98;5.34;False;CHEMBL3887894;Fluorescence Resonance Energy Transfer (FRET) Assay: Test Example 1: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence. The amino acid sequence of the 'core' peptide of the substrate is SEVNLDAEFK (SEQ ID NO:2). The amino terminus was derivatized with (7-methoxycoumarin-4-yl)acetyl (MCA), and the epsilon amine of the lysine side chain of the terminal residue (K in sequence SEVNLDAEFK (SEQ ID NO:2)) was derivatized with 2,4-dinitrophenyl (DNP). Assays were performed in a buffer of 0.1 M sodium acetate, pH 4.4, 0.08% 3-[(3-Cholamidopropyl)dimethylammonio]propanesulfonate (CHAPS), 0.005% Tween80. BACE1 enzyme (final concentration 65 nM) was pre-incubated with test compounds for 15 minutes at room temperature. Fluorescence intensities were measured 60 minutes after addition of the substrate (final concentration 3 uM) by Tecan Safire2.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886493;37;BindingDB Database;;2016;None
CHEMBL3955027;;0;480.01;0;3.71;BDBM190759;COc1cc(C#N)cc(-c2cc(Cl)c([C@]3(C)CS(=O)(=O)C4(CCOCC4)C(=N)N3)s2)c1;Ki;'=';161.0;nM;6.79;;341251;UO_0000065;14.15;0.30;3.08;6.05;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3925066;;0;461.54;0;3.50;BDBM242267;CN1C(=N)N[C@](C)(c2sc(-c3cccc(-c4noc(C5CC5)n4)c3)cc2F)CS1(=O)=O;Ki;'=';323.0;nM;6.49;;422394;UO_0000065;14.06;0.29;2.99;5.79;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3940738;;0;487.99;0;4.29;BDBM242322;CN1C(=N)N[C@](C)(c2sc3c(-c4ccc(-c5ncco5)cc4)nccc3c2Cl)CS1(=O)=O;Ki;'=';115.7;nM;6.94;;422449;UO_0000065;14.21;0.30;2.65;6.18;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3914234;;0;535.03;1;3.96;BDBM242337;COc1cnn(-c2ccc(-c3nccc4c(Cl)c([C@]5(C)CS(=O)(=O)N(C)C(=N)N5)sc34)c(F)c2)c1;Ki;'=';17.7;nM;7.75;;422464;UO_0000065;14.49;0.30;3.79;6.85;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3921452;;0;446.0;0;4.75;BDBM242284;CN1C(=N)N[C@](C)(c2sc(-c3cccc(-c4ccccc4)c3)cc2Cl)CS1(=O)=O;Ki;'=';161.0;nM;6.79;;422411;UO_0000065;15.23;0.32;2.04;9.27;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3893436;;0;436.95;0;2.66;BDBM242285;CN1C(=N)N[C@](C)(c2sc(-c3cccc(-n4nccn4)c3)cc2Cl)CS1(=O)=O;Ki;'=';30.3;nM;7.52;;422412;UO_0000065;17.21;0.37;4.86;7.23;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3930408;;0;446.99;0;4.15;BDBM242286;CN1C(=N)N[C@](C)(c2sc(-c3ccc(-c4cccnc4)cc3)cc2Cl)CS1(=O)=O;Ki;'=';2103.0;nM;5.68;;422413;UO_0000065;12.7;0.27;1.53;6.59;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3955239;;0;501.65;1;3.47;BDBM242317;CN1CCN(c2ccc(-c3cccc4c(F)c([C@]5(C)CS(=O)(=O)N(C)C(=N)N5)sc34)cc2)CC1;Ki;'=';9756.0;nM;5.01;;422444;UO_0000065;9.99;0.20;1.54;6.28;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3914207;;0;435.96;0;3.27;BDBM243022;CN1C(=N)N[C@](C)(c2sc(-c3cnn(-c4ccccc4)c3)cc2Cl)CS1(=O)=O;Ki;'=';265.0;nM;6.58;;423903;UO_0000065;15.09;0.32;3.31;7.22;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3354260;;0;478.64;0;4.72;51;CN1C(=N)N[C@](CCC2CCCCC2)(C[C@H]2CCC[C@@H](NC(=O)Nc3ccc(C#N)cc3)C2)C1=O;Ki;'=';3.0;nM;8.52;;;UO_0000065;17.81;0.33;3.80;7.04;False;CHEMBL3386389;Inhibition of purified human BACE1 by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3352601;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2014;None
CHEMBL3354248;;0;416.61;0;3.90;39;CN1C(=N)N[C@](CCC2CCCCC2)(C[C@@H]2CCN(C(=O)CC3CCCC3)C2)C1=O;Ki;'=';37000.0;nM;4.43;;;UO_0000065;10.64;0.20;0.53;5.79;False;CHEMBL3386389;Inhibition of purified human BACE1 by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3352601;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2014;None
CHEMBL3950717;;0;444.95;0;2.59;BDBM242969;CN1C(=N)N[C@](C)(c2sc(-c3nnc(-c4nccs4)o3)cc2Cl)CS1(=O)=O;Ki;'=';401.9;nM;6.4;;423850;UO_0000065;14.37;0.32;3.81;5.11;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3964022;;0;387.47;0;0.97;BDBM182838;COc1cccc(N2CC3C(c4ccccc4)(C2)NC(=N)N(C)S3(=O)=O)n1;Ki;'=';86.0;nM;7.07;;330386;UO_0000065;18.23;0.36;6.10;7.16;False;CHEMBL3887312;BACE1 HTRF FRET Assay: A homogeneous time-resolved FRET assay was used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitored the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contained an N-terminal QSY7 moiety that served as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence was low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors was manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul were preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886269;37;BindingDB Database;;2015;None
CHEMBL3921383;;0;428.82;0;4.47;BDBM234450;C[C@]1(F)CC(F)(F)[C@@](C)(c2cc(NC(=O)c3ccc(Cl)cn3)ccc2F)N=C1N;Ki;'=';12.0;nM;7.92;;408766;UO_0000065;18.47;0.37;3.45;9.86;False;CHEMBL3888549;SPA-Based Assay: The binding assay was performed as SPA-based assay using a biotinylated form of human BACE1 recombinantly expressed and subsequently purified from Freestyle HEK293 cells. The binding assay was run in a 50 mM sodium acetate buffer, pH 4.5 containing 50 mM NaCl and 0.03% Tween-20 in white clear bottom 384 plates (Corning #3653). 10 nM (final concentration) radioligand ([3H]-N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N-((R)-1-phenyl-ethyl)-isophthalamide) (TRQ11569 purchased from GE Healthcare) was mixed with test compound at a given concentration, 6 nM (final concentration) human BACE1 and 25 μg Streptavidin coated PVT core SPA beads (RPNQ0007, GE Healthcare Life Sciences) in a total volume of 40 μl.;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886758;37;BindingDB Database;;2016;CHEMBL3307715
CHEMBL3912999;;0;401.9;0;2.34;BDBM242985;CN1C(=N)N[C@](C)(c2sc(-c3nnc(C4CC4)o3)cc2Cl)CS1(=O)=O;Ki;'=';882.4;nM;6.05;;423866;UO_0000065;15.06;0.33;3.71;5.40;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3962501;;0;450.54;0;2.86;BDBM242923;CNS1(O)C[C@@](C)(c2cc(NC(=O)c3cnc(OC)cn3)ccc2F)NC(=N)C1(C)C;Ki;'=';14.0;nM;7.85;;423785;UO_0000065;17.43;0.35;4.99;5.94;False;CHEMBL3888940;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886895;37;BindingDB Database;;2016;None
CHEMBL4127138;;0;499.53;0;1.97;20;COc1cnc2c(C(=O)Nc3ccc(F)c([C@]45CCC[C@H]4S(=O)(=O)N(C)C(=N)N5)c3)nccc2n1;Ki;'=';36.0;nM;7.44;;;UO_0000065;14.9;0.29;5.47;4.95;False;CHEMBL4119788;Binding affinity to human BACE1 catalytic domain using QSY7-APPswe-Eu as substrate preincubated for 30 mins followed by substrate addition measured after 1.5 hrs by HTRF assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4118088;1;Scientific Literature;ACS Med Chem Lett;2017;None
CHEMBL3650778;;0;402.85;0;3.87;BDBM149865;CC1(C)Oc2ccc(-c3cc(F)cc(Cl)c3)cc2C2(COC(N)=N2)C12COC2;Ki;'=';188.0;nM;6.73;;361598;UO_0000065;16.7;0.33;2.86;10.18;False;CHEMBL3887894;Fluorescence Resonance Energy Transfer (FRET) Assay: Test Example 1: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence. The amino acid sequence of the 'core' peptide of the substrate is SEVNLDAEFK (SEQ ID NO:2). The amino terminus was derivatized with (7-methoxycoumarin-4-yl)acetyl (MCA), and the epsilon amine of the lysine side chain of the terminal residue (K in sequence SEVNLDAEFK (SEQ ID NO:2)) was derivatized with 2,4-dinitrophenyl (DNP). Assays were performed in a buffer of 0.1 M sodium acetate, pH 4.4, 0.08% 3-[(3-Cholamidopropyl)dimethylammonio]propanesulfonate (CHAPS), 0.005% Tween80. BACE1 enzyme (final concentration 65 nM) was pre-incubated with test compounds for 15 minutes at room temperature. Fluorescence intensities were measured 60 minutes after addition of the substrate (final concentration 3 uM) by Tecan Safire2.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886493;37;BindingDB Database;;2016;None
CHEMBL3650847;;0;425.45;0;1.47;BDBM149938;COc1cnc(C(=O)Nc2ccc3c(c2)[C@@]2(COC(N)=N2)C2(COC2)C(C)(C)O3)cn1;Ki;'=';42.9;nM;7.37;;361657;UO_0000065;17.32;0.32;5.90;5.66;False;CHEMBL3887894;Fluorescence Resonance Energy Transfer (FRET) Assay: Test Example 1: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence. The amino acid sequence of the 'core' peptide of the substrate is SEVNLDAEFK (SEQ ID NO:2). The amino terminus was derivatized with (7-methoxycoumarin-4-yl)acetyl (MCA), and the epsilon amine of the lysine side chain of the terminal residue (K in sequence SEVNLDAEFK (SEQ ID NO:2)) was derivatized with 2,4-dinitrophenyl (DNP). Assays were performed in a buffer of 0.1 M sodium acetate, pH 4.4, 0.08% 3-[(3-Cholamidopropyl)dimethylammonio]propanesulfonate (CHAPS), 0.005% Tween80. BACE1 enzyme (final concentration 65 nM) was pre-incubated with test compounds for 15 minutes at room temperature. Fluorescence intensities were measured 60 minutes after addition of the substrate (final concentration 3 uM) by Tecan Safire2.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886493;37;BindingDB Database;;2016;None
CHEMBL3952308;;0;470.56;0;3.30;BDBM242314;CN1C(=N)N[C@](C)(c2sc3c(-c4ccc(-n5nccn5)cc4)cccc3c2F)CS1(=O)=O;Ki;'=';1658.0;nM;5.78;;422441;UO_0000065;12.28;0.25;2.48;5.56;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL2178195;;0;611.56;2;5.41;22c;COc1ccc(-c2nsc(C)c2C(=O)/N=C(\N)NCc2cc(Cl)c(NC(=O)CNCc3ccccc3)c(Cl)c2)cc1;Ki;'=';6.0;nM;8.22;;;UO_0000065;13.44;0.27;2.81;6.29;False;CHEMBL2187886;Displacement of [3H]BMS-599240 from BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177026;1;Scientific Literature;J. Med. Chem.;2012;CHEMBL3307715
CHEMBL2178198;;0;403.27;0;4.20;8i;Cc1onc(-c2ccccc2)c1C(=O)/N=C(\N)NCc1cc(Cl)cc(Cl)c1;Ki;'=';3900.0;nM;5.41;;;UO_0000065;13.41;0.27;1.21;5.78;False;CHEMBL2187886;Displacement of [3H]BMS-599240 from BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177026;1;Scientific Literature;J. Med. Chem.;2012;CHEMBL3307715
CHEMBL2178197;;0;433.3;0;4.21;8h;COc1ccc(-c2noc(C)c2C(=O)/N=C(\N)NCc2ccc(Cl)c(Cl)c2)cc1;Ki;'=';910.0;nM;6.04;;;UO_0000065;13.94;0.28;1.83;5.88;False;CHEMBL2187886;Displacement of [3H]BMS-599240 from BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177026;1;Scientific Literature;J. Med. Chem.;2012;CHEMBL3307715
CHEMBL4067893;;0;663.75;1;1.59;6j;C[C@@H](NC(=O)c1cc(C(=O)N[C@@H](Cc2ccccc2)[C@H](O)[C@@H]2NC[C@H]3COC(=O)N3C2=O)cc(N(C)S(C)(=O)=O)c1)c1ccccc1;Ki;'=';23.0;nM;7.64;;;UO_0000065;11.51;0.22;6.05;4.38;False;CHEMBL4018279;Inhibition of recombinant human BACE1 (Ala8P to Ala326 residues) expressed in Escherichia coli BL21(DE3) using Arg-Glu(EDANS)-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys (Dabcyl)-Arg as substrate by fluorescence assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4017478;1;Scientific Literature;Bioorg Med Chem Lett;2017;None
CHEMBL78946;;0;893.01;3;-1.74;45, OM-99-2;CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(=O)O)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O;Ki;'=';1.6;nM;8.8;;;UO_0000065;9.85;0.19;10.54;2.34;True;CHEMBL981021;Inhibition of recombinant memapsin 2;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1153435;1;Scientific Literature;J. Med. Chem.;2009;None
CHEMBL2178152;;0;499.64;0;4.30;35;CC#Cc1cncc(-c2csc([C@]34CN(c5cccc(OC(C)C)c5)C[C@H]3C(=O)N(C)C(=N)N4)c2)c1;Ki;'=';2.0;nM;8.7;;;UO_0000065;17.41;0.33;4.40;10.67;False;CHEMBL2183861;Inhibition of BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177036;1;Scientific Literature;J. Med. Chem.;2012;None
CHEMBL4288838;;0;475.55;0;3.16;19;Cc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3cc(-c4cccc(C#N)c4)cs3)C2)nc(C)c1F;Ki;'=';1.0;nM;9.0;;;UO_0000065;18.93;0.36;5.84;8.26;False;CHEMBL4270026;Inhibition of recombinant human BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4266039;1;Scientific Literature;J Med Chem;2018;None
CHEMBL4114151;;0;456.45;0;1.09;BDBM182827;COc1nc(N2C[C@@H]3[C@](c4cc(F)ccc4F)(C2)NC(=N)N(C)S3(=O)=O)nc(C)c1F;Ki;'=';20.0;nM;7.7;;330375;UO_0000065;16.87;0.34;6.61;6.90;False;CHEMBL3887312;BACE1 HTRF FRET Assay: A homogeneous time-resolved FRET assay was used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitored the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contained an N-terminal QSY7 moiety that served as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence was low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors was manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul were preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886269;37;BindingDB Database;;2015;None
CHEMBL3946080;;0;555.01;2;5.04;BDBM242320;CN1C(=N)N[C@](C)(c2sc3c(-c4ccc(-c5cc(C(F)(F)F)n[nH]5)cc4)nccc3c2Cl)CS1(=O)=O;Ki;'=';424.7;nM;6.37;;422447;UO_0000065;11.48;0.24;1.33;5.55;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3947812;;0;519.02;2;5.34;BDBM242331;Cc1occc1-c1ccc(-c2nccc3c(Cl)c([C@]4(C)CS(=O)(=O)N(C)C(=N)N4)sc23)c(F)c1;Ki;'=';524.9;nM;6.28;;422458;UO_0000065;12.1;0.25;0.94;6.32;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3929836;;0;478.0;0;4.01;BDBM242239;CN1C(=N)N[C@](C)(c2sc(-c3cccc(-c4nnc(C5CC5)o4)c3)cc2Cl)CS1(=O)=O;Ki;'=';203.0;nM;6.69;;422366;UO_0000065;14.0;0.29;2.68;5.97;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3931442;;0;504.0;1;3.32;BDBM243008;CN1C(=N)N[C@](C)(c2sc(-c3nnc(-c4ccc(-n5cccn5)cc4)o3)cc2Cl)CS1(=O)=O;Ki;'=';155.3;nM;6.81;;423889;UO_0000065;13.51;0.28;3.49;5.24;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3975679;;0;455.92;0;3.27;BDBM242959;CN1C(=N)N[C@](C)(c2sc(-c3nnc(-c4ccc(F)cc4)o3)cc2Cl)CS1(=O)=O;Ki;'=';102.0;nM;6.99;;423902;UO_0000065;15.33;0.33;3.72;6.23;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL509486;KUSHENOL T;0;426.51;0;4.80;4;C=C(C)[C@H](CCC(C)(C)O)Cc1c(O)cc(O)c2c1O[C@H](c1ccccc1O)CC2=O;Ki;;;;;;Not Determined;;;;;;False;CHEMBL946249;Inhibition of human BACE1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1155037;1;Scientific Literature;Bioorg. Med. Chem.;2008;None
CHEMBL3914900;;0;451.54;0;3.99;BDBM242929;CCNS1(O)C[C@@](C)(c2cc(NC(=O)c3ccc(F)cn3)ccc2F)NC(=N)C1(C)C;Ki;'=';17.0;nM;7.77;;423790;UO_0000065;17.21;0.34;3.78;7.05;False;CHEMBL3888940;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886895;37;BindingDB Database;;2016;None
CHEMBL4107780;;0;464.49;0;2.37;BDBM236612;C[C@H]1OC[C@]2(c3cc(NC(=O)c4ccc(F)cn4)ccc3F)NC(=N)C(C)(C)S(=O)(=O)[C@H]12;Ki;'=';7.0;nM;8.15;;412128;UO_0000065;17.56;0.35;5.78;6.73;False;CHEMBL3888701;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886796;37;BindingDB Database;;2016;None
CHEMBL509188;;0;763.89;2;-1.09;OM99-1;CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O;Ki;'=';36.0;nM;7.44;;;UO_0000065;9.74;0.19;8.53;2.41;False;CHEMBL3062634;Inhibition of BACE1 (unknown origin);B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3044565;1;Scientific Literature;Med Chem Res;2012;None
CHEMBL2063202;;0;601.82;2;7.93;4a;Cc1nc(CN(C(=O)OC[C@@H](C2CCCCC2)N2Cc3cc(Oc4ccccc4)ccc3N=C2N)C2CCCCC2)cs1;Ki;'=';1463.0;nM;5.83;;;UO_0000065;9.7;0.19;-2.10;6.26;False;CHEMBL2067011;Inhibition of recombinant beta-secretase 1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2062429;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2012;None
CHEMBL2063208;;0;568.77;2;7.05;4h;NC1=Nc2ccc(Oc3ccccc3)cc2CN1[C@@H](CCC(=O)N(Cc1cn[nH]c1)C1CCCCC1)C1CCCCC1;Ki;'=';23.0;nM;7.64;;;UO_0000065;13.43;0.25;0.59;7.65;False;CHEMBL2067011;Inhibition of recombinant beta-secretase 1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2062429;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2012;None
CHEMBL3650831;;0;414.47;0;2.70;BDBM149919;NC1=NC2(CO1)c1cc(-c3cncnc3)ccc1OC(Cc1ccccc1)C21COC1;Ki;'=';92.1;nM;7.04;;361641;UO_0000065;16.98;0.31;4.34;7.66;False;CHEMBL3887894;Fluorescence Resonance Energy Transfer (FRET) Assay: Test Example 1: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence. The amino acid sequence of the 'core' peptide of the substrate is SEVNLDAEFK (SEQ ID NO:2). The amino terminus was derivatized with (7-methoxycoumarin-4-yl)acetyl (MCA), and the epsilon amine of the lysine side chain of the terminal residue (K in sequence SEVNLDAEFK (SEQ ID NO:2)) was derivatized with 2,4-dinitrophenyl (DNP). Assays were performed in a buffer of 0.1 M sodium acetate, pH 4.4, 0.08% 3-[(3-Cholamidopropyl)dimethylammonio]propanesulfonate (CHAPS), 0.005% Tween80. BACE1 enzyme (final concentration 65 nM) was pre-incubated with test compounds for 15 minutes at room temperature. Fluorescence intensities were measured 60 minutes after addition of the substrate (final concentration 3 uM) by Tecan Safire2.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886493;37;BindingDB Database;;2016;None
CHEMBL3703303;;0;389.46;0;2.85;BDBM149829;CC#Cc1cncc(-c2ccc3c(c2)C2(COC(N)=N2)C2(COC2)C(C)(C)O3)c1;Ki;'=';90.4;nM;7.04;;361562;UO_0000065;18.09;0.33;4.19;8.92;False;CHEMBL3887894;Fluorescence Resonance Energy Transfer (FRET) Assay: Test Example 1: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence. The amino acid sequence of the 'core' peptide of the substrate is SEVNLDAEFK (SEQ ID NO:2). The amino terminus was derivatized with (7-methoxycoumarin-4-yl)acetyl (MCA), and the epsilon amine of the lysine side chain of the terminal residue (K in sequence SEVNLDAEFK (SEQ ID NO:2)) was derivatized with 2,4-dinitrophenyl (DNP). Assays were performed in a buffer of 0.1 M sodium acetate, pH 4.4, 0.08% 3-[(3-Cholamidopropyl)dimethylammonio]propanesulfonate (CHAPS), 0.005% Tween80. BACE1 enzyme (final concentration 65 nM) was pre-incubated with test compounds for 15 minutes at room temperature. Fluorescence intensities were measured 60 minutes after addition of the substrate (final concentration 3 uM) by Tecan Safire2.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886493;37;BindingDB Database;;2016;None
CHEMBL3893282;;0;437.37;0;3.90;BDBM230875;Cc1cc(C#N)cnc1C(=O)Nc1ccc(F)c([C@@]2(C(F)F)N=C(N)CCC2(F)F)c1;Ki;'=';7.8;nM;8.11;;402958;UO_0000065;18.54;0.36;4.21;7.78;False;CHEMBL3888456;BACE1 Binding Assay: The binding assay was performed as SPA-based assay using a biotinylated form of human BACE1 recombinantly expressed and subsequently purified from Freestyle HEK293 cells. The binding assay was run in a 50 mM sodium acetate buffer, pH 4.5 containing 50 mM NaCl and 0.03% Tween-20 in white clear bottom 384 plates (Corning #3653). 10 nM (final concentration) radioligand ([3H]−N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N−((R)-1-phenyl-ethyl)-isophthalamide) (TRQ11569 purchased from GE Healthcare) was mixed with test compound at a given concentration, 6 nM (final concentration) human BACE1 and 25 μg Streptavidin coated PVT core SPA beads (RPNQ0007, GE Healthcare Life Sciences) in a total volume of 40 μl. Several concentrations of each test compound were tested in the assay for IC50 determination. The plates were incubated for one hour at room temperature and counted in a Wallac Trilux counter. Total and non-specific binding were determined using buffer and 1 μM (final concentration) of the high affinity BACE1 reference inhibitor (S)-6-[3-chloro-5-(5-prop-1-ynyl-pyridin-3-yl)-thiophen-2-yl]-2-imino-3,6-dimethyl-tetrahydro-pyrimidin-4-one, respectively.;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886720;37;BindingDB Database;;2016;CHEMBL3307715
CHEMBL260834;;0;564.68;1;4.03;24;CC(C)(C)c1cccc(CNC[C@@H](O)[C@H](Cc2ccccc2)NC(=O)[C@@H]2CN(Cc3cc(F)cc(F)c3)C(=O)N2)c1;Ki;'=';9.0;nM;8.05;;;UO_0000065;14.25;0.27;4.02;8.59;False;CHEMBL929344;Inhibition of human BACE1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1145643;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2008;None
CHEMBL260634;;0;551.64;1;2.80;15;CN(C)c1cccc(CNC[C@@H](O)[C@H](Cc2ccccc2)NC(=O)[C@@H]2CN(Cc3ccc(F)c(F)c3)C(=O)N2)c1;Ki;'=';272.0;nM;6.57;;;UO_0000065;11.9;0.22;3.77;6.77;False;CHEMBL929344;Inhibition of human BACE1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1145643;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2008;None
CHEMBL442807;;0;659.42;1;4.05;10;CN(C)c1cccc(CNC[C@@H](O)[C@H](Cc2ccccc2)NC(=O)[C@@H]2CN(c3cc(Br)cc(Br)c3)C(=O)N2)c1;Ki;'=';3500.0;nM;5.46;;;UO_0000065;8.27;0.19;1.41;5.63;False;CHEMBL929344;Inhibition of human BACE1;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1145643;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2008;None
CHEMBL3287409;;0;342.3;0;2.57;4;COc1cc2oc3c(c(=O)c2c(O)c1C)-c1ccc(O)cc1OC3O;Ki;'=';4280.0;nM;5.37;;;UO_0000065;15.68;0.29;2.80;4.91;False;CHEMBL3293239;Non-competitive inhibition of BACE1 (unknown origin) by Dixon plot analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3286369;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2014;None
CHEMBL3589001;;0;1326.47;None;None;4;CC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(N)=O)C(C)C;Ki;'=';2.0;nM;8.7;;;UO_0000065;6.56;None;None;None;False;CHEMBL3592345;Inhibition of human recombinant BACE1 using Mca-SEVNLDAEFK-DNP substrate assessed as substrate hydrolysis after 2 hrs by HPLC-FLU analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3588858;1;Scientific Literature;J. Med. Chem.;2015;None
CHEMBL3640258;;0;420.4;0;1.33;23;COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3c(F)cccc3F)C2)nc(C)c1F;Ki;'=';20.0;nM;7.7;;;UO_0000065;18.31;0.35;6.37;7.94;False;CHEMBL3801550;Inhibition of recombinant human BACE1 preincubated for 30 mins followed QSY7EISEVNLDAEFC-Eu-amide substrate addition measured after 90 mins by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3797133;1;Scientific Literature;J. Med. Chem.;2016;None
CHEMBL3919160;;0;462.52;0;3.53;BDBM190721;C[C@@]1(c2cc(NC(=O)c3ccc(F)cn3)ccc2F)CS(=O)(=O)C2(CCCCC2)C(=N)N1;Ki;'=';32.0;nM;7.5;;341216;UO_0000065;16.2;0.32;3.96;6.69;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3931727;;0;474.56;0;3.39;BDBM190722;COc1ccc(C(=O)Nc2ccc(F)c([C@]3(C)CS(=O)(=O)C4(CCCCC4)C(=N)N3)c2)nc1;Ki;'=';37.0;nM;7.43;;341217;UO_0000065;15.66;0.31;4.04;6.13;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3923660;;0;514.5;1;3.25;BDBM190730;C[C@@]1(c2cc(NC(=O)c3ccc(C(F)(F)F)cn3)ccc2F)CS(=O)(=O)C2(CCOCC2)C(=N)N1;Ki;'=';19.8;nM;7.7;;341225;UO_0000065;14.97;0.30;4.45;6.35;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3933119;;0;412.49;0;3.28;BDBM190736;C[C@@]1(c2cc(-c3cncc(C#N)c3)ccc2F)CS(=O)(=O)C2(CCCC2)C(=N)N1;Ki;'=';939.0;nM;6.03;;341230;UO_0000065;14.61;0.28;2.75;5.65;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3975049;;0;463.49;0;1.25;BDBM190766;COc1cnc(C(=O)Nc2ccc(F)c([C@]3(C)CS(=O)(=O)[C@]4(CCOC4)C(=N)N3)c2)cn1;Ki;'=';25.4;nM;7.59;;341258;UO_0000065;16.39;0.32;6.35;5.30;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3890092;;0;481.04;0;4.27;BDBM190829;Cc1cncc(NC(=O)c2cc(Cl)c([C@]3(C)CS(=O)(=O)C4(CCCCC4)C(=N)N3)s2)c1;Ki;'=';2156.0;nM;5.67;;341312;UO_0000065;11.78;0.25;1.40;5.06;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3640283;;0;430.43;0;2.20;BDBM102966;Cc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3cc(F)ccc3F)C2)nc(C2CC2)c1F;Ki;'=';26.0;nM;7.58;;220600;UO_0000065;17.62;0.33;5.39;8.65;False;CHEMBL3705045;Time-Resolved FRET Assay: A homogeneous time-resolved FRET assay was used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. The assay monitored the increase of 620nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide).;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638861;37;BindingDB Database;;2013;None
CHEMBL3908643;;0;432.78;0;4.37;BDBM230865;NC1=N[C@@](c2cc(NC(=O)c3ccc(Cl)cn3)ccc2F)(C(F)F)C(F)(F)CC1;Ki;'=';18.0;nM;7.75;;402948;UO_0000065;17.9;0.36;3.37;9.64;False;CHEMBL3888456;BACE1 Binding Assay: The binding assay was performed as SPA-based assay using a biotinylated form of human BACE1 recombinantly expressed and subsequently purified from Freestyle HEK293 cells. The binding assay was run in a 50 mM sodium acetate buffer, pH 4.5 containing 50 mM NaCl and 0.03% Tween-20 in white clear bottom 384 plates (Corning #3653). 10 nM (final concentration) radioligand ([3H]−N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N−((R)-1-phenyl-ethyl)-isophthalamide) (TRQ11569 purchased from GE Healthcare) was mixed with test compound at a given concentration, 6 nM (final concentration) human BACE1 and 25 μg Streptavidin coated PVT core SPA beads (RPNQ0007, GE Healthcare Life Sciences) in a total volume of 40 μl. Several concentrations of each test compound were tested in the assay for IC50 determination. The plates were incubated for one hour at room temperature and counted in a Wallac Trilux counter. Total and non-specific binding were determined using buffer and 1 μM (final concentration) of the high affinity BACE1 reference inhibitor (S)-6-[3-chloro-5-(5-prop-1-ynyl-pyridin-3-yl)-thiophen-2-yl]-2-imino-3,6-dimethyl-tetrahydro-pyrimidin-4-one, respectively.;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886720;37;BindingDB Database;;2016;CHEMBL3307715
CHEMBL3799879;;0;414.47;0;1.23;17;CNc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3ccc(C#N)s3)C2)nc(C)c1F;Ki;'=';336.0;nM;6.47;;;UO_0000065;15.62;0.30;5.24;5.35;False;CHEMBL3801550;Inhibition of recombinant human BACE1 preincubated for 30 mins followed QSY7EISEVNLDAEFC-Eu-amide substrate addition measured after 90 mins by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3797133;1;Scientific Literature;J. Med. Chem.;2016;None
CHEMBL1097325;;0;691.24;1;4.55;3g;CCCN(CCC)C(=O)c1cc(C)cc(C(=O)N[C@@H](Cc2cc(F)cc(F)c2)[C@H](O)[C@H]2CN(S(=O)(=O)c3ccc(Cl)cc3)CCN2)c1;Ki;'=';42.0;nM;7.38;;;UO_0000065;10.67;0.21;2.83;6.20;False;CHEMBL1109071;Inhibition oh BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157894;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL1097343;;0;636.76;1;2.13;3y;COC[C@H]1CCCN1C(=O)CCCC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)[C@H]1CN(S(=O)(=O)c2cccc(C)c2)CCN1;Ki;'=';3.0;nM;8.52;;;UO_0000065;13.38;0.26;6.39;6.64;False;CHEMBL1109071;Inhibition oh BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157894;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL2178192;;0;513.0;1;3.37;17r;COc1ccc(-c2noc(C)c2C(=O)/N=C(\N)NCc2cc(C)c(NC(=O)CN(C)C)c(Cl)c2)cc1;Ki;'=';50.0;nM;7.3;;;UO_0000065;14.23;0.28;3.93;5.40;False;CHEMBL2187886;Displacement of [3H]BMS-599240 from BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177026;1;Scientific Literature;J. Med. Chem.;2012;CHEMBL3307715
CHEMBL2151138;;0;324.41;0;2.89;10;CN1C(=N)N[C@](C)(c2cc(-c3cccc(C#N)c3)cs2)CC1=O;Ki;'=';57.0;nM;7.24;;;UO_0000065;22.33;0.43;4.35;9.06;False;CHEMBL2155063;Inhibition of human recombinant BACE1 by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2150878;1;Scientific Literature;ACS Med. Chem. Lett.;2012;None
CHEMBL578437;;0;330.35;0;3.64;9;O=C(Nc1ccncc1)c1ccc2c(c1)Nc1ccccc1NC2=O;Ki;'=';295.0;nM;6.53;;;UO_0000065;19.77;0.36;2.89;7.86;False;CHEMBL1045676;Inhibition of human recombinant BACE1 by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1154184;1;Scientific Literature;J. Med. Chem.;2009;None
CHEMBL572940;;0;347.35;0;4.39;10;O=C(Nc1ccc(F)cc1)c1ccc2c(c1)Nc1ccccc1NC2=O;Ki;'=';211.0;nM;6.68;;;UO_0000065;19.22;0.35;2.29;9.51;False;CHEMBL1045676;Inhibition of human recombinant BACE1 by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1154184;1;Scientific Literature;J. Med. Chem.;2009;None
CHEMBL575567;;0;396.41;0;4.03;11;O=C(Nc1ncc(-c2ccncc2)[nH]1)c1ccc2c(c1)Nc1ccccc1NC2=O;Ki;'=';348.0;nM;6.46;;;UO_0000065;16.29;0.29;2.43;5.78;False;CHEMBL1045676;Inhibition of human recombinant BACE1 by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1154184;1;Scientific Literature;J. Med. Chem.;2009;None
CHEMBL1095430;;0;544.74;2;6.70;20;COc1cc2c3cc1Oc1cccc(c1)CCN(C1CCCCC1)C(=O)CC[C@@H](C1CCCCC1)N(C3)C(N)=N2;Ki;'=';12.0;nM;7.92;;;UO_0000065;14.54;0.27;1.22;9.85;False;CHEMBL1103872;Inhibition of BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1157115;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2010;None
CHEMBL2177913;AZD-3839;1;431.42;0;4.63;"36; AZD 3839";NC1=N[C@@](c2cccc(-c3cncnc3)c2)(c2ccnc(C(F)F)c2)c2cccc(F)c21;Ki;'=';25.7;nM;7.59;;;UO_0000065;17.59;0.32;2.96;9.85;False;CHEMBL4194787;Inhibition of human BACE1 (1 to 460 residues) preincubated for 10 mins followed by (Europium)CEVNLDAEFK(Qsy7) substrate addition measured after 6.5 hrs by TR-FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4190376;1;Scientific Literature;J Med Chem;2018;None
CHEMBL3627973;;0;478.38;0;3.18;7g;CO[C@@H]1C[C@@H](C(=O)/N=C(\N)NCc2cc(Cl)c(NC(C)=O)c(Cl)c2)N(c2ccccc2)C1;Ki;'=';390.0;nM;6.41;;;UO_0000065;13.4;0.27;3.23;5.88;False;CHEMBL3630426;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 6.4 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL518543;KUWANON C;0;422.48;1;5.30;2;CC(C)=CCc1c(-c2ccc(O)cc2O)oc2c(CC=C(C)C)c(O)cc(O)c2c1=O;Ki;'=';2200.0;nM;5.66;;;UO_0000065;13.39;0.25;0.36;5.09;False;CHEMBL1771832;Noncompetitive inhibition of human recombinant BACE-1 by Dixon plot analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1770081;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2011;None
CHEMBL3703291;;0;457.45;0;3.78;BDBM149815;CC#Cc1cncc(-c2ccc3c(c2)C2(COC(N)=N2)C2(COC2)C(CCC(F)(F)F)O3)c1;Ki;'=';868.0;nM;6.06;;361549;UO_0000065;13.25;0.25;2.28;7.68;False;CHEMBL3887894;Fluorescence Resonance Energy Transfer (FRET) Assay: Test Example 1: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence. The amino acid sequence of the 'core' peptide of the substrate is SEVNLDAEFK (SEQ ID NO:2). The amino terminus was derivatized with (7-methoxycoumarin-4-yl)acetyl (MCA), and the epsilon amine of the lysine side chain of the terminal residue (K in sequence SEVNLDAEFK (SEQ ID NO:2)) was derivatized with 2,4-dinitrophenyl (DNP). Assays were performed in a buffer of 0.1 M sodium acetate, pH 4.4, 0.08% 3-[(3-Cholamidopropyl)dimethylammonio]propanesulfonate (CHAPS), 0.005% Tween80. BACE1 enzyme (final concentration 65 nM) was pre-incubated with test compounds for 15 minutes at room temperature. Fluorescence intensities were measured 60 minutes after addition of the substrate (final concentration 3 uM) by Tecan Safire2.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886493;37;BindingDB Database;;2016;None
CHEMBL3703254;;0;345.4;0;2.83;BDBM149772;CC#Cc1cncc(-c2ccc3c(c2)C2(COC(N)=N2)C2(CC2)CO3)c1;Ki;'=';252.0;nM;6.6;;361563;UO_0000065;19.1;0.35;3.77;9.46;False;CHEMBL3887894;Fluorescence Resonance Energy Transfer (FRET) Assay: Test Example 1: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence. The amino acid sequence of the 'core' peptide of the substrate is SEVNLDAEFK (SEQ ID NO:2). The amino terminus was derivatized with (7-methoxycoumarin-4-yl)acetyl (MCA), and the epsilon amine of the lysine side chain of the terminal residue (K in sequence SEVNLDAEFK (SEQ ID NO:2)) was derivatized with 2,4-dinitrophenyl (DNP). Assays were performed in a buffer of 0.1 M sodium acetate, pH 4.4, 0.08% 3-[(3-Cholamidopropyl)dimethylammonio]propanesulfonate (CHAPS), 0.005% Tween80. BACE1 enzyme (final concentration 65 nM) was pre-incubated with test compounds for 15 minutes at room temperature. Fluorescence intensities were measured 60 minutes after addition of the substrate (final concentration 3 uM) by Tecan Safire2.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886493;37;BindingDB Database;;2016;None
CHEMBL2011967;;0;371.44;0;3.60;4b;COc1cccc(-c2cccc(C3(c4ccccc4)NC(=N)N(C)C3=O)c2)c1;Ki;'=';190.0;nM;6.72;;;UO_0000065;18.1;0.33;3.12;10.27;False;CHEMBL2015090;Inhibition of human BACE1 using QSY7EISEVNLDAEFC-Eu-amide as substrate incubated for 30 mins prior to substrate addition measured after 90 mins by FRET analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2010674;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2012;None
CHEMBL2011973;;0;342.4;0;2.99;4i;CN1C(=N)NC(c2ccccc2)(c2cccc(-c3ccccn3)c2)C1=O;Ki;'=';1900.0;nM;5.72;;;UO_0000065;16.71;0.30;2.73;8.28;False;CHEMBL2015090;Inhibition of human BACE1 using QSY7EISEVNLDAEFC-Eu-amide as substrate incubated for 30 mins prior to substrate addition measured after 90 mins by FRET analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2010674;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2012;None
CHEMBL2011980;;0;376.85;0;3.64;4p;CN1C(=N)NC(c2ccccc2)(c2cccc(-c3cncc(Cl)c3)c2)C1=O;Ki;'=';90.0;nM;7.05;;;UO_0000065;18.7;0.36;3.41;10.20;False;CHEMBL2015090;Inhibition of human BACE1 using QSY7EISEVNLDAEFC-Eu-amide as substrate incubated for 30 mins prior to substrate addition measured after 90 mins by FRET analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2010674;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2012;None
CHEMBL2011991;;0;381.91;0;4.78;13g;CN1C(=N)NC(c2cccc(-c3cccc(Cl)c3)c2)(C2CCCCC2)C1=O;Ki;'=';470.0;nM;6.33;;;UO_0000065;16.57;0.32;1.55;11.26;False;CHEMBL2015090;Inhibition of human BACE1 using QSY7EISEVNLDAEFC-Eu-amide as substrate incubated for 30 mins prior to substrate addition measured after 90 mins by FRET analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2010674;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2012;None
CHEMBL3704768;;0;644.86;1;4.42;BDBM172740;CCCC(O)C(NCC(O)C(Cc1ccccc1)NC(=O)c1cc(C)cc(C(=O)N(C)C(C)c2ccccc2)c1)C(=O)NCC(C)C;Ki;'=';563.5;nM;6.25;;317736;UO_0000065;9.69;0.18;1.83;4.77;False;CHEMBL3707552;Inhibition Assay: Previously, one of the following compounds discussed below have been studied in memapsin 2 inhibition (Ghosh et al., 2008), which the others are previously unpublished. Given the closely related substrate specificity for memapsin 1 and memapsin 2, the inventors chose to screen these previously identified memapsin 2 inhibitors for lead compounds as memapsin 1 inhibitors. Recombinant memapsin 1 ectodomain was prepared as described by Turner et al. (2002) and assayed using a commercially purchased fluorescent substrate.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638586;37;BindingDB Database;;2015;None
CHEMBL3704770;;0;616.8;1;3.64;BDBM172742;Cc1cc(C(=O)NC(Cc2ccccc2)C(O)CNC(C(=O)NCC(C)C)C(C)O)cc(C(=O)N(C)C(C)c2ccccc2)c1;Ki;'=';1657.0;nM;5.78;;317737;UO_0000065;9.37;0.18;2.14;4.41;False;CHEMBL3707552;Inhibition Assay: Previously, one of the following compounds discussed below have been studied in memapsin 2 inhibition (Ghosh et al., 2008), which the others are previously unpublished. Given the closely related substrate specificity for memapsin 1 and memapsin 2, the inventors chose to screen these previously identified memapsin 2 inhibitors for lead compounds as memapsin 1 inhibitors. Recombinant memapsin 1 ectodomain was prepared as described by Turner et al. (2002) and assayed using a commercially purchased fluorescent substrate.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638586;37;BindingDB Database;;2015;None
CHEMBL3664019;;0;630.83;1;4.11;BDBM172750;CCCC(O)C(NCC(O)C(Cc1ccccc1)NC(=O)c1cccc(C(=O)N(C)C(C)c2ccccc2)c1)C(=O)NCC(C)C;Ki;'=';5245.0;nM;5.28;;317739;UO_0000065;8.37;0.16;1.17;4.03;False;CHEMBL3707552;Inhibition Assay: Previously, one of the following compounds discussed below have been studied in memapsin 2 inhibition (Ghosh et al., 2008), which the others are previously unpublished. Given the closely related substrate specificity for memapsin 1 and memapsin 2, the inventors chose to screen these previously identified memapsin 2 inhibitors for lead compounds as memapsin 1 inhibitors. Recombinant memapsin 1 ectodomain was prepared as described by Turner et al. (2002) and assayed using a commercially purchased fluorescent substrate.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638586;37;BindingDB Database;;2015;None
CHEMBL3640286;;0;438.39;0;1.47;BDBM102969;COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3c(F)ccc(F)c3F)C2)nc(C)c1F;Ki;'=';53.0;nM;7.28;;220609;UO_0000065;16.6;0.32;5.81;7.51;True;CHEMBL3705045;Time-Resolved FRET Assay: A homogeneous time-resolved FRET assay was used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. The assay monitored the increase of 620nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide).;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638861;37;BindingDB Database;;2013;None
CHEMBL3958334;;0;450.97;0;3.09;BDBM190752;C[C@@]1(c2sc(-c3cncc(C#N)c3)cc2Cl)CS(=O)(=O)C2(CCOCC2)C(=N)N1;Ki;'=';130.0;nM;6.89;;341244;UO_0000065;15.27;0.32;3.80;5.94;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3957887;;0;409.48;0;1.93;BDBM190841;CC1(C(=O)Nc2ccc(F)c([C@]3(C)CS(=O)(=O)[C@]4(CCOC4)C(=N)N3)c2)CC1;Ki;'=';998.0;nM;6.0;;341323;UO_0000065;14.65;0.29;4.07;5.54;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3980457;;0;468.46;0;2.12;BDBM190847;C[C@@]1(c2cc(NC(=O)c3ncc(F)cc3F)ccc2F)CS(=O)(=O)[C@]2(CCOC2)C(=N)N1;Ki;'=';26.0;nM;7.58;;341329;UO_0000065;16.19;0.32;5.47;6.26;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL2011964;;0;320.4;0;2.66;17i;Cc1cncc(-c2cccc(C3(C4CC4)NC(=N)N(C)C3=O)c2)c1;Ki;'=';250.0;nM;6.6;;;UO_0000065;20.61;0.38;3.94;9.56;False;CHEMBL2015090;Inhibition of human BACE1 using QSY7EISEVNLDAEFC-Eu-amide as substrate incubated for 30 mins prior to substrate addition measured after 90 mins by FRET analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2010674;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2012;None
CHEMBL3889548;;0;436.51;0;2.49;BDBM244048;CNS1(O)C[C@@](C)(c2cc(NC(=O)c3ccc(OC)cn3)ccc2F)NC(=N)N1C;Ki;'=';3.0;nM;8.52;;425633;UO_0000065;19.53;0.39;6.03;6.95;False;CHEMBL3888967;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window Inhibitor.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886899;37;BindingDB Database;;2016;None
CHEMBL2178717;;0;429.51;0;2.40;42;CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3ncccn3)C[C@H]2C1=O;Ki;'=';11.0;nM;7.96;;;UO_0000065;18.53;0.35;5.56;7.30;True;CHEMBL2183861;Inhibition of BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177036;1;Scientific Literature;J. Med. Chem.;2012;None
CHEMBL3962047;;0;519.01;1;2.92;BDBM243003;CN1C(=N)N[C@](C)(c2sc(-c3nnc(-c4ccc(C5(C#N)COC5)cc4)o3)cc2Cl)CS1(=O)=O;Ki;'=';1361.0;nM;5.87;;423884;UO_0000065;11.3;0.24;2.95;4.04;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3921171;;0;404.43;0;1.89;BDBM242948;CN1C(=N)N[C@](C)(c2cc(-c3ccc(-c4nnco4)[nH]3)ccc2F)CS1(=O)=O;Ki;'=';45.0;nM;7.35;;423829;UO_0000065;18.17;0.36;5.46;5.74;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3672917;;0;459.43;0;2.51;BDBM143219;CN1C(=N)N[C@](C)(c2cc(NC(=O)c3ccc(C(F)(F)F)cn3)ccc2F)CS1(=O)=O;Ki;'=';1.261;nM;8.9;;279432;UO_0000065;19.37;0.39;6.39;7.72;False;CHEMBL3706083;Homogeneous Time-Resolved FRET Assay: The protocol that was used to determine the recited values isdescribed as follows.BACE1 HTRF FRET AssayReagentsNa+-Acetate pH 5.01% Brij-35GlycerolDimethyl Sulfoxide (DMSO)Recombinant human soluble BACE1 catalytic domain (>95% pure)APP Swedish mutant peptide substrate (QSY7-APPswe-Eu):QSY7-EISEVNLDAEFC-Europium-amideA homogeneous time-resolved FRET assay was used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitored the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contained an N-terminal QSY7 moiety that served as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence was low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638453;37;BindingDB Database;;2015;None
CHEMBL3672919;;0;440.43;0;1.03;BDBM143222;COc1cnc(C(=O)Nc2cc(F)c(F)c([C@]3(C)CS(=O)(=O)N(C)C(=N)N3)c2)cn1;Ki;'=';1.05;nM;8.98;;279435;UO_0000065;20.39;0.41;7.95;6.54;False;CHEMBL3706083;Homogeneous Time-Resolved FRET Assay: The protocol that was used to determine the recited values isdescribed as follows.BACE1 HTRF FRET AssayReagentsNa+-Acetate pH 5.01% Brij-35GlycerolDimethyl Sulfoxide (DMSO)Recombinant human soluble BACE1 catalytic domain (>95% pure)APP Swedish mutant peptide substrate (QSY7-APPswe-Eu):QSY7-EISEVNLDAEFC-Europium-amideA homogeneous time-resolved FRET assay was used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitored the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contained an N-terminal QSY7 moiety that served as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence was low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638453;37;BindingDB Database;;2015;None
CHEMBL4106918;;0;435.48;0;1.18;BDBM236578;Cn1ccc(C(=O)Nc2ccc(F)c([C@]34COC[C@H]3S(=O)(=O)C(C)(C)C(=N)N4)c2)n1;Ki;'=';13.0;nM;7.89;;412094;UO_0000065;18.11;0.36;6.71;6.25;False;CHEMBL3888701;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886796;37;BindingDB Database;;2016;None
CHEMBL3798199;;0;424.89;0;1.98;12;COc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3ccc(Cl)s3)C2)nc(C)c1F;Ki;'=';10.0;nM;8.0;;;UO_0000065;18.83;0.39;6.02;8.47;False;CHEMBL3801550;Inhibition of recombinant human BACE1 preincubated for 30 mins followed QSY7EISEVNLDAEFC-Eu-amide substrate addition measured after 90 mins by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3797133;1;Scientific Literature;J. Med. Chem.;2016;None
CHEMBL65981;;0;676.86;2;1.64;4;CC(C)C[C@H](NC(=O)C(CC(N)=O)NC(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)C(O)CC(C)C(=O)NC(C)C(=O)NCc1ccccc1;Ki;'=';61.4;nM;7.21;;;UO_0000065;10.65;0.21;5.57;3.31;False;CHEMBL827180;Binding affinity against Beta-secretase;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1137865;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2004;None
CHEMBL3703234;;0;402.81;0;2.84;BDBM149751;NC1=NC2(CO1)c1cc(NC(=O)c3ncc(Cl)cc3F)ccc1OCC21CC1;Ki;'=';240.0;nM;6.62;;288422;UO_0000065;16.43;0.32;3.78;6.70;True;CHEMBL3705666;Fluorescence Resonance Energy Transfer (FRET) Assay: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638878;37;BindingDB Database;;2015;None
CHEMBL3703282;;0;381.43;0;2.48;BDBM149802;COc1cncc(-c2ccc3c(c2)C2(COC(N)=N2)C2(COC2)C(C)(C)O3)c1;Ki;'=';255.0;nM;6.59;;288466;UO_0000065;17.29;0.32;4.11;7.48;True;CHEMBL3705666;Fluorescence Resonance Energy Transfer (FRET) Assay: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638878;37;BindingDB Database;;2015;None
CHEMBL3972030;;0;431.44;0;1.79;BDBM190855;C[C@@]1(c2cc(NC(=O)C3CC3(F)F)ccc2F)CS(=O)(=O)[C@]2(CCOC2)C(=N)N1;Ki;'=';1247.0;nM;5.9;;341336;UO_0000065;13.68;0.28;4.11;5.45;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL4110120;;0;478.48;0;0.84;BDBM182842;CC(=O)N1CC2[C@](c3cc(NC(=O)c4ccc(F)cn4)ccc3F)(C1)NC(=N)N(C)S2(=O)=O;Ki;'=';32.0;nM;7.5;;330390;UO_0000065;15.66;0.31;6.65;5.53;False;CHEMBL3887312;BACE1 HTRF FRET Assay: A homogeneous time-resolved FRET assay was used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitored the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contained an N-terminal QSY7 moiety that served as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence was low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors was manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul were preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886269;37;BindingDB Database;;2015;None
CHEMBL273916;;0;640.84;1;2.30;Page 6608 (4);CC(C)C[C@H](NC(=O)[C@H](CS(C)(=O)=O)NC(=O)OC(C)(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C;Ki;'=';1129.0;nM;5.95;;;UO_0000065;9.28;0.18;3.65;3.30;True;CHEMBL884573;Binding affinity for beta-secretase;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1141123;1;Scientific Literature;J. Med. Chem.;2005;None
CHEMBL2012001;;0;335.41;0;2.96;17b;COc1cccc(-c2cccc(C3(C4CC4)NC(=N)N(C)C3=O)c2)c1;Ki;'=';99.0;nM;7.0;;;UO_0000065;20.88;0.38;4.04;10.71;False;CHEMBL2015090;Inhibition of human BACE1 using QSY7EISEVNLDAEFC-Eu-amide as substrate incubated for 30 mins prior to substrate addition measured after 90 mins by FRET analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2010674;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2012;None
CHEMBL3361302;;0;893.01;3;-1.74;1;CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](NC(=O)[C@@H](N)CCC(=O)O)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](Cc1ccccc1)C(=O)O;Ki;'=';1.6;nM;8.8;;;UO_0000065;9.85;0.19;10.54;2.34;False;CHEMBL3380862;Inhibition of recombinant BACE1 (unknown origin);B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3351680;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;None
CHEMBL3628122;;0;460.37;0;3.41;7n;CC(=O)Nc1c(Cl)cc(CN/C(N)=N/C(=O)C2C3CC3CN2c2ccccc2)cc1Cl;Ki;'=';100.0;nM;7.0;;;UO_0000065;15.21;0.31;3.59;7.01;False;CHEMBL3630425;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 5 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL3627962;;0;478.38;0;4.32;11c;COc1ccc(C2CCCN2C(=O)/N=C(\N)NCc2cc(Cl)c(NC(C)=O)c(Cl)c2)cc1;Ki;'=';2300.0;nM;5.64;;;UO_0000065;11.79;0.24;1.32;5.17;False;CHEMBL3630425;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 5 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL3627964;;0;448.35;0;4.14;11e;CC(=O)Nc1c(Cl)cc(CN/C(N)=N/C(=O)N[C@H]2CCCc3ccccc32)cc1Cl;Ki;'=';9100.0;nM;5.04;;;UO_0000065;11.24;0.23;0.90;4.64;False;CHEMBL3630426;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 6.4 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL3703302;;0;401.47;0;2.99;BDBM149828;CC#Cc1cncc(-c2ccc3c(c2)C2(COC(N)=N2)C2(COC2)C2(CCC2)O3)c1;Ki;'=';120.0;nM;6.92;;361561;UO_0000065;17.24;0.32;3.93;8.76;False;CHEMBL3887894;Fluorescence Resonance Energy Transfer (FRET) Assay: Test Example 1: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence. The amino acid sequence of the 'core' peptide of the substrate is SEVNLDAEFK (SEQ ID NO:2). The amino terminus was derivatized with (7-methoxycoumarin-4-yl)acetyl (MCA), and the epsilon amine of the lysine side chain of the terminal residue (K in sequence SEVNLDAEFK (SEQ ID NO:2)) was derivatized with 2,4-dinitrophenyl (DNP). Assays were performed in a buffer of 0.1 M sodium acetate, pH 4.4, 0.08% 3-[(3-Cholamidopropyl)dimethylammonio]propanesulfonate (CHAPS), 0.005% Tween80. BACE1 enzyme (final concentration 65 nM) was pre-incubated with test compounds for 15 minutes at room temperature. Fluorescence intensities were measured 60 minutes after addition of the substrate (final concentration 3 uM) by Tecan Safire2.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886493;37;BindingDB Database;;2016;None
CHEMBL3353632;;0;320.48;0;2.47;27;CN1C(=N)N[C@](CCC2CCCCC2)(C[C@@H]2CCCNC2)C1=O;Ki;'=';66000.0;nM;4.18;;;UO_0000065;13.04;0.25;1.71;6.13;False;CHEMBL3386389;Inhibition of purified human BACE1 by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3352601;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2014;None
CHEMBL3933963;;0;506.56;1;1.40;BDBM249110;COc1cnc(C(=O)Nc2ccc(F)c([C@]3(C)CS(=O)(=O)C4(CCN(C)CO4)C(=N)N3)c2)c(C)n1;Ki;'=';37.0;nM;7.43;;434648;UO_0000065;14.67;0.29;6.03;5.07;False;CHEMBL3889105;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 ul of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 ul in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window. Inhibitor IC50 values are derived from non-linear regression analysis of concentration response curves. Ki values are then calculated from IC50 values using the Cheng-Prusoff equation using a previously determined um value of 8 uM for the QSY7-APPswe-Eu substrate at BACE1.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886943;37;BindingDB Database;;2016;None
CHEMBL3977613;;0;426.51;0;1.09;BDBM249114;COCC(=O)Nc1ccc(F)c([C@]2(C)CS(=O)(=O)C3(CCN(C)CC3)C(=N)N2)c1;Ki;'=';548.0;nM;6.26;;434652;UO_0000065;14.68;0.29;5.17;5.61;False;CHEMBL3889105;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 ul of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 ul in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window. Inhibitor IC50 values are derived from non-linear regression analysis of concentration response curves. Ki values are then calculated from IC50 values using the Cheng-Prusoff equation using a previously determined um value of 8 uM for the QSY7-APPswe-Eu substrate at BACE1.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886943;37;BindingDB Database;;2016;None
CHEMBL3958480;;0;507.56;1;2.45;BDBM249108;CN1CCC2(CC1)C(=N)N[C@](C)(c1cc(NC(=O)c3ccc(OCF)cn3)ccc1F)CS2(=O)=O;Ki;'=';14.0;nM;7.85;;434646;UO_0000065;15.47;0.31;5.40;6.31;False;CHEMBL3889105;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 ul of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 ul in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window. Inhibitor IC50 values are derived from non-linear regression analysis of concentration response curves. Ki values are then calculated from IC50 values using the Cheng-Prusoff equation using a previously determined um value of 8 uM for the QSY7-APPswe-Eu substrate at BACE1.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886943;37;BindingDB Database;;2016;None
CHEMBL3934413;;0;498.58;0;2.33;BDBM249111;Cc1cc(C#N)cnc1C(=O)Nc1ccc(F)c([C@]2(C)CS(=O)(=O)C3(CCN(C)CC3)C(=N)N2)c1;Ki;'=';35.0;nM;7.46;;434649;UO_0000065;14.95;0.29;5.13;5.36;False;CHEMBL3889105;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 ul of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 ul in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window. Inhibitor IC50 values are derived from non-linear regression analysis of concentration response curves. Ki values are then calculated from IC50 values using the Cheng-Prusoff equation using a previously determined um value of 8 uM for the QSY7-APPswe-Eu substrate at BACE1.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886943;37;BindingDB Database;;2016;None
CHEMBL3937118;;0;416.33;0;3.86;BDBM230866;NC1=N[C@@](c2cc(NC(=O)c3ccc(F)cn3)ccc2F)(C(F)F)C(F)(F)CC1;Ki;'=';23.0;nM;7.64;;402949;UO_0000065;18.35;0.36;3.78;9.50;False;CHEMBL3888456;BACE1 Binding Assay: The binding assay was performed as SPA-based assay using a biotinylated form of human BACE1 recombinantly expressed and subsequently purified from Freestyle HEK293 cells. The binding assay was run in a 50 mM sodium acetate buffer, pH 4.5 containing 50 mM NaCl and 0.03% Tween-20 in white clear bottom 384 plates (Corning #3653). 10 nM (final concentration) radioligand ([3H]−N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N−((R)-1-phenyl-ethyl)-isophthalamide) (TRQ11569 purchased from GE Healthcare) was mixed with test compound at a given concentration, 6 nM (final concentration) human BACE1 and 25 μg Streptavidin coated PVT core SPA beads (RPNQ0007, GE Healthcare Life Sciences) in a total volume of 40 μl. Several concentrations of each test compound were tested in the assay for IC50 determination. The plates were incubated for one hour at room temperature and counted in a Wallac Trilux counter. Total and non-specific binding were determined using buffer and 1 μM (final concentration) of the high affinity BACE1 reference inhibitor (S)-6-[3-chloro-5-(5-prop-1-ynyl-pyridin-3-yl)-thiophen-2-yl]-2-imino-3,6-dimethyl-tetrahydro-pyrimidin-4-one, respectively.;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886720;37;BindingDB Database;;2016;CHEMBL3307715
CHEMBL3354246;;0;390.57;0;3.51;37;CCCCC(=O)N1CC[C@@H](C[C@@]2(CCC3CCCCC3)NC(=N)N(C)C2=O)C1;Ki;'=';17400.0;nM;4.76;;;UO_0000065;12.19;0.23;1.25;6.22;False;CHEMBL3386389;Inhibition of purified human BACE1 by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3352601;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2014;None
CHEMBL3353631;;0;420.6;0;4.12;26;CN1C(=N)N[C@](CCC2CCCCC2)(C[C@H]2CCCN(C(=O)OC(C)(C)C)C2)C1=O;Ki;'=';29000.0;nM;4.54;;;UO_0000065;10.79;0.21;0.42;5.29;False;CHEMBL3386389;Inhibition of purified human BACE1 by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3352601;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2014;None
CHEMBL3703236;;0;368.37;0;2.19;BDBM149753;NC1=NC2(CO1)c1cc(NC(=O)c3ccc(F)cn3)ccc1OCC21CC1;Ki;'=';1030.0;nM;5.99;;361494;UO_0000065;16.25;0.30;3.80;6.06;False;CHEMBL3887894;Fluorescence Resonance Energy Transfer (FRET) Assay: Test Example 1: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence. The amino acid sequence of the 'core' peptide of the substrate is SEVNLDAEFK (SEQ ID NO:2). The amino terminus was derivatized with (7-methoxycoumarin-4-yl)acetyl (MCA), and the epsilon amine of the lysine side chain of the terminal residue (K in sequence SEVNLDAEFK (SEQ ID NO:2)) was derivatized with 2,4-dinitrophenyl (DNP). Assays were performed in a buffer of 0.1 M sodium acetate, pH 4.4, 0.08% 3-[(3-Cholamidopropyl)dimethylammonio]propanesulfonate (CHAPS), 0.005% Tween80. BACE1 enzyme (final concentration 65 nM) was pre-incubated with test compounds for 15 minutes at room temperature. Fluorescence intensities were measured 60 minutes after addition of the substrate (final concentration 3 uM) by Tecan Safire2.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886493;37;BindingDB Database;;2016;None
CHEMBL4109445;;0;449.46;0;0.88;BDBM199093;COc1ccc(C(=O)Nc2ccc(F)c([C@]34COC[C@H]3S(=O)(=O)N(C)C(=N)N4)c2)nc1;Ki;'=';18.18;nM;7.74;;354108;UO_0000065;17.22;0.34;6.86;5.79;False;CHEMBL3887768;Homogeneous Time-Resolved FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 u) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886448;37;BindingDB Database;;2015;None
CHEMBL3650826;;0;442.9;0;3.02;BDBM149914;Cc1cc(Cl)cnc1C(=O)Nc1ccc2c(c1)C1(COC(N)=N1)C1(COC1)C(C)(C)O2;Ki;'=';64.5;nM;7.19;;288566;UO_0000065;16.23;0.32;4.17;6.65;True;CHEMBL3705666;Fluorescence Resonance Energy Transfer (FRET) Assay: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638878;37;BindingDB Database;;2015;None
CHEMBL3650848;;0;412.88;0;3.48;BDBM149939;CC1(C)Oc2ccc(NC(=O)c3ccc(Cl)cn3)cc2[C@@]2(COC(N)=N2)C12CC2;Ki;'=';37.8;nM;7.42;;288588;UO_0000065;17.98;0.35;3.94;7.51;True;CHEMBL3705666;Fluorescence Resonance Energy Transfer (FRET) Assay: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638878;37;BindingDB Database;;2015;None
CHEMBL3650849;;0;396.42;0;2.96;BDBM149940;CC1(C)Oc2ccc(NC(=O)c3ccc(F)cn3)cc2[C@@]2(COC(N)=N2)C12CC2;Ki;'=';91.5;nM;7.04;;288589;UO_0000065;17.76;0.33;4.08;7.12;True;CHEMBL3705666;Fluorescence Resonance Energy Transfer (FRET) Assay: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638878;37;BindingDB Database;;2015;None
CHEMBL3946832;;0;410.99;0;4.08;BDBM190813;C[C@@]1(c2sc(C#CC3CCCC3)cc2Cl)CS(=O)(=O)C2(CCC2)C(=N)N1;Ki;'=';109.9;nM;6.96;;341297;UO_0000065;16.93;0.37;2.88;9.94;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3921426;;0;495.07;0;4.52;BDBM190835;CCc1cccc(NC(=O)c2cc(Cl)c([C@]3(C)CS(=O)(=O)C4(CCCCC4)C(=N)N3)s2)n1;Ki;'=';717.0;nM;6.14;;341317;UO_0000065;12.41;0.26;1.62;5.49;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3921705;;0;341.41;0;1.17;BDBM190879;C[C@@]1(c2cc(N)ccc2F)CS(=O)(=O)C2(CCOCC2)C(=N)N1;Ki;'=';7015.0;nM;5.15;;341352;UO_0000065;15.1;0.31;3.98;4.90;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3977411;;0;472.57;0;3.28;BDBM242303;CN1C(=N)N[C@](C)(c2sc3c(-c4ccc(C5CC(=O)N5)cc4)cccc3c2F)CS1(=O)=O;Ki;'=';184.0;nM;6.74;;422430;UO_0000065;14.25;0.29;3.46;6.58;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3640257;;0;436.39;0;1.03;BDBM102939;COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3ccc(F)cc3F)C2)nc(OC)c1F;Ki;'=';1.8;nM;8.74;;220591;UO_0000065;20.04;0.39;7.71;8.24;False;CHEMBL3705045;Time-Resolved FRET Assay: A homogeneous time-resolved FRET assay was used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. The assay monitored the increase of 620nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide).;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638861;37;BindingDB Database;;2013;None
CHEMBL3640281;;0;462.89;0;2.41;BDBM102964;COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3cc(F)ccc3F)C2)nc(C2CC2)c1Cl;Ki;'=';6.5;nM;8.19;;220599;UO_0000065;17.69;0.35;5.78;8.45;False;CHEMBL3705045;Time-Resolved FRET Assay: A homogeneous time-resolved FRET assay was used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. The assay monitored the increase of 620nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide).;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638861;37;BindingDB Database;;2013;None
CHEMBL4109582;;0;450.47;0;1.98;BDBM236574;CC1(C)C(=N)N[C@@]2(c3cc(NC(=O)c4ccc(F)cn4)ccc3F)COC[C@H]2S1(=O)=O;Ki;'=';3.5;nM;8.46;;412090;UO_0000065;18.77;0.37;6.48;6.97;False;CHEMBL3888701;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886796;37;BindingDB Database;;2016;None
CHEMBL4113810;;0;477.54;0;2.16;BDBM236580;CC1(C)C(=N)N[C@@]2(c3cc(NC(=O)c4cn5ccsc5n4)ccc3F)COC[C@H]2S1(=O)=O;Ki;'=';25.0;nM;7.6;;412096;UO_0000065;15.92;0.32;5.44;6.05;False;CHEMBL3888701;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886796;37;BindingDB Database;;2016;None
CHEMBL4111126;;0;436.47;0;1.74;BDBM236582;Cc1cc(C(=O)Nc2ccc(F)c([C@]34COC[C@H]3S(=O)(=O)C(C)(C)C(=N)N4)c2)on1;Ki;'=';559.0;nM;6.25;;412098;UO_0000065;14.33;0.28;4.51;4.65;False;CHEMBL3888701;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886796;37;BindingDB Database;;2016;None
CHEMBL4110175;;0;471.51;0;2.02;BDBM236594;Cc1cc(C#N)cnc1C(=O)Nc1ccc(F)c([C@]23COC[C@H]2S(=O)(=O)C(C)(C)C(=N)N3)c1;Ki;'=';1.0;nM;9.0;;412110;UO_0000065;19.09;0.37;6.98;6.21;False;CHEMBL3888701;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886796;37;BindingDB Database;;2016;None
CHEMBL4107791;;0;471.46;0;2.04;BDBM236599;CC1(C)C(=N)N[C@@]2(c3cc(NC(=O)c4ccn(C(F)F)n4)ccc3F)COC[C@H]2S1(=O)=O;Ki;'=';1.0;nM;9.0;;412115;UO_0000065;19.09;0.38;6.96;7.13;False;CHEMBL3888701;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886796;37;BindingDB Database;;2016;None
CHEMBL3650827;;0;375.39;0;1.92;BDBM149915;N#Cc1ccc(C(=O)Nc2ccc3c(c2)C2(COC(N)=N2)C2(CC2)CO3)nc1;Ki;'=';342.0;nM;6.47;;361637;UO_0000065;17.22;0.32;4.55;5.27;False;CHEMBL3887894;Fluorescence Resonance Energy Transfer (FRET) Assay: Test Example 1: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence. The amino acid sequence of the 'core' peptide of the substrate is SEVNLDAEFK (SEQ ID NO:2). The amino terminus was derivatized with (7-methoxycoumarin-4-yl)acetyl (MCA), and the epsilon amine of the lysine side chain of the terminal residue (K in sequence SEVNLDAEFK (SEQ ID NO:2)) was derivatized with 2,4-dinitrophenyl (DNP). Assays were performed in a buffer of 0.1 M sodium acetate, pH 4.4, 0.08% 3-[(3-Cholamidopropyl)dimethylammonio]propanesulfonate (CHAPS), 0.005% Tween80. BACE1 enzyme (final concentration 65 nM) was pre-incubated with test compounds for 15 minutes at room temperature. Fluorescence intensities were measured 60 minutes after addition of the substrate (final concentration 3 uM) by Tecan Safire2.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886493;37;BindingDB Database;;2016;None
CHEMBL3940057;;0;402.32;0;3.62;BDBM230868;Cc1nc(C(=O)Nc2ccc(F)c([C@@]3(C(F)F)N=C(N)CCC3(F)F)c2)co1;Ki;'=';20.0;nM;7.7;;402951;UO_0000065;19.14;0.38;4.08;8.23;False;CHEMBL3888456;BACE1 Binding Assay: The binding assay was performed as SPA-based assay using a biotinylated form of human BACE1 recombinantly expressed and subsequently purified from Freestyle HEK293 cells. The binding assay was run in a 50 mM sodium acetate buffer, pH 4.5 containing 50 mM NaCl and 0.03% Tween-20 in white clear bottom 384 plates (Corning #3653). 10 nM (final concentration) radioligand ([3H]−N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N−((R)-1-phenyl-ethyl)-isophthalamide) (TRQ11569 purchased from GE Healthcare) was mixed with test compound at a given concentration, 6 nM (final concentration) human BACE1 and 25 μg Streptavidin coated PVT core SPA beads (RPNQ0007, GE Healthcare Life Sciences) in a total volume of 40 μl. Several concentrations of each test compound were tested in the assay for IC50 determination. The plates were incubated for one hour at room temperature and counted in a Wallac Trilux counter. Total and non-specific binding were determined using buffer and 1 μM (final concentration) of the high affinity BACE1 reference inhibitor (S)-6-[3-chloro-5-(5-prop-1-ynyl-pyridin-3-yl)-thiophen-2-yl]-2-imino-3,6-dimethyl-tetrahydro-pyrimidin-4-one, respectively.;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886720;37;BindingDB Database;;2016;CHEMBL3307715
CHEMBL4067413;;0;394.52;0;3.45;29;[2H]C1([2H])OC(N)=N[C@]12c1cc(-c3cncnc3)ccc1C[C@@]21CC[C@H](OC)[C@@H](CC)C1;Ki;'=';45.0;nM;7.35;;;UO_0000065;18.72;0.35;3.90;8.89;False;CHEMBL4049274;Inhibition of human BACE1 (1 to 460 residues) fused with Fc domain of IgG1 expressed in HEK293 cells preincubated for 10 mins followed by substrate addition measured after 17 mins by TR-FRET assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4043307;1;Scientific Literature;J Med Chem;2018;CHEMBL3307715
CHEMBL3589000;;0;1284.43;None;None;3;CC(C)C[C@H](NC(=O)[C@@H](N)CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(N)=O)C(C)C;Ki;'=';1.9;nM;8.72;;;UO_0000065;6.79;None;None;None;False;CHEMBL3592345;Inhibition of human recombinant BACE1 using Mca-SEVNLDAEFK-DNP substrate assessed as substrate hydrolysis after 2 hrs by HPLC-FLU analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3588858;1;Scientific Literature;J. Med. Chem.;2015;None
CHEMBL3672923;;0;422.44;0;0.89;BDBM143228;COc1cnc(C(=O)Nc2ccc(F)c([C@]3(C)CS(=O)(=O)N(C)C(=N)N3)c2)cn1;Ki;'=';1.64;nM;8.79;;300578;UO_0000065;20.8;0.41;7.90;6.40;False;CHEMBL3705433;HTRF FRET Assay: A homogeneous time-resolved FRET assay was used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitored the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contained an N-terminal QSY7 moiety that served as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence was low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors was manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul were preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30 C. in reaction buffer containing 20 mM Na-Acetate pH 5.0.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638621;37;BindingDB Database;;2015;None
CHEMBL3981430;;0;443.48;0;2.30;BDBM247289;CN1C(=N)N[C@](C)(c2cc(NC(=S)c3ccc(F)cn3)cc(F)c2F)CS1(=O)=O;Ki;'=';17.0;nM;7.77;;431492;UO_0000065;17.52;0.37;5.47;7.91;False;CHEMBL3889053;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886930;37;BindingDB Database;;2016;None
CHEMBL3900954;;0;484.56;0;2.02;BDBM249101;CN1CCC2(CC1)C(=N)N[C@](C)(c1cc(NC(=O)c3ccc(C#N)cn3)ccc1F)CS2(=O)=O;Ki;'=';6.4;nM;8.19;;434639;UO_0000065;16.91;0.33;6.17;5.89;False;CHEMBL3889105;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 ul of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 ul in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window. Inhibitor IC50 values are derived from non-linear regression analysis of concentration response curves. Ki values are then calculated from IC50 values using the Cheng-Prusoff equation using a previously determined um value of 8 uM for the QSY7-APPswe-Eu substrate at BACE1.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886943;37;BindingDB Database;;2016;None
CHEMBL3972967;;0;543.54;1;3.05;BDBM249106;CN1CCC2(CC1)C(=N)N[C@](C)(c1cc(NC(=O)c3ccc(OC(F)(F)F)cn3)ccc1F)CS2(=O)=O;Ki;'=';15.0;nM;7.82;;434644;UO_0000065;14.39;0.29;4.77;6.29;False;CHEMBL3889105;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 ul of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 ul in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window. Inhibitor IC50 values are derived from non-linear regression analysis of concentration response curves. Ki values are then calculated from IC50 values using the Cheng-Prusoff equation using a previously determined um value of 8 uM for the QSY7-APPswe-Eu substrate at BACE1.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886943;37;BindingDB Database;;2016;None
CHEMBL3956741;;0;504.54;1;1.09;BDBM249120;CNC(=O)N1CC2(C1)C(=N)N[C@](C)(c1cc(NC(=O)c3ccc(OC)cn3)ccc1F)CS2(=O)=O;Ki;'=';7.3;nM;8.14;;434658;UO_0000065;16.13;0.32;7.05;5.30;False;CHEMBL3889105;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 ul of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 ul in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window. Inhibitor IC50 values are derived from non-linear regression analysis of concentration response curves. Ki values are then calculated from IC50 values using the Cheng-Prusoff equation using a previously determined um value of 8 uM for the QSY7-APPswe-Eu substrate at BACE1.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886943;37;BindingDB Database;;2016;None
CHEMBL4112319;;0;467.45;0;1.01;BDBM199115;COc1cnc(C(=O)Nc2ccc(F)c([C@]34COC[C@H]3S(=O)(=O)N(C)C(=N)N4)c2)c(F)c1;Ki;'=';15.8;nM;7.8;;354119;UO_0000065;16.69;0.33;6.79;5.83;False;CHEMBL3887768;Homogeneous Time-Resolved FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 u) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886448;37;BindingDB Database;;2015;None
CHEMBL3960661;;0;439.52;0;3.21;BDBM190738;C[C@@]1(c2cc(-n3cc(-c4ccccc4)nn3)ccc2F)CS(=O)(=O)C2(CCC2)C(=N)N1;Ki;'=';2323.0;nM;5.63;;341232;UO_0000065;12.82;0.25;2.42;5.59;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3923964;;0;411.46;0;0.92;BDBM190840;C[C@@]1(c2cc(NC(=O)C3CCO3)ccc2F)CS(=O)(=O)[C@]2(CCOC2)C(=N)N1;Ki;'=';488.0;nM;6.31;;341322;UO_0000065;15.34;0.31;5.39;5.37;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3937345;;0;511.03;1;1.98;BDBM242342;Cc1nonc1N1CCN(c2nccc3c(Cl)c([C@]4(C)CS(=O)(=O)N(C)C(=N)N4)sc23)CC1;Ki;'=';726.4;nM;6.14;;422469;UO_0000065;12.01;0.25;4.16;4.67;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3939748;;0;432.51;0;2.42;BDBM242277;CN1C(=N)N[C@](C)(c2sc(-c3ccnc(-c4cncnc4)c3)cc2F)CS1(=O)=O;Ki;'=';1252.0;nM;5.9;;422404;UO_0000065;13.65;0.28;3.48;5.27;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3890972;;0;412.39;0;4.02;BDBM234493;Cc1nc(C(=O)Nc2ccc(F)c([C@@]3(C)N=C(N)[C@@](C)(F)CC3(F)F)c2)c(C)o1;Ki;'=';65.0;nM;7.19;;408810;UO_0000065;17.43;0.34;3.17;7.69;False;CHEMBL3888549;SPA-Based Assay: The binding assay was performed as SPA-based assay using a biotinylated form of human BACE1 recombinantly expressed and subsequently purified from Freestyle HEK293 cells. The binding assay was run in a 50 mM sodium acetate buffer, pH 4.5 containing 50 mM NaCl and 0.03% Tween-20 in white clear bottom 384 plates (Corning #3653). 10 nM (final concentration) radioligand ([3H]-N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N-((R)-1-phenyl-ethyl)-isophthalamide) (TRQ11569 purchased from GE Healthcare) was mixed with test compound at a given concentration, 6 nM (final concentration) human BACE1 and 25 μg Streptavidin coated PVT core SPA beads (RPNQ0007, GE Healthcare Life Sciences) in a total volume of 40 μl.;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886758;37;BindingDB Database;;2016;CHEMBL3307715
CHEMBL4085945;;0;424.58;1;7.13;2;CC(C)=CCC/C(=C/CC/C(C)=C/CCC1(C)C=Cc2cc(O)cc(C)c2O1)C(=O)O;Ki;'=';2900.0;nM;5.54;;;UO_0000065;13.04;0.24;-1.59;8.29;False;CHEMBL4055497;Noncompetitive inhibition of recombinant human BACE1 using Rh-EVNLDAEFK-Quencher as substrate after 60 mins by Dixon plot analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4052658;1;Scientific Literature;Bioorg Med Chem;2017;None
CHEMBL3352906;;0;710.98;2;3.47;4c;Cc1csc(C[C@H](C)C(=O)N[C@@H](CNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NCC(C)C)C(C)C)n1;Ki;'=';0.25;nM;9.6;;;UO_0000065;13.51;0.27;6.13;5.11;False;CHEMBL3380862;Inhibition of recombinant BACE1 (unknown origin);B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3351680;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;None
CHEMBL3628121;;0;462.38;0;3.94;7m;CC(=O)Nc1c(Cl)cc(CN/C(N)=N/C(=O)C2CCCCN2c2ccccc2)cc1Cl;Ki;'=';420.0;nM;6.38;;;UO_0000065;13.79;0.28;2.44;6.39;False;CHEMBL3630426;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 6.4 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL3893492;;0;386.49;0;2.40;BDBM242926;CNS1(O)C[C@@](C)(c2cc(NC(=O)COC)ccc2F)NC(=N)C1(C)C;Ki;'=';228.0;nM;6.64;;423787;UO_0000065;17.19;0.35;4.24;6.24;False;CHEMBL3888940;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886895;37;BindingDB Database;;2016;None
CHEMBL3650828;;0;419.44;0;1.93;BDBM149916;CC1(C)Oc2ccc(NC(=O)c3ccc(C#N)cn3)cc2C2(COC(N)=N2)C12COC2;Ki;'=';72.0;nM;7.14;;361638;UO_0000065;17.03;0.31;5.21;5.42;False;CHEMBL3887894;Fluorescence Resonance Energy Transfer (FRET) Assay: Test Example 1: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence. The amino acid sequence of the 'core' peptide of the substrate is SEVNLDAEFK (SEQ ID NO:2). The amino terminus was derivatized with (7-methoxycoumarin-4-yl)acetyl (MCA), and the epsilon amine of the lysine side chain of the terminal residue (K in sequence SEVNLDAEFK (SEQ ID NO:2)) was derivatized with 2,4-dinitrophenyl (DNP). Assays were performed in a buffer of 0.1 M sodium acetate, pH 4.4, 0.08% 3-[(3-Cholamidopropyl)dimethylammonio]propanesulfonate (CHAPS), 0.005% Tween80. BACE1 enzyme (final concentration 65 nM) was pre-incubated with test compounds for 15 minutes at room temperature. Fluorescence intensities were measured 60 minutes after addition of the substrate (final concentration 3 uM) by Tecan Safire2.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886493;37;BindingDB Database;;2016;None
CHEMBL3650849;;0;396.42;0;2.96;BDBM149940;CC1(C)Oc2ccc(NC(=O)c3ccc(F)cn3)cc2[C@@]2(COC(N)=N2)C12CC2;Ki;'=';91.5;nM;7.04;;361659;UO_0000065;17.76;0.33;4.08;7.12;False;CHEMBL3887894;Fluorescence Resonance Energy Transfer (FRET) Assay: Test Example 1: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence. The amino acid sequence of the 'core' peptide of the substrate is SEVNLDAEFK (SEQ ID NO:2). The amino terminus was derivatized with (7-methoxycoumarin-4-yl)acetyl (MCA), and the epsilon amine of the lysine side chain of the terminal residue (K in sequence SEVNLDAEFK (SEQ ID NO:2)) was derivatized with 2,4-dinitrophenyl (DNP). Assays were performed in a buffer of 0.1 M sodium acetate, pH 4.4, 0.08% 3-[(3-Cholamidopropyl)dimethylammonio]propanesulfonate (CHAPS), 0.005% Tween80. BACE1 enzyme (final concentration 65 nM) was pre-incubated with test compounds for 15 minutes at room temperature. Fluorescence intensities were measured 60 minutes after addition of the substrate (final concentration 3 uM) by Tecan Safire2.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886493;37;BindingDB Database;;2016;None
CHEMBL3913185;;0;466.92;0;2.50;BDBM190769;C[C@@]1(c2cc(NC(=O)c3ccc(Cl)cn3)ccc2F)CS(=O)(=O)[C@]2(CCOC2)C(=N)N1;Ki;'=';8.1;nM;8.09;;341261;UO_0000065;17.33;0.36;5.59;6.67;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3920832;;0;500.47;1;2.86;BDBM190770;C[C@@]1(c2cc(NC(=O)c3ccc(C(F)(F)F)cn3)ccc2F)CS(=O)(=O)[C@]2(CCOC2)C(=N)N1;Ki;'=';17.0;nM;7.77;;341262;UO_0000065;15.52;0.31;4.91;6.41;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3947187;;0;463.49;0;1.25;BDBM190781;COc1cnc(C(=O)Nc2ccc(F)c([C@]3(C)CS(=O)(=O)[C@@]4(CCOC4)C(=N)N3)c2)cn1;Ki;'=';41.0;nM;7.39;;341264;UO_0000065;15.94;0.32;6.14;5.15;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3966712;;0;450.47;0;1.98;BDBM190783;C[C@@]1(c2cc(NC(=O)c3ccc(F)cn3)ccc2F)CS(=O)(=O)[C@@]2(CCOC2)C(=N)N1;Ki;'=';18.7;nM;7.73;;341266;UO_0000065;17.16;0.34;5.75;6.37;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL2178164;;0;561.5;1;4.32;22g;COc1ccc(-c2nsc(C)c2C(=O)/N=C(\N)NCc2cc(Cl)c(NC(=O)CN3CCC3)c(Cl)c2)cc1;Ki;'=';4.0;nM;8.4;;;UO_0000065;14.96;0.31;4.08;6.89;False;CHEMBL2187886;Displacement of [3H]BMS-599240 from BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177026;1;Scientific Literature;J. Med. Chem.;2012;CHEMBL3307715
CHEMBL2178172;;0;468.94;0;3.95;19d;COc1ccc(-c2noc(C)c2C(=O)/N=C(\N)NCc2cc(Cl)cc(/C=C/CCO)c2)cc1;Ki;'=';140.0;nM;6.85;;;UO_0000065;14.62;0.28;2.90;5.57;False;CHEMBL2187886;Displacement of [3H]BMS-599240 from BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177026;1;Scientific Literature;J. Med. Chem.;2012;CHEMBL3307715
CHEMBL4128375;;0;547.41;1;3.33;22;CN1C(=N)N[C@@]2(c3cc(NC(=O)c4nccc5cc(Br)cnc45)ccc3F)CCC[C@H]2S1(=O)=O;Ki;'=';4.0;nM;8.4;;;UO_0000065;15.34;0.34;5.07;6.55;False;CHEMBL4119788;Binding affinity to human BACE1 catalytic domain using QSY7-APPswe-Eu as substrate preincubated for 30 mins followed by substrate addition measured after 1.5 hrs by HTRF assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4118088;1;Scientific Literature;ACS Med Chem Lett;2017;None
CHEMBL573106;;0;851.97;1;4.25;1;CO[C@H](C[C@H](O)[C@H](COc1cc(F)cc(F)c1)NC(=O)c1cc(C(=O)N[C@H](C)c2ccccc2)cc(N(C)S(C)(=O)=O)c1)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C;Ki;'<';1.0;nM;;;;UO_0000065;;;;;False;CHEMBL1069651;Inhibition of human BACE1 expressed in Escherichia coli BL21(DE3) by resolved fluorescence assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1156935;1;Scientific Literature;Bioorg. Med. Chem.;2010;None
CHEMBL591699;;0;866.0;1;4.64;2b;CCO[C@H](C[C@H](O)[C@H](COc1cc(F)cc(F)c1)NC(=O)c1cc(C(=O)N[C@H](C)c2ccccc2)cc(N(C)S(C)(=O)=O)c1)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C;Ki;'=';2.1;nM;8.68;;;UO_0000065;10.02;0.19;4.04;4.51;False;CHEMBL1069651;Inhibition of human BACE1 expressed in Escherichia coli BL21(DE3) by resolved fluorescence assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1156935;1;Scientific Literature;Bioorg. Med. Chem.;2010;None
CHEMBL591644;;0;896.02;1;4.27;2c;COCCO[C@H](C[C@H](O)[C@H](COc1cc(F)cc(F)c1)NC(=O)c1cc(C(=O)N[C@H](C)c2ccccc2)cc(N(C)S(C)(=O)=O)c1)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C;Ki;'=';3.1;nM;8.51;;;UO_0000065;9.5;0.18;4.24;4.22;False;CHEMBL1069651;Inhibition of human BACE1 expressed in Escherichia coli BL21(DE3) by resolved fluorescence assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1156935;1;Scientific Literature;Bioorg. Med. Chem.;2010;None
CHEMBL591478;;0;878.01;1;4.81;2d;C=CCO[C@H](C[C@H](O)[C@H](COc1cc(F)cc(F)c1)NC(=O)c1cc(C(=O)N[C@H](C)c2ccccc2)cc(N(C)S(C)(=O)=O)c1)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C;Ki;'=';3.3;nM;8.48;;;UO_0000065;9.66;0.19;3.67;4.41;False;CHEMBL1069651;Inhibition of human BACE1 expressed in Escherichia coli BL21(DE3) by resolved fluorescence assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1156935;1;Scientific Literature;Bioorg. Med. Chem.;2010;None
CHEMBL2178151;;0;485.61;0;4.40;34;CC(C)Oc1cccc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3cc(-c4cccc(C#N)c4)cs3)C2)c1;Ki;'=';15.0;nM;7.82;;;UO_0000065;16.11;0.31;3.42;8.46;False;CHEMBL2183861;Inhibition of BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177036;1;Scientific Literature;J. Med. Chem.;2012;None
CHEMBL3983667;;0;494.08;0;4.43;BDBM190758;C[C@@]1(c2sc(-c3cccc(N4CCCC4)c3)cc2Cl)CS(=O)(=O)C2(CCOCC2)C(=N)N1;Ki;'=';5743.0;nM;5.24;;341250;UO_0000065;10.61;0.22;0.81;6.35;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3984049;;0;494.06;0;4.56;BDBM190794;C[C@@]1(c2sc(-c3ccnc(-c4cccs4)c3)cc2Cl)CS(=O)(=O)[C@@]2(CCOC2)C(=N)N1;Ki;'=';986.4;nM;6.01;;341286;UO_0000065;12.16;0.26;1.45;6.52;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3941514;;0;442.01;0;2.22;BDBM190815;C[C@@]1(c2sc(C#CCN3CCOCC3)cc2Cl)CS(=O)(=O)C2(CCC2)C(=N)N1;Ki;'=';2362.0;nM;5.63;;341299;UO_0000065;12.73;0.27;3.41;6.82;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3913539;;0;488.06;0;3.10;BDBM190823;C[C@@]1(c2sc(C(=O)NCc3cnsn3)cc2Cl)CS(=O)(=O)C2(CCCCC2)C(=N)N1;Ki;'=';144.0;nM;6.84;;341306;UO_0000065;14.02;0.31;3.74;5.48;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3914564;;0;505.07;1;4.80;BDBM190828;[C-]#[N+]c1ccc(CNC(=O)c2cc(Cl)c([C@]3(C)CS(=O)(=O)C4(CCCCC4)C(=N)N3)s2)cc1;Ki;'=';851.0;nM;6.07;;341311;UO_0000065;12.02;0.25;1.27;5.87;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL4115054;;0;425.48;0;1.31;BDBM190846;C[C@@]1(c2cc(NC(=O)[C@H]3CCCO3)ccc2F)CS(=O)(=O)[C@]2(CCOC2)C(=N)N1;Ki;'=';1402.0;nM;5.85;;341328;UO_0000065;13.76;0.28;4.54;4.98;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3896318;;0;383.45;0;1.54;BDBM190848;CCC(=O)Nc1ccc(F)c([C@]2(C)CS(=O)(=O)[C@]3(CCOC3)C(=N)N2)c1;Ki;'=';949.0;nM;6.02;;341330;UO_0000065;15.71;0.32;4.48;5.56;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3650820;;0;430.26;0;2.20;BDBM149908;NC1=NC2(CO1)c1cc(NC(=O)c3ncc(Br)cn3)ccc1OCC21CC1;Ki;'=';623.0;nM;6.21;;288560;UO_0000065;14.42;0.31;4.01;5.55;True;CHEMBL3705666;Fluorescence Resonance Energy Transfer (FRET) Assay: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638878;37;BindingDB Database;;2015;None
CHEMBL3944361;;0;493.96;0;4.24;BDBM190756;C[C@@]1(c2sc(-c3cncc(C(F)(F)F)c3)cc2Cl)CS(=O)(=O)C2(CCOCC2)C(=N)N1;Ki;'=';157.0;nM;6.8;;341248;UO_0000065;13.77;0.30;2.56;7.38;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3982458;;0;504.06;1;4.75;BDBM242328;CN1C(=N)N[C@](C)(c2sc3c(-c4ccc(-c5nccs5)cc4)nccc3c2Cl)CS1(=O)=O;Ki;'=';270.3;nM;6.57;;422455;UO_0000065;13.03;0.28;1.82;6.63;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL4112989;;0;495.51;0;1.58;BDBM236581;CC1(C)C(=N)N[C@@]2(c3cc(NC(=O)c4cnc(OCCF)cn4)ccc3F)COC[C@H]2S1(=O)=O;Ki;'=';7.0;nM;8.15;;412097;UO_0000065;16.46;0.33;6.57;5.69;False;CHEMBL3888701;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886796;37;BindingDB Database;;2016;None
CHEMBL3694263;;0;727.88;1;3.28;5e;COc1cccc(CN2CCN[C@@H]([C@@H](O)[C@H](Cc3ccccc3)NC(=O)c3cc(C(=O)N[C@H](C)c4ccccc4)cc(N(C)S(C)(=O)=O)c3)C2=O)c1;Ki;'=';129.0;nM;6.89;;;UO_0000065;9.47;0.18;3.61;4.38;False;CHEMBL4018279;Inhibition of recombinant human BACE1 (Ala8P to Ala326 residues) expressed in Escherichia coli BL21(DE3) using Arg-Glu(EDANS)-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys (Dabcyl)-Arg as substrate by fluorescence assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4017478;1;Scientific Literature;Bioorg Med Chem Lett;2017;None
CHEMBL3981231;;0;446.5;0;2.61;BDBM190706;COc1ccc(C(=O)Nc2ccc(F)c([C@]3(C)CS(=O)(=O)C4(CCC4)C(=N)N3)c2)nc1;Ki;'=';10.7;nM;7.97;;341201;UO_0000065;17.85;0.35;5.36;6.57;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL4107633;;0;495.51;0;1.58;BDBM236605;COc1cnc(C(=O)Nc2ccc(F)c([C@]34COC(CF)[C@H]3S(=O)(=O)C(C)(C)C(=N)N4)c2)cn1;Ki;'=';204.0;nM;6.69;;412124;UO_0000065;13.5;0.27;5.11;4.67;False;CHEMBL3888701;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886796;37;BindingDB Database;;2016;None
CHEMBL3927055;;0;435.96;0;3.47;BDBM242939;CN1C(=N)N[C@](C)(c2sc(-c3ncc(-c4ccccc4)[nH]3)cc2Cl)CS1(=O)=O;Ki;'=';112.0;nM;6.95;;423820;UO_0000065;15.94;0.34;3.48;6.82;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3933652;;0;498.02;0;4.13;BDBM242937;COCCNS1(O)C[C@@](C)(c2cc(NC(=O)c3ccc(Cl)cn3)ccc2F)NC(=N)C1(C)C;Ki;'=';3.0;nM;8.52;;423797;UO_0000065;17.11;0.35;4.39;7.14;False;CHEMBL3888940;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886895;37;BindingDB Database;;2016;None
CHEMBL4087999;;0;711.88;1;3.66;6b;C[C@@H](NC(=O)c1cc(C(=O)N[C@@H](Cc2ccccc2)[C@H](O)[C@@H]2NC[C@@H](C)N(Cc3ccccc3)C2=O)cc(N(C)S(C)(=O)=O)c1)c1ccccc1;Ki;'=';175.5;nM;6.76;;;UO_0000065;9.49;0.18;3.10;4.56;False;CHEMBL4018279;Inhibition of recombinant human BACE1 (Ala8P to Ala326 residues) expressed in Escherichia coli BL21(DE3) using Arg-Glu(EDANS)-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys (Dabcyl)-Arg as substrate by fluorescence assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4017478;1;Scientific Literature;Bioorg Med Chem Lett;2017;None
CHEMBL3948757;;0;493.99;0;2.80;BDBM249105;CN1CCC2(CC1)C(=N)N[C@](C)(c1cc(NC(=O)c3ccc(Cl)cn3)ccc1F)CS2(=O)=O;Ki;'=';12.0;nM;7.92;;434643;UO_0000065;16.03;0.33;5.12;6.87;False;CHEMBL3889105;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 ul of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 ul in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window. Inhibitor IC50 values are derived from non-linear regression analysis of concentration response curves. Ki values are then calculated from IC50 values using the Cheng-Prusoff equation using a previously determined um value of 8 uM for the QSY7-APPswe-Eu substrate at BACE1.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886943;37;BindingDB Database;;2016;None
CHEMBL3917252;;0;462.0;0;3.90;BDBM242301;CN1C(=N)N[C@](C)(c2sc3c(-c4ccc(C5CC5)nc4)nccc3c2Cl)CS1(=O)=O;Ki;'=';282.0;nM;6.55;;422428;UO_0000065;14.18;0.30;2.65;6.61;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3948490;;0;516.57;2;5.06;BDBM242304;CN1C(=N)N[C@](C)(c2sc3c(-c4ccc(-c5ccc(F)cc5F)nc4)cccc3c2F)CS1(=O)=O;Ki;'=';93.0;nM;7.03;;422431;UO_0000065;13.61;0.27;1.97;8.16;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3907681;;0;470.56;0;3.30;BDBM242305;CN1C(=N)N[C@](C)(c2sc3c(-c4ccc(-n5ccnn5)cc4)cccc3c2F)CS1(=O)=O;Ki;'=';19.0;nM;7.72;;422432;UO_0000065;16.41;0.33;4.42;7.43;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3963413;;0;430.33;0;3.09;BDBM230873;COc1cnc(C(=O)Oc2ccc(F)c([C@@]3(C(F)F)N=C(N)CCC3(F)F)c2)nc1;Ki;'=';6.9;nM;8.16;;402956;UO_0000065;18.96;0.37;5.07;8.19;False;CHEMBL3888456;BACE1 Binding Assay: The binding assay was performed as SPA-based assay using a biotinylated form of human BACE1 recombinantly expressed and subsequently purified from Freestyle HEK293 cells. The binding assay was run in a 50 mM sodium acetate buffer, pH 4.5 containing 50 mM NaCl and 0.03% Tween-20 in white clear bottom 384 plates (Corning #3653). 10 nM (final concentration) radioligand ([3H]−N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N−((R)-1-phenyl-ethyl)-isophthalamide) (TRQ11569 purchased from GE Healthcare) was mixed with test compound at a given concentration, 6 nM (final concentration) human BACE1 and 25 μg Streptavidin coated PVT core SPA beads (RPNQ0007, GE Healthcare Life Sciences) in a total volume of 40 μl. Several concentrations of each test compound were tested in the assay for IC50 determination. The plates were incubated for one hour at room temperature and counted in a Wallac Trilux counter. Total and non-specific binding were determined using buffer and 1 μM (final concentration) of the high affinity BACE1 reference inhibitor (S)-6-[3-chloro-5-(5-prop-1-ynyl-pyridin-3-yl)-thiophen-2-yl]-2-imino-3,6-dimethyl-tetrahydro-pyrimidin-4-one, respectively.;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886720;37;BindingDB Database;;2016;CHEMBL3307715
CHEMBL3961890;;0;429.35;0;3.12;BDBM230867;COc1cnc(C(=O)Nc2ccc(F)c([C@@]3(C(F)F)N=C(N)CCC3(F)F)c2)cn1;Ki;'=';18.0;nM;7.75;;402961;UO_0000065;18.04;0.35;4.62;7.56;False;CHEMBL3888456;BACE1 Binding Assay: The binding assay was performed as SPA-based assay using a biotinylated form of human BACE1 recombinantly expressed and subsequently purified from Freestyle HEK293 cells. The binding assay was run in a 50 mM sodium acetate buffer, pH 4.5 containing 50 mM NaCl and 0.03% Tween-20 in white clear bottom 384 plates (Corning #3653). 10 nM (final concentration) radioligand ([3H]−N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N−((R)-1-phenyl-ethyl)-isophthalamide) (TRQ11569 purchased from GE Healthcare) was mixed with test compound at a given concentration, 6 nM (final concentration) human BACE1 and 25 μg Streptavidin coated PVT core SPA beads (RPNQ0007, GE Healthcare Life Sciences) in a total volume of 40 μl. Several concentrations of each test compound were tested in the assay for IC50 determination. The plates were incubated for one hour at room temperature and counted in a Wallac Trilux counter. Total and non-specific binding were determined using buffer and 1 μM (final concentration) of the high affinity BACE1 reference inhibitor (S)-6-[3-chloro-5-(5-prop-1-ynyl-pyridin-3-yl)-thiophen-2-yl]-2-imino-3,6-dimethyl-tetrahydro-pyrimidin-4-one, respectively.;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886720;37;BindingDB Database;;2016;CHEMBL3307715
CHEMBL3640258;;0;420.4;0;1.33;BDBM102940;COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3c(F)cccc3F)C2)nc(C)c1F;Ki;'=';32.0;nM;7.5;;220577;UO_0000065;17.83;0.34;6.16;7.73;False;CHEMBL3705045;Time-Resolved FRET Assay: A homogeneous time-resolved FRET assay was used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. The assay monitored the increase of 620nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide).;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638861;37;BindingDB Database;;2013;None
CHEMBL3640251;;0;398.44;0;1.44;BDBM102933;CCOc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3ccccc3)C2)nc(C)c1F;Ki;'=';59.0;nM;7.23;;220579;UO_0000065;18.14;0.34;5.79;7.46;False;CHEMBL3705045;Time-Resolved FRET Assay: A homogeneous time-resolved FRET assay was used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. The assay monitored the increase of 620nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide).;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638861;37;BindingDB Database;;2013;None
CHEMBL3640265;;0;462.89;0;2.41;BDBM102948;COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3ccc(F)cc3F)C2)nc(C2CC2)c1Cl;Ki;'=';6.8;nM;8.17;;220602;UO_0000065;17.64;0.35;5.76;8.43;False;CHEMBL3705045;Time-Resolved FRET Assay: A homogeneous time-resolved FRET assay was used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. The assay monitored the increase of 620nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide).;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638861;37;BindingDB Database;;2013;None
CHEMBL3640261;;0;419.46;0;1.79;BDBM102943;Cc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3cccc(C#N)c3)C2)nc(C2CC2)c1F;Ki;'=';43.0;nM;7.37;;220606;UO_0000065;17.56;0.32;5.58;6.61;False;CHEMBL3705045;Time-Resolved FRET Assay: A homogeneous time-resolved FRET assay was used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. The assay monitored the increase of 620nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide).;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638861;37;BindingDB Database;;2013;None
CHEMBL3588999;;0;1268.43;None;None;2;CC(C)C[C@H](NC(=O)[C@@H](N)CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(N)=O)C(C)C;Ki;'=';2.0;nM;8.7;;;UO_0000065;6.86;None;None;None;False;CHEMBL3592345;Inhibition of human recombinant BACE1 using Mca-SEVNLDAEFK-DNP substrate assessed as substrate hydrolysis after 2 hrs by HPLC-FLU analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3588858;1;Scientific Literature;J. Med. Chem.;2015;None
CHEMBL3936730;;0;420.44;0;2.36;BDBM190699;C[C@@]1(c2cc(NC(=O)c3ccc(F)cn3)ccc2F)CS(=O)(=O)C2(CC2)C(=N)N1;Ki;'=';5.5;nM;8.26;;341194;UO_0000065;19.65;0.39;5.90;7.37;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3896710;;0;447.49;0;2.01;BDBM190703;COc1cnc(C(=O)Nc2ccc(F)c([C@]3(C)CS(=O)(=O)C4(CCC4)C(=N)N3)c2)cn1;Ki;'=';11.7;nM;7.93;;341198;UO_0000065;17.73;0.35;5.92;5.91;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3911217;;0;441.49;0;3.16;BDBM190707;[C-]#[N+]c1ccc(C(=O)Nc2ccc(F)c([C@]3(C)CS(=O)(=O)C4(CCC4)C(=N)N3)c2)nc1;Ki;'=';5.4;nM;8.27;;341202;UO_0000065;18.73;0.36;5.11;7.10;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3954768;;0;477.52;0;1.64;BDBM190728;COc1cnc(C(=O)Nc2ccc(F)c([C@]3(C)CS(=O)(=O)C4(CCOCC4)C(=N)N3)c2)cn1;Ki;'=';16.3;nM;7.79;;341223;UO_0000065;16.31;0.32;6.15;5.43;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3896157;;0;476.53;0;2.24;BDBM190731;COc1ccc(C(=O)Nc2ccc(F)c([C@]3(C)CS(=O)(=O)C4(CCOCC4)C(=N)N3)c2)nc1;Ki;'=';16.4;nM;7.79;;341226;UO_0000065;16.34;0.32;5.55;5.97;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3897828;;0;374.46;0;1.23;BDBM247278;COCC(=S)Nc1ccc(F)c([C@]2(C)CS(=O)(=O)N(C)C(=N)N2)c1;Ki;'=';152.0;nM;6.82;;431481;UO_0000065;18.21;0.39;5.59;7.21;False;CHEMBL3889053;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886930;37;BindingDB Database;;2016;None
CHEMBL3895885;;0;392.45;0;1.37;BDBM247287;COCC(=S)Nc1cc(F)c(F)c([C@]2(C)CS(=O)(=O)N(C)C(=N)N2)c1;Ki;'=';188.0;nM;6.73;;431490;UO_0000065;17.14;0.37;5.36;7.12;False;CHEMBL3889053;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886930;37;BindingDB Database;;2016;None
CHEMBL3889548;;0;436.51;0;2.49;BDBM244047;CNS1(O)C[C@@](C)(c2cc(NC(=O)c3ccc(OC)cn3)ccc2F)NC(=N)N1C;Ki;'=';19.0;nM;7.72;;425632;UO_0000065;17.69;0.35;5.23;6.30;False;CHEMBL3888967;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window Inhibitor.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886899;37;BindingDB Database;;2016;None
CHEMBL3956676;;0;453.97;0;4.11;BDBM242918;CNS1(O)C[C@@](C)(c2cc(NC(=O)c3ccc(Cl)cn3)ccc2F)NC(=N)C1(C)C;Ki;'=';3.0;nM;8.52;;423779;UO_0000065;18.77;0.39;4.41;7.74;False;CHEMBL3888940;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886895;37;BindingDB Database;;2016;None
CHEMBL3902472;;0;468.0;0;4.50;BDBM242928;CCNS1(O)C[C@@](C)(c2cc(NC(=O)c3ccc(Cl)cn3)ccc2F)NC(=N)C1(C)C;Ki;'=';4.0;nM;8.4;;423788;UO_0000065;17.94;0.37;3.90;7.63;False;CHEMBL3888940;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886895;37;BindingDB Database;;2016;None
CHEMBL3947138;;0;504.98;1;3.79;BDBM243013;CN1C(=N)N[C@](C)(c2sc(-c3nnc(-c4ccc(-c5ccon5)cc4)o3)cc2Cl)CS1(=O)=O;Ki;'=';108.5;nM;6.96;;423894;UO_0000065;13.79;0.29;3.17;5.04;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL2299400;;0;768.03;2;2.87;2;CC(C)C[C@H](NCC(=O)[C@@H](CCS(C)(=O)=O)NC(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C(=O)NCc1ccccc1)C(C)C;Ki;'=';7998.34;nM;5.1;;;UO_0000065;6.64;0.13;2.23;2.44;False;CHEMBL3075361;Inhibition of BACE (unknown origin);B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3045025;1;Scientific Literature;Med Chem Res;2013;None
CHEMBL2178199;;0;421.26;0;4.34;8j;Cc1onc(-c2ccc(F)cc2)c1C(=O)/N=C(\N)NCc1cc(Cl)cc(Cl)c1;Ki;'=';2200.0;nM;5.66;;;UO_0000065;13.43;0.28;1.32;6.05;False;CHEMBL2187886;Displacement of [3H]BMS-599240 from BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177026;1;Scientific Literature;J. Med. Chem.;2012;CHEMBL3307715
CHEMBL2178196;;0;421.26;0;4.34;8g;Cc1onc(-c2ccc(F)cc2)c1C(=O)/N=C(\N)NCc1ccc(Cl)c(Cl)c1;Ki;'=';2400.0;nM;5.62;;;UO_0000065;13.34;0.27;1.28;6.01;False;CHEMBL2187886;Displacement of [3H]BMS-599240 from BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177026;1;Scientific Literature;J. Med. Chem.;2012;CHEMBL3307715
CHEMBL3627960;;0;409.27;0;3.69;11a;CC(=O)Nc1c(Cl)cc(CN/C(N)=N/C(=O)OCc2ccccc2)cc1Cl;Ki;'>';30000.0;nM;;;;UO_0000065;;;;;False;CHEMBL3630426;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 6.4 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL3627956;;0;445.31;0;3.38;7a;CC(=O)Nc1c(Cl)cc(CN/C(N)=N/C(=O)c2ccnn2-c2ccccc2)cc1Cl;Ki;'=';12000.0;nM;4.92;;;UO_0000065;11.05;0.22;1.54;4.30;False;CHEMBL3630426;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 6.4 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL2178715;;0;458.55;0;3.02;40;COc1cccc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3cc(-c4cccc(C#N)c4)cs3)C2)n1;Ki;'=';1.0;nM;9.0;;;UO_0000065;19.63;0.37;5.98;8.54;False;CHEMBL2183861;Inhibition of BACE1;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177036;1;Scientific Literature;J. Med. Chem.;2012;None
CHEMBL3703236;;0;368.37;0;2.19;BDBM149753;NC1=NC2(CO1)c1cc(NC(=O)c3ccc(F)cn3)ccc1OCC21CC1;Ki;'=';1030.0;nM;5.99;;288424;UO_0000065;16.25;0.30;3.80;6.06;True;CHEMBL3705666;Fluorescence Resonance Energy Transfer (FRET) Assay: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638878;37;BindingDB Database;;2015;None
CHEMBL4108703;;0;462.5;0;1.85;BDBM236576;COc1ccc(C(=O)Nc2ccc(F)c([C@]34COC[C@H]3S(=O)(=O)C(C)(C)C(=N)N4)c2)nc1;Ki;'=';5.8;nM;8.24;;412092;UO_0000065;17.81;0.35;6.39;6.31;False;CHEMBL3888701;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886796;37;BindingDB Database;;2016;None
CHEMBL4111108;;0;476.51;0;2.37;BDBM236613;C[C@@]1(C2CC2)C(=N)N[C@@]2(c3cc(NC(=O)c4ccc(F)cn4)ccc3F)COC[C@H]2S1(=O)=O;Ki;'=';39.0;nM;7.41;;412129;UO_0000065;15.55;0.31;5.04;6.11;False;CHEMBL3888701;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886796;37;BindingDB Database;;2016;None
CHEMBL4092875;;0;421.93;0;4.55;17;CO[C@H]1CC[C@]2(CC1)Cc1ccc(-c3cc(Cl)cc(C#N)c3)cc1[C@]21COC(N)=N1;Ki;'=';2700.0;nM;5.57;;;UO_0000065;13.2;0.25;1.02;6.91;False;CHEMBL4049274;Inhibition of human BACE1 (1 to 460 residues) fused with Fc domain of IgG1 expressed in HEK293 cells preincubated for 10 mins followed by substrate addition measured after 17 mins by TR-FRET assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4043307;1;Scientific Literature;J Med Chem;2018;CHEMBL3307715
CHEMBL4113002;;0;405.4;0;1.40;BDBM236587;CC1(C)C(=N)N[C@@]2(c3cc(NC(=O)C(F)F)ccc3F)COC[C@H]2S1(=O)=O;Ki;'=';258.0;nM;6.59;;412103;UO_0000065;16.25;0.33;5.19;6.08;False;CHEMBL3888701;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886796;37;BindingDB Database;;2016;None
CHEMBL4108059;;0;500.47;1;2.86;BDBM236600;CC1(C)C(=N)N[C@@]2(c3cc(NC(=O)c4ccc(C(F)(F)F)cn4)ccc3F)COC[C@H]2S1(=O)=O;Ki;'=';3.0;nM;8.52;;412116;UO_0000065;17.03;0.34;5.66;7.03;False;CHEMBL3888701;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886796;37;BindingDB Database;;2016;None
CHEMBL4111329;;0;463.49;0;1.24;BDBM236577;COc1cnc(C(=O)Nc2ccc(F)c([C@]34COC[C@H]3S(=O)(=O)C(C)(C)C(=N)N4)c2)cn1;Ki;'=';6.2;nM;8.21;;412093;UO_0000065;17.71;0.35;6.97;5.73;False;CHEMBL3888701;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886796;37;BindingDB Database;;2016;None
CHEMBL4114508;;0;487.51;0;1.25;BDBM236596;C#CCOc1cnc(C(=O)Nc2ccc(F)c([C@]34COC[C@H]3S(=O)(=O)C(C)(C)C(=N)N4)c2)cn1;Ki;'=';1.0;nM;9.0;;412112;UO_0000065;18.46;0.36;7.75;6.28;False;CHEMBL3888701;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886796;37;BindingDB Database;;2016;None
CHEMBL4114170;;0;453.88;0;1.52;BDBM199101;CN1C(=N)N[C@@]2(c3cc(NC(=O)c4ccc(Cl)cn4)ccc3F)COC[C@H]2S1(=O)=O;Ki;'=';5.07;nM;8.29;;354112;UO_0000065;18.28;0.38;6.77;6.66;False;CHEMBL3887768;Homogeneous Time-Resolved FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 u) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886448;37;BindingDB Database;;2015;None
CHEMBL3948118;;0;461.52;0;2.40;BDBM190713;COc1cnc(C(=O)Nc2ccc(F)c([C@]3(C)CS(=O)(=O)C4(CCCC4)C(=N)N3)c2)cn1;Ki;'=';3.6;nM;8.44;;341208;UO_0000065;18.3;0.36;6.04;6.30;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3973232;;0;438.43;0;2.49;BDBM190700;C[C@@]1(c2cc(NC(=O)c3ncc(F)cc3F)ccc2F)CS(=O)(=O)C2(CC2)C(=N)N1;Ki;'=';5.0;nM;8.3;;341195;UO_0000065;18.93;0.38;5.81;7.41;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3984091;;0;450.47;0;1.72;BDBM190807;C[C@@]1(c2cc(NC(=O)c3ccc(F)cn3)ccc2F)CS(=O)(=O)C2(CC(O)C2)C(=N)N1;Ki;'=';21.8;nM;7.66;;341291;UO_0000065;17.01;0.34;5.94;5.79;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3957560;;0;397.75;0;3.30;BDBM190884;C[C@@]1(c2sc(Br)cc2Cl)CS(=O)(=O)C2(CCC2)C(=N)N1;Ki;'=';1566.0;nM;5.8;;341356;UO_0000065;14.6;0.40;2.51;8.29;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL4108212;;0;484.91;0;2.63;BDBM236584;CC1(C)C(=N)N[C@@]2(c3cc(NC(=O)c4ncc(Cl)cc4F)ccc3F)COC[C@H]2S1(=O)=O;Ki;'=';3.0;nM;8.52;;412100;UO_0000065;17.58;0.36;5.89;7.03;False;CHEMBL3888701;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886796;37;BindingDB Database;;2016;None
CHEMBL4107721;;0;480.49;0;2.15;BDBM236597;CC1(C)C(=N)N[C@@]2(c3cc(NC(=O)c4ccc(OCF)cn4)ccc3F)COC[C@H]2S1(=O)=O;Ki;'=';3.0;nM;8.52;;412113;UO_0000065;17.74;0.35;6.37;6.53;False;CHEMBL3888701;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886796;37;BindingDB Database;;2016;None
CHEMBL3650834;;0;415.49;0;3.24;BDBM149924;CC#Cc1cncc(-c2ccc3c(c2)C2(COC(N)=N2)C2(COC2)C(CC2CC2)O3)c1;Ki;'=';82.5;nM;7.08;;288576;UO_0000065;17.05;0.31;3.84;8.97;True;CHEMBL3705666;Fluorescence Resonance Energy Transfer (FRET) Assay: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638878;37;BindingDB Database;;2015;None
CHEMBL382408;PENTAGALLOYL GLUCOSE;0;940.68;3;1.69;1,2,3,4,6-pentagalloylglucopyranoside;O=C(OC[C@H]1O[C@@H](OC(=O)c2cc(O)c(O)c(O)c2)[C@H](OC(=O)c2cc(O)c(O)c(O)c2)[C@@H](OC(=O)c2cc(O)c(O)c(O)c2)[C@@H]1OC(=O)c1cc(O)c(O)c(O)c1)c1cc(O)c(O)c(O)c1;Ki;'=';5130.0;nM;5.29;;;UO_0000065;5.62;0.11;3.60;1.19;False;CHEMBL3293240;Inhibition of BACE1 (unknown origin);B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3286369;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2014;None
CHEMBL3987008;;0;478.98;0;3.49;BDBM190789;C[C@@]1(c2sc(-c3cncc(-c4ncco4)c3)cc2Cl)CS(=O)(=O)[C@@]2(CCOC2)C(=N)N1;Ki;'=';106.6;nM;6.97;;341281;UO_0000065;14.56;0.31;3.48;5.90;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3955417;;0;494.06;0;4.56;BDBM190795;C[C@@]1(c2sc(-c3ccnc(-c4ccsc4)c3)cc2Cl)CS(=O)(=O)[C@@]2(CCOC2)C(=N)N1;Ki;'=';428.2;nM;6.37;;341287;UO_0000065;12.89;0.28;1.81;6.91;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3650820;;0;430.26;0;2.20;BDBM149908;NC1=NC2(CO1)c1cc(NC(=O)c3ncc(Br)cn3)ccc1OCC21CC1;Ki;'=';623.0;nM;6.21;;361630;UO_0000065;14.42;0.31;4.01;5.55;False;CHEMBL3887894;Fluorescence Resonance Energy Transfer (FRET) Assay: Test Example 1: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence. The amino acid sequence of the 'core' peptide of the substrate is SEVNLDAEFK (SEQ ID NO:2). The amino terminus was derivatized with (7-methoxycoumarin-4-yl)acetyl (MCA), and the epsilon amine of the lysine side chain of the terminal residue (K in sequence SEVNLDAEFK (SEQ ID NO:2)) was derivatized with 2,4-dinitrophenyl (DNP). Assays were performed in a buffer of 0.1 M sodium acetate, pH 4.4, 0.08% 3-[(3-Cholamidopropyl)dimethylammonio]propanesulfonate (CHAPS), 0.005% Tween80. BACE1 enzyme (final concentration 65 nM) was pre-incubated with test compounds for 15 minutes at room temperature. Fluorescence intensities were measured 60 minutes after addition of the substrate (final concentration 3 uM) by Tecan Safire2.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886493;37;BindingDB Database;;2016;None
CHEMBL3965570;;0;533.05;1;4.52;BDBM242340;CCc1cnn(-c2ccc(-c3nccc4c(Cl)c([C@]5(C)CS(=O)(=O)N(C)C(=N)N5)sc34)c(F)c2)c1;Ki;'=';228.6;nM;6.64;;422467;UO_0000065;12.46;0.26;2.12;6.39;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3894337;;0;445.37;0;4.15;BDBM234463;C[C@]1(F)CC(F)(F)[C@@](C)(c2cc(NC(=O)c3cnc(C(F)F)cn3)ccc2F)N=C1N;Ki;'=';58.0;nM;7.24;;408779;UO_0000065;16.25;0.32;3.09;7.76;False;CHEMBL3888549;SPA-Based Assay: The binding assay was performed as SPA-based assay using a biotinylated form of human BACE1 recombinantly expressed and subsequently purified from Freestyle HEK293 cells. The binding assay was run in a 50 mM sodium acetate buffer, pH 4.5 containing 50 mM NaCl and 0.03% Tween-20 in white clear bottom 384 plates (Corning #3653). 10 nM (final concentration) radioligand ([3H]-N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N-((R)-1-phenyl-ethyl)-isophthalamide) (TRQ11569 purchased from GE Healthcare) was mixed with test compound at a given concentration, 6 nM (final concentration) human BACE1 and 25 μg Streptavidin coated PVT core SPA beads (RPNQ0007, GE Healthcare Life Sciences) in a total volume of 40 μl.;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886758;37;BindingDB Database;;2016;CHEMBL3307715
CHEMBL4215348;;0;508.62;2;6.12;8e;Cc1ccn2c(NC3CCCCC3)c(-c3ccc(OCCCN4C(=O)c5ccccc5C4=O)cc3)nc2c1;Ki;'=';4.38;nM;8.36;;;UO_0000065;16.43;0.30;2.24;11.01;False;CHEMBL4192781;Inhibition of human BACE1 (1 to 460 residues) expressed in baculovirus expression system using Rh-EVNLDAEFK-quencher as substrate after 90 mins by FRET assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4190277;1;Scientific Literature;Eur J Med Chem;2017;None
CHEMBL4062699;;0;423.94;0;4.55;19;[2H]C1([2H])OC(N)=N[C@]12c1cc(-c3cc(Cl)cc(C#N)c3)ccc1C[C@]21CC[C@@H](OC)CC1;Ki;'=';18.0;nM;7.75;;;UO_0000065;18.36;0.35;3.19;9.61;False;CHEMBL4049274;Inhibition of human BACE1 (1 to 460 residues) fused with Fc domain of IgG1 expressed in HEK293 cells preincubated for 10 mins followed by substrate addition measured after 17 mins by TR-FRET assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4043307;1;Scientific Literature;J Med Chem;2018;CHEMBL3307715
CHEMBL4074071;;0;365.47;0;3.42;22;[2H]C1([2H])OC(N)=N[C@]12c1cc(-c3cccnc3)ccc1C[C@]21CC[C@@H](OC)CC1;Ki;'=';430.0;nM;6.37;;;UO_0000065;17.52;0.32;2.95;9.13;False;CHEMBL4049274;Inhibition of human BACE1 (1 to 460 residues) fused with Fc domain of IgG1 expressed in HEK293 cells preincubated for 10 mins followed by substrate addition measured after 17 mins by TR-FRET assay;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4043307;1;Scientific Literature;J Med Chem;2018;CHEMBL3307715
CHEMBL4285940;;0;516.61;1;3.14;17;CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3ncc(F)c(N4CCCC4)n3)C[C@H]2C1=O;Ki;'=';3.0;nM;8.52;;;UO_0000065;16.5;0.31;5.38;7.59;False;CHEMBL4270026;Inhibition of recombinant human BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4266039;1;Scientific Literature;J Med Chem;2018;None
CHEMBL4244219;;0;588.68;1;0.15;3i;COc1cccc(CNC[C@@H](O)[C@H](Cc2ccccc2)NC(=O)[C@H](CS(C)(=O)=O)NC(=O)C2=NO[C@@H]3OCC[C@H]23)c1;Ki;'=';41126.0;nM;4.39;;;UO_0000065;7.45;0.15;4.24;2.66;False;CHEMBL4233526;Inhibition of recombinant BACE1 (unknown origin) using fluorogenic substrate;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4229428;1;Scientific Literature;Bioorg Med Chem Lett;2018;None
CHEMBL3974476;;0;464.49;0;2.37;BDBM236611;C[C@@H]1OC[C@]2(c3cc(NC(=O)c4ccc(F)cn4)ccc3F)NC(=N)C(C)(C)S(=O)(=O)[C@H]12;Ki;'=';9.0;nM;8.05;;412127;UO_0000065;17.32;0.34;5.68;6.64;False;CHEMBL3888701;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886796;37;BindingDB Database;;2016;None
CHEMBL3954775;;0;488.0;0;3.21;BDBM242326;CN1C(=N)N[C@](C)(c2sc3c(-c4ccc(-n5ccnn5)cc4)nccc3c2Cl)CS1(=O)=O;Ki;'=';86.07;nM;7.07;;422453;UO_0000065;14.48;0.30;3.86;6.05;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3951647;;0;432.42;0;4.34;BDBM234462;C[C@]1(F)CC(F)(F)[C@@](C)(c2cc(NC(=O)c3nc(CF)cs3)ccc2F)N=C1N;Ki;'=';46.0;nM;7.34;;408778;UO_0000065;16.97;0.35;3.00;9.13;False;CHEMBL3888549;SPA-Based Assay: The binding assay was performed as SPA-based assay using a biotinylated form of human BACE1 recombinantly expressed and subsequently purified from Freestyle HEK293 cells. The binding assay was run in a 50 mM sodium acetate buffer, pH 4.5 containing 50 mM NaCl and 0.03% Tween-20 in white clear bottom 384 plates (Corning #3653). 10 nM (final concentration) radioligand ([3H]-N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N-((R)-1-phenyl-ethyl)-isophthalamide) (TRQ11569 purchased from GE Healthcare) was mixed with test compound at a given concentration, 6 nM (final concentration) human BACE1 and 25 μg Streptavidin coated PVT core SPA beads (RPNQ0007, GE Healthcare Life Sciences) in a total volume of 40 μl.;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886758;37;BindingDB Database;;2016;CHEMBL3307715
CHEMBL3919305;;0;452.94;0;3.21;BDBM244053;CCN1C(=N)N[C@](C)(c2cc(NC(=O)c3ccc(Cl)cn3)ccc2F)CS1(=O)=NC;Ki;'=';10.0;nM;8.0;;425638;UO_0000065;17.66;0.36;4.79;7.24;False;CHEMBL3888967;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window Inhibitor.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886899;37;BindingDB Database;;2016;None
CHEMBL4130055;;0;483.47;0;2.62;3;CN1C(=N)N[C@@]2(c3cc(NC(=O)c4ccc(OC(F)F)cn4)ccc3F)CCC[C@H]2S1(=O)=O;Ki;'=';4.0;nM;8.4;;;UO_0000065;17.37;0.35;5.78;6.75;False;CHEMBL4119788;Binding affinity to human BACE1 catalytic domain using QSY7-APPswe-Eu as substrate preincubated for 30 mins followed by substrate addition measured after 1.5 hrs by HTRF assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4118088;1;Scientific Literature;ACS Med Chem Lett;2017;None
CHEMBL3895721;;0;496.57;0;2.12;BDBM249099;CN1CC2(C1)C(=N)N[C@](C)(c1cc(NC(=O)c3ncc(C#N)cc3C3CC3)ccc1F)CS2(=O)=O;Ki;'=';1.3;nM;8.89;;434637;UO_0000065;17.89;0.35;6.77;6.39;False;CHEMBL3889105;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 ul of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 ul in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window. Inhibitor IC50 values are derived from non-linear regression analysis of concentration response curves. Ki values are then calculated from IC50 values using the Cheng-Prusoff equation using a previously determined um value of 8 uM for the QSY7-APPswe-Eu substrate at BACE1.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886943;37;BindingDB Database;;2016;None
CHEMBL3911062;;0;490.56;0;1.55;BDBM249104;COc1cnc(C(=O)Nc2ccc(F)c([C@]3(C)CS(=O)(=O)C4(CCN(C)CC4)C(=N)N3)c2)cn1;Ki;'=';19.0;nM;7.72;;434642;UO_0000065;15.74;0.31;6.17;5.62;False;CHEMBL3889105;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 ul of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 ul in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window. Inhibitor IC50 values are derived from non-linear regression analysis of concentration response curves. Ki values are then calculated from IC50 values using the Cheng-Prusoff equation using a previously determined um value of 8 uM for the QSY7-APPswe-Eu substrate at BACE1.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886943;37;BindingDB Database;;2016;None
CHEMBL3934446;;0;503.6;1;2.46;BDBM249109;COc1cnc(C(=O)Nc2ccc(F)c([C@]3(C)CS(=O)(=O)C4(CCN(C)CC4)C(=N)N3)c2)c(C)c1;Ki;'=';37.0;nM;7.43;;434647;UO_0000065;14.76;0.29;4.97;5.97;False;CHEMBL3889105;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 ul of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 ul in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window. Inhibitor IC50 values are derived from non-linear regression analysis of concentration response curves. Ki values are then calculated from IC50 values using the Cheng-Prusoff equation using a previously determined um value of 8 uM for the QSY7-APPswe-Eu substrate at BACE1.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886943;37;BindingDB Database;;2016;None
CHEMBL3891454;;0;447.49;0;1.03;BDBM249116;COc1ccc(C(=O)Nc2ccc(F)c([C@]3(C)CS(=O)(=O)C4(CNC4)C(=N)N3)c2)nc1;Ki;'=';22.0;nM;7.66;;434654;UO_0000065;17.11;0.34;6.63;5.75;False;CHEMBL3889105;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 ul of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 ul in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window. Inhibitor IC50 values are derived from non-linear regression analysis of concentration response curves. Ki values are then calculated from IC50 values using the Cheng-Prusoff equation using a previously determined um value of 8 uM for the QSY7-APPswe-Eu substrate at BACE1.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886943;37;BindingDB Database;;2016;None
CHEMBL3694260;;0;663.84;1;2.73;BDBM120272;CC(C)CN1CCN[C@@H]([C@@H](O)[C@H](Cc2ccccc2)NC(=O)c2cc(C(=O)N[C@H](C)c3ccccc3)cc(N(C)S(C)(=O)=O)c2)C1=O;Ki;'<';1000.0;nM;;;248248;UO_0000065;;;;;False;CHEMBL3706207;Inhibition Assay: The potencies of compounds were determined by measurement of their inhibition of memapsin 2 catalytic activity toward a fluorescent substrate. Kinetic inhibition experiments were performed using the procedure as described in Ermolieff, et al. Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety. Briefly, assays were performed at pH 4, 37° C., by pre-incubation of memapsin 2 enzyme with compound for 20 minutes. Activity measure was initiated by addition of a fluorogenic substrate FS-2 (Bachem Americas, Torrance, Calif.).;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3639069;37;BindingDB Database;;2014;None
CHEMBL3915082;;0;436.95;0;3.74;BDBM242949;CN1C(=N)N[C@](C)(c2sc(-c3cc(-c4ccccc4)on3)cc2Cl)CS1(=O)=O;Ki;'=';1171.0;nM;5.93;;423830;UO_0000065;13.57;0.29;2.19;5.97;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3953881;;0;441.93;0;1.87;BDBM242984;CN1C(=N)N[C@](C)(c2sc(-c3nnc(-c4ccnn4C)o3)cc2Cl)CS1(=O)=O;Ki;'=';1525.0;nM;5.82;;423865;UO_0000065;13.16;0.28;3.95;4.47;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3978016;;0;505.97;2;2.11;BDBM243007;CN1C(=N)N[C@](C)(c2sc(-c3nnc(-c4ccc(-n5cnnn5)cc4)o3)cc2Cl)CS1(=O)=O;Ki;'=';179.5;nM;6.75;;423888;UO_0000065;13.33;0.28;4.64;4.33;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3627976;;0;554.48;1;4.75;7j;CC(=O)Nc1c(Cl)cc(CN/C(N)=N/C(=O)[C@@H]2C[C@H](OCc3ccccc3)CN2c2ccccc2)cc1Cl;Ki;'=';1800.0;nM;5.75;;;UO_0000065;10.36;0.21;0.99;5.27;False;CHEMBL3630425;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 5 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL3703255;;0;361.4;0;2.07;BDBM149773;CC#Cc1cncc(-c2ccc3c(c2)C2(COC(N)=N2)C2(COC2)CO3)c1;Ki;'=';354.0;nM;6.45;;288490;UO_0000065;17.85;0.33;4.38;8.17;True;CHEMBL3705666;Fluorescence Resonance Energy Transfer (FRET) Assay: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638878;37;BindingDB Database;;2015;None
CHEMBL3703302;;0;401.47;0;2.99;BDBM149828;CC#Cc1cncc(-c2ccc3c(c2)C2(COC(N)=N2)C2(COC2)C2(CCC2)O3)c1;Ki;'=';120.0;nM;6.92;;288491;UO_0000065;17.24;0.32;3.93;8.76;True;CHEMBL3705666;Fluorescence Resonance Energy Transfer (FRET) Assay: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638878;37;BindingDB Database;;2015;None
CHEMBL3703254;;0;345.4;0;2.83;BDBM149772;CC#Cc1cncc(-c2ccc3c(c2)C2(COC(N)=N2)C2(CC2)CO3)c1;Ki;'=';252.0;nM;6.6;;288493;UO_0000065;19.1;0.35;3.77;9.46;True;CHEMBL3705666;Fluorescence Resonance Energy Transfer (FRET) Assay: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638878;37;BindingDB Database;;2015;None
CHEMBL3650827;;0;375.39;0;1.92;BDBM149915;N#Cc1ccc(C(=O)Nc2ccc3c(c2)C2(COC(N)=N2)C2(CC2)CO3)nc1;Ki;'=';342.0;nM;6.47;;288567;UO_0000065;17.22;0.32;4.55;5.27;True;CHEMBL3705666;Fluorescence Resonance Energy Transfer (FRET) Assay: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638878;37;BindingDB Database;;2015;None
CHEMBL3650831;;0;414.47;0;2.70;BDBM149919;NC1=NC2(CO1)c1cc(-c3cncnc3)ccc1OC(Cc1ccccc1)C21COC1;Ki;'=';92.1;nM;7.04;;288571;UO_0000065;16.98;0.31;4.34;7.66;True;CHEMBL3705666;Fluorescence Resonance Energy Transfer (FRET) Assay: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638878;37;BindingDB Database;;2015;None
CHEMBL3627970;;0;478.38;0;3.56;12f;COc1cccc(N2CCC[C@H]2C(=O)/N=C(\N)NCc2cc(Cl)c(NC(C)=O)c(Cl)c2)c1;Ki;'=';260.0;nM;6.58;;;UO_0000065;13.77;0.28;3.03;6.04;False;CHEMBL3630425;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 5 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL3627968;;0;516.35;1;4.57;12d;CC(=O)Nc1c(Cl)cc(CN/C(N)=N/C(=O)[C@@H]2CCCN2c2ccc(C(F)(F)F)cc2)cc1Cl;Ki;'=';600.0;nM;6.22;;;UO_0000065;12.05;0.25;1.65;6.23;False;CHEMBL3630426;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 6.4 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL3903858;;0;405.4;0;1.40;BDBM190850;C[C@@]1(c2cc(NC(=O)C(F)F)ccc2F)CS(=O)(=O)[C@]2(CCOC2)C(=N)N1;Ki;'=';639.0;nM;6.19;;341332;UO_0000065;15.28;0.31;4.79;5.72;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3627958;;0;448.35;0;3.55;7c;CC(=O)Nc1c(Cl)cc(CN/C(N)=N/C(=O)[C@@H]2CCCN2c2ccccc2)cc1Cl;Ki;'=';210.0;nM;6.68;;;UO_0000065;14.89;0.30;3.13;6.69;False;CHEMBL3630425;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 5 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL3929093;;0;462.37;0;4.83;BDBM234458;C[C@]1(F)CC(F)(F)[C@@](C)(c2cc(NC(=O)c3ccc(C(F)(F)F)cn3)ccc2F)N=C1N;Ki;'=';63.0;nM;7.2;;408774;UO_0000065;15.57;0.31;2.37;8.96;False;CHEMBL3888549;SPA-Based Assay: The binding assay was performed as SPA-based assay using a biotinylated form of human BACE1 recombinantly expressed and subsequently purified from Freestyle HEK293 cells. The binding assay was run in a 50 mM sodium acetate buffer, pH 4.5 containing 50 mM NaCl and 0.03% Tween-20 in white clear bottom 384 plates (Corning #3653). 10 nM (final concentration) radioligand ([3H]-N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N-((R)-1-phenyl-ethyl)-isophthalamide) (TRQ11569 purchased from GE Healthcare) was mixed with test compound at a given concentration, 6 nM (final concentration) human BACE1 and 25 μg Streptavidin coated PVT core SPA beads (RPNQ0007, GE Healthcare Life Sciences) in a total volume of 40 μl.;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886758;37;BindingDB Database;;2016;CHEMBL3307715
CHEMBL3640259;;0;384.42;0;1.05;BDBM102941;COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3ccccc3)C2)nc(C)c1F;Ki;'=';12.0;nM;7.92;;220574;UO_0000065;20.6;0.39;6.87;8.17;False;CHEMBL3705045;Time-Resolved FRET Assay: A homogeneous time-resolved FRET assay was used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. The assay monitored the increase of 620nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide).;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638861;37;BindingDB Database;;2013;None
CHEMBL3640278;;0;434.42;0;1.58;BDBM102961;CCc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3ccc(F)cc3F)C2)nc(OC)c1F;Ki;'=';5.3;nM;8.28;;220595;UO_0000065;19.05;0.36;6.70;8.54;False;CHEMBL3705045;Time-Resolved FRET Assay: A homogeneous time-resolved FRET assay was used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. The assay monitored the increase of 620nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide).;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638861;37;BindingDB Database;;2013;None
CHEMBL1923702;;0;466.54;0;4.26;8;C[C@H](NC(=O)c1cc(-c2nc3cc(F)ccc3[nH]2)cc(N(C)S(C)(=O)=O)c1)c1ccccc1;Ki;'=';758.0;nM;6.12;;;UO_0000065;13.12;0.25;1.86;6.43;False;CHEMBL1926456;Inhibition of BACE1 expressing APP Swedish mutant using rhodamine-labeled EVNLDAEFK-quencher as substrate after 60 mins by Michaelis-Menten equation;B;BAO_0000357;single protein format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL1921672;1;Scientific Literature;J. Med. Chem.;2011;None
CHEMBL3703282;;0;381.43;0;2.48;BDBM149802;COc1cncc(-c2ccc3c(c2)C2(COC(N)=N2)C2(COC2)C(C)(C)O3)c1;Ki;'=';255.0;nM;6.59;;361536;UO_0000065;17.29;0.32;4.11;7.48;False;CHEMBL3887894;Fluorescence Resonance Energy Transfer (FRET) Assay: Test Example 1: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence. The amino acid sequence of the 'core' peptide of the substrate is SEVNLDAEFK (SEQ ID NO:2). The amino terminus was derivatized with (7-methoxycoumarin-4-yl)acetyl (MCA), and the epsilon amine of the lysine side chain of the terminal residue (K in sequence SEVNLDAEFK (SEQ ID NO:2)) was derivatized with 2,4-dinitrophenyl (DNP). Assays were performed in a buffer of 0.1 M sodium acetate, pH 4.4, 0.08% 3-[(3-Cholamidopropyl)dimethylammonio]propanesulfonate (CHAPS), 0.005% Tween80. BACE1 enzyme (final concentration 65 nM) was pre-incubated with test compounds for 15 minutes at room temperature. Fluorescence intensities were measured 60 minutes after addition of the substrate (final concentration 3 uM) by Tecan Safire2.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886493;37;BindingDB Database;;2016;None
CHEMBL3966088;;0;494.06;0;4.56;BDBM190777;C[C@@]1(c2sc(-c3ccnc(-c4cccs4)c3)cc2Cl)CS(=O)(=O)[C@]2(CCOC2)C(=N)N1;Ki;'=';305.3;nM;6.51;;341274;UO_0000065;13.19;0.29;1.96;7.07;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3906972;;0;520.08;2;5.62;BDBM190831;Cc1cc2cccc(NC(=O)c3cc(Cl)c([C@]4(C)CS(=O)(=O)C5(CCCCC5)C(=N)N4)s3)c2o1;Ki;'=';6048.0;nM;5.22;;341313;UO_0000065;10.03;0.21;-0.40;4.65;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3982379;;0;470.02;0;3.30;BDBM190832;Cn1ccc(NC(=O)c2cc(Cl)c([C@]3(C)CS(=O)(=O)C4(CCCCC4)C(=N)N3)s2)n1;Ki;'=';2009.0;nM;5.7;;341314;UO_0000065;12.12;0.26;2.40;4.87;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3984388;;0;423.35;0;3.59;BDBM230871;N#Cc1ccc(C(=O)Nc2ccc(F)c([C@@]3(C(F)F)N=C(N)CCC3(F)F)c2)nc1;Ki;'=';7.4;nM;8.13;;402954;UO_0000065;19.21;0.37;4.54;7.81;False;CHEMBL3888456;BACE1 Binding Assay: The binding assay was performed as SPA-based assay using a biotinylated form of human BACE1 recombinantly expressed and subsequently purified from Freestyle HEK293 cells. The binding assay was run in a 50 mM sodium acetate buffer, pH 4.5 containing 50 mM NaCl and 0.03% Tween-20 in white clear bottom 384 plates (Corning #3653). 10 nM (final concentration) radioligand ([3H]−N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N−((R)-1-phenyl-ethyl)-isophthalamide) (TRQ11569 purchased from GE Healthcare) was mixed with test compound at a given concentration, 6 nM (final concentration) human BACE1 and 25 μg Streptavidin coated PVT core SPA beads (RPNQ0007, GE Healthcare Life Sciences) in a total volume of 40 μl. Several concentrations of each test compound were tested in the assay for IC50 determination. The plates were incubated for one hour at room temperature and counted in a Wallac Trilux counter. Total and non-specific binding were determined using buffer and 1 μM (final concentration) of the high affinity BACE1 reference inhibitor (S)-6-[3-chloro-5-(5-prop-1-ynyl-pyridin-3-yl)-thiophen-2-yl]-2-imino-3,6-dimethyl-tetrahydro-pyrimidin-4-one, respectively.;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886720;37;BindingDB Database;;2016;CHEMBL3307715
CHEMBL3891425;;0;436.95;0;3.74;BDBM242228;CN1C(=N)N[C@](C)(c2sc(-c3cccc(-c4ncco4)c3)cc2Cl)CS1(=O)=O;Ki;'=';4.7;nM;8.33;;422355;UO_0000065;19.06;0.41;4.59;8.39;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3918042;;0;439.47;0;2.76;BDBM242258;CN1C(=N)N[C@](C)(c2sc(-c3cccc(-c4nnco4)c3F)cc2F)CS1(=O)=O;Ki;'=';1149.0;nM;5.94;;422385;UO_0000065;13.52;0.28;3.18;5.29;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3908395;;0;431.52;0;3.03;BDBM242296;CN1C(=N)N[C@](C)(c2sc(-c3ccnc(-c4cccnc4)c3)cc2F)CS1(=O)=O;Ki;'=';199.0;nM;6.7;;422423;UO_0000065;15.53;0.32;3.67;6.77;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3627975;;0;540.45;1;4.61;7i;CC(=O)Nc1c(Cl)cc(CN/C(N)=N/C(=O)[C@@H]2C[C@H](Oc3ccccc3)CN2c2ccccc2)cc1Cl;Ki;'=';1900.0;nM;5.72;;;UO_0000065;10.59;0.21;1.11;5.25;False;CHEMBL3630425;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 5 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL3627973;;0;478.38;0;3.18;7g;CO[C@@H]1C[C@@H](C(=O)/N=C(\N)NCc2cc(Cl)c(NC(C)=O)c(Cl)c2)N(c2ccccc2)C1;Ki;'=';78.0;nM;7.11;;;UO_0000065;14.86;0.30;3.93;6.52;False;CHEMBL3630425;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 5 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL3627972;;0;464.35;0;2.52;7f;CC(=O)Nc1c(Cl)cc(CN/C(N)=N/C(=O)[C@@H]2C[C@@H](O)CN2c2ccccc2)cc1Cl;Ki;'=';610.0;nM;6.21;;;UO_0000065;13.38;0.27;3.69;5.18;False;CHEMBL3630425;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 5 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL3627967;;0;466.34;0;3.69;12c;CC(=O)Nc1c(Cl)cc(CN/C(N)=N/C(=O)[C@@H]2CCCN2c2ccc(F)cc2)cc1Cl;Ki;'=';450.0;nM;6.35;;;UO_0000065;13.61;0.28;2.66;6.36;False;CHEMBL3630425;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 5 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL3627961;;0;422.32;0;3.83;11b;CC(=O)Nc1c(Cl)cc(CN/C(N)=N/C(=O)N[C@@H](C)c2ccccc2)cc1Cl;Ki;'=';990.0;nM;6.0;;;UO_0000065;14.22;0.29;2.17;5.53;False;CHEMBL3630425;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 5 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL2151137;;0;356.43;0;3.38;9;CN1C(=N)N[C@](c2ccccc2)(c2cccc(-c3cccnc3)c2)CC1=O;Ki;'=';44000.0;nM;4.36;;;UO_0000065;12.22;0.22;0.98;6.31;False;CHEMBL2155063;Inhibition of human recombinant BACE1 by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2150878;1;Scientific Literature;ACS Med. Chem. Lett.;2012;None
CHEMBL3354242;;0;404.6;0;3.90;33;CCCCC(=O)N1CCC[C@@H](C[C@@]2(CCC3CCCCC3)NC(=N)N(C)C2=O)C1;Ki;'=';17000.0;nM;4.77;;;UO_0000065;11.79;0.22;0.87;6.23;False;CHEMBL3386389;Inhibition of purified human BACE1 by FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3352601;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2014;None
CHEMBL3982750;;0;439.91;0;1.92;BDBM242973;CN1C(=N)N[C@](C)(c2sc(-c3nnc(-c4ncccn4)o3)cc2Cl)CS1(=O)=O;Ki;'=';778.2;nM;6.11;;423854;UO_0000065;13.89;0.30;4.19;4.43;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3984093;;0;547.08;1;4.91;BDBM242339;CCCc1cnn(-c2ccc(-c3nccc4c(Cl)c([C@]5(C)CS(=O)(=O)N(C)C(=N)N5)sc34)c(F)c2)c1;Ki;'=';259.1;nM;6.59;;422466;UO_0000065;12.04;0.25;1.68;6.34;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3933652;;0;498.02;0;4.13;BDBM242937;COCCNS1(O)C[C@@](C)(c2cc(NC(=O)c3ccc(Cl)cn3)ccc2F)NC(=N)C1(C)C;Ki;'=';4.0;nM;8.4;;423798;UO_0000065;16.86;0.35;4.27;7.04;False;CHEMBL3888940;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886895;37;BindingDB Database;;2016;None
CHEMBL2178165;;0;541.08;1;3.98;22h;COc1ccc(-c2nsc(C)c2C(=O)/N=C(\N)NCc2cc(C)c(NC(=O)CN3CCC3)c(Cl)c2)cc1;Ki;'=';5.0;nM;8.3;;;UO_0000065;15.34;0.31;4.32;6.81;False;CHEMBL2187886;Displacement of [3H]BMS-599240 from BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177026;1;Scientific Literature;J. Med. Chem.;2012;CHEMBL3307715
CHEMBL2178161;;0;591.14;2;5.06;22d;COc1ccc(-c2nsc(C)c2C(=O)/N=C(\N)NCc2cc(C)c(NC(=O)CNCc3ccccc3)c(Cl)c2)cc1;Ki;'=';10.0;nM;8.0;;;UO_0000065;13.53;0.27;2.94;6.12;False;CHEMBL2187886;Displacement of [3H]BMS-599240 from BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177026;1;Scientific Literature;J. Med. Chem.;2012;CHEMBL3307715
CHEMBL3904722;;0;440.94;0;2.77;BDBM242946;Cc1nnc(-c2ccc(-c3cc(Cl)c([C@]4(C)CS(=O)(=O)N(C)C(=N)N4)s3)[nH]2)o1;Ki;'=';8.1;nM;8.09;;423827;UO_0000065;18.35;0.39;5.32;6.32;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3975679;;0;455.92;0;3.27;BDBM242959;CN1C(=N)N[C@](C)(c2sc(-c3nnc(-c4ccc(F)cc4)o3)cc2Cl)CS1(=O)=O;Ki;'=';65.54;nM;7.18;;423840;UO_0000065;15.76;0.34;3.91;6.40;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3984724;;0;415.45;0;2.56;BDBM242961;CN1C(=N)N[C@](C)(c2cc(-c3nnc(-c4ccccc4)o3)ccc2F)CS1(=O)=O;Ki;'=';9868.0;nM;5.01;;423842;UO_0000065;12.05;0.24;2.45;4.46;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL2178200;;0;433.3;0;4.21;8k;COc1ccc(-c2noc(C)c2C(=O)/N=C(\N)NCc2cc(Cl)cc(Cl)c2)cc1;Ki;'=';670.0;nM;6.17;;;UO_0000065;14.25;0.29;1.96;6.01;False;CHEMBL2187886;Displacement of [3H]BMS-599240 from BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177026;1;Scientific Literature;J. Med. Chem.;2012;CHEMBL3307715
CHEMBL2179139;;0;623.82;1;2.97;21;CCc1cn2c3c(cc(C(=O)N[C@H](CN[C@H](C(=O)NCC(C)C)[C@H](C)O)Cc4ccccc4)cc13)N(C)S(=O)(=O)C1(CC1)C2;Ki;'=';7.2;nM;8.14;;;UO_0000065;13.05;0.25;5.17;6.13;False;CHEMBL2185581;Inhibition of recombinant BACE1 expressed in Escherichia coli using Arg- Glu(EDANS)-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys(Dabcyl)-Arg as substrate by fluorimetric analysis;B;BAO_0000019;assay format;None;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL2177024;1;Scientific Literature;J. Med. Chem.;2012;None
CHEMBL3989948;LANABECESTAT;3;412.54;0;4.24;AZD3839;CC#Cc1cncc(-c2ccc3c(c2)[C@@]2(N=C(C)C(N)=N2)[C@]2(CC[C@H](OC)CC2)C3)c1;Ki;'=';26.0;nM;7.58;;;UO_0000065;18.39;0.33;3.35;10.41;False;CHEMBL4049296;Inhibition of recombinant human BACE1 (1 to 460 residues) using CEVNLDAEFK as substrate preincubated for 10 mins followed by substrate addition measured after 6.5 hrs by TR-FRET assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4043307;1;Scientific Literature;J Med Chem;2018;None
CHEMBL3703237;;0;384.82;0;2.70;BDBM149754;NC1=NC2(CO1)c1cc(NC(=O)c3ccc(Cl)cn3)ccc1OCC21CC1;Ki;'=';378.0;nM;6.42;;361495;UO_0000065;16.69;0.32;3.72;6.50;False;CHEMBL3887894;Fluorescence Resonance Energy Transfer (FRET) Assay: Test Example 1: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence. The amino acid sequence of the 'core' peptide of the substrate is SEVNLDAEFK (SEQ ID NO:2). The amino terminus was derivatized with (7-methoxycoumarin-4-yl)acetyl (MCA), and the epsilon amine of the lysine side chain of the terminal residue (K in sequence SEVNLDAEFK (SEQ ID NO:2)) was derivatized with 2,4-dinitrophenyl (DNP). Assays were performed in a buffer of 0.1 M sodium acetate, pH 4.4, 0.08% 3-[(3-Cholamidopropyl)dimethylammonio]propanesulfonate (CHAPS), 0.005% Tween80. BACE1 enzyme (final concentration 65 nM) was pre-incubated with test compounds for 15 minutes at room temperature. Fluorescence intensities were measured 60 minutes after addition of the substrate (final concentration 3 uM) by Tecan Safire2.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886493;37;BindingDB Database;;2016;None
CHEMBL3640267;;0;428.44;0;1.76;BDBM102950;COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3ccc(F)cc3)C2)nc(C2CC2)c1F;Ki;'=';4.8;nM;8.32;;220614;UO_0000065;19.42;0.37;6.56;8.58;False;CHEMBL3705045;Time-Resolved FRET Assay: A homogeneous time-resolved FRET assay was used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. The assay monitored the increase of 620nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide).;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638861;37;BindingDB Database;;2013;None
CHEMBL3898071;;0;489.53;0;1.29;BDBM249118;COc1ccc(C(=O)Nc2ccc(F)c([C@]3(C)CS(=O)(=O)C4(CN(C(C)=O)C4)C(=N)N3)c2)nc1;Ki;'=';1.6;nM;8.8;;434656;UO_0000065;17.97;0.35;7.51;6.21;False;CHEMBL3889105;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 ul of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 ul in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window. Inhibitor IC50 values are derived from non-linear regression analysis of concentration response curves. Ki values are then calculated from IC50 values using the Cheng-Prusoff equation using a previously determined um value of 8 uM for the QSY7-APPswe-Eu substrate at BACE1.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886943;37;BindingDB Database;;2016;None
CHEMBL3627963;;0;434.33;0;3.75;11d;CC(=O)Nc1c(Cl)cc(CN/C(N)=N/C(=O)N[C@H]2CCc3ccccc32)cc1Cl;Ki;'=';10000.0;nM;5.0;;;UO_0000065;11.51;0.24;1.25;4.60;False;CHEMBL3630425;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 5 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL3627960;;0;409.27;0;3.69;11a;CC(=O)Nc1c(Cl)cc(CN/C(N)=N/C(=O)OCc2ccccc2)cc1Cl;Ki;'=';7000.0;nM;5.16;;;UO_0000065;12.6;0.26;1.46;4.87;False;CHEMBL3630425;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 5 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL3627957;;0;444.32;0;3.99;7b;CC(=O)Nc1c(Cl)cc(CN/C(N)=N/C(=O)c2cccn2-c2ccccc2)cc1Cl;Ki;'=';710.0;nM;6.15;;;UO_0000065;13.84;0.28;2.16;6.06;False;CHEMBL3630425;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 5 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL3650845;;0;428.88;0;2.72;BDBM149944;CC1(C)Oc2ccc(NC(=O)c3ccc(Cl)cn3)cc2[C@@]2(COC(N)=N2)C12COC2;Ki;'=';30200.0;nM;4.52;;288593;UO_0000065;10.54;0.21;1.80;4.18;False;CHEMBL3705666;Fluorescence Resonance Energy Transfer (FRET) Assay: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638878;37;BindingDB Database;;2015;None
CHEMBL3650831;;0;414.47;0;2.70;BDBM149919;NC1=NC2(CO1)c1cc(-c3cncnc3)ccc1OC(Cc1ccccc1)C21COC1;Ki;'=';113.0;nM;6.95;;361643;UO_0000065;16.76;0.31;4.25;7.56;False;CHEMBL3887894;Fluorescence Resonance Energy Transfer (FRET) Assay: Test Example 1: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence. The amino acid sequence of the 'core' peptide of the substrate is SEVNLDAEFK (SEQ ID NO:2). The amino terminus was derivatized with (7-methoxycoumarin-4-yl)acetyl (MCA), and the epsilon amine of the lysine side chain of the terminal residue (K in sequence SEVNLDAEFK (SEQ ID NO:2)) was derivatized with 2,4-dinitrophenyl (DNP). Assays were performed in a buffer of 0.1 M sodium acetate, pH 4.4, 0.08% 3-[(3-Cholamidopropyl)dimethylammonio]propanesulfonate (CHAPS), 0.005% Tween80. BACE1 enzyme (final concentration 65 nM) was pre-incubated with test compounds for 15 minutes at room temperature. Fluorescence intensities were measured 60 minutes after addition of the substrate (final concentration 3 uM) by Tecan Safire2.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886493;37;BindingDB Database;;2016;None
CHEMBL3916859;;0;473.91;0;3.41;BDBM242996;CN1C(=N)N[C@](C)(c2sc(-c3nnc(-c4ccc(F)c(F)c4)o3)cc2Cl)CS1(=O)=O;Ki;'=';117.7;nM;6.93;;423877;UO_0000065;14.62;0.32;3.52;6.18;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3911835;;0;478.0;0;3.35;BDBM242975;CN1C(=N)N[C@](C)(c2sc(-c3nnc(C4Cc5ccccc5C4)o3)cc2Cl)CS1(=O)=O;Ki;'=';254.6;nM;6.59;;423856;UO_0000065;13.8;0.29;3.24;5.88;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3890281;;0;477.96;0;2.78;BDBM242971;CN1C(=N)N[C@](C)(c2sc(-c3nnc(-c4cccc5ccnn45)o3)cc2Cl)CS1(=O)=O;Ki;'=';561.4;nM;6.25;;423852;UO_0000065;13.08;0.28;3.47;4.83;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL4065655;;0;657.84;1;3.46;5g;CCc1cn2c3c(cc(C(=O)N[C@@H](Cc4ccccc4)[C@H](O)[C@@H]4NCCN(Cc5ccccc5)C4=O)cc13)N(C)S(=O)(=O)C(C)(C)C2;Ki;'=';67.1;nM;7.17;;;UO_0000065;10.9;0.21;3.71;5.79;False;CHEMBL4018279;Inhibition of recombinant human BACE1 (Ala8P to Ala326 residues) expressed in Escherichia coli BL21(DE3) using Arg-Glu(EDANS)-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys (Dabcyl)-Arg as substrate by fluorescence assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4017478;1;Scientific Literature;Bioorg Med Chem Lett;2017;None
CHEMBL4078781;;0;647.8;1;2.24;6h;C[C@@H](NC(=O)c1cc(C(=O)N[C@@H](Cc2ccccc2)[C@H](O)[C@@H]2NC[C@H]3CCCN3C2=O)cc(N(C)S(C)(=O)=O)c1)c1ccccc1;Ki;'=';26.0;nM;7.58;;;UO_0000065;11.71;0.23;5.35;5.12;False;CHEMBL4018279;Inhibition of recombinant human BACE1 (Ala8P to Ala326 residues) expressed in Escherichia coli BL21(DE3) using Arg-Glu(EDANS)-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys (Dabcyl)-Arg as substrate by fluorescence assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4017478;1;Scientific Literature;Bioorg Med Chem Lett;2017;None
CHEMBL3703255;;0;361.4;0;2.07;BDBM149773;CC#Cc1cncc(-c2ccc3c(c2)C2(COC(N)=N2)C2(COC2)CO3)c1;Ki;'=';354.0;nM;6.45;;361560;UO_0000065;17.85;0.33;4.38;8.17;False;CHEMBL3887894;Fluorescence Resonance Energy Transfer (FRET) Assay: Test Example 1: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence. The amino acid sequence of the 'core' peptide of the substrate is SEVNLDAEFK (SEQ ID NO:2). The amino terminus was derivatized with (7-methoxycoumarin-4-yl)acetyl (MCA), and the epsilon amine of the lysine side chain of the terminal residue (K in sequence SEVNLDAEFK (SEQ ID NO:2)) was derivatized with 2,4-dinitrophenyl (DNP). Assays were performed in a buffer of 0.1 M sodium acetate, pH 4.4, 0.08% 3-[(3-Cholamidopropyl)dimethylammonio]propanesulfonate (CHAPS), 0.005% Tween80. BACE1 enzyme (final concentration 65 nM) was pre-incubated with test compounds for 15 minutes at room temperature. Fluorescence intensities were measured 60 minutes after addition of the substrate (final concentration 3 uM) by Tecan Safire2.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886493;37;BindingDB Database;;2016;None
CHEMBL3914820;;0;420.5;0;2.15;BDBM242299;CN1C(=N)N[C@](C)(c2sc(-c3ccnc(-n4cccn4)c3)cc2F)CS1(=O)=O;Ki;'=';162.0;nM;6.79;;422426;UO_0000065;16.15;0.33;4.64;6.53;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL4126480;;0;432.48;0;1.72;6;Cc1cnc(C(=O)Nc2ccc(F)c([C@]34CCC[C@H]3S(=O)(=O)N(C)C(=N)N4)c2)cn1;Ki;'=';126.0;nM;6.9;;;UO_0000065;15.95;0.31;5.18;5.38;False;CHEMBL4119788;Binding affinity to human BACE1 catalytic domain using QSY7-APPswe-Eu as substrate preincubated for 30 mins followed by substrate addition measured after 1.5 hrs by HTRF assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4118088;1;Scientific Literature;ACS Med Chem Lett;2017;None
CHEMBL3948098;;0;452.46;0;2.88;BDBM190705;C[C@@]1(c2cc(NC(=O)c3ncc(F)cc3F)ccc2F)CS(=O)(=O)C2(CCC2)C(=N)N1;Ki;'=';12.6;nM;7.9;;341200;UO_0000065;17.46;0.35;5.02;7.05;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3938241;;0;464.95;0;3.65;BDBM190708;C[C@@]1(c2cc(NC(=O)c3ccc(Cl)cn3)ccc2F)CS(=O)(=O)C2(CCCC2)C(=N)N1;Ki;'=';1.3;nM;8.89;;341203;UO_0000065;19.11;0.39;5.24;7.93;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3969910;;0;406.92;0;3.76;BDBM190797;[C-]#[N+]c1cncc(-c2cc(Cl)c([C@]3(C)CS(=O)(=O)C4(CC4)C(=N)N3)s2)c1;Ki;'=';108.0;nM;6.97;;341289;UO_0000065;17.12;0.37;3.21;7.98;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3891094;;0;450.47;0;1.72;BDBM190808;C[C@@]1(c2cc(NC(=O)c3ccc(F)cn3)ccc2F)CS(=O)(=O)[C@]2(C[C@H](O)C2)C(=N)N1;Ki;'=';12.5;nM;7.9;;341292;UO_0000065;17.54;0.35;6.18;5.98;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3892339;;0;409.48;0;1.93;BDBM190842;C[C@@]1(c2cc(NC(=O)C3CCC3)ccc2F)CS(=O)(=O)[C@]2(CCOC2)C(=N)N1;Ki;'=';2080.0;nM;5.68;;341324;UO_0000065;13.88;0.28;3.75;5.24;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3935480;;0;373.82;0;1.62;BDBM190887;C[C@@]1(c2cc([N+](=O)[O-])ccc2Cl)CS(=O)(=O)[C@@]2(CCOC2)C(=N)N1;Ki;'=';6120.0;nM;5.21;;341358;UO_0000065;13.95;0.30;3.59;4.26;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL4239247;;0;588.68;1;0.15;3j;COc1cccc(CNC[C@@H](O)[C@H](Cc2ccccc2)NC(=O)[C@H](CS(C)(=O)=O)NC(=O)C2=NO[C@H]3OCC[C@@H]23)c1;Ki;'=';28758.0;nM;4.54;;;UO_0000065;7.71;0.15;4.39;2.76;False;CHEMBL4233526;Inhibition of recombinant BACE1 (unknown origin) using fluorogenic substrate;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4229428;1;Scientific Literature;Bioorg Med Chem Lett;2018;None
CHEMBL3900676;;0;462.5;0;1.85;BDBM190767;COc1ccc(C(=O)Nc2ccc(F)c([C@]3(C)CS(=O)(=O)[C@]4(CCOC4)C(=N)N3)c2)nc1;Ki;'=';30.3;nM;7.52;;341259;UO_0000065;16.26;0.32;5.67;5.76;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3919398;;0;466.92;0;2.50;BDBM190784;C[C@@]1(c2cc(NC(=O)c3ccc(Cl)cn3)ccc2F)CS(=O)(=O)[C@@]2(CCOC2)C(=N)N1;Ki;'=';5.9;nM;8.23;;341267;UO_0000065;17.62;0.36;5.73;6.79;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3969301;;0;457.49;0;2.39;BDBM190785;[C-]#[N+]c1ccc(C(=O)Nc2ccc(F)c([C@]3(C)CS(=O)(=O)[C@@]4(CCOC4)C(=N)N3)c2)nc1;Ki;'=';5.2;nM;8.28;;341268;UO_0000065;18.11;0.35;5.89;6.60;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3914118;;0;461.54;0;3.50;BDBM242240;CN1C(=N)N[C@](C)(c2sc(-c3cccc(-c4nnc(C5CC5)o4)c3)cc2F)CS1(=O)=O;Ki;'=';177.0;nM;6.75;;422367;UO_0000065;14.63;0.30;3.25;6.02;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3650825;;0;398.85;0;3.01;BDBM149913;Cc1cc(Cl)cnc1C(=O)Nc1ccc2c(c1)C1(COC(N)=N1)C1(CC1)CO2;Ki;'=';313.0;nM;6.5;;288565;UO_0000065;16.31;0.32;3.49;6.58;True;CHEMBL3705666;Fluorescence Resonance Energy Transfer (FRET) Assay: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638878;37;BindingDB Database;;2015;None
CHEMBL3921186;;0;497.04;0;2.67;BDBM190791;C[C@@]1(c2sc(-c3cncc(N4CCOCC4)c3)cc2Cl)CS(=O)(=O)[C@@]2(CCOC2)C(=N)N1;Ki;'=';3689.0;nM;5.43;;341283;UO_0000065;10.93;0.23;2.76;5.19;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL4115588;;0;530.53;1;3.26;BDBM236609;C[C@]1(c2ccc(F)cc2)C(=N)N[C@@]2(c3cc(NC(=O)c4ccc(F)cn4)ccc3F)COC[C@H]2S1(=O)=O;Ki;'=';84.0;nM;7.08;;412125;UO_0000065;13.34;0.26;3.82;5.84;False;CHEMBL3888701;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886796;37;BindingDB Database;;2016;None
CHEMBL3936033;;0;520.08;1;3.89;BDBM190824;C[C@@]1(c2sc(C(=O)NCc3cnn4ccccc34)cc2Cl)CS(=O)(=O)C2(CCCCC2)C(=N)N1;Ki;'=';41.0;nM;7.39;;341307;UO_0000065;14.2;0.30;3.50;6.35;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3943544;;0;478.99;0;3.41;BDBM242279;CN1C(=N)N[C@](C)(c2sc(-c3cncc(-c4nnc(C5CC5)o4)c3)cc2Cl)CS1(=O)=O;Ki;'=';566.2;nM;6.25;;422406;UO_0000065;13.04;0.28;2.84;4.99;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3902116;;0;418.39;0;4.09;BDBM230872;Cc1csc(C(=O)Nc2ccc(F)c([C@@]3(C(F)F)N=C(N)CCC3(F)F)c2)n1;Ki;'=';71.0;nM;7.15;;402955;UO_0000065;17.09;0.35;3.06;8.89;False;CHEMBL3888456;BACE1 Binding Assay: The binding assay was performed as SPA-based assay using a biotinylated form of human BACE1 recombinantly expressed and subsequently purified from Freestyle HEK293 cells. The binding assay was run in a 50 mM sodium acetate buffer, pH 4.5 containing 50 mM NaCl and 0.03% Tween-20 in white clear bottom 384 plates (Corning #3653). 10 nM (final concentration) radioligand ([3H]−N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N−((R)-1-phenyl-ethyl)-isophthalamide) (TRQ11569 purchased from GE Healthcare) was mixed with test compound at a given concentration, 6 nM (final concentration) human BACE1 and 25 μg Streptavidin coated PVT core SPA beads (RPNQ0007, GE Healthcare Life Sciences) in a total volume of 40 μl. Several concentrations of each test compound were tested in the assay for IC50 determination. The plates were incubated for one hour at room temperature and counted in a Wallac Trilux counter. Total and non-specific binding were determined using buffer and 1 μM (final concentration) of the high affinity BACE1 reference inhibitor (S)-6-[3-chloro-5-(5-prop-1-ynyl-pyridin-3-yl)-thiophen-2-yl]-2-imino-3,6-dimethyl-tetrahydro-pyrimidin-4-one, respectively.;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886720;37;BindingDB Database;;2016;CHEMBL3307715
CHEMBL3940488;;0;515.49;1;2.27;BDBM249092;CN1CC2(C1)C(=N)N[C@](C)(c1cc(NC(=O)c3ccc(OC(F)(F)F)cn3)ccc1F)CS2(=O)=O;Ki;'=';3.3;nM;8.48;;434630;UO_0000065;16.45;0.33;6.21;6.81;False;CHEMBL3889105;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 ul of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 ul in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window. Inhibitor IC50 values are derived from non-linear regression analysis of concentration response curves. Ki values are then calculated from IC50 values using the Cheng-Prusoff equation using a previously determined um value of 8 uM for the QSY7-APPswe-Eu substrate at BACE1.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886943;37;BindingDB Database;;2016;None
CHEMBL3967867;;0;450.92;0;3.26;BDBM190702;C[C@@]1(c2cc(NC(=O)c3ccc(Cl)cn3)ccc2F)CS(=O)(=O)C2(CCC2)C(=N)N1;Ki;'=';8.0;nM;8.1;;341197;UO_0000065;17.96;0.37;4.84;7.23;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3936864;;0;448.5;0;3.14;BDBM190709;C[C@@]1(c2cc(NC(=O)c3ccc(F)cn3)ccc2F)CS(=O)(=O)C2(CCCC2)C(=N)N1;Ki;'=';3.1;nM;8.51;;341204;UO_0000065;18.97;0.37;5.37;7.60;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL4210406;;0;508.62;2;6.12;8d;Cc1ccc2nc(-c3ccc(OCCCN4C(=O)c5ccccc5C4=O)cc3)c(NC3CCCCC3)n2c1;Ki;'=';2.74;nM;8.56;;;UO_0000065;16.83;0.31;2.44;11.28;False;CHEMBL4192781;Inhibition of human BACE1 (1 to 460 residues) expressed in baculovirus expression system using Rh-EVNLDAEFK-quencher as substrate after 90 mins by FRET assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4190277;1;Scientific Literature;Eur J Med Chem;2017;None
CHEMBL78946;;0;893.01;3;-1.74;OM99-2;CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(=O)O)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O;Ki;'=';9.8;nM;8.01;;;UO_0000065;8.97;0.17;9.75;2.13;False;CHEMBL3592358;Inhibition of pro-BACE1 (unknown origin);B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3588858;1;Scientific Literature;J. Med. Chem.;2015;None
CHEMBL4239838;;0;659.85;1;0.49;3e;CC(C)CNC(=O)[C@@H](NC(=O)[C@H](C)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](CS(C)(=O)=O)NC(=O)C1=NO[C@@H]2OCCC[C@H]12)C(C)C;Ki;'=';28.1;nM;7.55;;;UO_0000065;11.44;0.23;7.06;3.75;False;CHEMBL4233526;Inhibition of recombinant BACE1 (unknown origin) using fluorogenic substrate;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4229428;1;Scientific Literature;Bioorg Med Chem Lett;2018;None
CHEMBL3627977;;0;554.48;1;4.75;7k;CC(=O)Nc1c(Cl)cc(CN/C(N)=N/C(=O)[C@@H]2C[C@@H](OCc3ccccc3)CN2c2ccccc2)cc1Cl;Ki;'=';420.0;nM;6.38;;;UO_0000065;11.5;0.23;1.63;5.85;False;CHEMBL3630425;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 5 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL3627968;;0;516.35;1;4.57;12d;CC(=O)Nc1c(Cl)cc(CN/C(N)=N/C(=O)[C@@H]2CCCN2c2ccc(C(F)(F)F)cc2)cc1Cl;Ki;'=';130.0;nM;6.89;;;UO_0000065;13.34;0.28;2.32;6.90;False;CHEMBL3630425;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 5 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL3627966;;0;482.8;0;4.21;12b;CC(=O)Nc1c(Cl)cc(CN/C(N)=N/C(=O)[C@@H]2CCCN2c2ccc(Cl)cc2)cc1Cl;Ki;'=';150.0;nM;6.82;;;UO_0000065;14.13;0.30;2.61;6.84;False;CHEMBL3630425;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 5 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL3939487;;0;527.62;1;2.55;BDBM249112;CC#CCOc1ccc(C(=O)Nc2ccc(F)c([C@]3(C)CS(=O)(=O)C4(CCN(C)CC4)C(=N)N3)c2)nc1;Ki;'=';2.3;nM;8.64;;434650;UO_0000065;16.37;0.32;6.09;6.94;False;CHEMBL3889105;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 ul of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 ul in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window. Inhibitor IC50 values are derived from non-linear regression analysis of concentration response curves. Ki values are then calculated from IC50 values using the Cheng-Prusoff equation using a previously determined um value of 8 uM for the QSY7-APPswe-Eu substrate at BACE1.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886943;37;BindingDB Database;;2016;None
CHEMBL3926149;;0;525.58;1;0.71;BDBM249119;COc1ccc(C(=O)Nc2ccc(F)c([C@]3(C)CS(=O)(=O)C4(CN(S(C)(=O)=O)C4)C(=N)N3)c2)nc1;Ki;'=';6.5;nM;8.19;;434657;UO_0000065;15.58;0.32;7.48;5.16;False;CHEMBL3889105;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 ul of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 ul in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window. Inhibitor IC50 values are derived from non-linear regression analysis of concentration response curves. Ki values are then calculated from IC50 values using the Cheng-Prusoff equation using a previously determined um value of 8 uM for the QSY7-APPswe-Eu substrate at BACE1.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886943;37;BindingDB Database;;2016;None
CHEMBL3903739;;0;424.48;0;2.62;BDBM244050;CNS1(O)C[C@@](C)(c2cc(NC(=O)c3ccc(F)cn3)ccc2F)NC(=N)N1C;Ki;'=';10.0;nM;8.0;;425635;UO_0000065;18.85;0.38;5.38;7.06;False;CHEMBL3888967;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window Inhibitor.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886899;37;BindingDB Database;;2016;None
CHEMBL3927068;;0;433.41;0;3.99;BDBM234465;Cc1cc(C#N)cnc1C(=O)Nc1ccc(F)c([C@@]2(C)N=C(N)[C@@](C)(F)CC2(F)F)c1;Ki;'=';4.3;nM;8.37;;408781;UO_0000065;19.3;0.37;4.38;8.03;False;CHEMBL3888549;SPA-Based Assay: The binding assay was performed as SPA-based assay using a biotinylated form of human BACE1 recombinantly expressed and subsequently purified from Freestyle HEK293 cells. The binding assay was run in a 50 mM sodium acetate buffer, pH 4.5 containing 50 mM NaCl and 0.03% Tween-20 in white clear bottom 384 plates (Corning #3653). 10 nM (final concentration) radioligand ([3H]-N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N-((R)-1-phenyl-ethyl)-isophthalamide) (TRQ11569 purchased from GE Healthcare) was mixed with test compound at a given concentration, 6 nM (final concentration) human BACE1 and 25 μg Streptavidin coated PVT core SPA beads (RPNQ0007, GE Healthcare Life Sciences) in a total volume of 40 μl.;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886758;37;BindingDB Database;;2016;CHEMBL3307715
CHEMBL3897396;;0;478.0;0;4.09;BDBM190776;C[C@@]1(c2sc(-c3ccnc(-c4ccoc4)c3)cc2Cl)CS(=O)(=O)[C@]2(CCOC2)C(=N)N1;Ki;'=';295.6;nM;6.53;;341273;UO_0000065;13.66;0.29;2.44;6.20;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3927261;;0;439.91;0;1.92;BDBM242976;CN1C(=N)N[C@](C)(c2sc(-c3nnc(-c4cncnc4)o3)cc2Cl)CS1(=O)=O;Ki;'=';5400.0;nM;5.27;;423857;UO_0000065;11.97;0.26;3.35;3.82;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL4288644;;0;465.49;0;2.68;4;CN1C(=N)N[C@@]2(c3cc(-c4cc(F)cc(C#N)c4)cs3)CN(c3ncc(F)cn3)C[C@H]2C1=O;Ki;'=';2.0;nM;8.7;;;UO_0000065;18.69;0.36;6.02;7.98;False;CHEMBL4270026;Inhibition of recombinant human BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4266039;1;Scientific Literature;J Med Chem;2018;None
CHEMBL3948430;;0;437.52;0;3.60;BDBM242921;CNS1(O)C[C@@](C)(c2cc(NC(=O)c3ccc(F)cn3)ccc2F)NC(=N)C1(C)C;Ki;'=';10.0;nM;8.0;;423781;UO_0000065;18.28;0.36;4.40;7.26;False;CHEMBL3888940;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886895;37;BindingDB Database;;2016;None
CHEMBL3948430;;0;437.52;0;3.60;BDBM242921;CNS1(O)C[C@@](C)(c2cc(NC(=O)c3ccc(F)cn3)ccc2F)NC(=N)C1(C)C;Ki;'=';21.0;nM;7.68;;423782;UO_0000065;17.55;0.35;4.08;6.97;False;CHEMBL3888940;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886895;37;BindingDB Database;;2016;None
CHEMBL3962501;;0;450.54;0;2.86;BDBM242923;CNS1(O)C[C@@](C)(c2cc(NC(=O)c3cnc(OC)cn3)ccc2F)NC(=N)C1(C)C;Ki;'=';6.0;nM;8.22;;423784;UO_0000065;18.25;0.36;5.36;6.22;False;CHEMBL3888940;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886895;37;BindingDB Database;;2016;None
CHEMBL3902472;;0;468.0;0;4.50;BDBM242928;CCNS1(O)C[C@@](C)(c2cc(NC(=O)c3ccc(Cl)cn3)ccc2F)NC(=N)C1(C)C;Ki;'=';7.0;nM;8.15;;423789;UO_0000065;17.43;0.36;3.65;7.40;False;CHEMBL3888940;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886895;37;BindingDB Database;;2016;None
CHEMBL3968289;;0;461.54;0;3.50;BDBM242262;CN1C(=N)N[C@](C)(c2sc(-c3cccc(-c4nc(C5CC5)no4)c3)cc2F)CS1(=O)=O;Ki;'=';623.0;nM;6.21;;422389;UO_0000065;13.45;0.27;2.71;5.53;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3986760;;0;495.61;0;4.49;BDBM242310;Cc1cnc(-c2ccc(-c3cccc4c(F)c([C@]5(C)CS(=O)(=O)N(C)C(=N)N5)sc34)cc2)nc1;Ki;'=';9135.0;nM;5.04;;422437;UO_0000065;10.17;0.20;0.55;5.09;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3917662;;0;437.43;0;1.01;BDBM199089;CN1C(=N)N[C@]2(c3cc(NC(=O)c4ccc(F)cn4)ccc3F)COC[C@@H]2S1(=O)=O;Ki;'=';3529.0;nM;5.45;;354107;UO_0000065;12.46;0.25;4.44;4.38;False;CHEMBL3887768;Homogeneous Time-Resolved FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 u) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886448;37;BindingDB Database;;2015;None
CHEMBL4239092;;0;613.82;1;1.41;3a;CSC[C@H](NC(=O)C1=NO[C@@H]2OCC[C@H]12)C(=O)N[C@@H](CC(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NCC(C)C)C(C)C;Ki;'=';10.9;nM;7.96;;;UO_0000065;12.97;0.26;6.55;4.76;False;CHEMBL4233526;Inhibition of recombinant BACE1 (unknown origin) using fluorogenic substrate;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4229428;1;Scientific Literature;Bioorg Med Chem Lett;2018;None
CHEMBL3640289;;0;436.39;0;0.51;BDBM102972;COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3ccc(F)cc3F)C2)nc(CO)c1F;Ki;'=';16.0;nM;7.8;;220612;UO_0000065;17.86;0.34;7.29;6.65;False;CHEMBL3705045;Time-Resolved FRET Assay: A homogeneous time-resolved FRET assay was used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. The assay monitored the increase of 620nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide).;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638861;37;BindingDB Database;;2013;None
CHEMBL3975471;;0;433.44;0;2.70;BDBM242252;CN1C(=N)N[C@](C)(c2cc(-c3cc(F)cc(-c4nnco4)c3)ccc2F)CS1(=O)=O;Ki;'=';869.0;nM;6.06;;422379;UO_0000065;13.98;0.28;3.36;5.40;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL4059708;;0;697.9;1;4.14;6c;C[C@@H](NC(=O)c1cc(C(=O)N[C@@H](Cc2ccccc2)[C@H](O)[C@H]2CN(Cc3ccccc3)[C@H](C)CN2)cc(N(C)S(C)(=O)=O)c1)c1ccccc1;Ki;'=';300.0;nM;6.52;;;UO_0000065;9.35;0.18;2.38;4.98;False;CHEMBL4018279;Inhibition of recombinant human BACE1 (Ala8P to Ala326 residues) expressed in Escherichia coli BL21(DE3) using Arg-Glu(EDANS)-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys (Dabcyl)-Arg as substrate by fluorescence assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4017478;1;Scientific Literature;Bioorg Med Chem Lett;2017;None
CHEMBL3984492;;0;495.01;0;3.74;BDBM243010;CN1C(=N)N[C@](C)(c2sc(-c3nnc(-c4ccc5scnc5c4)o3)cc2Cl)CS1(=O)=O;Ki;'=';170.7;nM;6.77;;423891;UO_0000065;13.67;0.30;3.03;5.41;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3969146;;0;488.54;0;4.52;BDBM243019;CN1C(=N)N[C@](C)(c2sc3c(-c4coc(-c5ccc(F)cc5)n4)cccc3c2F)CS1(=O)=O;Ki;'=';4887.0;nM;5.31;;423900;UO_0000065;10.87;0.22;0.79;5.35;False;CHEMBL3888942;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886896;37;BindingDB Database;;2016;None
CHEMBL3969624;;0;428.36;0;3.73;BDBM230869;COc1ccc(C(=O)Nc2ccc(F)c([C@@]3(C(F)F)N=C(N)CCC3(F)F)c2)nc1;Ki;'=';6.7;nM;8.17;;402952;UO_0000065;19.08;0.37;4.44;9.12;False;CHEMBL3888456;BACE1 Binding Assay: The binding assay was performed as SPA-based assay using a biotinylated form of human BACE1 recombinantly expressed and subsequently purified from Freestyle HEK293 cells. The binding assay was run in a 50 mM sodium acetate buffer, pH 4.5 containing 50 mM NaCl and 0.03% Tween-20 in white clear bottom 384 plates (Corning #3653). 10 nM (final concentration) radioligand ([3H]−N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N−((R)-1-phenyl-ethyl)-isophthalamide) (TRQ11569 purchased from GE Healthcare) was mixed with test compound at a given concentration, 6 nM (final concentration) human BACE1 and 25 μg Streptavidin coated PVT core SPA beads (RPNQ0007, GE Healthcare Life Sciences) in a total volume of 40 μl. Several concentrations of each test compound were tested in the assay for IC50 determination. The plates were incubated for one hour at room temperature and counted in a Wallac Trilux counter. Total and non-specific binding were determined using buffer and 1 μM (final concentration) of the high affinity BACE1 reference inhibitor (S)-6-[3-chloro-5-(5-prop-1-ynyl-pyridin-3-yl)-thiophen-2-yl]-2-imino-3,6-dimethyl-tetrahydro-pyrimidin-4-one, respectively.;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886720;37;BindingDB Database;;2016;CHEMBL3307715
CHEMBL4089241;;0;649.81;1;2.49;5c;CCCN1CCN[C@@H]([C@@H](O)[C@H](Cc2ccccc2)NC(=O)c2cc(C(=O)N[C@H](C)c3ccccc3)cc(N(C)S(C)(=O)=O)c2)C1=O;Ki;'=';20.5;nM;7.69;;;UO_0000065;11.83;0.23;5.20;5.19;False;CHEMBL4018279;Inhibition of recombinant human BACE1 (Ala8P to Ala326 residues) expressed in Escherichia coli BL21(DE3) using Arg-Glu(EDANS)-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys (Dabcyl)-Arg as substrate by fluorescence assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4017478;1;Scientific Literature;Bioorg Med Chem Lett;2017;None
CHEMBL3650821;;0;474.32;0;2.22;BDBM149909;CC1(C)Oc2ccc(NC(=O)c3ncc(Br)cn3)cc2C2(COC(N)=N2)C12COC2;Ki;'=';83.5;nM;7.08;;288561;UO_0000065;14.92;0.32;4.86;5.85;True;CHEMBL3705666;Fluorescence Resonance Energy Transfer (FRET) Assay: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638878;37;BindingDB Database;;2015;None
CHEMBL3963849;;0;436.95;0;2.66;BDBM242293;CN1C(=N)N[C@](C)(c2sc(-c3ccc(-n4ccnn4)cc3)cc2Cl)CS1(=O)=O;Ki;'=';1600.0;nM;5.8;;422420;UO_0000065;13.26;0.28;3.14;5.57;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3650825;;0;398.85;0;3.01;BDBM149913;Cc1cc(Cl)cnc1C(=O)Nc1ccc2c(c1)C1(COC(N)=N1)C1(CC1)CO2;Ki;'=';313.0;nM;6.5;;361635;UO_0000065;16.31;0.32;3.49;6.58;False;CHEMBL3887894;Fluorescence Resonance Energy Transfer (FRET) Assay: Test Example 1: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence. The amino acid sequence of the 'core' peptide of the substrate is SEVNLDAEFK (SEQ ID NO:2). The amino terminus was derivatized with (7-methoxycoumarin-4-yl)acetyl (MCA), and the epsilon amine of the lysine side chain of the terminal residue (K in sequence SEVNLDAEFK (SEQ ID NO:2)) was derivatized with 2,4-dinitrophenyl (DNP). Assays were performed in a buffer of 0.1 M sodium acetate, pH 4.4, 0.08% 3-[(3-Cholamidopropyl)dimethylammonio]propanesulfonate (CHAPS), 0.005% Tween80. BACE1 enzyme (final concentration 65 nM) was pre-incubated with test compounds for 15 minutes at room temperature. Fluorescence intensities were measured 60 minutes after addition of the substrate (final concentration 3 uM) by Tecan Safire2.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886493;37;BindingDB Database;;2016;None
CHEMBL3935385;;0;514.58;1;4.52;BDBM242230;CN1/C(=N\C(=O)OC(C)(C)C)N[C@](C)(c2cc(-c3cccc(-c4ncco4)c3)ccc2F)CS1(=O)=O;Ki;'=';1951.0;nM;5.71;;422357;UO_0000065;11.1;0.22;1.19;5.00;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3897125;;0;442.48;0;0.90;BDBM249115;C[C@@]1(c2cc(NC(=O)c3ccc(C#N)cn3)ccc2F)CS(=O)(=O)C2(CNC2)C(=N)N1;Ki;'=';3.7;nM;8.43;;434653;UO_0000065;19.06;0.37;7.53;5.70;False;CHEMBL3889105;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 ul of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 ul in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window. Inhibitor IC50 values are derived from non-linear regression analysis of concentration response curves. Ki values are then calculated from IC50 values using the Cheng-Prusoff equation using a previously determined um value of 8 uM for the QSY7-APPswe-Eu substrate at BACE1.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886943;37;BindingDB Database;;2016;None
CHEMBL3956676;;0;453.97;0;4.11;BDBM242919;CNS1(O)C[C@@](C)(c2cc(NC(=O)c3ccc(Cl)cn3)ccc2F)NC(=N)C1(C)C;Ki;'=';8.0;nM;8.1;;423780;UO_0000065;17.84;0.37;3.99;7.35;False;CHEMBL3888940;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886895;37;BindingDB Database;;2016;None
CHEMBL3650848;;0;412.88;0;3.48;BDBM149939;CC1(C)Oc2ccc(NC(=O)c3ccc(Cl)cn3)cc2[C@@]2(COC(N)=N2)C12CC2;Ki;'=';37.8;nM;7.42;;361658;UO_0000065;17.98;0.35;3.94;7.51;False;CHEMBL3887894;Fluorescence Resonance Energy Transfer (FRET) Assay: Test Example 1: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence. The amino acid sequence of the 'core' peptide of the substrate is SEVNLDAEFK (SEQ ID NO:2). The amino terminus was derivatized with (7-methoxycoumarin-4-yl)acetyl (MCA), and the epsilon amine of the lysine side chain of the terminal residue (K in sequence SEVNLDAEFK (SEQ ID NO:2)) was derivatized with 2,4-dinitrophenyl (DNP). Assays were performed in a buffer of 0.1 M sodium acetate, pH 4.4, 0.08% 3-[(3-Cholamidopropyl)dimethylammonio]propanesulfonate (CHAPS), 0.005% Tween80. BACE1 enzyme (final concentration 65 nM) was pre-incubated with test compounds for 15 minutes at room temperature. Fluorescence intensities were measured 60 minutes after addition of the substrate (final concentration 3 uM) by Tecan Safire2.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886493;37;BindingDB Database;;2016;None
CHEMBL3650850;;0;409.45;0;2.23;BDBM149941;COc1cnc(C(=O)Nc2ccc3c(c2)[C@@]2(COC(N)=N2)C2(CC2)C(C)(C)O3)cn1;Ki;'=';61.2;nM;7.21;;361660;UO_0000065;17.62;0.33;4.98;5.96;False;CHEMBL3887894;Fluorescence Resonance Energy Transfer (FRET) Assay: Test Example 1: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence. The amino acid sequence of the 'core' peptide of the substrate is SEVNLDAEFK (SEQ ID NO:2). The amino terminus was derivatized with (7-methoxycoumarin-4-yl)acetyl (MCA), and the epsilon amine of the lysine side chain of the terminal residue (K in sequence SEVNLDAEFK (SEQ ID NO:2)) was derivatized with 2,4-dinitrophenyl (DNP). Assays were performed in a buffer of 0.1 M sodium acetate, pH 4.4, 0.08% 3-[(3-Cholamidopropyl)dimethylammonio]propanesulfonate (CHAPS), 0.005% Tween80. BACE1 enzyme (final concentration 65 nM) was pre-incubated with test compounds for 15 minutes at room temperature. Fluorescence intensities were measured 60 minutes after addition of the substrate (final concentration 3 uM) by Tecan Safire2.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886493;37;BindingDB Database;;2016;None
CHEMBL4107884;;0;419.38;0;3.68;BDBM234479;C[C@@]1(F)CC(F)(F)[C@@](C)(c2cc(NC(=O)c3ccc(C#N)cn3)ccc2F)N=C1N;Ki;'=';51.0;nM;7.29;;408795;UO_0000065;17.39;0.33;3.61;7.00;False;CHEMBL3888549;SPA-Based Assay: The binding assay was performed as SPA-based assay using a biotinylated form of human BACE1 recombinantly expressed and subsequently purified from Freestyle HEK293 cells. The binding assay was run in a 50 mM sodium acetate buffer, pH 4.5 containing 50 mM NaCl and 0.03% Tween-20 in white clear bottom 384 plates (Corning #3653). 10 nM (final concentration) radioligand ([3H]-N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N-((R)-1-phenyl-ethyl)-isophthalamide) (TRQ11569 purchased from GE Healthcare) was mixed with test compound at a given concentration, 6 nM (final concentration) human BACE1 and 25 μg Streptavidin coated PVT core SPA beads (RPNQ0007, GE Healthcare Life Sciences) in a total volume of 40 μl.;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886758;37;BindingDB Database;;2016;CHEMBL3307715
CHEMBL4113159;;0;399.35;0;3.11;BDBM234482;Cc1nc(C(=O)Nc2ccc(F)c([C@@]3(C)N=C(N)[C@](C)(F)CC3(F)F)c2)no1;Ki;'=';680.0;nM;6.17;;408798;UO_0000065;15.44;0.30;3.06;5.80;False;CHEMBL3888549;SPA-Based Assay: The binding assay was performed as SPA-based assay using a biotinylated form of human BACE1 recombinantly expressed and subsequently purified from Freestyle HEK293 cells. The binding assay was run in a 50 mM sodium acetate buffer, pH 4.5 containing 50 mM NaCl and 0.03% Tween-20 in white clear bottom 384 plates (Corning #3653). 10 nM (final concentration) radioligand ([3H]-N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N-((R)-1-phenyl-ethyl)-isophthalamide) (TRQ11569 purchased from GE Healthcare) was mixed with test compound at a given concentration, 6 nM (final concentration) human BACE1 and 25 μg Streptavidin coated PVT core SPA beads (RPNQ0007, GE Healthcare Life Sciences) in a total volume of 40 μl.;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886758;37;BindingDB Database;;2016;CHEMBL3307715
CHEMBL3922540;;0;442.39;0;3.96;BDBM234492;COc1cnc(C(=O)Nc2ccc(F)c([C@@]3(C)N=C(N)[C@@](C)(F)CC3(F)F)c2)c(F)c1;Ki;'=';14.0;nM;7.85;;408809;UO_0000065;17.75;0.35;3.89;8.77;False;CHEMBL3888549;SPA-Based Assay: The binding assay was performed as SPA-based assay using a biotinylated form of human BACE1 recombinantly expressed and subsequently purified from Freestyle HEK293 cells. The binding assay was run in a 50 mM sodium acetate buffer, pH 4.5 containing 50 mM NaCl and 0.03% Tween-20 in white clear bottom 384 plates (Corning #3653). 10 nM (final concentration) radioligand ([3H]-N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N-((R)-1-phenyl-ethyl)-isophthalamide) (TRQ11569 purchased from GE Healthcare) was mixed with test compound at a given concentration, 6 nM (final concentration) human BACE1 and 25 μg Streptavidin coated PVT core SPA beads (RPNQ0007, GE Healthcare Life Sciences) in a total volume of 40 μl.;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886758;37;BindingDB Database;;2016;CHEMBL3307715
CHEMBL3936940;;0;438.43;0;4.13;BDBM234496;COc1cnc(C(=O)Nc2ccc(F)c([C@@]3(C)N=C(N)[C@@](C)(F)CC3(F)F)c2)c(C)c1;Ki;'=';14.0;nM;7.85;;408811;UO_0000065;17.91;0.35;3.72;8.77;False;CHEMBL3888549;SPA-Based Assay: The binding assay was performed as SPA-based assay using a biotinylated form of human BACE1 recombinantly expressed and subsequently purified from Freestyle HEK293 cells. The binding assay was run in a 50 mM sodium acetate buffer, pH 4.5 containing 50 mM NaCl and 0.03% Tween-20 in white clear bottom 384 plates (Corning #3653). 10 nM (final concentration) radioligand ([3H]-N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N-((R)-1-phenyl-ethyl)-isophthalamide) (TRQ11569 purchased from GE Healthcare) was mixed with test compound at a given concentration, 6 nM (final concentration) human BACE1 and 25 μg Streptavidin coated PVT core SPA beads (RPNQ0007, GE Healthcare Life Sciences) in a total volume of 40 μl.;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886758;37;BindingDB Database;;2016;CHEMBL3307715
CHEMBL3703289;;0;403.48;0;3.24;BDBM149811;CC#Cc1cncc(-c2ccc3c(c2)C2(COC(N)=N2)C2(COC2)C(CCC)O3)c1;Ki;'=';87.9;nM;7.06;;288475;UO_0000065;17.49;0.32;3.82;8.94;True;CHEMBL3705666;Fluorescence Resonance Energy Transfer (FRET) Assay: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638878;37;BindingDB Database;;2015;None
CHEMBL3953747;;0;449.55;0;3.47;BDBM242922;CNS1(O)C[C@@](C)(c2cc(NC(=O)c3ccc(OC)cn3)ccc2F)NC(=N)C1(C)C;Ki;'=';11.0;nM;7.96;;423783;UO_0000065;17.7;0.35;4.49;6.67;False;CHEMBL3888940;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886895;37;BindingDB Database;;2016;None
CHEMBL3928892;;0;413.47;0;1.17;BDBM236588;CO[C@@H](C)C(=O)Nc1ccc(F)c([C@]23COC[C@H]2S(=O)(=O)C(C)(C)C(=N)N3)c1;Ki;'=';213.0;nM;6.67;;412104;UO_0000065;16.14;0.33;5.50;5.67;False;CHEMBL3888701;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886796;37;BindingDB Database;;2016;None
CHEMBL4113105;;0;457.49;0;1.71;BDBM236591;CC1(C)C(=N)N[C@@]2(c3cc(NC(=O)c4ccc(C#N)cn4)ccc3F)COC[C@H]2S1(=O)=O;Ki;'=';1.0;nM;9.0;;412107;UO_0000065;19.67;0.38;7.29;6.21;False;CHEMBL3888701;HTRF FRET Assay: This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence. Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 μl in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886796;37;BindingDB Database;;2016;None
CHEMBL4064628;;0;598.79;1;4.00;6g;CCCN(CCC)C(=O)c1cc(C)cc(C(=O)N[C@@H](Cc2ccccc2)[C@H](O)[C@@H]2NC[C@@H](Cc3ccccc3)N(C)C2=O)c1;Ki;'=';320.0;nM;6.5;;;UO_0000065;10.85;0.20;2.49;6.37;False;CHEMBL4018279;Inhibition of recombinant human BACE1 (Ala8P to Ala326 residues) expressed in Escherichia coli BL21(DE3) using Arg-Glu(EDANS)-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys (Dabcyl)-Arg as substrate by fluorescence assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4017478;1;Scientific Literature;Bioorg Med Chem Lett;2017;None
CHEMBL3913535;;0;456.5;0;1.24;BDBM249087;CN1CC2(C1)C(=N)N[C@](C)(c1cc(NC(=O)c3ccc(C#N)cn3)ccc1F)CS2(=O)=O;Ki;'=';1.7;nM;8.77;;434625;UO_0000065;19.21;0.37;7.53;6.31;False;CHEMBL3889105;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 ul of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 ul in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window. Inhibitor IC50 values are derived from non-linear regression analysis of concentration response curves. Ki values are then calculated from IC50 values using the Cheng-Prusoff equation using a previously determined um value of 8 uM for the QSY7-APPswe-Eu substrate at BACE1.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886943;37;BindingDB Database;;2016;None
CHEMBL3937168;;0;461.52;0;1.38;BDBM249089;COc1ccc(C(=O)Nc2ccc(F)c([C@]3(C)CS(=O)(=O)C4(CN(C)C4)C(=N)N3)c2)nc1;Ki;'=';6.3;nM;8.2;;434627;UO_0000065;17.77;0.35;6.82;6.59;False;CHEMBL3889105;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 ul of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 ul in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window. Inhibitor IC50 values are derived from non-linear regression analysis of concentration response curves. Ki values are then calculated from IC50 values using the Cheng-Prusoff equation using a previously determined um value of 8 uM for the QSY7-APPswe-Eu substrate at BACE1.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886943;37;BindingDB Database;;2016;None
CHEMBL3903468;;0;465.94;0;2.02;BDBM249091;CN1CC2(C1)C(=N)N[C@](C)(c1cc(NC(=O)c3ccc(Cl)cn3)ccc1F)CS2(=O)=O;Ki;'=';2.2;nM;8.66;;434629;UO_0000065;18.58;0.38;6.64;7.51;False;CHEMBL3889105;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 ul of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 ul in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window. Inhibitor IC50 values are derived from non-linear regression analysis of concentration response curves. Ki values are then calculated from IC50 values using the Cheng-Prusoff equation using a previously determined um value of 8 uM for the QSY7-APPswe-Eu substrate at BACE1.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886943;37;BindingDB Database;;2016;None
CHEMBL3945094;;0;479.51;0;1.67;BDBM249094;CN1CC2(C1)C(=N)N[C@](C)(c1cc(NC(=O)c3ccc(OCF)cn3)ccc1F)CS2(=O)=O;Ki;'=';4.9;nM;8.31;;434632;UO_0000065;17.33;0.34;6.64;6.68;False;CHEMBL3889105;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 ul of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 ul in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window. Inhibitor IC50 values are derived from non-linear regression analysis of concentration response curves. Ki values are then calculated from IC50 values using the Cheng-Prusoff equation using a previously determined um value of 8 uM for the QSY7-APPswe-Eu substrate at BACE1.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886943;37;BindingDB Database;;2016;None
CHEMBL3917191;;0;475.55;0;1.68;BDBM249095;COc1cnc(C(=O)Nc2ccc(F)c([C@]3(C)CS(=O)(=O)C4(CN(C)C4)C(=N)N3)c2)c(C)c1;Ki;'=';6.3;nM;8.2;;434633;UO_0000065;17.24;0.34;6.52;6.59;False;CHEMBL3889105;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 ul of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 ul in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window. Inhibitor IC50 values are derived from non-linear regression analysis of concentration response curves. Ki values are then calculated from IC50 values using the Cheng-Prusoff equation using a previously determined um value of 8 uM for the QSY7-APPswe-Eu substrate at BACE1.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886943;37;BindingDB Database;;2016;None
CHEMBL4294236;;0;491.55;0;2.94;15;CCOc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3cc(-c4cccc(C#N)c4)cs3)C2)ncc1F;Ki;'=';1.0;nM;9.0;;;UO_0000065;18.31;0.35;6.06;7.61;False;CHEMBL4270026;Inhibition of recombinant human BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4266039;1;Scientific Literature;J Med Chem;2018;None
CHEMBL3969079;;0;498.94;0;3.03;BDBM190732;C[C@@]1(c2cc(NC(=O)c3ncc(Cl)cc3F)ccc2F)CS(=O)(=O)C2(CCOCC2)C(=N)N1;Ki;'=';6.5;nM;8.19;;341227;UO_0000065;16.41;0.34;5.16;6.75;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3905107;;0;555.67;2;5.76;BDBM190737;COc1cccc2cc(-c3ccc(F)c([C@]4(C)CS(=O)(=O)C5(CCCC5)C(=N)N4)c3)n(C(=O)OC(C)(C)C)c12;Ki;'=';1326.0;nM;5.88;;341231;UO_0000065;10.58;0.21;0.12;5.32;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3934307;;0;426.95;0;2.62;BDBM190753;C[C@@]1(c2sc(-c3cncnc3)cc2Cl)CS(=O)(=O)C2(CCOCC2)C(=N)N1;Ki;'=';688.0;nM;6.16;;341245;UO_0000065;14.43;0.31;3.54;5.87;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3985948;;0;462.5;0;1.85;BDBM190782;COc1ccc(C(=O)Nc2ccc(F)c([C@]3(C)CS(=O)(=O)[C@@]4(CCOC4)C(=N)N3)c2)nc1;Ki;'=';24.2;nM;7.62;;341265;UO_0000065;16.47;0.33;5.77;5.84;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3914455;;0;488.03;0;4.50;BDBM190780;C[C@@]1(c2sc(-c3ccnc(-c4ccccc4)c3)cc2Cl)CS(=O)(=O)[C@]2(CCOC2)C(=N)N1;Ki;'=';312.8;nM;6.5;;341277;UO_0000065;13.33;0.28;2.00;7.06;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3911444;;0;436.47;0;1.74;BDBM190868;Cc1cc(C(=O)Nc2ccc(F)c([C@]3(C)CS(=O)(=O)[C@]4(CCOC4)C(=N)N3)c2)no1;Ki;'=';1334.0;nM;5.88;;341347;UO_0000065;13.46;0.27;4.13;4.37;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL3926569;;0;425.8;0;4.08;BDBM190882;C[C@@]1(c2sc(Br)cc2Cl)CS(=O)(=O)C2(CCCCC2)C(=N)N1;Ki;'=';2611.0;nM;5.58;;341354;UO_0000065;13.11;0.35;1.50;7.97;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL4128525;;0;498.54;0;2.58;19;COc1cnc2c(C(=O)Nc3ccc(F)c([C@]45CCC[C@H]4S(=O)(=O)N(C)C(=N)N5)c3)nccc2c1;Ki;'=';31.0;nM;7.51;;;UO_0000065;15.06;0.29;4.93;5.47;False;CHEMBL4119788;Binding affinity to human BACE1 catalytic domain using QSY7-APPswe-Eu as substrate preincubated for 30 mins followed by substrate addition measured after 1.5 hrs by HTRF assay;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4118088;1;Scientific Literature;ACS Med Chem Lett;2017;None
CHEMBL3898798;;0;430.53;0;3.63;BDBM242276;CN1C(=N)N[C@](C)(c2sc(-c3ccnc(-c4ccccc4)c3)cc2F)CS1(=O)=O;Ki;'=';132.0;nM;6.88;;422403;UO_0000065;15.98;0.32;3.25;7.99;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3962552;;0;462.99;0;3.30;BDBM242300;CN1C(=N)N[C@](C)(c2sc3c(-c4cnc(C5CC5)nc4)nccc3c2Cl)CS1(=O)=O;Ki;'=';162.0;nM;6.79;;422427;UO_0000065;14.67;0.31;3.49;6.07;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3972435;;0;483.59;0;4.12;BDBM242308;CN1C(=N)N[C@](C)(c2sc3c(-c4ccc(-c5nccn5C)cc4)cccc3c2F)CS1(=O)=O;Ki;'=';5616.0;nM;5.25;;422435;UO_0000065;10.86;0.22;1.13;5.76;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3901823;;0;505.0;1;4.16;BDBM242336;CN1C(=N)N[C@](C)(c2sc3c(-c4ccc(-c5cn[nH]c5)cc4F)nccc3c2Cl)CS1(=O)=O;Ki;'=';329.9;nM;6.48;;422463;UO_0000065;12.83;0.27;2.32;5.64;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3640274;;0;386.41;0;1.49;BDBM102957;Cc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3ccc(F)cc3)C2)nc(C)c1F;Ki;'=';64.0;nM;7.19;;220589;UO_0000065;18.62;0.35;5.70;8.20;False;CHEMBL3705045;Time-Resolved FRET Assay: A homogeneous time-resolved FRET assay was used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. The assay monitored the increase of 620nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide).;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638861;37;BindingDB Database;;2013;None
CHEMBL3907858;;0;440.46;0;2.15;BDBM242281;CN1C(=N)N[C@](C)(c2sc(-c3cc(-c4nnco4)ncc3F)cc2F)CS1(=O)=O;Ki;'=';107.0;nM;6.97;;422408;UO_0000065;15.83;0.33;4.82;5.57;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3975767;;0;519.02;2;5.34;BDBM242332;Cc1cocc1-c1ccc(-c2nccc3c(Cl)c([C@]4(C)CS(=O)(=O)N(C)C(=N)N4)sc23)c(F)c1;Ki;'=';111.5;nM;6.95;;422459;UO_0000065;13.4;0.28;1.61;7.00;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3891075;;0;439.47;0;2.76;BDBM242256;CN1C(=N)N[C@](C)(c2sc(-c3ccc(F)c(-c4nnco4)c3)cc2F)CS1(=O)=O;Ki;'=';6.7;nM;8.17;;422383;UO_0000065;18.6;0.38;5.41;7.29;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL4110849;;0;464.5;0;1.02;BDBM249090;COc1cnc(C(=O)Nc2ccc(F)c([C@]3(C)CS(=O)(=O)C4(C[O+](C)C4)C(=N)N3)c2)cn1;Ki;'=';7.9;nM;8.1;;434628;UO_0000065;17.44;0.35;7.08;5.92;False;CHEMBL3889105;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 ul of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 ul in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window. Inhibitor IC50 values are derived from non-linear regression analysis of concentration response curves. Ki values are then calculated from IC50 values using the Cheng-Prusoff equation using a previously determined um value of 8 uM for the QSY7-APPswe-Eu substrate at BACE1.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886943;37;BindingDB Database;;2016;None
CHEMBL3917788;;0;568.59;1;2.86;BDBM249123;COc1ccc(C(=O)Nc2ccc(F)c([C@]3(C)CS(=O)(=O)C4(CN(c5ccc([N+](=O)[O-])cc5)C4)C(=N)N3)c2)nc1;Ki;'=';1.4;nM;8.85;;434660;UO_0000065;15.57;0.30;5.99;5.28;False;CHEMBL3889105;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 ul of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 ul in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window. Inhibitor IC50 values are derived from non-linear regression analysis of concentration response curves. Ki values are then calculated from IC50 values using the Cheng-Prusoff equation using a previously determined um value of 8 uM for the QSY7-APPswe-Eu substrate at BACE1.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886943;37;BindingDB Database;;2016;None
CHEMBL261063;SARGAHYDROQUINOIC ACID;0;426.6;1;7.16;1;CC(C)=CCC/C(=C/CC/C(C)=C/CC/C(C)=C/Cc1cc(O)cc(C)c1O)C(=O)O;Ki;'=';1600.0;nM;5.8;;;UO_0000065;13.59;0.26;-1.36;7.45;False;CHEMBL4055496;Mixed type inhibition of recombinant human BACE1 using Rh-EVNLDAEFK-Quencher as substrate after 60 mins by Dixon plot analysis;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4052658;1;Scientific Literature;Bioorg Med Chem;2017;None
CHEMBL4289763;;0;461.53;0;2.85;12;Cc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3cc(-c4cccc(C#N)c4)cs3)C2)ncc1F;Ki;'=';0.7;nM;9.15;;;UO_0000065;19.84;0.38;6.30;8.40;False;CHEMBL4270026;Inhibition of recombinant human BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4266039;1;Scientific Literature;J Med Chem;2018;None
CHEMBL3932766;;0;424.4;0;3.82;BDBM234464;COc1ccc(C(=O)Nc2ccc(F)c([C@@]3(C)N=C(N)[C@@](C)(F)CC3(F)F)c2)nc1;Ki;'=';11.0;nM;7.96;;408780;UO_0000065;18.75;0.36;4.14;8.88;False;CHEMBL3888549;SPA-Based Assay: The binding assay was performed as SPA-based assay using a biotinylated form of human BACE1 recombinantly expressed and subsequently purified from Freestyle HEK293 cells. The binding assay was run in a 50 mM sodium acetate buffer, pH 4.5 containing 50 mM NaCl and 0.03% Tween-20 in white clear bottom 384 plates (Corning #3653). 10 nM (final concentration) radioligand ([3H]-N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N-((R)-1-phenyl-ethyl)-isophthalamide) (TRQ11569 purchased from GE Healthcare) was mixed with test compound at a given concentration, 6 nM (final concentration) human BACE1 and 25 μg Streptavidin coated PVT core SPA beads (RPNQ0007, GE Healthcare Life Sciences) in a total volume of 40 μl.;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886758;37;BindingDB Database;;2016;CHEMBL3307715
CHEMBL4107938;;0;416.35;0;3.88;BDBM234477;C[C@@]1(F)CC(F)(F)[C@@](C)(c2cc(NC(=O)c3nc(CF)co3)ccc2F)N=C1N;Ki;'=';260.0;nM;6.58;;408793;UO_0000065;15.82;0.31;2.71;7.04;False;CHEMBL3888549;SPA-Based Assay: The binding assay was performed as SPA-based assay using a biotinylated form of human BACE1 recombinantly expressed and subsequently purified from Freestyle HEK293 cells. The binding assay was run in a 50 mM sodium acetate buffer, pH 4.5 containing 50 mM NaCl and 0.03% Tween-20 in white clear bottom 384 plates (Corning #3653). 10 nM (final concentration) radioligand ([3H]-N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N-((R)-1-phenyl-ethyl)-isophthalamide) (TRQ11569 purchased from GE Healthcare) was mixed with test compound at a given concentration, 6 nM (final concentration) human BACE1 and 25 μg Streptavidin coated PVT core SPA beads (RPNQ0007, GE Healthcare Life Sciences) in a total volume of 40 μl.;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886758;37;BindingDB Database;;2016;CHEMBL3307715
CHEMBL4293298;;0;491.55;0;2.86;20;COc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3cc(-c4cccc(C#N)c4)cs3)C2)nc(C)c1F;Ki;'=';0.7;nM;9.15;;;UO_0000065;18.62;0.36;6.29;7.74;False;CHEMBL4270026;Inhibition of recombinant human BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4266039;1;Scientific Literature;J Med Chem;2018;None
CHEMBL4278154;;0;532.61;1;2.38;18;CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3ncc(F)c(N4CCOCC4)n3)C[C@H]2C1=O;Ki;'=';1.0;nM;9.0;;;UO_0000065;16.9;0.32;6.62;7.41;False;CHEMBL4270026;Inhibition of recombinant human BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4266039;1;Scientific Literature;J Med Chem;2018;None
CHEMBL3703303;;0;389.46;0;2.85;BDBM149829;CC#Cc1cncc(-c2ccc3c(c2)C2(COC(N)=N2)C2(COC2)C(C)(C)O3)c1;Ki;'=';90.4;nM;7.04;;288492;UO_0000065;18.09;0.33;4.19;8.92;True;CHEMBL3705666;Fluorescence Resonance Energy Transfer (FRET) Assay: Potency of test compounds were determined by measurement of their inhibition of BACE1 activity toward a fluorescent substrate. Experiments were performed by reference to the procedure as described in Ermolieff, et al. (Biochemistry 39:12450-12456 (2000), the teachings of which are incorporated hereby in their entirety). Briefly, the recombinant protease unit of BACE1 was prepared from E. coli expression as inclusion bodies, refolded, and purified as described in Lin, et al., (Proc. Nat. Acad. Sci. 97:1456-1460 (2000)). Fluorogenic substrate, MCA-SEVNLDAEFK(DNP)-NH2 (SEQ ID NO:1) was purchased. (M-2485, Bachem Americas, Torrance, Calif.). The substrate was derived from 10 amino acids of the human amyloid precursor protein (APP), with the Swedish variant amino acids at the beta-secretase cleavage site. The terminal amino acid was modified from arginine to lysine to facilitate derivatization with a functional group for detection by autofluorescence.;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3638878;37;BindingDB Database;;2015;None
CHEMBL2178718;;0;447.5;0;2.54;1;CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3ncc(F)cn3)C[C@H]2C1=O;Ki;'=';4.0;nM;8.4;;;UO_0000065;18.77;0.36;5.86;7.70;False;CHEMBL4270026;Inhibition of recombinant human BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4266039;1;Scientific Literature;J Med Chem;2018;None
CHEMBL4286732;;0;465.49;0;2.68;2;CN1C(=N)N[C@@]2(c3cc(-c4ccc(F)c(C#N)c4)cs3)CN(c3ncc(F)cn3)C[C@H]2C1=O;Ki;'=';4.0;nM;8.4;;;UO_0000065;18.04;0.35;5.72;7.70;False;CHEMBL4270026;Inhibition of recombinant human BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4266039;1;Scientific Literature;J Med Chem;2018;None
CHEMBL3627966;;0;482.8;0;4.21;12b;CC(=O)Nc1c(Cl)cc(CN/C(N)=N/C(=O)[C@@H]2CCCN2c2ccc(Cl)cc2)cc1Cl;Ki;'=';370.0;nM;6.43;;;UO_0000065;13.32;0.28;2.22;6.44;False;CHEMBL3630426;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 6.4 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL3627967;;0;466.34;0;3.69;12c;CC(=O)Nc1c(Cl)cc(CN/C(N)=N/C(=O)[C@@H]2CCCN2c2ccc(F)cc2)cc1Cl;Ki;'=';7200.0;nM;5.14;;;UO_0000065;11.03;0.23;1.45;5.15;False;CHEMBL3630426;Displacement of [3H]BMS-599240 from BACE1 (unknown origin) expressed in HEK293 cells at pH 6.4 after 1.5 hrs by Microbeta liquid scintillation counting analysis;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3627595;1;Scientific Literature;Bioorg. Med. Chem. Lett.;2015;CHEMBL3307715
CHEMBL3944434;;0;411.77;0;3.69;BDBM190881;C[C@@]1(c2sc(Br)cc2Cl)CS(=O)(=O)C2(CCCC2)C(=N)N1;Ki;'=';447.0;nM;6.35;;341353;UO_0000065;15.42;0.41;2.66;9.07;False;CHEMBL3887512;HTRF FRET Assay: A homogeneous time-resolved FRET assay can be used to determine IC50 values for inhibitors of the soluble human BACE1 catalytic domain. This assay monitors the increase of 620 nm fluorescence that resulted from BACE1 cleavage of an APPswedish APPswe mutant peptide FRET substrate (QSY7-EISEVNLDAEFC-Europium-amide). This substrate contains an N-terminal QSY7 moiety that serves as a quencher of the C-terminal Europium fluorophore (620 nm Em). In the absence of enzyme activity, 620 nm fluorescence is low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme Inhibition of BACE1 cleavage of the QSY7-APPswe-Eu substrate by inhibitors is manifested as a suppression of 620 nm fluorescence.Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 10 ul are preincubated with purified human BACE1 catalytic domain (3 nM in 10 ul) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886347;37;BindingDB Database;;2015;None
CHEMBL4279084;;0;475.55;0;3.11;13;CCc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3cc(-c4cccc(C#N)c4)cs3)C2)ncc1F;Ki;'=';1.0;nM;9.0;;;UO_0000065;18.93;0.36;5.89;8.26;False;CHEMBL4270026;Inhibition of recombinant human BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4266039;1;Scientific Literature;J Med Chem;2018;None
CHEMBL4249165;;0;659.85;1;0.49;3f;CC(C)CNC(=O)[C@@H](NC(=O)[C@H](C)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](CS(C)(=O)=O)NC(=O)C1=NO[C@H]2OCCC[C@@H]12)C(C)C;Ki;'=';630.0;nM;6.2;;;UO_0000065;9.4;0.19;5.71;3.08;False;CHEMBL4233526;Inhibition of recombinant BACE1 (unknown origin) using fluorogenic substrate;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4229428;1;Scientific Literature;Bioorg Med Chem Lett;2018;None
CHEMBL4209831;;0;547.45;2;6.04;8n;CC(C)(C)Nc1c(-c2ccc(OCCCN3C(=O)c4ccccc4C3=O)cc2)nc2ccc(Br)cn12;Ki;'=';209.27;nM;6.68;;;UO_0000065;12.2;0.25;0.64;8.80;False;CHEMBL4192781;Inhibition of human BACE1 (1 to 460 residues) expressed in baculovirus expression system using Rh-EVNLDAEFK-quencher as substrate after 90 mins by FRET assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4190277;1;Scientific Literature;Eur J Med Chem;2017;None
CHEMBL4282976;;0;425.29;0;1.77;8;CN1C(=N)N[C@@]2(c3cc(Br)cs3)CN(c3ncc(F)cn3)C[C@H]2C1=O;Ki;'=';100.0;nM;7.0;;;UO_0000065;16.46;0.38;5.23;8.21;False;CHEMBL4270026;Inhibition of recombinant human BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4266039;1;Scientific Literature;J Med Chem;2018;None
CHEMBL4206562;;0;494.6;1;5.81;8a;O=C1c2ccccc2C(=O)N1CCCOc1ccc(-c2nc3ccccn3c2NC2CCCCC2)cc1;Ki;'=';104.73;nM;6.98;;;UO_0000065;14.11;0.26;1.17;9.19;False;CHEMBL4192781;Inhibition of human BACE1 (1 to 460 residues) expressed in baculovirus expression system using Rh-EVNLDAEFK-quencher as substrate after 90 mins by FRET assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4190277;1;Scientific Literature;Eur J Med Chem;2017;None
CHEMBL3917414;;0;451.96;0;3.44;BDBM242237;Cc1nnc(-c2cccc(-c3cc(Cl)c([C@]4(C)CS(=O)(=O)N(C)C(=N)N4)s3)c2)o1;Ki;'=';129.0;nM;6.89;;422364;UO_0000065;15.24;0.32;3.45;6.14;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL3952769;;0;478.0;0;4.01;BDBM242266;CN1C(=N)N[C@](C)(c2sc(-c3cccc(-c4noc(C5CC5)n4)c3)cc2Cl)CS1(=O)=O;Ki;'=';267.0;nM;6.57;;422393;UO_0000065;13.75;0.29;2.56;5.86;False;CHEMBL3888913;HTRF FRET Assay: Varying concentrations of inhibitors at 3× the final desired concentration in a volume of 10 μl are preincubated with purified human BACE1 catalytic domain (3 nM in 10 μl) for 30 minutes at 30° C. in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1% Brij-35 and 7.5% DSMO. Reactions are initiated by addition of 10 μl of 600 nM QSY7-APPswe-Eu substrate (200 nM final) to give a final reaction volume of 30 in a 384 well Nunc HTRF plate. The reactions are incubated at 30° C. for 1.5 hours. The 620 nm fluorescence is then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 millisecond delay followed by a 400 millisecond acquisition time window.;B;BAO_0000357;single protein format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL3886884;37;BindingDB Database;;2016;None
CHEMBL2178714;;0;446.51;0;3.15;9;CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3ccc(F)cn3)C[C@H]2C1=O;Ki;'=';6.0;nM;8.22;;;UO_0000065;18.41;0.35;5.07;8.55;False;CHEMBL4270026;Inhibition of recombinant human BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4266039;1;Scientific Literature;J Med Chem;2018;None
CHEMBL4206975;;0;482.58;1;5.59;8f;Cc1ccn2c(NC(C)(C)C)c(-c3ccc(OCCCN4C(=O)c5ccccc5C4=O)cc3)nc2c1;Ki;'=';20.13;nM;7.7;;;UO_0000065;15.95;0.29;2.11;10.13;False;CHEMBL4192781;Inhibition of human BACE1 (1 to 460 residues) expressed in baculovirus expression system using Rh-EVNLDAEFK-quencher as substrate after 90 mins by FRET assay;B;BAO_0000019;assay format;Homo sapiens;None;None;None;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4190277;1;Scientific Literature;Eur J Med Chem;2017;None
CHEMBL4291347;;0;458.47;0;2.95;6;CN1C(=N)N[C@@]2(c3cc(-c4cc(F)cc(F)c4)cs3)CN(c3ncc(F)cn3)C[C@H]2C1=O;Ki;'=';10.0;nM;8.0;;;UO_0000065;17.45;0.34;5.05;9.39;False;CHEMBL4270026;Inhibition of recombinant human BACE1 expressed in HEK293 cells;B;BAO_0000219;cell-based format;Homo sapiens;None;None;HEK293;None;CHEMBL4822;Beta-secretase 1;Homo sapiens;SINGLE PROTEIN;CHEMBL4266039;1;Scientific Literature;J Med Chem;2018;None
